,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,label
3,hypercalcemia,24,25,152,165,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,1,1
5,phosphate,4,5,34,43,The animals received supplemental phosphate to enhance PTH secretion.,10027919_5,0,-1,0
6,phosphate,6,7,34,43,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,0,-1,0
7,calcium,5,6,36,43,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,0,-1,0
9,hypercalcemia,7,8,46,59,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,1,1
10,fibrosis,15,16,76,84,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,1,1
11,hypercalcemia,16,17,103,116,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,1,1
13,Hypotension,0,1,0,11,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,-1,1,1
14,bradycardia,2,3,13,24,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,-1,1,1
15,asystole,5,6,30,38,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,-1,1,1
16,methylprednisolone,9,10,67,85,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0,-1,0
17,hypotension,5,6,20,31,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,-1,1,1
18,bradycardia,7,8,33,44,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,-1,1,1
19,asystole,10,11,50,58,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,-1,1,1
20,methylprednisolone,16,17,105,123,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,0,-1,0
23,arrhythmia,8,9,55,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,1,1
24,death,9,10,61,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,1,1
25,methylprednisolone,16,17,100,118,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0,-1,0
27,arrhythmia,21,22,138,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,1,1
28,dyskinesias,3,4,30,41,Worsening of levodopa-induced dyskinesias by motor and mental tasks.,10091616_0,-1,1,1
30,dyskinesia,9,10,56,66,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,1,1
31,dyskinesia,52,53,312,322,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,1,1
32,apomorphine,61,62,379,390,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,0,-1,0
33,dyskinesia,15,16,78,88,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,1,1
34,dyskinesia,19,20,111,121,"These results suggest that activation tasks such as ""speaking aloud"" could be used for objective assessment of dyskinesia severity.",10091616_3,-1,1,1
35,hypotension,2,3,28,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,1,1
40,selegiline,32,33,180,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0,-1,0
41,selegiline,7,8,37,47,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0
42,orthostatic hypotension,15,17,98,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,1,1
43,selegiline,23,24,159,169,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0
44,selegiline,29,30,174,184,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,0,-1,0
45,orthostatic hypotension,46,48,274,297,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,-1,1,1
47,selegiline,17,18,116,126,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,0,-1,0
48,orthostatic hypotension,6,8,38,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,1,1
50,selegiline,18,19,107,117,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,0,-1,0
51,orthostatic hypotension,4,6,19,42,A lesser degree of orthostatic hypotension occurred with standing.,10091617_7,-1,1,1
52,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,-1,1,1
53,selegiline,9,10,67,77,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,0,-1,0
54,selegiline,1,2,9,19,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0,-1,0
55,selegiline,9,10,58,68,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,0,-1,0
56,orthostatic hypotension,18,20,125,148,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,-1,1,1
58,amphetamine,18,19,128,139,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0,-1,0
59,cystitis,18,19,145,153,The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.,1009330_2,-1,1,1
60,cystitis,12,13,101,109,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,-1,1,1
61,cystitis,10,11,70,78,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,1,1
62,thrombosis,7,8,57,67,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,1,1
63,platelet aggregation,12,14,86,106,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,1,1
68,thrombosis,16,17,95,105,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,1,1
69,epinephrine,21,22,131,142,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0,-1,0
70,platelet aggregation,29,31,161,181,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,1,1
71,blood coagulation,32,34,186,203,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,1,1
74,acetylsalicylic acid,36,38,153,173,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0,-1,0
85,proteinuria,15,16,91,102,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,1,1
87,proteinuria,16,17,91,102,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,-1,1,1
88,lignocaine,10,11,66,76,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,0,-1,0
89,lignocaine,10,11,64,74,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,0,-1,0
90,lignocaine,6,7,26,36,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0,-1,0
91,neurotoxicity,10,11,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,-1,1,1
92,lignocaine,15,16,84,94,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,0,-1,0
93,neurotoxicity,7,8,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,-1,1,1
94,lignocaine,4,5,29,39,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,0,-1,0
95,toxicity,1,2,9,17,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,1,1
96,sirolimus,5,6,46,55,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0
97,rapamycin,8,9,66,75,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0
98,psoriasis,11,12,81,90,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,1,1
100,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0
101,rapamycin,5,6,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0
102,psoriasis,4,5,25,34,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,1,1
104,sirolimus,14,15,101,110,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0,-1,0
106,psoriasis,35,36,226,235,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,1,1
107,psoriasis,8,9,54,63,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,-1,1,1
108,sirolimus,28,29,194,203,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,0,-1,0
109,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0
110,fever,8,9,57,62,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,1,1
111,anemia,10,11,64,70,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,1,1
113,psoriasis,4,5,29,38,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,1,1
114,Angioedema,0,1,0,10,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,1,1
115,angioedema,4,5,27,37,The estimated incidence of angioedema during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.,10342929_1,-1,1,1
116,lithium,2,3,10,17,Effect of lithium maintenance therapy on thyroid and parathyroid function.,10354657_0,0,-1,0
117,lithium,7,8,41,48,"OBJECTIVES: To assess changes induced by lithium maintenance therapy on the incidence of thyroid, parathyroid and ion alterations.",10354657_1,0,-1,0
118,lithium,9,10,53,60,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,0,-1,0
121,lithium,18,19,93,100,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,0,-1,0
122,psychiatric,9,10,51,62,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,-1,1,1
123,calcium,6,7,41,48,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0
124,magnesium,8,9,50,59,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0
125,lithium,16,17,126,133,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0
126,Hypothyroidism,2,3,9,23,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,-1,1,1
127,hypothyroid,13,14,80,91,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,-1,1,1
128,hypothyroidism,13,14,96,110,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,1,1
129,lithium,20,21,137,144,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,0,-1,0
130,lithium,36,37,228,235,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,0,-1,0
131,hypothyroidism,11,12,55,69,Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age (34.6% versus 31.9%).,10354657_10,-1,1,1
132,Magnesium,0,1,0,9,Magnesium levels in patients on lithium treatment were unchanged from baseline levels.,10354657_11,0,-1,0
133,lithium,5,6,32,39,Magnesium levels in patients on lithium treatment were unchanged from baseline levels.,10354657_11,0,-1,0
134,lithium,1,2,6,13,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0
135,calcium,4,5,25,32,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0
136,lithium,2,3,6,13,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,0,-1,0
137,calcium,9,10,60,67,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,0,-1,0
138,hypothyroidism,10,11,59,73,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,1,1
139,hypercalcemia,12,13,78,91,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,1,1
140,lithium,14,15,99,106,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,0,-1,0
142,psychiatric,7,8,52,63,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,1,1
148,psychiatric,24,25,148,159,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,1,1
151,depressive,15,16,93,103,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,1,1
156,brain damage,9,11,57,69,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1
157,ischemic stroke,12,14,80,95,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1
159,inflammation,6,7,49,61,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,1,1
160,ischemic stroke,8,10,67,82,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,1,1
161,brain damage,14,16,95,107,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,1,1
163,hematoma,1,2,4,12,The hematoma was assessed in vivo by magnetic resonance imaging.,10406016_5,-1,1,1
164,inflammation,20,21,132,144,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,1,1
165,hematoma,26,27,168,176,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,1,1
166,hemorrhage,14,15,95,105,They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test.,10406016_8,-1,1,1
167,edema,3,4,19,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,1,1
168,hematoma,14,15,84,92,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,1,1
170,hemolytic anemia,2,4,14,30,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,1,1
171,cephalosporins,3,4,29,43,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,0,-1,0
172,hemolytic anemia,17,19,131,147,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,1,1
174,hemolytic anemia,7,9,38,54,Eight of these cases of severe immune hemolytic anemia are described.,10411803_3,-1,1,1
177,acetaminophen,35,36,170,183,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,0,-1,0
178,acetaminophen,45,46,209,222,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,0,-1,0
179,platelet aggregation,1,3,8,28,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,1,1
181,acetaminophen,15,16,68,81,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,0,-1,0
182,platelet aggregation,4,6,21,41,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,1,1
183,acetaminophen,9,10,59,72,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,0,-1,0
184,platelet aggregation,21,23,144,164,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,1,1
185,hematoma,10,11,75,83,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,1,1
189,acetaminophen,3,4,19,32,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,0,-1,0
190,aneurysms,9,10,56,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,1,1
191,hemorrhage,19,20,109,119,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,1,1
192,bradycardia,7,8,50,61,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,1,1
193,propofol,4,5,28,36,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0
194,ephedrine,8,9,57,66,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0
196,propofol,25,26,165,173,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0
197,ephedrine,11,12,69,78,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0,-1,0
198,propofol,13,14,82,90,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0,-1,0
199,hypotensive,19,20,114,125,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,-1,1,1
200,ephedrine,12,13,54,63,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0
201,propofol,17,18,77,85,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0
203,ephedrine,3,4,16,25,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0
204,propofol,5,6,29,37,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0
205,hypotensive,15,16,89,100,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,-1,1,1
206,propofol,18,19,113,121,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0
207,tachycardia,3,4,16,27,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,-1,1,1
208,ephedrine,9,10,55,64,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0,-1,0
209,propofol,13,14,85,93,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0,-1,0
210,tachycardia,6,7,24,35,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,1,1
213,hypertension,9,10,63,75,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,1,1
215,hypertension,34,35,203,215,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,1,1
216,hypertension,14,15,88,100,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,-1,1,1
217,depressed,22,23,121,130,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,-1,1,1
218,lead acetate,12,14,79,91,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0,-1,0
220,malondialdehyde,9,10,51,66,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0,-1,0
222,hypertension,4,5,38,50,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,1,1
224,hypertension,4,5,28,40,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,1,1
225,hypertension,28,29,173,185,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,-1,1,1
230,pain,10,11,59,63,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,1,1
234,pain,20,21,112,116,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,1,1
237,headache,21,22,106,114,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,1,1
241,Headache,0,1,0,8,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,1,1
243,headache,6,7,33,41,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,1,1
244,headache,14,15,93,101,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,1,1
245,headache,5,6,25,33,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,1,1
247,Headache,22,23,138,146,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,1,1
248,pain,10,11,57,61,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,1,1
250,depression,3,4,25,35,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,1,1
251,depression,25,26,161,171,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,1,1
252,headache,27,28,176,184,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,1,1
254,Gemcitabine,0,1,0,11,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0
255,vinorelbine,2,3,17,28,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0
256,carcinoma,7,8,51,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,1,1
257,cisplatin,20,21,123,132,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0
258,carcinoma,9,10,58,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,1,1
260,toxicity,27,28,158,166,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,1,1
261,vinorelbine,8,9,55,66,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0
263,gemcitabine,13,14,76,87,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0
265,toxicity,33,34,168,176,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,1,1
266,toxicity,7,8,38,46,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,1,1
270,cisplatin,28,29,170,179,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0,-1,0
272,cisplatin,33,34,171,180,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0,-1,0
273,toxicity,7,8,45,53,All patients were evaluable for response and toxicity.,10526274_6,-1,1,1
276,Toxicity,17,18,82,90,The median time to progression was 16 weeks and the 1-year survival rate was 33%. Toxicity was mild.,10526274_14,-1,1,1
277,neutropenia,14,15,59,70,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1
278,thrombocytopenia,27,28,102,118,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1
279,neurotoxicity,39,40,152,165,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1
280,neutropenia,4,5,27,38,Three patients with severe neutropenia (6%) died of sepsis.,10526274_16,-1,1,1
281,sepsis,11,12,52,58,Three patients with severe neutropenia (6%) died of sepsis.,10526274_16,-1,1,1
282,neutropenia,11,12,54,65,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,1,1
285,myelosuppression,8,9,40,56,This age group had an increased risk of myelosuppression.,10526274_19,-1,1,1
286,toxicity,8,9,61,69,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,1,1
288,tetany,5,6,53,59,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,1,1
290,tetany,6,7,36,42,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,1,1
291,diltiazem,16,17,108,117,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,0,-1,0
293,tetany,10,11,70,76,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,1,1
294,tetany,8,9,62,68,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,1,1
295,diltiazem,15,16,117,126,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,0,-1,0
303,enalapril,24,25,139,148,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,0,-1,0
305,enalapril,7,8,46,55,There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.,10539815_4,0,-1,0
306,creatinine,10,11,56,66,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,0,-1,0
307,creatinine,21,22,146,156,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0,-1,0
308,hypertension,36,37,211,223,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,1,1
309,diabetes,38,39,225,233,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,1,1
310,enalapril,6,7,39,48,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,0,-1,0
311,enalapril,9,10,50,59,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,0,-1,0
312,diabetes,18,19,100,108,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,1,1
313,enalapril,23,24,133,142,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0,-1,0
314,enalapril,26,27,150,159,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0,-1,0
315,enalapril,49,50,240,249,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0,-1,0
316,enalapril,15,16,96,105,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,0,-1,0
317,enalapril,2,3,12,21,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,0,-1,0
318,diabetes,36,37,154,162,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,-1,1,1
319,Enalapril,2,3,13,22,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,0,-1,0
321,Diabetes,0,1,0,8,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,1,1
323,enalapril,23,24,126,135,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,0,-1,0
324,olanzapine,4,5,35,45,Hypomania-like syndrome induced by olanzapine.,10565806_0,0,-1,0
326,olanzapine,26,27,159,169,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0,-1,0
327,dopamine,2,3,12,20,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,0,-1,0
330,5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide,2,22,9,114,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0,-1,0
331,dopamine,30,31,153,161,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0,-1,0
333,dopamine,8,9,46,54,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,0,-1,0
334,dopamine,16,17,100,108,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,0,-1,0
336,dopamine,8,9,53,61,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0,-1,0
337,serotonin,17,18,90,99,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0,-1,0
339,clozapine,2,3,12,21,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,0,-1,0
340,locomotor hyperactivity,4,6,34,57,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,1,1
341,methamphetamine,8,9,69,84,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,0,-1,0
343,clozapine,2,3,12,21,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,0,-1,0
345,clozapine,2,3,12,21,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,0,-1,0
346,catalepsy,5,6,44,53,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,1,1
348,clozapine,2,3,12,21,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,0,-1,0
349,apomorphine,17,18,109,120,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,0,-1,0
351,clozapine,2,3,12,21,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,0,-1,0
354,artery calcification,1,3,17,37,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1
357,artery calcification,23,25,167,187,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1
358,Warfarin,31,32,222,230,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,0,-1,0
359,calcification,41,42,287,300,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1
360,artery calcification,14,16,83,103,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,-1,1,1
361,Warfarin,5,6,27,35,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,0,-1,0
362,calcification,9,10,57,70,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,1,1
363,calcification,21,22,135,148,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,1,1
364,artery calcification,4,6,16,36,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,1,1
365,Warfarin,18,19,104,112,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,0,-1,0
366,artery calcification,9,11,65,85,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,1,1
367,Warfarin,7,8,49,57,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,0,-1,0
368,calcification,11,12,81,94,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,1,1
369,artery calcification,24,26,160,180,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,1,1
370,artery calcification,7,9,53,73,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1
371,phosphate,28,29,183,192,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,0,-1,0
372,artery calcification,32,34,215,235,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1
373,phosphate,42,43,269,278,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,0,-1,0
374,artery calcification,60,62,383,403,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1
375,artery calcification,8,10,76,96,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,-1,1,1
376,phosphate,16,17,130,139,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,0,-1,0
378,Warfarin,13,14,82,90,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,0,-1,0
379,artery calcification,15,17,94,114,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,1,1
381,calcification,9,10,43,56,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,1,1
383,Warfarin,7,8,39,47,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,0,-1,0
384,calcification,13,14,72,85,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,1,1
385,Warfarin,17,18,103,111,"In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.",10669626_11,0,-1,0
387,artery calcification,13,15,67,87,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1
389,calcium,27,28,147,154,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0,-1,0
391,artery calcification,36,38,197,217,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1
392,calcium,43,44,246,253,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0,-1,0
393,Warfarin,1,2,8,16,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0
394,calcium,11,12,67,74,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0
396,Warfarin,20,21,118,126,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0
398,Warfarin,32,33,191,199,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0,-1,0
399,calcification,42,43,249,262,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,1,1
400,artery calcification,11,13,56,76,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,1,1
402,Warfarin,20,21,113,121,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,0,-1,0
403,calcification,31,32,217,230,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,-1,1,1
404,Apomorphine,0,1,0,11,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0,-1,0
406,hypothermia,20,21,121,132,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,-1,1,1
407,dopamine,28,29,169,177,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0,-1,0
408,hyperactivity,6,7,42,55,"In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.",10683478_4,-1,1,1
409,apomorphine,11,12,75,86,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,0,-1,0
410,hypothermia,15,16,108,119,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,-1,1,1
411,apomorphine,3,4,9,20,"In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage.",10683478_6,0,-1,0
412,Dopamine,0,1,0,8,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0,-1,0
416,dopamine,6,7,52,60,"However, apomorphine-induced reductions in striatal dopamine turnover were detected in both novel and home cage environments.",10683478_10,0,-1,0
418,confusion,1,2,6,15,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,1,1
420,Hemolysis,0,1,0,9,Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.,10704919_0,-1,1,1
421,tamoxifen,6,7,43,52,Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.,10704919_0,0,-1,0
422,Tamoxifen,0,1,0,9,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,0,-1,0
424,breast cancer,15,17,87,100,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1
425,hemolytic anemia,27,29,162,178,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1
427,hemolytic anemia,20,22,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,1,1
429,hemolysis,2,3,12,21,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,1,1
430,hemolysis,3,4,17,26,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,1,1
432,hemolysis,16,17,99,108,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,1,1
435,hemolysis,29,30,196,205,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,1,1
436,oxygen,7,8,41,47,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,0,-1,0
437,hemolysis,18,19,130,139,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,-1,1,1
439,Hemolysis,0,1,0,9,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,1,1
441,hemolysis,24,25,131,140,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,1,1
444,hemolysis,7,8,47,56,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,1,1
446,hemolysis,3,4,23,32,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,-1,1,1
448,hemolytic anemia,17,19,118,134,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,1,1
450,sodium,2,3,11,17,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0,-1,0
453,hypertension,18,19,106,118,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,1,1
454,hypertension,6,7,45,57,Inhibition of NO synthesis induces sustained hypertension.,10706004_2,-1,1,1
455,hypertension,4,5,21,33,"In several models of hypertension, elevation of intracellular sodium level was documented in cardiac tissue.",10706004_3,-1,1,1
456,sodium,9,10,62,68,"In several models of hypertension, elevation of intracellular sodium level was documented in cardiac tissue.",10706004_3,0,-1,0
457,hypertension,24,25,149,161,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,-1,1,1
459,hypertension,3,4,20,32,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,1,1
461,hypertension,6,7,47,59,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,1,1
462,depressed,9,10,75,84,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,1,1
463,isoproterenol,5,6,39,52,Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.,10721819_0,0,-1,0
464,tachycardia,8,9,78,89,Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.,10721819_0,-1,1,1
465,tachycardia,6,7,45,56,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,-1,1,1
466,dopamine,20,21,122,130,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0,-1,0
467,isoproterenol,31,32,180,193,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0,-1,0
468,isoproterenol,10,11,72,85,This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.,10721819_2,0,-1,0
469,tachycardia,14,15,122,133,This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.,10721819_2,-1,1,1
470,Isoproterenol,0,1,0,13,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,0,-1,0
471,cardiac hypertrophy,6,8,46,65,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,-1,1,1
472,bromocriptine,5,6,29,42,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0,-1,0
473,hypotension,12,13,79,90,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,-1,1,1
474,tachycardia,14,15,95,106,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,-1,1,1
475,hypotension,1,2,22,33,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,-1,1,1
476,isoproterenol,5,6,52,65,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,0,-1,0
477,tachycardia,9,10,86,97,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,-1,1,1
478,bradycardia,14,15,126,137,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,-1,1,1
479,isoproterenol,9,10,58,71,Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment.,10721819_7,0,-1,0
480,isoproterenol,5,6,31,44,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,0,-1,0
481,tachycardia,13,14,112,123,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,-1,1,1
482,bradycardia,15,16,127,138,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,-1,1,1
483,tachycardia,11,12,57,68,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,-1,1,1
484,bromocriptine,13,14,72,85,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0
485,bradycardia,21,22,125,136,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,-1,1,1
486,dopamine,27,28,167,175,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0
487,Vasopressin,0,1,0,11,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,0,-1,0
488,hypotension,6,7,50,61,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,1,1
492,hypotension,23,24,160,171,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,1,1
494,hypotension,7,8,50,61,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,1,1
495,vasopressin,16,17,107,118,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0,-1,0
496,clonidine,4,5,28,37,A developmental analysis of clonidine's effects on cardiac rate and ultrasound production in infant rats.,10737864_0,0,-1,0
497,clonidine,23,24,163,172,"Under controlled conditions, infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha(2) adrenoceptor agonist, clonidine.",10737864_1,0,-1,0
498,clonidine,9,10,61,70,"Previous investigations have determined that, in response to clonidine, ultrasound production increases through the 2nd-week postpartum and decreases thereafter.",10737864_2,0,-1,0
499,clonidine,14,15,97,106,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,0,-1,0
500,bradycardia,19,20,142,153,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,-1,1,1
501,clonidine,24,25,176,185,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,0,-1,0
502,clonidine,10,11,53,62,"Therefore, in the present experiment, the effects of clonidine administration (0.5 mg/kg) on cardiac rate and ultrasound production were examined in 2-, 8-, 15-, and 20-day-old rats.",10737864_4,0,-1,0
503,bradycardia,18,19,154,165,"Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.",10737864_5,-1,1,1
504,clonidine,23,24,162,171,This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by-product of a physiological maneuver that compensates for clonidine's detrimental effects on cardiovascular function.,10737864_6,0,-1,0
505,oral contraceptives,4,6,23,42,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,0,-1,0
509,oral contraceptives,16,18,105,124,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0,-1,0
518,ketamine,5,6,50,58,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,0,-1,0
519,lidocaine,7,8,63,72,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,0,-1,0
520,hyperalgesia,12,13,95,107,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,-1,1,1
521,capsaicin,16,17,131,140,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,0,-1,0
522,ketamine,9,10,58,66,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0
523,lidocaine,11,12,71,80,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0
524,pain,17,18,107,111,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,1,1
525,hyperalgesia,23,24,141,153,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,1,1
526,capsaicin,26,27,165,174,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,0,-1,0
527,Capsaicin,0,1,0,9,Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i.v.,10743446_3,0,-1,0
528,ketamine,2,3,12,20,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,0,-1,0
529,lidocaine,21,22,102,111,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,0,-1,0
530,capsaicin,7,8,43,52,Infusion started 15 min after injection of capsaicin.,10743446_5,0,-1,0
531,pain,6,7,41,45,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1
532,pain,8,9,47,51,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1
533,hyperalgesia,25,26,142,154,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1
534,Ketamine,0,1,0,8,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,0,-1,0
535,hyperalgesia,9,10,67,79,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1
536,hyperalgesia,9,10,67,79,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1
537,pain,17,18,131,135,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1
538,Lidocaine,0,1,0,9,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,0,-1,0
539,hyperalgesia,6,7,46,58,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,-1,1,1
540,pain,8,9,46,50,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,-1,1,1
541,pain,15,16,79,83,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,-1,1,1
542,ketamine,4,5,28,36,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,0,-1,0
543,lidocaine,6,7,41,50,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,0,-1,0
544,hyperalgesia,11,12,73,85,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1
545,hyperalgesia,18,19,116,128,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1
546,cyclosporine,8,9,65,77,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,0,-1,0
547,tacrolimus,1,2,5,15,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,0,-1,0
548,tacrolimus,2,3,17,27,"We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.",10743694_2,0,-1,0
549,tacrolimus,6,7,37,47,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0
550,tacrolimus,31,32,208,218,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0
551,neurotoxicity,5,6,38,51,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
553,nephrotoxicity,22,23,108,122,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
554,toxicity,31,32,150,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
555,cardiomyopathy,37,38,168,182,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
556,neurotoxicity,47,48,217,230,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
558,nephrotoxicity,57,58,248,262,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
559,toxicity,63,64,271,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
560,hepatotoxicity,68,69,285,299,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
561,cardiomyopathy,83,84,358,372,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
562,hemolytic anemia,88,90,378,394,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
563,pruritus,95,96,404,412,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1
564,tacrolimus,1,2,5,15,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,0,-1,0
565,aggressive behavior,3,5,35,54,Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.,10791295_0,-1,1,1
566,aggressive behavior,12,14,67,86,The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.,10791295_1,-1,1,1
567,apomorphine,5,6,26,37,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,0,-1,0
568,aggressive behavior,12,14,81,100,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,-1,1,1
569,aggressiveness,21,22,144,158,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,-1,1,1
570,aggressiveness,9,10,44,58,"In female rats, only a weak tendency toward aggressiveness was found.",10791295_3,-1,1,1
571,aggressive behavior,15,17,111,130,"In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.",10791295_4,-1,1,1
572,rheumatoid arthritis,4,6,34,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,1,1
573,rheumatoid arthritis,6,8,34,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,1,1
574,arthritis,23,24,132,141,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,1,1
577,corticosteroids,27,28,149,164,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,0,-1,0
578,Cataract,0,1,0,8,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,1,1
579,chloroquine,2,3,8,19,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,0,-1,0
580,corticosteroids,2,3,26,41,Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.,1079693_12,0,-1,0
581,cataracts,17,18,118,127,Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.,1079693_12,-1,1,1
582,cataracts,3,4,22,31,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,1,1
583,glaucoma,9,10,55,63,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,1,1
584,aneurysms,1,2,13,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,1,1
585,cocaine,3,4,27,34,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,0,-1,0
587,cocaine,9,10,66,73,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,0,-1,0
588,aneurysms,15,16,97,106,METHODS: A review of admissions during a 6-year period revealed 14 patients with cocaine-related aneurysms.,10807237_3,-1,1,1
589,aneurysms,13,14,75,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,1,1
590,cocaine,18,19,103,110,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,0,-1,0
592,aneurysm,21,22,115,123,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,1,1
593,aneurysm,26,27,141,149,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,1,1
594,aneurysms,8,9,36,45,"In patients in the study group, all aneurysms were located in the anterior circulation.",10807237_7,-1,1,1
595,aneurysms,4,5,22,31,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,1,1
596,aneurysms,26,27,129,138,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,1,1
597,Cocaine,2,3,12,19,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,0,-1,0
598,aneurysms,16,17,106,115,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,1,1
599,nimodipine,3,4,22,32,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,0,-1,0
600,stroke,11,12,75,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,1,1
601,Nimodipine,6,7,40,50,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,0,-1,0
602,Stroke,9,10,65,71,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,1,1
603,stroke,32,33,203,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,1,1
604,ischemic stroke,8,10,47,62,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,1,1
605,nimodipine,30,31,156,166,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0
606,nimodipine,41,42,198,208,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0
607,Nimodipine,0,1,0,10,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,0,-1,0
608,death,26,27,142,147,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,1,1
609,death,51,52,232,237,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,1,1
610,stroke,23,24,157,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,1,1
611,nimodipine,2,3,13,23,"For low-dose nimodipine, the results were not conclusive.",10835440_11,0,-1,0
612,nimodipine,11,12,70,80,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0,-1,0
613,cystitis,1,2,25,33,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,1,1
616,Cyclophosphamide,0,1,0,16,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0,-1,0
617,cystitis,28,29,158,166,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,1,1
618,morphine,3,4,15,23,The effects of morphine (0.5 to 4 mg./kg.,10840460_5,0,-1,0
619,naloxone,13,14,86,94,i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg.,10840460_6,0,-1,0
620,morphine,18,19,86,94,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,0,-1,0
621,Morphine,0,1,0,8,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,0,-1,0
622,naloxone,8,9,58,66,This effect was completely prevented by pretreatment with naloxone.,10840460_16,0,-1,0
623,morphine,6,7,33,41,"At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.",10840460_17,0,-1,0
624,edema,21,22,126,131,"At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.",10840460_17,-1,1,1
625,cystitis,13,14,88,96,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,1,1
627,pyridoxine,1,2,9,19,Neonatal pyridoxine responsive convulsions due to isoniazid therapy.,1085609_0,0,-1,0
628,convulsions,3,4,31,42,Neonatal pyridoxine responsive convulsions due to isoniazid therapy.,1085609_0,-1,1,1
629,isoniazid,6,7,50,59,Neonatal pyridoxine responsive convulsions due to isoniazid therapy.,1085609_0,0,-1,0
630,isoniazid,4,5,23,32,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,0,-1,0
631,tuberculosis,14,15,87,99,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,1,1
632,pyridoxine,9,10,62,72,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,0,-1,0
633,pyridoxine,15,16,101,111,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,0,-1,0
634,isoniazid,19,20,136,145,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,0,-1,0
635,Ketamine,0,1,0,8,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,0,-1,0
636,fractures,8,9,50,59,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,1,1
637,ketamine,12,13,71,79,"BACKGROUND: There recently has been a resurgence in the utilization of ketamine, a unique anesthetic, for emergency-department procedures requiring sedation.",10901305_1,0,-1,0
638,ketamine,14,15,75,83,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,0,-1,0
639,fractures,23,24,128,137,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,1,1
640,Ketamine,0,1,0,8,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,0,-1,0
643,pain,1,2,4,8,Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS).,10901305_6,-1,1,1
644,Pain,23,24,144,148,Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS).,10901305_6,-1,1,1
645,ketamine,9,10,61,69,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,0,-1,0
646,Pain,12,13,74,78,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1
647,pain,30,31,150,154,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,1,1
648,nausea,4,5,28,34,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,1,1
649,nausea,18,19,100,106,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,1,1
650,hallucinations,10,11,54,68,"No long-term sequelae were noted, and no patients had hallucinations or nightmares.",10901305_14,-1,1,1
651,Ketamine,2,3,13,21,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,0,-1,0
652,fractures,20,21,133,142,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,1,1
653,Ketamine,0,1,0,8,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,0,-1,0
654,atrophy,7,8,58,65,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,1,1
655,acetylcholine,11,12,82,95,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,0,-1,0
656,prednisolone,10,11,59,71,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,0,-1,0
657,acetylcholine,26,27,162,175,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,0,-1,0
658,prednisolone,18,19,124,136,"With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days.",10910842_3,0,-1,0
659,prednisolone,26,27,160,172,"With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days.",10910842_3,0,-1,0
661,depressed,6,7,29,38,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,1,1
663,prednisolone,8,9,61,73,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,0,-1,0
666,acetylcholine,20,21,129,142,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,0,-1,0
667,Cyclosporine,0,1,0,12,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,0,-1,0
668,thrombotic microangiopathy,3,5,39,65,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,-1,1,1
669,thrombotic microangiopathy,3,5,19,45,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,1,1
671,cyclosporine,13,14,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0,-1,0
672,cyclosporine,7,8,57,69,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0,-1,0
674,tacrolimus,8,9,42,52,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0
675,cyclosporine,23,24,147,159,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0
676,tacrolimus,6,7,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0,-1,0
678,tacrolimus,6,7,40,50,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0,-1,0
681,cyclosporine,16,17,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0
682,tacrolimus,18,19,122,132,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0
684,cyclosporine,21,22,137,149,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0,-1,0
685,tacrolimus,2,3,16,26,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0,-1,0
687,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0
688,tacrolimus,7,8,47,57,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0
691,Apomorphine,0,1,0,11,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,0,-1,0
693,Apomorphine,0,1,0,11,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,0,-1,0
696,apomorphine,24,25,168,179,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,0,-1,0
697,apomorphine,13,14,96,107,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0
698,levodopa,26,27,193,201,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0
699,apomorphine,29,30,211,222,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0
700,apomorphine,2,3,24,35,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,0,-1,0
702,apomorphine,13,14,87,98,Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.,11009181_5,0,-1,0
703,apomorphine,13,14,97,108,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.",11009181_6,0,-1,0
704,dyskinesias,23,24,188,199,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.",11009181_6,-1,1,1
705,apomorphine,6,7,38,49,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,0,-1,0
706,psychiatric,18,19,129,140,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,-1,1,1
707,apomorphine,8,9,52,63,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,0,-1,0
710,pilocarpine,29,30,147,158,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,0,-1,0
711,Scopolamine,0,1,0,11,Scopolamine was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly.,11022397_3,0,-1,0
712,pilocarpine,26,27,130,141,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,0,-1,0
713,scopolamine,9,10,41,52,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,0,-1,0
714,pilocarpine,13,14,84,95,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,0,-1,0
715,pilocarpine,9,10,58,69,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,0,-1,0
716,pilocarpine,2,3,6,17,"Thus, pilocarpine may be useful to assess variations in central cholinergic function in elderly patients.",11022397_17,0,-1,0
717,Pain,0,1,0,4,Pain responses in methadone-maintained opioid abusers.,11027904_0,-1,1,1
718,pain,1,2,10,14,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1
719,pain,21,22,127,131,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1
720,pain,6,7,36,40,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,1,1
721,pain,15,16,88,92,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,1,1
722,pain,11,12,74,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,1,1
723,pain,3,4,20,24,Their complaints of pain should be evaluated seriously and managed aggressively.,11027904_7,-1,1,1
724,ketamine,4,5,32,40,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,0,-1,0
725,cancer,6,7,44,50,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,-1,1,1
726,morphine,9,10,63,71,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,0,-1,0
727,Pain,0,1,0,4,Pain not responsive to morphine is often problematic.,11027905_1,-1,1,1
728,morphine,4,5,23,31,Pain not responsive to morphine is often problematic.,11027905_1,0,-1,0
730,ketamine,15,16,97,105,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,0,-1,0
731,pain,26,27,167,171,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1
732,neuropathic pain,31,33,191,207,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1
733,ketamine,7,8,37,45,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,0,-1,0
734,cancer,19,20,89,95,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,1,1
735,pain,22,23,111,115,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,1,1
736,morphine,26,27,134,142,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,0,-1,0
737,Pain,0,1,0,4,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1
739,confusion,16,17,78,87,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1
740,dry mouth,19,21,93,102,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1
741,Ketamine,0,1,0,8,"Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses.",11027905_5,0,-1,0
742,pain,10,11,61,65,"Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses.",11027905_5,-1,1,1
743,Hallucinations,0,1,0,14,"Hallucinations occurred in 4 patients, and an unpleasant sensation (""empty head"") was also reported by 2 patients.",11027905_7,-1,1,1
744,diazepam,7,8,52,60,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,0,-1,0
745,ketamine,10,11,75,83,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,0,-1,0
746,ketamine,19,20,125,133,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,0,-1,0
747,ketamine,16,17,92,100,A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine.,11027905_10,0,-1,0
748,Ketamine,0,1,0,8,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,0,-1,0
749,morphine,3,4,21,29,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,0,-1,0
750,pain,7,8,53,57,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1
751,neuropathic pain,12,14,77,93,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1
752,ketamine,9,10,58,66,This observation should be tested in studies of prolonged ketamine administration.,11027905_13,0,-1,0
753,methylprednisolone,1,2,10,28,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,0,-1,0
754,methylprednisolone,14,15,77,95,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,0,-1,0
755,myopathy,14,15,86,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,1,1
756,methylprednisolone,17,18,110,128,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,0,-1,0
757,methylprednisolone,3,4,14,32,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0,-1,0
758,steroids,14,15,84,92,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0,-1,0
761,methylprednisolone,34,35,211,229,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,0,-1,0
762,methylprednisolone,14,15,84,102,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0,-1,0
763,myopathy,22,23,156,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,1,1
764,rapamycin,2,3,14,23,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0,-1,0
765,cyclosporine,18,19,103,115,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0
767,tacrolimus,23,24,125,135,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0
769,toxicity,27,28,142,150,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,1,1
770,rapamycin,11,12,72,81,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0,-1,0
775,hepatotoxicity,43,44,207,221,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,1,1
776,nephrotoxicity,10,11,56,70,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,1,1
777,creatinine,18,19,113,123,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,0,-1,0
780,deaths,3,4,14,20,There were no deaths.,11063349_10,-1,1,1
782,vigabatrin,11,12,77,87,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0,-1,0
783,vigabatrin,8,9,45,55,Six of the patients were no longer receiving vigabatrin.,11077455_3,0,-1,0
784,vigabatrin,11,12,75,85,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,0,-1,0
785,vigabatrin,9,10,75,85,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,0,-1,0
787,spasm,6,7,43,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,1,1
788,dobutamine,8,9,56,66,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,0,-1,0
789,Dobutamine,0,1,0,10,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0,-1,0
792,coronary spasm,14,16,78,92,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,1,1
793,dobutamine,19,20,107,117,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,0,-1,0
795,variant angina,14,16,85,99,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,1,1
796,Coronary spasm,0,2,0,14,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,1,1
797,acetylcholine,8,9,57,70,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,0,-1,0
798,dobutamine,5,6,35,45,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0,-1,0
803,dobutamine,4,5,29,39,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0,-1,0
804,coronary spasm,7,9,52,66,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,1,1
807,coronary spasm,18,20,102,116,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,1,1
808,metoprolol,3,4,22,32,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,0,-1,0
809,metoprolol,6,7,48,58,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,0,-1,0
811,metoprolol,8,9,44,54,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0
812,dobutamine,10,11,58,68,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0
813,metoprolol,35,36,244,254,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0
814,dobutamine,4,5,33,43,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,0,-1,0
815,dobutamine,1,2,7,17,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0,-1,0
816,metoprolol,23,24,135,145,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0,-1,0
817,metoprolol,25,26,149,159,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0,-1,0
818,Metoprolol,0,1,0,10,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,0,-1,0
819,Metoprolol,5,6,31,41,"MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control.",11079278_8,0,-1,0
820,Metoprolol,0,1,0,10,Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control.,11079278_9,0,-1,0
821,metoprolol,9,10,63,73,No significant differences were found in any parameter between metoprolol and metoprolol-glucagon.,11079278_11,0,-1,0
822,dobutamine,3,4,19,29,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0,-1,0
823,metoprolol,7,8,46,56,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0,-1,0
825,parkinsonian,27,28,157,169,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,1,1
826,dyskinesias,34,35,203,214,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,1,1
828,levodopa,8,9,68,76,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,0,-1,0
829,levodopa,15,16,115,123,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,0,-1,0
832,parkinsonian,50,51,260,272,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,1,1
833,dyskinesias,19,20,108,119,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,-1,1,1
834,parkinsonian,21,22,123,135,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,-1,1,1
835,levodopa,5,6,37,45,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,0,-1,0
836,parkinsonian,11,12,80,92,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1
838,dyskinesias,27,28,174,185,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1
839,parkinsonian,29,30,190,202,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1
840,parkinsonian,48,49,324,336,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1
841,dyskinesias,54,55,353,364,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1
842,parkinsonism,13,14,62,74,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,1,1
844,parkinsonism,20,21,126,138,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,-1,1,1
845,dyskinesias,22,23,143,154,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,-1,1,1
846,Paclitaxel,0,1,0,10,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0
847,cisplatin,2,3,12,21,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0
848,gemcitabine,5,6,27,38,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0
849,carcinoma,18,19,145,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,1,1
850,carcinoma,16,17,122,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,1,1
852,toxicity,17,18,90,98,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,1,1
853,paclitaxel,20,21,104,114,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0
854,cisplatin,22,23,116,125,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0
855,gemcitabine,25,26,131,142,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0
858,paclitaxel,26,27,175,185,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0
859,cisplatin,41,42,241,250,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0
860,gemcitabine,57,58,310,321,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0
862,toxicity,23,24,187,195,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,1,1
863,toxicity,8,9,44,52,RESULTS: All the patients were examined for toxicity; 34 were examinable for response.,11135224_6,-1,1,1
864,paclitaxel,15,16,76,86,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0
865,cisplatin,25,26,112,121,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0
866,gemcitabine,36,37,152,163,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0
867,neutropenia,7,8,36,47,"World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively.",11135224_10,-1,1,1
868,thrombocytopenia,9,10,52,68,"World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively.",11135224_10,-1,1,1
869,death,4,5,32,37,There was one treatment-related death.,11135224_11,-1,1,1
870,toxicities,1,2,15,25,Nonhematologic toxicities were mild.,11135224_12,-1,1,1
871,paclitaxel,5,6,32,42,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0
872,cisplatin,7,8,44,53,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0
873,gemcitabine,10,11,59,70,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0
875,antidepressants,1,2,13,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,0,-1,0
877,antidepressants,3,4,22,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,0,-1,0
879,incontinence,7,8,46,58,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,-1,1,1
880,venlafaxine,10,11,72,83,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0,-1,0
881,incontinence,12,13,74,86,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,1,1
882,serotonin,17,18,114,123,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0
883,paroxetine,20,21,144,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0
884,sertraline,22,23,159,169,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0
885,venlafaxine,35,36,224,235,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0
887,incontinence,4,5,28,40,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,1,1
888,antidepressants,8,9,67,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,0,-1,0
889,seizures,2,3,22,30,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,-1,1,1
890,seizures,15,16,96,104,Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.,11166519_1,-1,1,1
891,cocaine,22,23,138,145,Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.,11166519_1,0,-1,0
892,Cocaine,0,1,0,7,Cocaine was injected ip over a range of doses (50-100 mg/kg) and behavior was monitored for 20 minutes.,11166519_2,0,-1,0
893,Seizure,0,1,0,7,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,1,1
894,seizure,15,16,94,101,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,1,1
895,seizure,21,22,134,141,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,-1,1,1
896,cocaine,4,5,24,31,"Additionally, levels of cocaine determined in hippocampus and cortex were not different between sensitive and resistant strains.",11166519_7,0,-1,0
897,seizures,15,16,113,121,Additional studies of these murine strains may be useful for investigating genetic influences on cocaine-induced seizures.,11166519_8,-1,1,1
898,seizure,8,9,58,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,1,1
899,cocaine,18,19,109,116,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,0,-1,0
900,amphetamine,20,21,120,131,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,0,-1,0
901,seizure,25,26,162,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,1,1
902,seizure,8,9,63,70,METHODS: This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation.,11185967_2,-1,1,1
903,amphetamine,4,5,22,33,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0,-1,0
904,cocaine,7,8,42,49,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0,-1,0
905,benzoylecgonine,9,10,61,76,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0,-1,0
906,benzoylecgonine,3,4,20,35,Plasma samples with benzoylecgonine greater than 150 ng/mL or an amphetamine greater than 500 ng/mL were defined as positive.,11185967_4,0,-1,0
907,amphetamine,10,11,65,76,Plasma samples with benzoylecgonine greater than 150 ng/mL or an amphetamine greater than 500 ng/mL were defined as positive.,11185967_4,0,-1,0
908,seizure,9,10,68,75,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,1,1
909,seizure,15,16,106,113,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,1,1
910,cocaine,24,25,160,167,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,0,-1,0
911,amphetamine,26,27,171,182,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,0,-1,0
912,benzoylecgonine,23,24,106,121,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,0,-1,0
913,amphetamine,42,43,175,186,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,0,-1,0
914,cocaine,17,18,99,106,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,0,-1,0
915,amphetamine,19,20,110,121,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,0,-1,0
916,cocaine,11,12,68,75,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,0,-1,0
917,seizure,16,17,102,109,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,1,1
923,convulsions,11,12,76,87,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,1,1
925,zonisamide,4,5,28,38,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0,-1,0
926,sodium,8,9,50,56,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0,-1,0
927,weakness,17,18,91,99,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,1,1
929,Hypotension,0,1,0,11,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,1,1
930,angiotensin,12,13,80,91,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,0,-1,0
931,hypertension,18,19,132,144,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,1,1
933,angiotensin,4,5,32,43,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,0,-1,0
935,hypotension,16,17,114,125,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,1,1
936,angiotensin,12,13,78,89,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,0,-1,0
937,hypertension,19,20,130,142,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,1,1
938,hypotension,22,23,157,168,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,1,1
940,hypertension,20,21,137,149,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,1,1
941,seizures,9,10,82,90,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,-1,1,1
942,seizures,21,22,106,114,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,1,1
943,benzodiazepine,16,17,104,118,"injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.",11206082_2,0,-1,0
944,seizures,22,23,181,189,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,1,1
945,diazepam,19,20,114,122,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0,-1,0
946,picrotoxin,21,22,124,134,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0,-1,0
948,nephropathy,12,13,80,91,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,1,1
951,adriamycin,25,26,146,156,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,0,-1,0
953,nephropathy,8,9,57,68,Rats were stratified into control groups and ADR-induced nephropathy groups.,11208990_4,-1,1,1
955,inflammation,21,22,155,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,1,1
956,proteinuria,7,8,45,56,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,1,1
957,phenylephrine,3,4,12,25,In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.,11208990_10,0,-1,0
958,acetylcholine,5,6,30,43,In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.,11208990_10,0,-1,0
959,Sodium,0,1,0,6,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,0,-1,0
960,cardiotoxicity,1,2,8,22,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,1,1
961,doxorubicin,8,9,81,92,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0
962,cyclophosphamide,10,11,97,113,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0
963,doxorubicin,14,15,141,152,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0
964,cyclophosphamide,16,17,157,173,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0
965,breast cancer,25,27,223,236,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,1,1
966,doxorubicin,8,9,60,71,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0,-1,0
967,cyclophosphamide,24,25,148,164,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0,-1,0
969,breast cancer,39,41,298,311,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,1,1
970,doxorubicin,32,33,189,200,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0
971,cyclophosphamide,44,45,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0
973,toxicity,57,58,319,327,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,1,1
974,Cardiotoxicity,0,1,0,14,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,1,1
977,tumor,6,7,45,50,"Antitumor efficacy was assessed by objective tumor response rates (World Health Organization criteria), time to progression, and survival.",11230490_4,-1,1,1
979,cardiotoxicity,21,22,102,116,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,1,1
980,doxorubicin,2,3,18,29,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,0,-1,0
981,neutropenia,7,8,42,53,MC patients also experienced less grade 4 neutropenia.,11230490_7,-1,1,1
984,doxorubicin,8,9,53,64,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0,-1,0
985,cardiotoxicity,12,13,91,105,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,1,1
986,neutropenia,16,17,118,129,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,1,1
987,cyclophosphamide,28,29,204,220,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0,-1,0
988,convulsion,7,8,50,60,The role of nitrergic system in lidocaine-induced convulsion in the mouse.,11243580_0,-1,1,1
990,convulsions,27,28,166,177,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,1,1
991,diazepam,35,36,142,150,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0,-1,0
992,lidocaine,9,10,57,66,"Thirty minutes after these injections, all mice received lidocaine (50 mg/kg, i.p.).",11243580_3,0,-1,0
993,lidocaine,31,32,168,177,"In the second experiment, four groups of mice received similar treatment in the first experiment, and 30 min after these injections, all mice received a higher dose of lidocaine (80 mg/kg).",11243580_4,0,-1,0
994,diazepam,9,10,29,37,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,0,-1,0
995,lidocaine,19,20,89,98,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,0,-1,0
996,convulsions,23,24,118,129,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,-1,1,1
997,lidocaine,10,11,65,74,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,0,-1,0
998,convulsions,16,17,100,111,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,1,1
999,convulsions,12,13,83,94,These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.,11243580_7,-1,1,1
1000,cyclophosphamide,6,7,56,72,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,0,-1,0
1001,tumors,10,11,93,99,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,1,1
1002,anemia,11,12,51,57,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,1,1
1003,cyclophosphamide,25,26,147,163,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0,-1,0
1004,tumors,29,30,186,192,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,1,1
1005,Anemia,0,1,0,6,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,-1,1,1
1006,carboplatin,8,9,42,53,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0,-1,0
1007,anemia,8,9,38,44,"In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c.",11245434_3,-1,1,1
1008,carboplatin,6,7,40,51,three times/week starting 7 days before carboplatin application.,11245434_4,0,-1,0
1009,carboplatin,3,4,16,27,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,0,-1,0
1010,tumors,6,7,39,45,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,-1,1,1
1011,carboplatin,1,2,8,19,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0,-1,0
1012,tumor,6,7,52,57,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,1,1
1014,tumors,1,2,5,11,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,-1,1,1
1015,cyclophosphamide,9,10,47,63,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,0,-1,0
1016,tumors,30,31,156,162,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,-1,1,1
1017,anemia,2,3,7,13,"In the anemia group, the growth delay was significantly shorter compared with nonanemic controls (13.3 days versus 8.6 days).",11245434_8,-1,1,1
1018,anemia,4,5,19,25,"In the group where anemia was prevented by rHuEPO treatment, growth delay was comparable with that of nonanemic controls (13.3 days).",11245434_9,-1,1,1
1019,anemia,5,6,48,54,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,1,1
1020,cyclophosphamide,9,10,79,95,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0,-1,0
1021,tumors,11,12,99,105,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,1,1
1022,anemia,16,17,129,135,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,1,1
1023,oxygen,35,36,235,241,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0,-1,0
1024,tumor,38,39,252,257,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,1,1
1025,vasculitis,5,6,95,105,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,-1,1,1
1026,pericarditis,9,10,126,138,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,-1,1,1
1027,vasculitis,8,9,58,68,OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.,11250767_1,-1,1,1
1028,pericarditis,11,12,86,98,OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.,11250767_1,-1,1,1
1029,hyperthyroidism,12,13,58,73,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,-1,1,1
1030,propylthiouracil,15,16,87,103,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,0,-1,0
1031,pericarditis,21,22,126,138,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,-1,1,1
1032,fever,23,24,140,145,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,-1,1,1
1033,glomerulonephritis,26,27,151,169,"METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.",11250767_2,-1,1,1
1035,pericarditis,16,17,88,100,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,1,1
1036,Propylthiouracil,0,1,0,16,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0,-1,0
1037,prednisone,14,15,85,95,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0,-1,0
1038,pericarditis,8,9,49,61,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,1,1
1039,vasculitis,12,13,89,99,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,1,1
1040,Pericarditis,2,3,12,24,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,1,1
1041,vasculitis,10,11,74,84,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,-1,1,1
1042,anuria,2,3,19,25,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,1,1
1043,losartan,4,5,36,44,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,0,-1,0
1045,hypertensive,7,8,36,48,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,1,1
1048,anuria,23,24,148,154,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,1,1
1049,losartan,25,26,161,169,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,0,-1,0
1052,losartan,5,6,35,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,0,-1,0
1053,losartan,9,10,41,49,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0
1054,anuria,14,15,71,77,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,1,1
1055,furosemide,22,23,122,132,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0
1056,losartan,7,8,28,36,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0,-1,0
1057,anuria,28,29,146,152,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,1,1
1058,hypotension,12,13,71,82,"During these two episodes, his blood pressure diminished but no severe hypotension was noted.",11256525_6,-1,1,1
1061,losartan,9,10,59,67,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0,-1,0
1063,losartan,12,13,81,89,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,0,-1,0
1064,pain,2,3,30,34,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,1,1
1065,pain,1,2,5,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,-1,1,1
1066,pain,9,10,60,64,Treatment strategies depend on the correct diagnosis of the pain.,11263551_2,-1,1,1
1067,pain,4,5,26,30,"Nine patients with severe pain in their feet, which was registered after transplantation, were investigated.",11263551_3,-1,1,1
1068,Pain,0,1,0,4,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1
1071,polyneuropathy,16,17,95,109,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1
1072,osteoporosis,24,25,137,149,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1
1077,tacrolimus,5,6,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0
1079,pain,19,20,127,131,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,1,1
1080,Pain,3,4,34,38,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,1,1
1081,cyclosporine,16,17,91,103,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0
1082,tacrolimus,18,19,107,117,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0
1083,myocarditis,2,3,19,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,1,1
1084,cyclophosphamide,5,6,44,60,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,0,-1,0
1085,myocarditis,1,2,13,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,-1,1,1
1086,cyclophosphamide,9,10,65,81,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,0,-1,0
1087,cardiotoxicity,8,9,66,80,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,-1,1,1
1088,cardiotoxicity,11,12,90,104,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,1,1
1089,cardiotoxicity,1,2,4,18,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,-1,1,1
1090,anthracycline,4,5,35,48,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0,-1,0
1091,cardiac dysfunction,21,23,149,168,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,-1,1,1
1092,cardiotoxicity,25,26,159,173,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,1,1
1102,cardiotoxicity,17,18,118,132,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,-1,1,1
1103,verapamil,2,3,11,20,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,0,-1,0
1106,verapamil,19,20,106,115,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0,-1,0
1107,Diltiazem,0,1,0,9,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,0,-1,0
1108,atropine,11,12,68,76,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,0,-1,0
1109,Verapamil,2,3,9,18,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,0,-1,0
1110,verapamil,23,24,157,166,Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil.,11282081_7,0,-1,0
1111,verapamil,4,5,22,31,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,0,-1,0
1113,Diltiazem,0,1,0,9,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0,-1,0
1114,verapamil,22,23,125,134,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0,-1,0
1115,verapamil,7,8,39,48,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,0,-1,0
1116,verapamil,1,2,8,17,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,0,-1,0
1117,diltiazem,3,4,22,31,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,0,-1,0
1118,verapamil,4,5,34,43,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,0,-1,0
1119,Verapamil,2,3,13,22,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,0,-1,0
1120,diltiazem,25,26,152,161,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,0,-1,0
1121,Calcitonin,0,1,0,10,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,0,-1,0
1122,headache,7,8,67,75,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,-1,1,1
1123,headache,13,14,114,122,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,-1,1,1
1125,headache,11,12,52,60,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,1,1
1126,calcitonin,21,22,116,126,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0,-1,0
1129,headache,13,14,74,82,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,1,1
1130,headache,30,31,174,182,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,1,1
1131,headache,8,9,70,78,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,1,1
1132,headache,20,21,126,134,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,1,1
1135,headache,7,8,54,62,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,1,1
1144,cardiomyopathy,38,39,237,251,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,1,1
1148,ventricular tachycardia,20,22,143,166,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,1,1
1150,depression,4,5,26,36,The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.,11302406_4,-1,1,1
1151,potassium,10,11,77,86,The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.,11302406_4,0,-1,0
1154,ventricular arrhythmias,17,19,122,145,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,1,1
1155,Nephrotoxicity,0,1,0,14,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,-1,1,1
1157,necrosis,5,6,37,45,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,1,1
1160,gentamicin,25,26,171,181,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,0,-1,0
1161,nephrotoxicity,16,17,94,108,Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity.,1130930_2,-1,1,1
1163,necrotic,9,10,58,66,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1
1164,deaths,11,12,72,78,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1
1165,nephrotoxicity,14,15,108,122,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1
1166,toxicity,18,19,148,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1
1167,cardiotoxicity,21,22,181,195,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1
1172,acetaminophen,16,17,95,108,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0,-1,0
1173,nephrotoxicity,18,19,123,137,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,1,1
1174,amiodarone,20,21,139,149,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0,-1,0
1175,toxicity,23,24,169,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,1,1
1176,doxorubicin,26,27,183,194,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0,-1,0
1177,cardiotoxicity,28,29,209,223,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,1,1
1193,death,16,17,74,79,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,1,1
1194,necrosis,20,21,95,103,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,1,1
1200,death,12,13,75,80,"Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.",11334364_14,-1,1,1
1202,vasculitis,2,3,27,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,1,1
1204,Necrotic,0,1,0,8,Necrotic blisters were noted on his fingers.,11337188_2,-1,1,1
1205,vasculitis,7,8,61,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,1,1
1206,corticosteroids,8,9,56,71,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,0,-1,0
1207,rash,1,2,4,8,The rash disappeared after three weeks and renal function returned to normal.,11337188_5,-1,1,1
1208,vasculitis,1,2,17,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,1,1
1210,infections,6,7,50,60,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,1,1
1211,corticosteroids,20,21,133,148,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,0,-1,0
1212,vasculitis,11,12,77,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,1,1
1214,bipolar,3,4,32,39,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,1,1
1216,antidepressants,12,13,80,95,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,0,-1,0
1219,Depression,26,27,169,179,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,1,1
1220,manic,4,5,27,32,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1
1221,bipolar,26,27,149,156,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1
1222,bipolar,29,30,163,170,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1
1223,manic,36,37,195,200,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1
1224,antidepressant,41,42,219,233,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0
1225,antidepressant,48,49,278,292,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0
1226,serotonin,56,57,333,342,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0
1227,lithium,71,72,407,414,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0
1229,manic,45,46,173,178,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,1,1
1230,bipolar,6,7,21,28,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,1,1
1231,bipolar,9,10,35,42,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,1,1
1232,lithium,11,12,68,75,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,0,-1,0
1233,lithium,24,25,122,129,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,0,-1,0
1234,manic,4,5,23,28,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,1,1
1235,antidepressant,10,11,66,80,CONCLUSION: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment.,11379838_9,0,-1,0
1236,lithium,16,17,107,114,CONCLUSION: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment.,11379838_9,0,-1,0
1240,glomerulonephritis,17,18,97,115,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,1,1
1241,thrombotic microangiopathy,14,16,86,112,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1
1244,acute tubular necrosis,25,28,172,194,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1
1248,thrombotic microangiopathy,8,10,51,77,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1
1250,glomerulonephritis,18,19,135,153,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1
1254,proteinuria,13,14,80,91,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,1,1
1261,lithium,12,13,72,79,"It is suggested that these changes represent a specific toxic effect of lithium, reported here for the first time in man.",1141447_3,0,-1,0
1265,caffeine,30,31,214,222,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,0,-1,0
1266,Cocaine,0,1,0,7,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,0,-1,0
1270,"1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine",24,25,192,242,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0,-1,0
1274,dopamine,15,16,104,112,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0,-1,0
1276,convulsions,17,18,116,127,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,1,1
1281,toxicity,34,35,280,288,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,1,1
1282,cocaine,36,37,292,299,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0,-1,0
1283,cocaine,25,26,161,168,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0,-1,0
1284,convulsive,32,33,231,241,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,1,1
1285,cocaine,38,39,279,286,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0,-1,0
1286,interstitial nephritis,2,4,25,47,Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.,11431197_0,-1,1,1
1287,Ranitidine,0,1,0,10,Ranitidine frequently is used for preventing peptic ulceration after renal transplantation.,11431197_1,0,-1,0
1288,interstitial nephritis,8,10,54,76,This drug occasionally has been associated with acute interstitial nephritis in native kidneys.,11431197_2,-1,1,1
1289,interstitial nephritis,7,9,45,67,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,1,1
1290,jaundice,1,2,12,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,1,1
1291,jaundice,7,8,46,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,1,1
1292,cholestasis,8,9,56,67,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,-1,1,1
1293,edema,12,13,81,86,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,-1,1,1
1294,inflammation,19,20,122,134,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,-1,1,1
1295,jaundice,9,10,60,68,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,-1,1,1
1296,jaundice,5,6,23,31,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,1,1
1297,hepatotoxicity,24,25,144,158,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,1,1
1298,Liver disease,0,2,0,13,Liver disease caused by propylthiouracil.,1147734_0,-1,1,1
1299,propylthiouracil,4,5,24,40,Liver disease caused by propylthiouracil.,1147734_0,0,-1,0
1300,hepatitis,23,24,141,150,"This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.",1147734_1,-1,1,1
1301,propylthiouracil,29,30,183,199,"This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.",1147734_1,0,-1,0
1303,toxicity,1,2,9,17,"Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.",11524350_0,-1,1,1
1304,toxicity,4,5,25,33,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,1,1
1305,bupivacaine,6,7,37,48,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0,-1,0
1306,Bupivacaine,0,1,0,11,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0,-1,0
1307,asystole,1,2,5,13,"When asystole was recorded, drug infusion was stopped and a resuscitation sequence was begun.",11524350_6,-1,1,1
1308,Epinephrine,0,1,0,11,Epinephrine 0.01 mg/kg was administered at 1-min intervals while external cardiac compressions were applied.,11524350_7,0,-1,0
1309,seizures,9,10,70,78,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,1,1
1310,bupivacaine,18,19,122,133,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0,-1,0
1311,asystole,9,10,71,79,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,1,1
1312,bupivacaine,26,27,173,184,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0,-1,0
1313,epinephrine,6,7,27,38,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,0,-1,0
1314,toxicity,5,6,30,38,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,1,1
1315,bupivacaine,15,16,106,117,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0
1316,cardiac arrest,25,27,182,196,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,1,1
1317,bupivacaine,38,39,262,273,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0
1318,risperidone,7,8,61,72,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,0,-1,0
1319,risperidone,8,9,50,61,The patient developed RS during dose reduction of risperidone.,11532387_3,0,-1,0
1320,trihexyphenidyl,6,7,42,57,The symptom was treated successfully with trihexyphenidyl anticholinergic therapy.,11532387_4,0,-1,0
1321,risperidone,19,20,127,138,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0,-1,0
1322,serotonin,31,32,222,231,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0,-1,0
1323,cisapride,8,9,68,77,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0
1324,terfenadine,10,11,79,90,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0
1325,terodiline,12,13,95,105,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0
1328,ventricular tachycardia,10,12,49,72,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,1,1
1330,terfenadine,17,18,87,98,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0,-1,0
1331,terodiline,19,20,103,113,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0,-1,0
1334,terfenadine,13,14,78,89,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0
1335,terodiline,15,16,91,101,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0
1336,cisapride,17,18,103,112,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0
1338,terfenadine,10,11,53,64,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0
1339,terodiline,16,17,75,85,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0
1340,cisapride,22,23,95,104,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0
1342,terfenadine,10,11,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0
1343,terodiline,12,13,62,72,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0
1344,cisapride,14,15,74,83,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0
1347,seizures,2,3,23,31,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,1,1
1348,seizure,17,18,107,114,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,1,1
1350,seizures,11,12,81,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,1,1
1352,seizures,22,23,152,160,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,1,1
1353,didanosine,5,6,45,55,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,0,-1,0
1354,hydrocortisone,11,12,84,98,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,0,-1,0
1355,prochlorperazine,14,15,104,120,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,0,-1,0
1356,phenytoin,3,4,26,35,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,0,-1,0
1357,seizures,8,9,55,63,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,1,1
1358,meningitis,5,6,34,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,1,1
1359,seizures,17,18,99,107,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,1,1
1360,alcohol,6,7,29,36,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,0,-1,0
1361,alcohol,9,10,44,51,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,0,-1,0
1362,seizures,18,19,96,104,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,1,1
1363,Didanosine,0,1,0,10,Didanosine also has a potential for inducing seizures.,11573852_6,0,-1,0
1364,seizures,7,8,45,53,Didanosine also has a potential for inducing seizures.,11573852_6,-1,1,1
1365,seizure,7,8,41,48,"However, these other potential causes of seizure were ruled out.",11573852_7,-1,1,1
1367,seizures,14,15,77,85,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,1,1
1370,seizures,12,13,66,74,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,1,1
1371,seizures,7,8,29,37,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,1,1
1373,fentanyl,12,13,77,85,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,0,-1,0
1374,pain,13,14,74,78,"Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit, as well as to facilitate synchrony between ventilator and spontaneous breaths.",11581460_1,-1,1,1
1375,Fentanyl,0,1,0,8,"Fentanyl, an opioid analgesic, is frequently used in the neonatal intensive care unit setting for these very purposes.",11581460_2,0,-1,0
1376,fentanyl,5,6,33,41,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,0,-1,0
1377,rigidity,10,11,76,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1
1378,hypotension,12,13,86,97,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1
1380,bradycardia,18,19,127,138,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,1,1
1381,fentanyl,22,23,148,156,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,0,-1,0
1382,Sirolimus,0,1,0,9,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0,-1,0
1384,cyclosporine,5,6,32,44,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0
1385,tacrolimus,7,8,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0
1386,nephrotoxicity,21,22,145,159,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,-1,1,1
1387,nephrotoxicity,1,2,6,20,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,1,1
1388,nephrotoxicity,22,23,126,140,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,1,1
1389,nephrotoxicity,3,4,18,32,Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases.,11583940_4,-1,1,1
1391,sirolimus,9,10,75,84,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0
1392,rapamycin,11,12,86,95,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0
1393,nephrotoxicity,16,17,106,120,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,1,1
1394,vincristine,9,10,55,66,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,0,-1,0
1395,vincristine,14,15,76,87,"The girl died seven days, the man four weeks after intrathecal injection of vincristine.",11587867_2,0,-1,0
1396,paralysis,18,19,114,123,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,1,1
1398,vincristine,26,27,184,195,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,0,-1,0
1399,vincristine,6,7,46,57,A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended.,11587867_7,0,-1,0
1400,depressed,4,5,25,34,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,-1,1,1
1401,citalopram,7,8,49,59,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0,-1,0
1402,major depression,17,19,97,113,Current estimates suggest that between 0.4% and 8.3% of children and adolescents are affected by major depression.,11642480_1,-1,1,1
1403,citalopram,8,9,49,59,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0,-1,0
1404,major depression,14,16,86,102,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,1,1
1405,citalopram,8,9,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0,-1,0
1406,sulphasalazine,2,3,11,25,The 3-week sulphasalazine syndrome strikes again.,11672959_0,0,-1,0
1407,dermatitis,7,8,48,58,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1
1408,fever,9,10,60,65,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1
1409,lymphadenopathy,11,12,67,82,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1
1410,hepatitis,13,14,87,96,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1
1411,sulphasalazine,25,26,144,158,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,0,-1,0
1412,rheumatoid arthritis,28,30,177,197,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1
1413,hepatitis,6,7,37,46,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,1,1
1414,sepsis,31,32,197,203,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,1,1
1415,necrosis,7,8,66,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,1,1
1417,necrosis,21,22,180,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,1,1
1418,malignancy,27,28,210,220,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,1,1
1419,sulphasalazine,20,21,125,139,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0,-1,0
1420,sulphasalazine,34,35,203,217,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0,-1,0
1421,prochlorperazine,3,4,30,46,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,0,-1,0
1424,prochlorperazine,15,16,96,112,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,0,-1,0
1425,prochlorperazine,8,9,45,61,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,0,-1,0
1426,headache,10,11,66,74,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1
1427,nausea,12,13,76,82,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1
1428,vomiting,15,16,87,95,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1
1429,prochlorperazine,9,10,55,71,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,0,-1,0
1433,agitation,11,12,72,81,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,1,1
1436,headache,3,4,17,25,The intensity of headache and nausea was measured with a 100-mm visual analog scale.,11679859_7,-1,1,1
1437,nausea,5,6,30,36,The intensity of headache and nausea was measured with a 100-mm visual analog scale.,11679859_7,-1,1,1
1438,headache,12,13,73,81,Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea.,11679859_10,-1,1,1
1439,nausea,20,21,102,108,Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea.,11679859_10,-1,1,1
1441,headache,21,22,120,128,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,1,1
1442,nausea,14,15,75,81,The difference in the percentage of patients with a 50% reduction in their nausea was 12.6% (95% CI -4.6% to 29.8%).,11679859_13,-1,1,1
1444,prochlorperazine,12,13,63,79,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,0,-1,0
1445,prochlorperazine,3,4,16,32,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,0,-1,0
1446,headache,8,9,53,61,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,-1,1,1
1447,nausea,10,11,66,72,"The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.",11679859_15,-1,1,1
1448,paracetamol,4,5,31,42,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0,-1,0
1449,paracetamol,8,9,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0
1450,paracetamol,11,12,77,88,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0,-1,0
1451,paracetamol,17,18,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0,-1,0
1452,paracetamol,8,9,72,83,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0,-1,0
1453,paracetamol,14,15,73,84,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0,-1,0
1454,paracetamol,26,27,131,142,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0,-1,0
1455,urticaria,11,12,58,67,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1
1456,angioedema,24,25,147,157,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1
1457,urticaria,31,32,189,198,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,-1,1,1
1458,paracetamol,12,13,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0,-1,0
1459,urticaria,19,20,114,123,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,-1,1,1
1460,angioedema,30,31,170,180,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,-1,1,1
1461,timolol,6,7,44,51,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,0,-1,0
1462,glaucoma,20,21,129,137,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,-1,1,1
1463,glaucoma,14,15,94,102,PURPOSE: Topical beta-blocker treatment is routine therapy in the management of patients with glaucoma.,11704023_1,-1,1,1
1464,timolol,13,14,65,72,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0
1465,timolol,15,16,74,81,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0
1466,timolol,22,23,103,110,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0
1467,timolol,34,35,174,181,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0,-1,0
1468,glaucoma,48,49,256,264,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,-1,1,1
1470,glaucoma,8,9,64,72,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,1,1
1472,timolol,52,53,271,278,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0,-1,0
1473,timolol,64,65,327,334,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0,-1,0
1474,timolol,3,4,14,21,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,0,-1,0
1475,timolol,6,7,35,42,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,0,-1,0
1476,Timolol,0,1,0,7,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0,-1,0
1477,timolol,17,18,113,120,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0,-1,0
1478,timolol,12,13,61,68,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0,-1,0
1479,timolol,20,21,113,120,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0,-1,0
1480,timolol,3,4,18,25,CONCLUSIONS: Both timolol solution and timolol gellan decrease the mean 24-hour heart rate compared with placebo.,11704023_9,0,-1,0
1481,timolol,6,7,39,46,CONCLUSIONS: Both timolol solution and timolol gellan decrease the mean 24-hour heart rate compared with placebo.,11704023_9,0,-1,0
1482,bradycardia,5,6,31,42,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,1,1
1483,glaucoma,19,20,138,146,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,1,1
1484,hemolytic anemia,4,6,44,60,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,1,1
1487,hemolytic anemia,12,14,96,112,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,1,1
1488,ribavirin,14,15,83,92,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,0,-1,0
1489,ribavirin,7,8,43,52,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,0,-1,0
1490,cardiomyopathy,4,5,39,53,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,1,1
1493,cardiomyopathy,10,11,62,76,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,1,1
1496,mitochondrial dysfunction,27,29,148,173,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,1,1
1498,zidovudine,33,34,197,207,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0,-1,0
1499,lamivudine,35,36,209,219,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0,-1,0
1500,indinavir,38,39,225,234,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0,-1,0
1510,cisplatin,5,6,20,29,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0
1511,amifostine,9,10,44,54,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0
1512,breast carcinoma,13,15,71,87,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1
1513,Cisplatin,24,25,153,162,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0
1514,breast carcinoma,38,40,253,269,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1
1515,cisplatin,16,17,76,85,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0,-1,0
1516,cisplatin,8,9,55,64,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0
1517,toxicities,12,13,84,94,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1
1518,cisplatin,15,16,111,120,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0
1519,nephrotoxicity,19,20,128,142,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1
1520,ototoxicity,21,22,144,155,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1
1521,neurotoxicity,24,25,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1
1522,breast carcinoma,34,36,216,232,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1
1523,amifostine,2,3,11,21,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0,-1,0
1524,Amifostine,0,1,0,10,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0
1526,cisplatin,16,17,108,117,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0
1527,cisplatin,3,4,16,25,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0
1528,amifostine,5,6,30,40,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0
1529,nephrotoxicity,15,16,109,123,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1
1530,ototoxicity,17,18,125,136,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1
1531,neuropathy,20,21,142,152,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1
1532,cisplatin,10,11,48,57,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0
1533,amifostine,12,13,63,73,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0
1534,breast carcinoma,20,22,128,144,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,-1,1,1
1535,amifostine,2,3,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0,-1,0
1536,amifostine,4,5,24,34,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0
1537,cisplatin,7,8,45,54,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0
1538,mannitol,3,4,26,34,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0
1539,cisplatin,9,10,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0
1542,toxicity,1,2,11,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,1,1
1543,toxicities,3,4,33,43,Seven different life-threatening toxicities were observed in patients while receiving treatment.,11745184_16,-1,1,1
1544,cisplatin,5,6,32,41,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0
1545,amifostine,7,8,46,56,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0
1546,toxicity,6,7,46,54,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,-1,1,1
1547,amifostine,16,17,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0
1548,cisplatin,18,19,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0
1549,Oral contraceptives,0,2,0,19,Oral contraceptives and the risk of myocardial infarction.,11752354_0,0,-1,0
1551,oral contraceptives,8,10,46,65,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,0,-1,0
1553,desogestrel,17,18,107,118,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0
1554,oral contraceptives,28,30,178,197,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0
1555,estrogen,34,35,211,219,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0
1561,oral contraceptive,38,40,220,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0,-1,0
1562,oral contraceptives,21,23,116,135,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0
1563,oral contraceptives,40,42,227,246,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0
1564,oral contraceptives,4,6,21,40,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0
1566,oral contraceptives,59,61,332,351,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0
1567,oral contraceptives,9,11,56,75,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0
1568,oral contraceptives,26,28,180,199,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0
1570,oral contraceptives,11,13,67,86,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0,-1,0
1571,adenosine,11,12,87,96,Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans.,11752998_0,0,-1,0
1572,adenosine,6,7,47,56,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,0,-1,0
1574,adenosine,35,36,220,229,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,0,-1,0
1575,hypersensitivity,42,43,262,278,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,-1,1,1
1576,adenosine,15,16,83,92,"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.",11752998_2,0,-1,0
1577,hypersensitivity,29,30,182,198,"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.",11752998_2,-1,1,1
1578,adenosine,32,33,214,223,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,0,-1,0
1579,adenosine,46,47,293,302,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,0,-1,0
1580,pain,9,10,67,71,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1
1581,hyperalgesia,21,22,138,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1
1583,capsaicin,26,27,183,192,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,0,-1,0
1584,Adenosine,2,3,9,18,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0
1585,pain,7,8,41,45,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1
1586,hyperalgesia,19,20,125,137,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1
1588,capsaicin,24,25,169,178,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0
1590,adenosine,37,38,239,248,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0
1592,adenosine,9,10,68,77,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,0,-1,0
1593,hypersensitivity,11,12,81,97,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,-1,1,1
1594,capsaicin,22,23,168,177,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,0,-1,0
1595,neuropathic pain,15,17,105,121,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,1,1
1596,adenosine,25,26,163,172,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,0,-1,0
1599,tacrolimus,7,8,56,66,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0,-1,0
1600,nephrotoxic,13,14,88,99,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,1,1
1603,chronic renal failure,11,14,74,95,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,1,1
1608,creatinine,20,21,95,105,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0,-1,0
1612,renal dysfunction,12,14,57,74,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,1,1
1616,creatinine,13,14,84,94,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0
1618,creatinine,42,43,271,281,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0
1619,creatinine,16,17,135,145,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,0,-1,0
1630,creatinine,11,12,70,80,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,0,-1,0
1632,creatinine,6,7,30,40,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,0,-1,0
1642,convulsive,8,9,45,55,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,1,1
1645,convulsive,14,15,98,108,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,1,1
1646,seizures,4,5,20,28,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,1,1
1649,seizures,9,10,56,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,1,1
1651,convulsive,33,34,188,198,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,1,1
1653,convulsive,6,7,44,54,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,1,1
1655,thrombocytopenia,2,3,30,46,Delayed-onset heparin-induced thrombocytopenia.,11827497_0,-1,1,1
1656,thrombocytopenia,3,4,28,44,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,1,1
1657,heparin,10,11,73,80,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,0,-1,0
1658,thrombocytopenia,6,7,53,69,Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.,11827497_2,-1,1,1
1659,thrombocytopenia,19,20,125,141,OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.,11827497_3,-1,1,1
1660,thrombocytopenia,12,13,72,88,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,1,1
1661,thromboembolic,19,20,134,148,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,1,1
1663,heparin,10,11,69,76,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,0,-1,0
1664,thrombocytopenia,19,20,110,126,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,1,1
1665,thromboembolic,35,36,192,206,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,1,1
1666,heparin,7,8,49,56,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,0,-1,0
1667,heparin,41,42,217,224,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,0,-1,0
1668,warfarin,29,30,163,171,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0,-1,0
1669,thrombocytopenia,4,5,43,59,CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized.,11827497_15,-1,1,1
1670,thrombocytopenia,9,10,71,87,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,1,1
1671,heparin,25,26,204,211,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,0,-1,0
1672,hyperprolactinemia,3,4,33,51,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,1,1
1674,Risperidone,2,3,12,23,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0,-1,0
1675,hyperprolactinemia,20,21,123,141,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,-1,1,1
1676,hyperprolactinemia,14,15,102,120,These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.,11838826_3,-1,1,1
1677,hyperprolactinemia,7,8,58,76,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,1,1
1678,hyperprolactinemia,13,14,92,110,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,1,1
1681,risperidone,21,22,110,121,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,-1,0
1682,hyperprolactinemia,11,12,80,98,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,1,1
1683,hepatitis,2,3,18,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,1,1
1684,isoflurane,6,7,46,56,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,0,-1,0
1685,hepatitis,9,10,49,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,1,1
1686,isoflurane,16,17,109,119,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,0,-1,0
1687,hepatitis,12,13,80,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,1,1
1688,hepatitis,13,14,68,77,"There was no evidence for viral, autoimmune, or metabolic causes of hepatitis.",11847945_3,-1,1,1
1689,alanine,1,2,4,11,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0
1690,bilirubin,15,16,92,101,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0,-1,0
1692,Isoflurane,2,3,13,23,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,0,-1,0
1693,hepatitis,13,14,81,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,1,1
1695,metoclopramide,5,6,30,44,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0,-1,0
1698,metoclopramide,6,7,39,53,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0
1699,procainamide,29,30,179,191,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0
1701,metoclopramide,24,25,162,176,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,0,-1,0
1703,cisapride,8,9,52,61,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,0,-1,0
1704,metoclopramide,6,7,37,51,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,0,-1,0
1706,Metoclopramide,0,1,0,14,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,0,-1,0
1708,Dopamine,0,1,0,8,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0,-1,0
1709,death,7,8,54,59,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,-1,1,1
1710,Dopamine,0,1,0,8,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,0,-1,0
1713,death,5,6,40,45,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,1,1
1714,seizures,15,16,94,102,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,1,1
1716,death,20,21,116,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,1,1
1717,seizures,6,7,34,42,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1
1718,neurotoxicity,8,9,47,60,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1
1719,pilocarpine,18,19,114,125,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,0,-1,0
1721,glutamate,17,18,89,98,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,0,-1,0
1722,seizures,6,7,34,42,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1
1723,neurotoxicity,22,23,129,142,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1
1724,seizures,3,4,29,37,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,1,1
1725,death,10,11,75,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,1,1
1726,seizures,10,11,50,58,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,-1,1,1
1727,glutamate,14,15,75,84,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,0,-1,0
1728,acetylcholine,16,17,89,102,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,0,-1,0
1729,Steroid,0,1,0,7,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,0,-1,0
1730,steroid,6,7,39,46,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,0,-1,0
1731,amnesia,20,21,135,142,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,1,1
1732,scopolamine,12,13,57,68,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,0,-1,0
1733,scopolamine,19,20,125,136,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0,-1,0
1735,amnesia,26,27,184,191,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,1,1
1736,steroids,15,16,111,119,These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.,11860495_11,0,-1,0
1738,cardiotoxicity,10,11,63,77,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,1,1
1739,doxorubicin,12,13,81,92,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0,-1,0
1741,anthracycline,21,22,124,137,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0,-1,0
1742,cardiotoxicity,14,15,84,98,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,-1,1,1
1743,cardiac dysfunction,32,34,200,219,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,1,1
1747,depressed,11,12,83,92,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,1,1
1748,cardiac dysfunction,6,8,45,64,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,1,1
1751,cardiotoxicity,7,8,41,55,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,1,1
1755,cancer,15,16,95,101,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,1,1
1756,Nephrotoxicity,18,19,122,136,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,1,1
1759,toxicity,4,5,36,44,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,1,1
1760,potassium,12,13,86,95,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,0,-1,0
1762,Potassium,25,26,164,173,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,0,-1,0
1763,toxicity,31,32,213,221,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,1,1
1765,spironolactone,43,44,279,293,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,0,-1,0
1766,potassium,46,47,304,313,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,0,-1,0
1770,spironolactone,23,24,144,158,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,0,-1,0
1771,infection,35,36,223,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,1,1
1773,spironolactone,7,8,48,62,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,0,-1,0
1774,potassium,12,13,95,104,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,0,-1,0
1777,spironolactone,5,6,33,47,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,0,-1,0
1778,potassium,9,10,76,85,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,0,-1,0
1779,potassium,15,16,127,136,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,0,-1,0
1780,potassium,3,4,18,27,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,0,-1,0
1782,spironolactone,13,14,89,103,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,0,-1,0
1784,spironolactone,6,7,35,49,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,0,-1,0
1785,potassium,9,10,61,70,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,0,-1,0
1786,potassium,17,18,128,137,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,0,-1,0
1788,exencephaly,3,4,27,38,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1
1789,exencephaly,22,23,164,175,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1
1790,anencephaly,24,25,179,190,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1
1791,Anencephaly,0,1,0,11,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,-1,1,1
1792,exencephaly,7,8,47,58,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,-1,1,1
1793,exencephaly,3,4,16,27,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,-1,1,1
1794,5-azacytidine,6,7,39,52,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0,-1,0
1795,exencephaly,7,8,50,61,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,-1,1,1
1796,anencephaly,9,10,65,76,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,-1,1,1
1797,exencephalic,7,8,28,40,"However, in many cases, the exencephalic brain tissue was preserved with more or less reduction during this period.",11875660_5,-1,1,1
1798,exencephaly,9,10,58,69,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1
1799,exencephalic,16,17,95,107,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1
1800,exencephalic,7,8,40,52,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,1,1
1801,anencephaly,18,19,108,119,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,1,1
1802,exencephalic,29,30,174,186,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,1,1
1803,exencephaly,6,7,52,63,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1
1804,exencephalic,23,24,160,172,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1
1805,exencephalic,35,36,227,239,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1
1806,exencephalic,15,16,102,114,"From observations of the vasculature, altered distribution patterns of vessels were identified in the exencephalic head.",11875660_9,-1,1,1
1807,exencephalic,7,8,46,58,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1
1808,exencephalic,29,30,212,224,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1
1809,exencephaly,43,44,308,319,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1
1810,anencephaly,45,46,323,334,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1
1812,6-hydroxydopamine,12,13,82,99,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,0,-1,0
1813,dopamine,2,3,17,25,Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats.,11890511_5,0,-1,0
1818,acute myocardial infarction,10,13,82,109,Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction.,11897407_1,-1,1,1
1819,infarction,6,7,33,43,The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.,11897407_2,-1,1,1
1820,isoproterenol,18,19,119,132,The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.,11897407_2,0,-1,0
1823,acute myocardial infarction,21,24,130,157,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,1,1
1825,isoproterenol,12,13,80,93,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,0,-1,0
1828,Nicotine,0,1,0,8,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,0,-1,0
1829,catalepsy,4,5,42,51,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,-1,1,1
1830,nicotine,7,8,33,41,"In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.",11900788_1,0,-1,0
1831,catalepsy,9,10,45,54,"In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.",11900788_1,-1,1,1
1832,morphine,12,13,66,74,"In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.",11900788_1,0,-1,0
1833,Morphine,0,1,0,8,Morphine but not nicotine induced a dose-dependent catalepsy.,11900788_2,0,-1,0
1834,nicotine,3,4,17,25,Morphine but not nicotine induced a dose-dependent catalepsy.,11900788_2,0,-1,0
1835,catalepsy,7,8,51,60,Morphine but not nicotine induced a dose-dependent catalepsy.,11900788_2,-1,1,1
1836,morphine,3,4,16,24,The response of morphine was potentiated by nicotine.,11900788_3,0,-1,0
1837,nicotine,7,8,44,52,The response of morphine was potentiated by nicotine.,11900788_3,0,-1,0
1838,atropine,3,4,34,42,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0
1839,naloxone,5,6,44,52,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0
1840,hexamethonium,10,11,72,85,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0
1841,catalepsy,14,15,102,111,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,1,1
1842,morphine,20,21,140,148,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0
1843,nicotine,22,23,154,162,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0
1844,atropine,3,4,37,45,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0
1845,hexamethonium,5,6,47,60,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0
1846,naloxone,8,9,66,74,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0
1847,catalepsy,11,12,90,99,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,-1,1,1
1848,morphine,14,15,111,119,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0
1849,nicotine,16,17,125,133,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0
1850,atropine,3,4,34,42,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0
1851,hexamethonium,12,13,108,121,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0
1852,morphine,22,23,164,172,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0
1854,morphine,19,20,118,126,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,0,-1,0
1855,nicotine,22,23,138,146,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,0,-1,0
1856,dyskinesias,4,5,36,47,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,1,1
1859,levodopa,18,19,113,121,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,0,-1,0
1860,dyskinesias,24,25,164,175,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,1,1
1865,dyskinesias,24,25,124,135,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,1,1
1869,dyskinesia,13,14,67,77,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,1,1
1870,levodopa,26,27,143,151,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,0,-1,0
1875,levodopa,21,22,123,131,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,0,-1,0
1882,dyskinesias,3,4,22,33,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,1,1
1884,dyskinesias,11,12,69,80,A close relationship was seen between the overshooting of forces and dyskinesias in the ON-drug condition.,11912119_12,-1,1,1
1886,Bupropion,0,1,0,9,Bupropion (Zyban) toxicity.,11928786_0,0,-1,0
1887,toxicity,4,5,18,26,Bupropion (Zyban) toxicity.,11928786_0,-1,1,1
1888,Bupropion,0,1,0,9,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0
1889,antidepressant,4,5,26,40,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0
1890,amphetamine,8,9,65,76,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0
1891,bupropion,6,7,42,51,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0,-1,0
1892,smoking,17,18,106,113,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0,-1,0
1893,overdose,11,12,52,60,"In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre.",11928786_3,-1,1,1
1894,toxicity,5,6,33,41,8 patients developed symptoms of toxicity.,11928786_4,-1,1,1
1895,tachycardia,3,4,25,36,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,1,1
1896,hallucinations,7,8,50,64,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,1,1
1897,convulsions,9,10,69,80,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,1,1
1898,cardiac arrhythmias,4,6,30,49,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,-1,1,1
1899,cardiac arrest,15,17,106,120,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,-1,1,1
1900,bupropion,30,31,165,174,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0,-1,0
1901,seizures,1,2,10,18,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,-1,1,1
1902,diazepam,5,6,37,45,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,0,-1,0
1903,tachycardia,9,10,64,75,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,-1,1,1
1904,adenosine,14,15,106,115,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,0,-1,0
1905,toxicity,6,7,57,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,1,1
1906,overdose,8,9,69,77,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,1,1
1907,smoking,12,13,74,81,The potential toxic effects should be considered when prescribing it as a smoking cessation aid.,11928786_11,0,-1,0
1913,proteinuria,32,33,123,134,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,1,1
1914,proteinuria,49,50,212,223,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,1,1
1915,glomerulosclerosis,52,53,240,258,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,1,1
1921,reserpine,24,25,157,166,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0,-1,0
1924,Reserpine,0,1,0,9,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,0,-1,0
1925,dyskinesia,19,20,99,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,1,1
1927,Reserpine,0,1,0,9,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,0,-1,0
1928,tremor,3,4,24,30,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,1,1
1929,catalepsy,5,6,35,44,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,1,1
1932,catalepsy,23,24,133,142,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,1,1
1933,reserpine,26,27,154,163,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,0,-1,0
1935,tremor,9,10,61,67,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,1,1
1936,Reserpine,0,1,0,9,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0,-1,0
1937,dyskinesia,31,32,150,160,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,1,1
1938,reserpine,5,6,19,28,"On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.",11999899_8,0,-1,0
1939,tremor,9,10,50,56,"On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.",11999899_8,-1,1,1
1940,catalepsy,11,12,61,70,"On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.",11999899_8,-1,1,1
1942,catalepsy,8,9,49,58,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,1,1
1943,tremor,10,11,63,69,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,1,1
1944,reserpine,13,14,81,90,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,0,-1,0
1945,reserpine,2,3,18,27,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0,-1,0
1947,tremor,28,29,166,172,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,1,1
1948,catalepsy,30,31,177,186,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,1,1
1950,reserpine,48,49,272,281,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0,-1,0
1951,reserpine,4,5,24,33,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,0,-1,0
1953,catalepsy,20,21,124,133,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,1,1
1954,tremor,22,23,138,144,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,1,1
1955,schizophrenic,7,8,64,77,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,1,1
1956,schizophrenic,1,2,4,17,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,1,1
1959,risperidone,26,27,162,173,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,0,-1,0
1960,risperidone,17,18,125,136,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,0,-1,0
1961,Risperidone,0,1,0,11,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,0,-1,0
1962,risperidone,21,22,130,141,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,0,-1,0
1963,aplastic anemia,7,9,67,82,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,1,1
1964,aplastic anemia,8,10,58,73,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,1,1
1965,aplastic anemia,11,13,86,101,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,1,1
1966,nephrolithiasis,1,2,19,34,Topiramate-induced nephrolithiasis.,12042105_0,-1,1,1
1967,seizures,20,21,147,155,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,1,1
1968,metabolic acidosis,9,11,58,76,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,-1,1,1
1970,nephrolithiasis,8,9,52,67,We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.,12042105_4,-1,1,1
1971,morphine,2,3,22,30,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,0,-1,0
1972,constipation,6,7,55,67,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,1,1
1973,morphine,0,1,0,8,morphine with 177.8 mg/kg s.c.,12063090_2,0,-1,0
1974,morphine,3,4,31,39,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,0,-1,0
1975,morphine,3,4,26,34,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,0,-1,0
1976,naloxone,12,13,87,95,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,0,-1,0
1977,morphine,4,5,23,31,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,0,-1,0
1978,morphine,10,11,73,81,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,0,-1,0
1979,constipation,25,26,181,193,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,1,1
1980,morphine,7,8,54,62,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,0,-1,0
1983,asterixis,4,5,42,51,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,1,1
1984,ifosfamide,7,8,46,56,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0,-1,0
1985,myoclonus,14,15,79,88,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,1,1
1986,ifosfamide,25,26,146,156,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0,-1,0
1987,encephalopathy,15,16,134,148,"An electroencephalogram showed continuous, generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy.",12084448_5,-1,1,1
1988,ifosfamide,3,4,22,32,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,0,-1,0
1990,asterixis,11,12,70,79,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,1,1
1991,asterixis,8,9,42,51,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,1,1
1992,ifosfamide,12,13,71,81,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,0,-1,0
1993,myoclonus,34,35,225,234,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,1,1
1994,anemia,10,11,88,94,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,12090760_0,-1,1,1
1995,Azidothymidine,0,1,0,14,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0,-1,0
1996,anemia,2,3,29,35,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,-1,1,1
1997,Ketamine,0,1,0,8,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,0,-1,0
1998,ketamine,18,19,129,137,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,0,-1,0
1999,diazepam,3,4,25,33,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0
2000,glycopyrrolate,5,6,35,49,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0
2001,ketamine,16,17,110,118,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0
2002,ketamine,27,28,165,173,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0
2003,Diazepam,0,1,0,8,"Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.",12091028_4,0,-1,0
2004,ketamine,14,15,92,100,"Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.",12091028_4,0,-1,0
2005,hallucinations,31,32,215,229,"Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.",12091028_4,-1,1,1
2007,glycopyrrolate,13,14,73,87,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0,-1,0
2008,ribavirin,1,2,12,21,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,0,-1,0
2010,ribavirin,5,6,40,49,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,0,-1,0
2011,Ribavirin,0,1,0,9,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,0,-1,0
2012,Ribavirin,0,1,0,9,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,0,-1,0
2013,infection,13,14,87,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,1,1
2015,ribavirin,26,27,174,183,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,0,-1,0
2016,infection,33,34,215,224,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,1,1
2018,ribavirin,7,8,46,55,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,0,-1,0
2019,anemia,11,12,75,81,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,-1,1,1
2020,infection,7,8,42,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,1,1
2021,nephrotoxicity,21,22,122,136,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,1,1
2022,ribavirin,8,9,53,62,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,0,-1,0
2023,ribavirin,14,15,103,112,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,0,-1,0
2026,ribavirin,1,2,12,21,Intravenous ribavirin was administered on a compassionate-use protocol.,12093990_16,0,-1,0
2028,ribavirin,1,2,12,21,Intravenous ribavirin therapy was well tolerated.,12093990_19,0,-1,0
2030,neutropenia,13,14,78,89,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,1,1
2031,ribavirin,2,3,21,30,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,0,-1,0
2032,infection,36,37,206,215,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,1,1
2033,ribavirin,13,14,87,96,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,0,-1,0
2034,infection,23,24,147,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,1,1
2035,ribavirin,31,32,214,223,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,0,-1,0
2036,cardiac arrest,2,4,18,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,1,1
2038,calcium,13,14,100,107,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,0,-1,0
2039,overdose,8,9,31,39,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,1,1
2040,diltiazem,15,16,63,72,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0
2041,paracetamol,17,18,74,85,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0
2042,aspirin,19,20,87,94,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0
2043,alcohol,25,26,120,127,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0
2044,hypotension,10,11,61,72,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,1,1
2045,overdose,4,5,25,33,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,-1,1,1
2046,seizures,10,11,70,78,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,-1,1,1
2047,bradycardia,6,7,50,61,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,1,1
2048,calcium,11,12,56,63,He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).,12101159_5,0,-1,0
2049,adrenaline,13,14,68,78,He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).,12101159_5,0,-1,0
2050,epinephrine,15,16,80,91,He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).,12101159_5,0,-1,0
2051,calcium,12,13,72,79,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,0,-1,0
2053,asystole,24,25,149,157,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,1,1
2054,cardiac arrest,8,10,42,56,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,1,1
2056,toxicity,8,9,51,59,The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered.,12101159_9,-1,1,1
2057,heparin,1,2,21,28,Low-molecular-weight heparin for the treatment of patients with mechanical heart valves.,12109865_0,0,-1,0
2058,heparin,1,2,15,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,0,-1,0
2059,heparin,1,2,21,28,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,0,-1,0
2060,thromboembolic,4,5,22,36,Data to establish the thromboembolic risk were incomplete.,12109865_8,-1,1,1
2061,hemorrhage,36,37,134,144,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,1,1
2062,Cardiac arrest,0,2,0,14,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1
2063,metoclopramide,4,5,33,47,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0
2064,metoclopramide,13,14,88,102,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0
2065,cardiac arrest,18,20,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1
2066,metoclopramide,8,9,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0,-1,0
2067,asystole,13,14,96,104,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,-1,1,1
2068,metoclopramide,3,4,21,35,The patient received metoclopramide 10 mg i.v.,12139551_2,0,-1,0
2070,metoclopramide,23,24,146,160,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,0,-1,0
2071,asystole,32,33,200,208,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,-1,1,1
2073,atropine,3,4,21,29,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,0,-1,0
2074,cardiac arrest,6,8,33,47,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,-1,1,1
2075,metoclopramide,10,11,58,72,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,0,-1,0
2076,dopamine,13,14,81,89,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,0,-1,0
2079,tumor,20,21,110,115,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,1,1
2080,theophylline,34,35,195,207,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0,-1,0
2083,theophylline,9,10,58,70,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0,-1,0
2086,tumor,35,36,216,221,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,1,1
2087,theophylline,19,20,136,148,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,0,-1,0
2088,theophylline,2,3,16,28,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,0,-1,0
2089,acetylcholine,4,5,37,50,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,0,-1,0
2091,alcohol,31,32,221,228,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,0,-1,0
2092,alcohol,10,11,75,82,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,0,-1,0
2093,ethanol,20,21,140,147,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,0,-1,0
2094,nicotine,3,4,26,34,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0
2095,carbachol,5,6,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0
2096,tremor,21,22,122,128,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,1,1
2097,acetylcholine,9,10,69,82,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,0,-1,0
2099,Potassium,0,1,0,9,"Potassium was applied by reverse dialysis twice, separated by 75 min.",12198388_6,0,-1,0
2101,convulsions,9,10,70,81,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,1,1
2102,convulsion,5,6,32,42,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,1,1
2103,nicotine,9,10,64,72,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0,-1,0
2104,carbachol,11,12,74,83,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0,-1,0
2110,convulsions,9,10,70,81,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,1,1
2112,ethanol,20,21,155,162,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,0,-1,0
2113,alcohol,28,29,223,230,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,0,-1,0
2114,pain,2,3,25,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,1,1
2115,pain,16,17,118,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,1,1
2116,Capsaicin,0,1,0,9,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,0,-1,0
2117,pain,14,15,71,75,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,-1,1,1
2118,pain,27,28,176,180,"Short-latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before, during, and after the pain.",12202650_4,-1,1,1
2119,pain,8,9,64,68,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,1,1
2120,pain,9,10,66,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,-1,1,1
2121,glutamate,22,23,120,129,"The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors.",12231232_0,0,-1,0
2122,Haloperidol,0,1,0,11,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,0,-1,0
2126,locomotor hyperactivity,15,17,104,127,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,-1,1,1
2127,locomotor hyperactivity,30,32,171,194,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,-1,1,1
2128,cocaine,34,35,206,213,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,0,-1,0
2132,cocaine,1,2,9,16,Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats.,12369736_4,0,-1,0
2134,cocaine,14,15,75,82,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,0,-1,0
2135,locomotor hyperactivity,20,22,140,163,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,1,1
2137,cocaine,13,14,65,72,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,0,-1,0
2139,cocaine,28,29,139,146,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,0,-1,0
2141,cocaine,4,5,27,34,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0,-1,0
2143,Cocaine,0,1,0,7,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,0,-1,0
2145,cocaine,16,17,88,95,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,0,-1,0
2146,cocaine,14,15,89,96,The emergency nurse ought to be familiar with some of the cardiovascular consequences of cocaine use.,12443032_1,0,-1,0
2147,cocaine,6,7,31,38,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,0,-1,0
2151,cocaine,7,8,39,46,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,0,-1,0
2152,cocaine,10,11,59,66,"Finally, moral issues relating to the testing of potential cocaine users will be addressed.",12443032_4,0,-1,0
2153,thalidomide,5,6,20,31,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,0,-1,0
2154,thalidomide,5,6,20,31,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,0,-1,0
2155,carcinoma,11,12,66,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,1,1
2156,toxicity,5,6,28,36,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,1,1
2157,thalidomide,9,10,53,64,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0,-1,0
2158,cancer,17,18,113,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,1,1
2160,thalidomide,12,13,62,73,PATIENTS AND METHODS: 29 patients were enrolled on a study of thalidomide using an intra-patient dose escalation schedule.,12448656_2,0,-1,0
2161,thalidomide,2,3,15,26,Patients began thalidomide at 400 mg/d and escalated as tolerated to 1200 mg/d by day 54.,12448656_3,0,-1,0
2162,Somnolence,0,1,0,10,Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.,12448656_7,-1,1,1
2163,constipation,2,3,15,27,Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.,12448656_7,-1,1,1
2164,toxicities,5,6,43,53,Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.,12448656_7,-1,1,1
2165,thalidomide,13,14,73,84,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,0,-1,0
2166,carcinoma,17,18,99,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,1,1
2167,thalidomide,8,9,43,54,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,0,-1,0
2168,carcinoma,12,13,70,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,1,1
2169,lidocaine,1,2,4,13,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,0,-1,0
2170,succinylcholine,3,4,21,36,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,0,-1,0
2172,lidocaine,15,16,120,129,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,0,-1,0
2173,myalgia,21,22,183,190,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,-1,1,1
2174,succinylcholine,11,12,56,71,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0,-1,0
2175,lidocaine,21,22,99,108,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0,-1,0
2176,succinylcholine,28,29,129,144,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0,-1,0
2177,Morphine,0,1,0,8,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,0,-1,0
2178,succinylcholine,12,13,67,82,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,0,-1,0
2179,fasciculation,12,13,70,83,"Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.",12452237_5,-1,1,1
2180,myalgia,5,6,29,36,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,1,1
2181,fasciculation,5,6,33,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,1,1
2182,fasciculation,24,25,136,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,1,1
2184,myalgia,7,8,26,33,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,1,1
2185,myalgia,9,10,53,60,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,1,1
2186,fasciculation,15,16,90,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,1,1
2187,succinylcholine,4,5,21,36,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,0,-1,0
2188,lidocaine,8,9,46,55,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,0,-1,0
2189,myalgia,22,23,137,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,1,1
2190,rizatriptan,7,8,52,63,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0,-1,0
2191,migraine,13,14,100,108,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,1,1
2192,Rizatriptan,0,1,0,11,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0,-1,0
2193,migraine,22,23,135,143,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,-1,1,1
2194,rizatriptan,12,13,87,98,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0,-1,0
2195,ergotamine,18,19,117,127,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0,-1,0
2196,migraine,30,31,191,199,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,1,1
2197,rizatriptan,16,17,79,90,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,0,-1,0
2198,headache,3,4,17,25,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,-1,1,1
2199,rizatriptan,19,20,110,121,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,0,-1,0
2200,pain,5,6,33,37,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,1,1
2202,rizatriptan,15,16,71,82,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,0,-1,0
2203,pain,5,6,36,40,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,1,1
2205,rizatriptan,10,11,56,67,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0,-1,0
2206,rizatriptan,27,28,140,151,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0,-1,0
2208,Headache,0,1,0,8,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,1,1
2210,rizatriptan,9,10,37,48,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0,-1,0
2211,rizatriptan,24,25,106,117,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0,-1,0
2212,rizatriptan,6,7,30,41,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,0,-1,0
2213,pain,8,9,47,51,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,1,1
2216,Rizatriptan,0,1,0,11,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,0,-1,0
2217,nausea,13,14,92,98,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,1,1
2218,vomiting,15,16,100,108,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,1,1
2221,rizatriptan,16,17,85,96,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,0,-1,0
2223,rizatriptan,6,7,33,44,Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine.,12464714_11,0,-1,0
2224,rizatriptan,17,18,72,83,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,0,-1,0
2225,dizziness,24,25,128,137,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,-1,1,1
2226,nausea,32,33,154,160,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,-1,1,1
2227,somnolence,40,41,180,190,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,-1,1,1
2228,sodium,1,2,8,14,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0,-1,0
2229,seizures,15,16,108,116,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,-1,1,1
2231,Sodium,0,1,0,6,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,0,-1,0
2234,sodium,20,21,124,130,The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.,12481039_4,0,-1,0
2236,seizures,7,8,54,62,"beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.",12481039_7,-1,1,1
2237,seizures,18,19,134,142,"beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.",12481039_7,-1,1,1
2239,toxicity,4,5,26,34,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,1,1
2240,carboplatin,9,10,67,78,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,0,-1,0
2241,Glioblastoma,2,3,12,24,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,1,1
2242,tumor,6,7,40,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,1,1
2243,glioblastoma,4,5,25,37,"Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.",12483326_3,-1,1,1
2244,carboplatin,2,3,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0
2245,cisplatin,11,12,64,73,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0
2246,toxicity,17,18,100,108,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,-1,1,1
2247,toxicity,11,12,60,68,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,-1,1,1
2248,carboplatin,16,17,101,112,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0,-1,0
2249,carboplatin,10,11,62,73,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,0,-1,0
2250,pain,3,4,17,21,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,1,1
2253,corticosteroids,9,10,59,74,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,0,-1,0
2254,glaucoma,10,11,84,92,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,1,1
2258,atrophy,8,9,46,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,1,1
2260,carboplatin,7,8,54,65,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0,-1,0
2261,toxicity,18,19,119,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,-1,1,1
2262,Visual hallucinations,0,2,0,21,Visual hallucinations associated with zonisamide.,12523465_0,-1,1,1
2263,zonisamide,4,5,38,48,Visual hallucinations associated with zonisamide.,12523465_0,0,-1,0
2264,Zonisamide,0,1,0,10,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0,-1,0
2265,seizures,12,13,81,89,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,-1,1,1
2266,visual hallucinations,1,3,9,30,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1
2267,visual hallucinations,22,24,141,162,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1
2268,zonisamide,29,30,195,205,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,0,-1,0
2269,epilepsy,7,8,42,50,"All three had been diagnosed earlier with epilepsy, and their electroencephalogram (EEG) findings were abnormal.",12523465_3,-1,1,1
2270,visual hallucinations,3,5,19,40,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,-1,1,1
2271,visual hallucinations,6,8,37,58,None of the patients had experienced visual hallucinations before this event.,12523465_5,-1,1,1
2272,zonisamide,14,15,86,96,The only recent change in their treatment was the introduction or increased dosage of zonisamide.,12523465_6,0,-1,0
2273,zonisamide,14,15,86,96,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,0,-1,0
2274,seizures,5,6,45,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,1,1
2275,epilepsy,9,10,56,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,1,1
2276,carbamazepine,13,14,89,102,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0
2277,vigabatrin,15,16,107,117,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0
2278,seizure,12,13,80,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,1,1
2279,epilepsy,17,18,141,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,1,1
2280,seizure,5,6,37,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,1,1
2281,seizure,22,23,144,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,1,1
2282,seizure,13,14,100,107,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,1,1
2283,seizure,17,18,129,136,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,1,1
2284,epilepsy,7,8,53,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,1,1
2285,epilepsy,20,21,134,142,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,1,1
2286,seizures,25,26,176,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,1,1
2287,Acute liver failure,0,3,0,19,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,-1,1,1
2288,bupropion,5,6,36,45,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0,-1,0
2289,carbimazole,7,8,50,61,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0,-1,0
2291,bupropion,16,17,94,103,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0,-1,0
2292,carbimazole,18,19,108,119,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0,-1,0
2293,hyperthyroidism,11,12,58,73,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,-1,1,1
2294,carbimazole,16,17,96,107,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0
2295,propranolol,18,19,112,123,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0
2296,bupropion,6,7,31,40,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0,-1,0
2297,smoking,11,12,55,62,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0,-1,0
2298,acute liver failure,2,5,13,32,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,1,1
2299,liver injury,8,10,63,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,1,1
2300,sepsis,6,7,41,47,His condition was further complicated by sepsis and coagulopathy.,12549952_6,-1,1,1
2301,coagulopathy,8,9,52,64,His condition was further complicated by sepsis and coagulopathy.,12549952_6,-1,1,1
2302,Death,0,1,0,5,Death resulted 19 days after the onset of symptoms.,12549952_7,-1,1,1
2303,bupropion,3,4,20,29,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0,-1,0
2304,hepatotoxicity,5,6,38,52,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,-1,1,1
2305,hepatotoxicity,8,9,53,67,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,-1,1,1
2306,bupropion,11,12,79,88,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0
2307,acute liver failure,25,28,155,174,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,-1,1,1
2308,bupropion,32,33,198,207,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0
2309,carbimazole,38,39,244,255,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0
2310,bupropion,15,16,92,101,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0,-1,0
2311,hepatotoxic,20,21,132,143,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,1,1
2312,infection,11,12,76,85,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,1,1
2313,inflammation,13,14,90,102,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,1,1
2314,infection,8,9,49,58,There is no evidence of antecedent or concurrent infection in this patient.,1255900_3,-1,1,1
2315,heparin,8,9,53,60,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,0,-1,0
2316,hemorrhage,19,20,137,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,1,1
2317,Nephrotoxic,0,1,0,11,Nephrotoxic effects in high-risk patients undergoing angiography.,12571256_0,-1,1,1
2318,nephropathy,11,12,63,74,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,1,1
2319,nephrotoxic,6,7,44,55,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,1,1
2320,nephrotoxic,15,16,95,106,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,1,1
2321,iodixanol,27,28,169,178,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0,-1,0
2322,diabetes,6,7,37,45,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,1,1
2323,creatinine,9,10,57,67,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,0,-1,0
2324,creatinine,13,14,66,76,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0,-1,0
2325,creatinine,8,9,41,51,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0
2326,creatinine,33,34,164,174,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0
2327,creatinine,3,4,13,23,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0,-1,0
2328,iodixanol,12,13,92,101,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0,-1,0
2329,creatinine,12,13,47,57,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0
2330,iodixanol,20,21,91,100,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0
2331,iodixanol,37,38,182,191,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0
2332,iodixanol,7,8,30,39,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0
2333,creatinine,18,19,81,91,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0
2334,iodixanol,55,56,261,270,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0
2335,iodixanol,3,4,21,30,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0,-1,0
2336,creatinine,5,6,23,33,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0
2337,iodixanol,20,21,101,110,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0
2338,iodixanol,37,38,187,196,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0
2339,Nephropathy,2,3,13,24,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,1,1
2340,iodixanol,17,18,109,118,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0,-1,0
2341,dexamethasone,1,2,9,22,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,0,-1,0
2342,hypertension,3,4,32,44,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1
2343,renal injury,5,7,49,61,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1
2344,Dexamethasone,0,1,0,13,Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development.,12574103_1,0,-1,0
2345,dexamethasone,11,12,62,75,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,0,-1,0
2346,renal injury,20,22,132,144,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,1,1
2347,dexamethasone,12,13,81,94,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,0,-1,0
2349,dexamethasone,4,5,31,44,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,0,-1,0
2351,dexamethasone,7,8,44,57,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,0,-1,0
2352,dexamethasone,5,6,33,46,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,0,-1,0
2354,dexamethasone,3,4,17,30,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,0,-1,0
2355,glomerulosclerosis,15,16,86,104,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,-1,1,1
2356,dexamethasone,5,6,31,44,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,0,-1,0
2358,glomerulosclerosis,16,17,98,116,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,1,1
2359,hypertension,19,20,122,134,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,1,1
2360,Hypertension,0,1,0,12,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,1,1
2361,hypertension,43,44,239,251,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,1,1
2363,tacrolimus,12,13,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0
2364,sirolimus,14,15,104,113,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0
2365,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0,-1,0
2368,nephrotoxic,2,3,10,21,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,1,1
2370,nephrotoxic,13,14,78,89,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,1,1
2372,nephrotoxic,18,19,116,127,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,1,1
2375,tacrolimus,32,33,183,193,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0
2381,fibrosis,16,17,118,126,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,-1,1,1
2382,fibrosis,19,20,140,148,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,-1,1,1
2383,fibrosis,37,38,251,259,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,-1,1,1
2394,fibrosis,28,29,165,173,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,1,1
2397,fibrosis,12,13,73,81,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,1,1
2398,nephrotoxic,8,9,54,65,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,1,1
2404,myocardial damage,11,13,60,77,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,1,1
2405,cardiomyopathy,15,16,101,115,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,1,1
2406,myocardial damage,13,15,75,92,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,1,1
2407,doxorubicin,20,21,111,122,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,0,-1,0
2408,cardiomyopathy,22,23,137,151,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,1,1
2413,toxicity,11,12,62,70,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,1,1
2416,fibrosis,17,18,127,135,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,1,1
2417,fibrosis,11,12,73,81,Only five of the controls exhibited evidence of very slight perivascular fibrosis.,12589964_13,-1,1,1
2423,myocardial damage,19,21,108,125,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,1,1
2426,cardiotoxicity,63,64,366,380,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,1,1
2427,pulmonary hypertension,3,5,33,55,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,1,1
2428,Pulmonary hypertension,0,2,0,22,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,1,1
2429,octreotide,10,11,82,92,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0,-1,0
2433,Streptomycin,0,1,0,12,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,0,-1,0
2441,acne,22,23,127,131,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,1,1
2446,oral contraceptives,20,22,144,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0,-1,0
2447,acne,29,30,178,182,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,1,1
2451,acne,19,20,107,111,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,1,1
2457,gentamicin,21,22,114,124,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,0,-1,0
2459,nephrotoxicity,25,26,130,144,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,1,1
2464,Nephrotoxicity,0,1,0,14,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,1,1
2465,creatinine,8,9,63,73,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0
2466,urea,10,11,78,82,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0
2467,glutathione,16,17,109,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0
2470,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0
2471,urea,15,16,111,115,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0
2473,necrosis,68,69,356,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,1,1
2478,chronic renal failure,17,20,99,120,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,-1,1,1
2480,docetaxel,9,10,70,79,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0
2481,thalidomide,11,12,84,95,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0
2482,prostate cancer,17,19,145,160,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,1,1
2485,prostate cancer,18,20,122,137,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,1,1
2486,docetaxel,24,25,160,169,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0,-1,0
2487,thalidomide,30,31,199,210,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0,-1,0
2488,prostate cancer,14,16,76,91,"PATIENTS: Seventy men, aged 50-80 years, with advanced androgen-independent prostate cancer.",12627929_4,-1,1,1
2489,docetaxel,7,8,55,64,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0
2490,thalidomide,27,28,166,177,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0
2491,docetaxel,35,36,213,222,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0
2492,toxicity,11,12,69,77,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,1,1
2494,docetaxel,11,12,64,73,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0
2496,docetaxel,27,28,139,148,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0
2497,thalidomide,29,30,154,165,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0
2499,thalidomide,5,6,28,39,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0,-1,0
2500,docetaxel,7,8,43,52,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0,-1,0
2501,prostate cancer,12,14,73,88,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,1,1
2503,thalidomide,10,11,70,81,Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens.,12627929_9,0,-1,0
2504,hepatitis,2,3,32,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,1,1
2505,hepatitis,9,10,64,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,1,1
2506,hepatitis,8,9,61,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,1,1
2507,ticlopidine,11,12,87,98,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0,-1,0
2508,ticlopidine,6,7,51,62,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0,-1,0
2509,hepatitis,3,4,24,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,1,1
2510,ticlopidine,12,13,83,94,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,0,-1,0
2511,jaundice,3,4,23,31,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,1,1
2512,ticlopidine,7,8,57,68,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,0,-1,0
2513,hepatitis,17,18,139,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,1,1
2514,Hepatitis,0,1,0,9,"Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course, but complete remission was observed in all reported cases.",12639165_6,-1,1,1
2515,ticlopidine,17,18,106,117,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,0,-1,0
2516,cholestasis,5,6,43,54,The mechanisms of this ticlopidine-induced cholestasis are unclear.,12639165_8,-1,1,1
2517,hepatotoxicity,9,10,48,62,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,1,1
2518,hepatitis,3,4,25,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,1,1
2519,ticlopidine,10,11,63,74,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0,-1,0
2520,ticlopidine,12,13,68,79,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0
2521,clopidogrel,21,22,130,141,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0
2525,sodium,6,7,44,50,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,0,-1,0
2526,salt,6,7,38,42,The molecular mechanism(s) leading to salt retention has not been completely elucidated.,12653683_2,0,-1,0
2527,sodium,6,7,49,55,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,0,-1,0
2531,sodium,5,6,28,34,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,0,-1,0
2532,aldosterone,9,10,53,64,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,0,-1,0
2533,proteinuria,12,13,83,94,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,1,1
2534,sodium,4,5,24,30,The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.,12653683_7,0,-1,0
2535,proteinuria,10,11,63,74,The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.,12653683_7,-1,1,1
2536,Sodium,0,1,0,6,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,0,-1,0
2538,sodium,15,16,94,100,A significant up-regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3.,12653683_9,0,-1,0
2539,aldosterone,20,21,123,134,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0,-1,0
2540,sodium,30,31,183,189,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0,-1,0
2541,sodium,14,15,96,102,"The amounts of alphaENaC, betaENaC and gammaENaC proteins were not increased during PAN-induced sodium retention.",12653683_11,0,-1,0
2543,aldosterone,36,37,210,221,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,0,-1,0
2545,vigabatrin,6,7,39,49,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0,-1,0
2546,dopamine,14,15,107,115,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0,-1,0
2549,visual field defects,15,18,97,117,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,1,1
2550,dopamine,45,46,279,287,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,0,-1,0
2552,cocaine,9,10,58,65,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,0,-1,0
2553,dopamine,15,16,109,117,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,0,-1,0
2554,dystonia,2,3,31,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,1,1
2555,dyskinesias,1,2,17,28,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,1,1
2558,dystonia,12,13,88,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,1,1
2560,neurotoxicity,8,9,69,82,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,1,1
2562,tacrolimus,27,28,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0,-1,0
2564,tacrolimus,17,18,111,121,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,0,-1,0
2571,necrosis,21,22,122,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,1,1
2572,neurotoxicity,14,15,105,118,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,-1,1,1
2573,hypertension,6,7,53,65,L-arginine transport in humans with cortisol-induced hypertension.,12707296_0,-1,1,1
2574,hypertension,9,10,77,89,A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.,12707296_1,-1,1,1
2575,Hydrocortisone acetate,0,2,0,22,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0,-1,0
2576,cortisol,1,2,7,15,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,0,-1,0
2577,cortisol,62,63,357,365,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0
2578,cortisol,75,76,434,442,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0,-1,0
2579,bleeding,2,3,10,18,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,1,1
2580,hematoma,4,5,23,31,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,1,1
2584,stroke,13,14,74,80,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,1,1
2588,bleeding,16,17,100,108,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,1,1
2589,hematoma,35,36,231,239,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,1,1
2590,hematoma,4,5,22,30,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,1,1
2591,hematoma,12,13,78,86,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,1,1
2594,heparin,7,8,47,54,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,0,-1,0
2595,hematoma,10,11,68,76,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,1,1
2596,bleeding,22,23,139,147,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,1,1
2604,hypertensive,6,7,33,45,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,1,1
2607,myocardial injury,9,11,50,67,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,1,1
2608,overdose,14,15,85,93,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,1,1
2609,myocardial injury,9,11,56,73,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,1,1
2611,myocardial injury,12,14,56,73,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,1,1
2614,myopathy,14,15,100,108,We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced myopathy.,12739036_1,-1,1,1
2615,azathioprine,23,24,138,150,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0,-1,0
2616,cyclophosphamide,25,26,155,171,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0,-1,0
2617,chloroquine,3,4,24,35,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,0,-1,0
2619,steroids,10,11,57,65,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,0,-1,0
2622,myopathy,17,18,98,106,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,1,1
2623,myopathy,4,5,35,43,"As it revealed chloroquine-induced myopathy, medication was stopped.",12739036_10,-1,1,1
2624,Seizure,0,1,0,7,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,1,1
2626,bupropion,7,8,64,73,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,0,-1,0
2627,seizure,6,7,41,48,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,1,1
2628,bupropion,10,11,83,92,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,0,-1,0
2630,smoking,19,20,125,132,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0,-1,0
2631,bupropion,24,25,171,180,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0,-1,0
2632,bupropion,4,5,17,26,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,0,-1,0
2633,seizure,14,15,83,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,1,1
2634,seizures,8,9,42,50,The patient had no other risk factors for seizures.,12745515_4,-1,1,1
2636,seizures,12,13,78,86,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,1,1
2637,Estradiol,0,1,0,9,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,0,-1,0
2645,estradiol,3,4,10,19,"In males, estradiol increased the total damage score.",12757899_8,0,-1,0
2646,estradiol,7,8,43,52,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,0,-1,0
2647,seizure,9,10,56,63,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,-1,1,1
2648,myalgia,1,2,14,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,-1,1,1
2649,succinylcholine,3,4,28,43,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,0,-1,0
2650,succinylcholine,6,7,37,52,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,0,-1,0
2651,myalgia,9,10,70,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,1,1
2652,myalgia,4,5,25,32,The pathogenesis of this myalgia is still unclear; inflammation has been suggested but without convincing evidence.,12760988_2,-1,1,1
2653,inflammation,9,10,51,63,The pathogenesis of this myalgia is still unclear; inflammation has been suggested but without convincing evidence.,12760988_2,-1,1,1
2654,myalgia,14,15,98,105,We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia.,12760988_3,-1,1,1
2655,myalgia,14,15,98,105,We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia.,12760988_3,-1,1,1
2656,myalgia,6,7,57,64,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,1,1
2657,dexamethasone,16,17,121,134,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,0,-1,0
2658,succinylcholine,18,19,142,157,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,0,-1,0
2659,myalgia,4,5,26,33,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1
2660,dexamethasone,18,19,106,119,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,0,-1,0
2661,myalgia,22,23,140,147,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1
2662,myalgia,34,35,206,213,"Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).",12760988_5,-1,1,1
2664,myalgia,14,15,70,77,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,1,1
2665,myalgia,16,17,84,91,"We found an increase of IL-6 for only three patients, but only one patient reported myalgia; no relationship between myalgia and the increase of IL-6 was found.",12760988_8,-1,1,1
2666,myalgia,21,22,117,124,"We found an increase of IL-6 for only three patients, but only one patient reported myalgia; no relationship between myalgia and the increase of IL-6 was found.",12760988_8,-1,1,1
2667,myalgia,13,14,93,100,"In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.",12760988_9,-1,1,1
2668,dexamethasone,4,5,32,45,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,0,-1,0
2669,succinylcholine,6,7,53,68,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,0,-1,0
2670,myalgia,20,21,172,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,1,1
2671,myalgia,9,10,73,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,1,1
2672,inflammation,20,21,142,154,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,-1,1,1
2673,dexamethasone,2,3,18,31,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,0,-1,0
2674,myalgia,9,10,74,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,-1,1,1
2675,succinylcholine,11,12,88,103,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,0,-1,0
2677,hypertrophy,15,16,86,97,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,1,1
2679,anemia,3,4,35,41,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,1,1
2680,prostate cancer,5,7,45,60,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,1,1
2681,anemia,13,14,90,96,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,1,1
2682,prostate cancer,15,17,100,115,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,1,1
2683,anemia,32,33,154,160,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,1,1
2684,Testosterone,4,5,12,24,"Hb, PSA and Testosterone measurements were recorded.",12820454_4,0,-1,0
2685,anemia,4,5,30,36,Severe and clinically evident anemia of Hb < 11 g/dl with clinical symptoms was detected in 6 patients (14.3%).,12820454_8,-1,1,1
2686,anemia,2,3,17,23,This CAB-induced anemia was normochromic and normocytic.,12820454_9,-1,1,1
2687,anemia,8,9,45,51,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,1,1
2689,anemia,33,34,141,147,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,1,1
2691,anemia,4,5,26,32,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,1,1
2692,anemia,5,6,38,44,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,1,1
2693,prostate cancer,7,9,48,63,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,1,1
2694,anemia,4,5,30,36,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,-1,1,1
2695,anemia,9,10,70,76,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1
2696,prostate cancer,15,17,96,111,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1
2697,lindane,2,3,10,17,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,0,-1,0
2698,lindane,15,16,92,99,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,0,-1,0
2699,neurotoxicity,17,18,108,121,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,-1,1,1
2700,lindane,3,4,23,30,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0,-1,0
2702,lindane,26,27,143,150,A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days.,12842176_2,0,-1,0
2703,lindane,29,30,177,184,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0
2704,convulsions,31,32,193,204,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1
2705,phenobarbital,35,36,224,237,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0
2706,ethanol,46,47,274,281,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0
2707,lindane,61,62,368,375,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0,-1,0
2708,convulsions,63,64,384,395,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1
2709,convulsions,63,64,384,395,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,1,1
2710,lindane,7,8,48,55,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0
2711,convulsions,15,16,100,111,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,1,1
2712,lindane,22,23,150,157,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0
2713,lindane,25,26,174,181,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0
2715,ethanol,35,36,224,231,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0,-1,0
2716,toxicity,44,45,294,302,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,1,1
2722,oral contraceptives,29,31,173,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0,-1,0
2727,aspirin,5,6,42,49,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0,-1,0
2728,acetylsalicylic acid,7,9,51,71,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0,-1,0
2729,Aspirin,0,1,0,7,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0
2730,acetylsalicylic acid,2,4,9,29,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0
2734,toxicity,54,55,314,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,1,1
2740,benzodiazepine,3,4,20,34,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0,-1,0
2742,diazepam,12,13,99,107,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0,-1,0
2744,Diazepam,7,8,54,62,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0,-1,0
2745,benzodiazepine,18,19,123,137,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0,-1,0
2748,diazepam,32,33,151,159,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0
2749,fentanyl,39,40,191,199,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0
2750,morphine,44,45,216,224,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0
2753,nausea,6,7,37,43,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1
2754,vomiting,8,9,48,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1
2756,nausea,14,15,85,91,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1
2757,pain,17,18,111,115,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,1,1
2759,diazepam,9,10,61,69,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,0,-1,0
2760,Delirium,0,1,0,8,Delirium during clozapine treatment: incidence and associated risk factors.,12905102_0,-1,1,1
2761,clozapine,2,3,16,25,Delirium during clozapine treatment: incidence and associated risk factors.,12905102_0,0,-1,0
2762,delirium,7,8,43,51,BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.,12905102_1,-1,1,1
2763,clozapine,9,10,59,68,BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.,12905102_1,0,-1,0
2764,psychiatric,11,12,69,80,"METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.",12905102_2,-1,1,1
2765,clozapine,15,16,105,114,"METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.",12905102_2,0,-1,0
2766,delirium,32,33,192,200,"METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.",12905102_2,-1,1,1
2767,clozapine,32,33,127,136,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,0,-1,0
2768,Delirium,0,1,0,8,"Delirium was diagnosed in 14 (10.1 % incidence, or 1.48 cases/person-years of exposure); 71.4 % of cases were moderate or severe.",12905102_4,-1,1,1
2769,clozapine,38,39,225,234,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,0,-1,0
2770,Delirium,2,3,13,21,"CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.",12905102_6,-1,1,1
2771,Delirium,0,1,0,8,"Delirium was inconsistently recognized clinically in milder cases and was associated with increased length-of-stay and higher costs, and inferior clinical outcome.",12905102_7,-1,1,1
2773,neurotoxicity,13,14,103,116,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,1,1
2774,dopamine,20,21,150,158,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0,-1,0
2775,hyperthermia,25,26,185,197,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,1,1
2776,glutamate,12,13,62,71,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0
2777,methamphetamine,23,24,115,130,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0,-1,0
2778,Methamphetamine,0,1,0,15,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,0,-1,0
2779,dopamine,15,16,78,86,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,0,-1,0
2781,2-methyl-6-(phenylethynyl)pyridine,6,7,34,68,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0,-1,0
2783,methamphetamine,22,23,142,157,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0,-1,0
2784,methamphetamine,27,28,197,212,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0,-1,0
2786,dopamine,13,14,69,77,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0,-1,0
2787,dopamine,22,23,112,120,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0,-1,0
2788,methamphetamine,27,28,150,165,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0,-1,0
2790,methamphetamine,6,7,40,55,"Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.",12907309_5,0,-1,0
2791,hyperthermia,11,12,78,90,"Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.",12907309_5,-1,1,1
2793,dopamine,14,15,96,104,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,0,-1,0
2795,toxicity,19,20,136,144,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,1,1
2797,dopamine,13,14,101,109,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,0,-1,0
2798,hyperthermia,31,32,201,213,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,1,1
2799,depression,5,6,44,54,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,1,1
2801,methylphenidate,14,15,100,115,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,0,-1,0
2802,methylphenidate,10,11,88,103,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,0,-1,0
2803,psychiatric,5,6,25,36,"The patient had no prior psychiatric history, but he had a sister with obsessive-compulsive disorder.",12907924_3,-1,1,1
2804,methylphenidate,3,4,16,31,It appears that methylphenidate precipitated the patient's pathological behavior.,12907924_4,0,-1,0
2805,interstitial nephritis,2,4,28,50,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,-1,1,1
2806,autoimmune hemolytic anemia,5,8,55,82,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,-1,1,1
2807,Ciprofloxacin,0,1,0,13,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,0,-1,0
2808,interstitial nephritis,9,11,70,92,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1
2809,hemolytic anemia,12,14,97,113,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1
2810,interstitial nephritis,10,12,60,82,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1
2811,autoimmune hemolytic anemia,13,16,87,114,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1
2812,Hemolytic anemia,0,2,0,16,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,-1,1,1
2813,steroid,10,11,68,75,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,0,-1,0
2814,interstitial nephritis,3,5,21,43,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,1,1
2815,steroids,4,5,35,43,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,0,-1,0
2816,cocaine,6,7,52,59,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,0,-1,0
2817,steroids,1,2,12,20,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,0,-1,0
2818,psychiatric,14,15,108,119,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,1,1
2819,seizures,4,5,30,38,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,1,1
2820,steroid,13,14,88,95,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0
2821,cocaine,35,36,233,240,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0
2822,cocaine,39,40,264,271,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0
2823,seizure,42,43,288,295,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,-1,1,1
2824,seizures,40,41,361,369,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,1,1
2825,seizures,1,2,8,16,Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.,12921865_5,-1,1,1
2826,cocaine,10,11,66,73,Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.,12921865_5,0,-1,0
2827,seizures,12,13,78,86,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,1,1
2828,steroids,6,7,49,57,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,0,-1,0
2829,cocaine,13,14,109,116,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,0,-1,0
2830,furosemide,4,5,32,42,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,0,-1,0
2831,nephropathy,7,8,60,71,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,-1,1,1
2832,furosemide,11,12,58,68,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,0,-1,0
2833,nephropathy,22,23,138,149,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,-1,1,1
2835,furosemide,9,10,52,62,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,0,-1,0
2838,furosemide,9,10,71,81,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0
2839,creatinine,23,24,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0
2843,Furosemide,0,1,0,10,Furosemide may be deleterious in the prevention of radiocontrast nephropathy.,1300436_8,0,-1,0
2844,nephropathy,9,10,65,76,Furosemide may be deleterious in the prevention of radiocontrast nephropathy.,1300436_8,-1,1,1
2845,blood coagulation,3,5,26,43,Progestational agents and blood coagulation.,133615_0,-1,1,1
2846,Thromboembolic,0,1,0,14,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,1,1
2847,oral contraceptive,5,7,42,60,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0,-1,0
2849,oral contraceptives,21,23,119,138,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,0,-1,0
2850,blood coagulation,7,9,48,65,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,-1,1,1
2851,blood coagulation,5,7,25,42,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,-1,1,1
2853,thromboembolic,9,10,72,86,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,1,1
2854,oral contraceptive,19,21,109,127,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0,-1,0
2855,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,1,1
2856,hypertensive,12,13,126,138,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,1,1
2857,prazosin,7,8,51,59,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,0,-1,0
2858,hypertensive,24,25,189,201,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,-1,1,1
2859,prazosin,25,26,120,128,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,0,-1,0
2860,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,1,1
2861,prazosin,13,14,66,74,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,0,-1,0
2862,orthostatic hypotension,6,8,34,57,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,1,1
2863,prazosin,13,14,82,90,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,0,-1,0
2864,prazosin,10,11,46,54,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,0,-1,0
2865,prazosin,6,7,35,43,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,0,-1,0
2866,orthostatic hypotension,8,10,44,67,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,1,1
2867,prazosin,20,21,124,132,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,0,-1,0
2868,prazosin,14,15,70,78,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0,-1,0
2869,bradycardia,6,7,29,40,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,1,1
2870,noradrenaline,37,38,178,191,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0,-1,0
2871,prazosin,56,57,285,293,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0,-1,0
2872,bradycardia,4,5,21,32,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,1,1
2873,prazosin,12,13,81,89,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,0,-1,0
2874,bradycardia,21,22,112,123,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,1,1
2875,prazosin,28,29,156,164,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,0,-1,0
2876,bradycardia,3,4,17,28,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,-1,1,1
2877,prazosin,18,19,131,139,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,0,-1,0
2878,hyperactivity,2,3,21,34,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,1,1
2879,scopolamine,6,7,54,65,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,0,-1,0
2880,hyperactivity,21,22,120,133,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,1,1
2881,morphine,24,25,146,154,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,0,-1,0
2882,tyrosine,18,19,90,98,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0,-1,0
2883,morphine,27,28,171,179,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0,-1,0
2884,serotonin,21,22,90,99,"On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.",137340_6,0,-1,0
2885,hyperactivity,30,31,146,159,"On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.",137340_6,-1,1,1
2886,morphine,8,9,59,67,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,0,-1,0
2887,catecholamines,15,16,99,113,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,0,-1,0
2888,morphine,32,33,208,216,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,0,-1,0
2889,acetylcholine,39,40,250,263,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,0,-1,0
2890,morphine,12,13,85,93,It is also suggested from collected evidence that the activity-increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity-increasing effects of morphine in rats.,137340_8,0,-1,0
2891,morphine,28,29,199,207,It is also suggested from collected evidence that the activity-increasing effects of morphine in mice are mediated by mechanisms different from those which mediate the activity-increasing effects of morphine in rats.,137340_8,0,-1,0
2892,chronic renal failure,9,12,70,91,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,-1,1,1
2893,nephropathy,3,4,26,37,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,1,1
2895,lithium,3,4,19,26,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0,-1,0
2896,lithium,9,10,70,77,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0,-1,0
2897,lithium,41,42,258,265,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0,-1,0
2898,lithium,2,3,14,21,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,0,-1,0
2900,Lithium,0,1,0,7,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,0,-1,0
2901,proteinuria,3,4,20,31,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1
2902,hypertension,6,7,45,57,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1
2903,glomerulosclerosis,10,11,72,90,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1
2905,creatinine,18,19,109,119,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0,-1,0
2906,lithium,21,22,130,137,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0,-1,0
2907,nephropathy,5,6,37,48,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,1,1
2908,proteinuria,19,20,113,124,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,1,1
2909,hypertension,23,24,147,159,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,-1,1,1
2910,chronic renal failure,4,7,17,38,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,-1,1,1
2911,quinine,6,7,55,62,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,0,-1,0
2912,quinine,3,4,36,43,"Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.",1415380_1,0,-1,0
2913,quinine,17,18,105,112,The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine.,1415380_3,0,-1,0
2914,prednisone,8,9,47,57,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0
2915,aspirin,10,11,59,66,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0
2916,dipyridamole,13,14,72,84,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0
2917,quinine,14,15,79,86,"It is important to recognize this reaction when it occurs and to avoid further quinine exposure, since the reaction seems to be recurrent.",1415380_8,0,-1,0
2928,nausea,18,19,104,110,"There were no serious clinical side effects, but dose reduction was required in two patients because of nausea.",1420741_7,-1,1,1
2933,dementia,7,8,54,62,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,1,1
2935,toxicity,8,9,50,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,1,1
2936,depressive,2,3,11,21,Changes in depressive status associated with topical beta-blockers.,1428568_0,-1,1,1
2937,Depression,0,1,0,10,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,-1,1,1
2938,sexual dysfunction,2,4,15,33,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,-1,1,1
2939,timolol,17,18,108,115,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,0,-1,0
2940,timolol,6,7,53,60,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,0,-1,0
2941,depression,11,12,86,96,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,1,1
2942,depression,6,7,32,42,"During the six-month follow up, depression was quantified through the Beck and Zung-Conde scales every two months.",1428568_4,-1,1,1
2943,timolol,13,14,74,81,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,0,-1,0
2944,depression,17,18,109,119,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,1,1
2945,timolol,12,13,80,87,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,0,-1,0
2946,neurotoxicity,3,4,39,52,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,1,1
2947,dopamine,6,7,69,77,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0,-1,0
2949,amino acid,15,17,124,134,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0,-1,0
2953,glutamate,22,23,178,187,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0,-1,0
2954,dopamine,9,10,58,66,Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole-treated rats is reported.,1436384_2,0,-1,0
2955,amphetamine,14,15,86,97,Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole-treated rats is reported.,1436384_2,0,-1,0
2956,dopamine,25,26,143,151,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,0,-1,0
2957,dopamine,4,5,28,36,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0,-1,0
2965,dopamine,13,14,75,83,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,0,-1,0
2966,amphetamine,27,28,137,148,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,0,-1,0
2967,amphetamine,36,37,183,194,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,0,-1,0
2968,dopamine,2,3,13,21,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0,-1,0
2970,amphetamine,17,18,106,117,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0,-1,0
2972,amphetamine,37,38,202,213,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0,-1,0
2973,dopamine,4,5,27,35,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,0,-1,0
2974,methamphetamine,15,16,90,105,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,0,-1,0
2976,neurotoxic,7,8,42,52,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,1,1
2977,amphetamine,10,11,63,74,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0,-1,0
2978,dopamine,16,17,118,126,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0,-1,0
2982,hemolytic anemia,2,4,25,41,Cefotetan-induced immune hemolytic anemia.,1445986_0,-1,1,1
2983,hemolytic anemia,1,3,7,23,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,1,1
2984,cephalosporins,18,19,143,157,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,0,-1,0
2985,anemia,6,7,36,42,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,1,1
2986,hemolysis,12,13,90,99,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1
2987,hemolytic anemia,18,20,134,150,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1
2988,weakness,4,5,29,37,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,1,1
2989,paralysis,9,10,59,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,1,1
2990,tremor,13,14,85,91,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,1,1
2992,ketoconazole,21,22,122,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,0,-1,0
2994,ketoconazole,17,18,87,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,0,-1,0
2995,dyskinesias,3,4,32,43,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1
2996,parkinsonian,5,6,47,59,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1
2997,dyskinesias,1,2,17,28,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,1,1
3002,parkinsonism,8,9,59,71,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,1,1
3003,levodopa,32,33,200,208,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,0,-1,0
3006,levodopa,20,21,117,125,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,0,-1,0
3007,dyskinesia,23,24,144,154,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,1,1
3008,levodopa,31,32,187,195,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,0,-1,0
3010,levodopa,20,21,128,136,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,0,-1,0
3012,dyskinesia,31,32,191,201,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,1,1
3013,levodopa,40,41,247,255,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,0,-1,0
3014,levodopa,9,10,55,63,All animals were similarly symptomatic at the start of levodopa treatment and had similar therapeutic responses to the drug.,14568327_6,0,-1,0
3016,levodopa,24,25,159,167,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,0,-1,0
3018,amphetamine,13,14,89,100,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,0,-1,0
3019,amphetamine,22,23,142,153,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,0,-1,0
3023,amphetamine,15,16,84,95,Nine days later locomotor activity was measured in response to a single low dose of amphetamine (0.5 mg/kg).,14596845_6,0,-1,0
3024,amphetamine,14,15,89,100,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0
3025,amphetamine,30,31,180,191,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0
3026,amphetamine,37,38,227,238,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0
3027,amphetamine,44,45,271,282,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0,-1,0
3028,amphetamine,33,34,201,212,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,0,-1,0
3029,dopamine,43,44,258,266,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,0,-1,0
3030,dexamethasone,2,3,7,20,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0,-1,0
3031,mesna,4,5,26,31,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0,-1,0
3034,ifosfamide,14,15,78,88,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,0,-1,0
3035,dexamethasone,11,12,56,69,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0,-1,0
3036,mesna,15,16,90,95,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0,-1,0
3037,mesna,21,22,84,89,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,0,-1,0
3039,mesna,7,8,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0
3040,dexamethasone,11,12,52,65,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0
3041,dexamethasone,15,16,80,93,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0
3042,mesna,17,18,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0
3043,Cystitis,0,1,0,8,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,1,1
3045,mesna,14,15,67,72,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0
3046,dexamethasone,16,17,78,91,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0
3047,dexamethasone,5,6,26,39,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0
3048,mesna,12,13,65,70,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0
3049,mesna,20,21,110,115,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0
3050,Dexamethasone,2,3,12,25,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0,-1,0
3051,mesna,6,7,46,51,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0,-1,0
3052,mesna,9,10,46,51,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0
3053,mesna,16,17,78,83,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0
3054,dexamethasone,19,20,95,108,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0
3058,Fever,0,1,0,5,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,1,1
3060,steroids,6,7,38,46,All patients received short course of steroids.,14648024_5,0,-1,0
3061,Fever,0,1,0,5,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,-1,1,1
3063,steroid,3,4,18,25,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,0,-1,0
3065,dilated cardiomyopathy,1,3,11,33,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,1,1
3067,dilated cardiomyopathy,6,8,36,58,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,1,1
3073,toxicity,23,24,172,180,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,1,1
3075,migraine,1,2,11,19,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,1,1
3076,calcitonin,8,9,54,64,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0
3078,serotonin,20,21,146,155,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0
3079,calcitonin,13,14,70,80,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0
3081,serotonin,22,23,136,145,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0
3082,5-hydroxytriptamine,24,25,147,166,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0
3084,headache,32,33,203,211,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,1,1
3085,migraine,37,38,236,244,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,1,1
3086,nitroglycerin,41,42,264,277,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0
3087,nitroglycerin,1,2,11,24,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,0,-1,0
3088,nitroglycerin,16,17,86,99,"Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).",14659530_4,0,-1,0
3089,migraine,29,30,159,167,"Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).",14659530_4,-1,1,1
3090,migraine,6,7,29,37,In those subjects who had no migraine attack (11 subjects) a similar time schedule was used.,14659530_5,-1,1,1
3092,migraine,10,11,70,78,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,1,1
3093,migraine,21,22,138,146,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,1,1
3096,headache,10,11,70,78,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,1,1
3097,migraine,17,18,107,115,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,1,1
3100,migraine,19,20,125,133,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,1,1
3101,serotonin,1,2,9,18,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,0,-1,0
3102,nitroglycerin,9,10,66,79,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,0,-1,0
3103,migraine,14,15,100,108,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,1,1
3104,migraine,25,26,171,179,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,1,1
3108,migraine,26,27,166,174,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,1,1
3109,serotonin,3,4,13,22,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,0,-1,0
3110,migraine,10,11,63,71,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,1,1
3111,headache,17,18,100,108,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,1,1
3113,oxygen,1,2,11,17,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,0,-1,0
3116,cyclophosphamide,10,11,60,76,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,0,-1,0
3118,hemorrhage,20,21,149,159,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,1,1
3119,oxygen,4,5,24,30,"We then used hyperbaric oxygen at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks.",1468485_3,0,-1,0
3120,bleeding,1,2,4,12,The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter.,1468485_4,-1,1,1
3121,hematuria,15,16,88,97,The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter.,1468485_4,-1,1,1
3124,phenytoin,6,7,38,47,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,0,-1,0
3126,epileptic,17,18,122,131,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,1,1
3128,phenytoin,10,11,69,78,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,0,-1,0
3130,phenytoin,10,11,68,77,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,0,-1,0
3131,epileptic,14,15,96,105,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1
3132,seizures,26,27,168,176,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1
3134,seizure,16,17,102,109,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,1,1
3136,carbamazepine,14,15,75,88,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0,-1,0
3137,bicuculline,4,5,32,43,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0,-1,0
3140,bicuculline,5,6,19,30,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0
3141,aminophylline,7,8,32,45,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0
3144,Doxorubicin,2,3,12,23,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,0,-1,0
3145,nephropathy,6,7,52,63,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,1,1
3146,doxorubicin,7,8,44,55,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,0,-1,0
3148,superoxide,15,16,77,87,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,0,-1,0
3149,depressed,14,15,79,88,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,1,1
3152,superoxide,35,36,253,263,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,0,-1,0
3153,superoxide,25,26,187,197,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,0,-1,0
3154,ephedrine,8,9,53,62,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,0,-1,0
3155,sexual dysfunction,12,14,87,105,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,1,1
3156,ephedrine,9,10,53,62,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,0,-1,0
3157,sexual dysfunction,32,34,218,236,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,-1,1,1
3158,fluoxetine,6,7,55,65,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0,-1,0
3159,sertraline,8,9,67,77,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0,-1,0
3160,paroxetine,11,12,82,92,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0,-1,0
3161,ephedrine,27,28,193,202,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0,-1,0
3162,ephedrine,17,18,122,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,0,-1,0
3163,breast cancer,7,9,42,55,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,1,1
3164,breast cancer,8,10,54,67,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,-1,1,1
3165,tamoxifen,9,10,61,70,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,0,-1,0
3166,breast cancer,25,27,132,145,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,1,1
3167,breast cancer,20,22,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,1,1
3168,quinine,7,8,49,56,Risks of the consumption of beverages containing quinine.,14765563_0,0,-1,0
3169,quinine,23,24,132,139,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,0,-1,0
3170,quinine,7,8,60,67,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,0,-1,0
3171,confusion,14,15,118,127,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,1,1
3172,seizures,20,21,152,160,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,1,1
3173,coma,23,24,166,170,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,1,1
3174,Doxorubicin,0,1,0,11,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,0,-1,0
3175,Doxorubicin,0,1,0,11,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,0,-1,0
3176,doxorubicin,13,14,86,97,Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment.,14975762_4,0,-1,0
3177,Doxorubicin,0,1,0,11,Doxorubicin induced myocardial cell apoptosis in wild-type mice but not in transgenic mice.,14975762_6,0,-1,0
3179,overdose,6,7,69,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,1,1
3182,hypoxia,34,35,233,240,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,1,1
3183,overdose,27,28,158,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,1,1
3184,hypotension,14,15,86,97,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,1,1
3185,jaundice,2,3,32,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,1,1
3186,jaundice,5,6,31,39,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,1,1
3187,propranolol,19,20,104,115,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0,-1,0
3188,hyperthyroidism,28,29,145,160,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,1,1
3189,jaundice,12,13,75,83,The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.,14982270_3,-1,1,1
3190,pruritus,16,17,83,91,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,1,1
3191,cholestasis,1,2,20,31,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,-1,1,1
3192,propranolol,6,7,51,62,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0,-1,0
3193,bilirubin,11,12,60,69,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,0,-1,0
3194,jaundice,19,20,107,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,1,1
3197,Capsaicin,0,1,0,9,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,0,-1,0
3199,atropine,14,15,94,102,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0,-1,0
3200,acetylcholine,12,13,63,76,The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges.,15009014_9,0,-1,0
3202,convulsions,1,2,24,35,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,1,1
3204,toxicity,2,3,10,18,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,1,1
3205,acetylcholine,25,26,133,146,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,0,-1,0
3209,diazepam,16,17,97,105,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0
3210,adenosine,27,28,171,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0
3214,atropine,58,59,335,343,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0,-1,0
3216,atropine,4,5,26,34,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0,-1,0
3221,toxicity,9,10,68,76,The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.,15036754_7,-1,1,1
3223,diazepam,3,4,10,18,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,0,-1,0
3225,poisoning,25,26,153,162,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,1,1
3228,diazepam,5,6,20,28,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,0,-1,0
3230,atropine,11,12,58,66,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,0,-1,0
3231,poisoning,19,20,112,121,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,1,1
3232,toxicity,24,25,143,151,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,1,1
3239,cardiac arrhythmias,4,6,29,48,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,1,1
3240,cardiac toxicity,1,3,4,20,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,1,1
3241,arrhythmia,18,19,134,144,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,1,1
3242,Hypersensitivity,0,1,0,16,Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.,1504402_0,-1,1,1
3243,hepatitis,8,9,73,82,Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.,1504402_0,-1,1,1
3244,liver injury,24,26,162,174,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,1,1
3245,liver injury,11,13,76,88,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,-1,1,1
3246,liver injury,28,30,216,228,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,1,1
3249,sodium,6,7,43,49,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,0,-1,0
3250,edema,10,11,76,81,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,-1,1,1
3251,sodium,9,10,53,59,"However, the molecular basis for the decreased renal sodium excretion remains undefined.",15075188_2,0,-1,0
3253,sodium,17,18,109,115,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,0,-1,0
3257,proteinuria,8,9,48,59,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,1,1
3258,sodium,14,15,96,102,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,0,-1,0
3259,ascites,19,20,128,135,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,1,1
3260,sodium,34,35,196,202,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,0,-1,0
3262,sodium,19,20,101,107,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,0,-1,0
3263,isoniazid,6,7,55,64,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,0,-1,0
3264,irritability,10,11,67,79,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,1,1
3265,isoniazid,20,21,147,156,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,0,-1,0
3266,pyridoxine,6,7,45,55,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,0,-1,0
3267,isoniazid,2,3,20,29,After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine.,150790_3,0,-1,0
3268,pyridoxine,15,16,101,111,After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine.,150790_3,0,-1,0
3269,pyridoxine,12,13,61,71,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,0,-1,0
3270,pyridoxine,3,4,23,33,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,0,-1,0
3272,pyridoxine,14,15,84,94,The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior.,150790_8,0,-1,0
3277,dyskinesias,16,17,82,93,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,1,1
3278,rigidity,29,30,134,142,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,1,1
3279,rigidity,5,6,47,55,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,1,1
3280,dyskinesias,21,22,139,150,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,1,1
3281,temporal lobe epilepsy,11,14,63,85,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,-1,1,1
3282,pilocarpine,5,6,26,37,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,0,-1,0
3285,seizures,19,20,123,131,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,1,1
3286,bicuculline,5,6,41,52,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,0,-1,0
3289,glutamate,37,38,207,216,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,0,-1,0
3290,glutamate,1,2,6,15,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,0,-1,0
3292,seizure,17,18,132,139,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,-1,1,1
3293,temporal lobe epilepsy,29,32,208,230,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,-1,1,1
3296,cyclophosphamide,12,13,74,90,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,0,-1,0
3297,bladder cancer,9,11,50,64,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,1,1
3298,cyclophosphamide,16,17,86,102,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,0,-1,0
3301,Cancer,5,6,33,39,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,-1,1,1
3302,bladder cancer,15,17,93,107,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,-1,1,1
3303,cyclophosphamide,16,17,105,121,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,0,-1,0
3304,bladder cancer,18,20,126,140,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,1,1
3305,bladder cancer,7,9,37,51,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1
3307,bladder cancer,22,24,128,142,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1
3309,cyclophosphamide,7,8,40,56,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,0,-1,0
3310,bladder cancer,3,5,12,26,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,1,1
3311,cyclophosphamide,12,13,63,79,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,0,-1,0
3312,bladder cancer,4,6,22,36,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1
3314,bladder cancer,25,27,134,148,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1
3316,cyclophosphamide,9,10,70,86,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,0,-1,0
3317,bladder cancer,14,16,103,117,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,1,1
3319,estrogen,3,4,27,35,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,0,-1,0
3320,hypotension,9,10,94,105,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,1,1
3321,estrogen,5,6,28,36,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,0,-1,0
3322,hypotensive,9,10,62,73,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,-1,1,1
3323,clonidine,12,13,84,93,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,0,-1,0
3324,estrogen,8,9,54,62,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0,-1,0
3326,estrogen,55,56,364,372,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0,-1,0
3327,hypotension,9,10,72,83,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,1,1
3330,hypotensive,4,5,31,42,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,1,1
3331,hypotension,16,17,113,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,1,1
3332,hypotension,3,4,30,41,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,1,1
3333,Estrogen,0,1,0,8,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0,-1,0
3334,estrogen,4,5,28,36,These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.,15145918_10,0,-1,0
3335,hypotension,10,11,88,99,These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.,15145918_10,-1,1,1
3337,cardiomyopathy,1,2,22,36,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.,15188772_1,-1,1,1
3338,catecholamines,8,9,73,87,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.,15188772_1,0,-1,0
3339,overdose,11,12,71,79,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,1,1
3340,epinephrine,13,14,79,90,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,0,-1,0
3342,necrosis,45,46,320,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,1,1
3350,oxygen,17,18,126,132,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,0,-1,0
3352,isoproterenol,7,8,54,67,TCR protected against pathological changes induced by isoproterenol in rat heart.,15233872_5,0,-1,0
3354,isoproterenol,16,17,94,107,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,0,-1,0
3355,thrombotic,15,16,136,146,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,1,1
3356,arthritis,20,21,171,180,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,1,1
3357,thrombotic,9,10,57,67,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,1,1
3358,rheumatoid arthritis,19,21,141,161,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,1,1
3359,thrombotic,4,5,32,42,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1
3360,thrombotic,16,17,113,123,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1
3361,diclofenac,35,36,209,219,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0,-1,0
3362,ibuprofen,40,41,231,240,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0,-1,0
3363,rheumatoid arthritis,59,61,332,352,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1
3364,aspirin,28,29,119,126,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,0,-1,0
3365,aspirin,37,38,154,161,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,0,-1,0
3366,thrombotic,5,6,42,52,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,1,1
3367,thrombotic,4,5,20,30,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,1,1
3368,Thrombotic,0,1,0,10,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,1,1
3369,aspirin,8,9,53,60,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,0,-1,0
3370,aspirin,13,14,84,91,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,0,-1,0
3371,aspirin,7,8,32,39,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,0,-1,0
3372,thrombotic,32,33,184,194,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,1,1
3373,rheumatoid arthritis,43,45,267,287,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,1,1
3375,cardiomyopathy,4,5,55,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,1,1
3376,myocarditis,8,9,52,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,1,1
3377,cardiomyopathy,11,12,90,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,1,1
3378,cardiomyopathy,9,10,59,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,1,1
3379,dobutamine,20,21,145,155,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,0,-1,0
3381,mitral regurgitation,15,17,118,138,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,1,1
3382,cardiomyopathy,10,11,65,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,1,1
3383,myocarditis,12,13,84,95,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,1,1
3384,Myocarditis,0,1,0,11,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,1,1
3385,myocarditis,5,6,37,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,1,1
3386,hypersensitivity,5,6,22,38,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,1,1
3387,myocarditis,9,10,54,65,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,1,1
3388,dobutamine,13,14,81,91,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,0,-1,0
3389,myocarditis,1,2,13,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,1,1
3390,tinnitus,2,3,13,21,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,-1,1,1
3391,lignocaine,7,8,55,65,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0
3392,lidocaine,9,10,67,76,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0
3393,tinnitus,2,3,22,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,1,1
3394,lignocaine,12,13,81,91,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0,-1,0
3395,lidocaine,14,15,93,102,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0,-1,0
3396,tinnitus,5,6,46,54,"Fifty-two patients suffering from intractable tinnitus entered this therapeutic trial, but only nine finished all five courses.",1527456_3,-1,1,1
3397,tinnitus,5,6,20,28,"In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one.",1527456_4,-1,1,1
3398,tinnitus,19,20,109,117,"In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one.",1527456_4,-1,1,1
3399,vomiting,11,12,64,72,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,1,1
3400,tinnitus,24,25,141,149,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,1,1
3401,acetylcholine,5,6,31,44,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,0,-1,0
3402,seizures,12,13,98,106,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,1,1
3403,nicotine,2,3,11,19,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,0,-1,0
3404,acetylcholine,5,6,33,46,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,0,-1,0
3405,tremors,25,26,159,166,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,-1,1,1
3406,seizures,28,29,171,179,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,-1,1,1
3407,death,30,31,184,189,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,-1,1,1
3409,seizures,10,11,63,71,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,1,1
3410,nicotine,10,11,53,61,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,0,-1,0
3411,seizures,35,36,196,204,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,-1,1,1
3412,seizures,9,10,61,69,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,-1,1,1
3413,seizures,16,17,105,113,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,1,1
3414,hemorrhage,4,5,35,45,Time trends in warfarin-associated hemorrhage.,15276120_0,-1,1,1
3415,bleeding,5,6,41,49,"The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.",15276120_1,-1,1,1
3416,bleeding,8,9,55,63,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,-1,1,1
3417,sevoflurane,3,4,15,26,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0,-1,0
3418,convulsions,6,7,48,59,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,-1,1,1
3419,sevoflurane,3,4,17,28,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0,-1,0
3420,convulsions,6,7,50,61,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,-1,1,1
3421,convulsive,1,2,4,14,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,1,1
3422,lidocaine,19,20,71,80,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0
3423,sevoflurane,43,44,201,212,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0
3424,sevoflurane,17,18,60,71,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0
3425,sevoflurane,26,27,114,125,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0
3426,convulsive,7,8,43,53,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,-1,1,1
3427,sevoflurane,10,11,72,83,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0,-1,0
3428,enflurane,12,13,88,97,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0,-1,0
3429,sevoflurane,12,13,76,87,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0
3430,enflurane,14,15,91,100,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0
3431,convulsions,22,23,145,156,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,-1,1,1
3432,sevoflurane,28,29,189,200,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0
3433,enflurane,37,38,223,232,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0
3434,lidocaine,9,10,52,61,"However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.",15278670_6,0,-1,0
3437,sevoflurane,19,20,143,154,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0,-1,0
3439,convulsive,11,12,46,56,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,1,1
3440,sevoflurane,4,5,21,32,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,0,-1,0
3441,convulsive,7,8,45,55,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,1,1
3443,depression,19,20,126,136,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,1,1
3444,Cardiac toxicity,0,2,0,16,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,-1,1,1
3445,breast cancer,11,13,107,120,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,-1,1,1
3446,Cyclophosphamide,2,3,14,30,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,0,-1,0
3447,toxicity,7,8,50,58,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,1,1
3448,cardiomyopathy,9,10,62,76,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,-1,1,1
3449,paclitaxel,5,6,26,36,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0
3450,melphalan,7,8,38,47,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0
3451,cyclophosphamide,10,11,62,78,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0
3452,carboplatin,15,16,94,105,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0
3453,breast cancer,26,28,176,189,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,1,1
3454,breast cancer,9,11,75,88,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1
3455,cyclophosphamide,14,15,115,131,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0,-1,0
3458,hypertension,52,53,373,385,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1
3459,smoking,58,59,410,417,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0,-1,0
3462,cyclophosphamide,18,19,96,112,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,0,-1,0
3463,cardiac toxicity,4,6,48,64,Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.,15325671_6,-1,1,1
3466,cyclophosphamide,5,6,41,57,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0,-1,0
3468,Tremor,0,1,0,6,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,-1,1,1
3469,salbutamol,4,5,23,33,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0,-1,0
3470,tremor,4,5,20,26,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,-1,1,1
3471,salbutamol,8,9,43,53,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,0,-1,0
3472,Tremor,2,3,9,15,METHODS: Tremor was measured using a laser pointer technique.,15338796_4,-1,1,1
3473,tremor,5,6,37,43,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,1,1
3474,salbutamol,19,20,133,143,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,0,-1,0
3475,tremor,12,13,79,85,"In another series of measurements, reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions, at 9 a.m., 4 p.m. and 9 a.m., respectively, 1 week later.",15338796_8,-1,1,1
3476,tremor,1,2,9,15,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,-1,1,1
3477,tremor,10,11,73,79,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,-1,1,1
3478,tremor,20,21,129,135,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,-1,1,1
3479,Tremor,0,1,0,6,Tremor was measured simultaneously by two independent observers.,15338796_11,-1,1,1
3480,Salbutamol,2,3,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0,-1,0
3481,tremor,5,6,44,50,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,-1,1,1
3482,tremor,8,9,53,59,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,1,1
3483,tremor,1,2,9,15,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,1,1
3484,tremor,5,6,29,35,"Support of the arm decreased tremor severity, exhaustion increased tremor severity significantly.",15338796_16,-1,1,1
3485,tremor,10,11,67,73,"Support of the arm decreased tremor severity, exhaustion increased tremor severity significantly.",15338796_16,-1,1,1
3486,tremor,3,4,24,30,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,-1,1,1
3487,Yohimbine,0,1,0,9,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0,-1,0
3488,serotonin,8,9,54,63,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0,-1,0
3489,yohimbine,8,9,58,67,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,0,-1,0
3491,yohimbine,6,7,35,44,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0,-1,0
3492,clomipramine,17,18,93,105,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0,-1,0
3493,yohimbine,3,4,21,30,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0,-1,0
3494,serotonin,14,15,84,93,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0,-1,0
3497,serotonin,25,26,168,177,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0
3498,yohimbine,30,31,207,216,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0
3499,yohimbine,3,4,17,26,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,0,-1,0
3500,yohimbine,13,14,87,96,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0,-1,0
3501,yohimbine,7,8,38,47,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0,-1,0
3502,yohimbine,3,4,16,25,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0,-1,0
3504,yohimbine,9,10,52,61,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0,-1,0
3505,serotonin,22,23,130,139,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0,-1,0
3506,yohimbine,13,14,92,101,Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication.,1535072_11,0,-1,0
3509,cyclophosphamide,9,10,72,88,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,0,-1,0
3510,mesna,19,20,122,127,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0
3511,cyclophosphamide,27,28,173,189,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0
3514,mesna,10,11,59,64,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,0,-1,0
3520,estrogen,16,17,102,110,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,0,-1,0
3521,tamoxifen,19,20,122,131,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,0,-1,0
3523,osteoporosis,22,23,145,157,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,1,1
3526,cataracts,5,6,42,51,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1
3527,gallbladder disease,7,9,53,72,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1
3529,cancer,14,15,105,111,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1
3534,cataracts,6,7,37,46,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1
3535,gallbladder disease,19,21,73,92,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1
3537,endometrial cancer,48,50,172,190,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1
3540,cataracts,20,21,125,134,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1
3541,gallbladder disease,22,24,136,155,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1
3543,endometrial cancer,29,31,185,203,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1
3544,levodopa,2,3,16,24,Optimization of levodopa therapy.,1549199_0,0,-1,0
3545,levodopa,9,10,51,59,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,0,-1,0
3546,toxicity,47,48,272,280,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,1,1
3548,orthostatic hypotension,10,12,68,91,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,1,1
3552,desferrioxamine,3,4,24,39,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0,-1,0
3554,sensorineural hearing loss,17,20,79,105,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,1,1
3560,cardiotoxicity,3,4,31,45,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,1,1
3564,infections,19,20,106,116,This is primarily due to complications related to either the stage of the disease at transplant or due to infections.,15517007_5,-1,1,1
3565,deaths,3,4,14,20,The number of deaths related to cardiac toxicity is low.,15517007_6,-1,1,1
3566,cardiac toxicity,6,8,32,48,The number of deaths related to cardiac toxicity is low.,15517007_6,-1,1,1
3567,cyclophosphamide,6,7,34,50,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0
3568,mitoxantrone,11,12,77,89,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0
3572,diabetic,14,15,76,84,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,1,1
3573,atherosclerosis,18,19,107,122,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,1,1
3577,stroke,32,33,155,161,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1
3578,diabetic,45,46,219,227,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1
3581,diabetes,36,37,235,243,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1
3582,diabetes,42,43,273,281,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,1,1
3587,stroke,27,28,116,122,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,1,1
3590,diabetes,23,24,155,163,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,1,1
3591,neuropathy,12,13,95,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,1,1
3592,neuropathy,18,19,102,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,1,1
3593,tuberculosis,9,10,61,73,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,1,1
3594,neuropathy,8,9,49,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,1,1
3595,neuropathy,9,10,40,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,1,1
3596,neuropathy,11,12,73,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,1,1
3598,neuropathy,8,9,50,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,1,1
3599,neuropathy,11,12,70,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,1,1
3600,neuropathy,9,10,58,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,1,1
3601,renal damage,13,15,106,118,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,-1,1,1
3602,renal damage,15,17,86,98,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,-1,1,1
3603,adriamycin,23,24,132,142,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,0,-1,0
3604,proteinuria,6,7,26,37,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,1,1
3605,adriamycin,10,11,53,63,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,0,-1,0
3606,Proteinuria,0,1,0,11,Proteinuria was measured every 2 weeks.,15572383_7,-1,1,1
3607,adriamycin,5,6,25,35,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,0,-1,0
3608,nephrotic,7,8,45,54,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1
3609,proteinuria,9,10,61,72,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1
3611,proteinuria,10,11,67,78,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,1,1
3612,adriamycin,12,13,85,95,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0,-1,0
3614,renal damage,13,15,100,112,CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.,15572383_13,-1,1,1
3615,renal damage,17,19,110,122,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,-1,1,1
3616,Hypoxia,0,1,0,7,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,1,1
3617,proteinuria,5,6,30,41,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,1,1
3618,hypertension,8,9,60,72,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,1,1
3620,hypoxia,11,12,73,80,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,1,1
3621,hypoxia,11,12,59,66,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,1,1
3623,hypoxia,22,23,151,158,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,1,1
3625,hypoxia,3,4,14,21,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,1,1
3626,hypoxia,10,11,79,86,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,1,1
3627,ribavirin,3,4,19,28,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,0,-1,0
3628,hemolysis,8,9,56,65,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,1,1
3629,ribavirin,15,16,111,120,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,0,-1,0
3631,Hemolytic anemia,21,23,157,173,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,1,1
3632,ribavirin,37,38,254,263,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,0,-1,0
3633,hemolytic anemia,3,5,29,45,"Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.",15580403_1,-1,1,1
3634,ribavirin,13,14,84,93,In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.,15580403_2,0,-1,0
3635,hemolysis,18,19,121,130,In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.,15580403_2,-1,1,1
3636,anemia,22,23,135,141,"METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.",15580403_3,-1,1,1
3637,ribavirin,11,12,57,66,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,0,-1,0
3638,ribavirin,3,4,19,28,"After reduction of ribavirin, 27 of 37 patients could continue combination therapy for a total of 24 weeks (group A).",15580403_5,0,-1,0
3639,ribavirin,9,10,45,54,"However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).",15580403_6,0,-1,0
3640,ribavirin,10,11,61,70,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,0,-1,0
3641,ribavirin,9,10,48,57,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,0,-1,0
3642,ribavirin,4,5,26,35,CONCLUSIONS: Reduction of ribavirin at hemoglobin level > or =10 g/dl is suitable in terms of efficacy and side effects.,15580403_10,0,-1,0
3643,interstitial nephritis,2,4,16,38,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,-1,1,1
3644,azithromycin,6,7,50,62,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,0,-1,0
3645,interstitial nephritis,11,13,75,97,"A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.",15602202_1,-1,1,1
3647,renal injury,21,23,140,152,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,-1,1,1
3649,hyperkalemia,4,5,47,59,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,1,1
3651,spironolactone,11,12,73,87,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,0,-1,0
3653,hyperkalemia,21,22,137,149,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,1,1
3656,spironolactone,11,12,72,86,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,0,-1,0
3657,hyperkalemia,11,12,77,89,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,1,1
3660,spironolactone,21,22,153,167,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,0,-1,0
3662,spironolactone,14,15,82,96,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,0,-1,0
3663,hyperkalemia,5,6,34,46,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,1,1
3666,spironolactone,13,14,72,86,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,0,-1,0
3667,hyperkalemia,16,17,94,106,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,1,1
3669,hyperkalemia,3,4,23,35,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,1,1
3670,diabetes,11,12,71,79,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,1,1
3671,potassium,17,18,107,116,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,0,-1,0
3672,potassium,22,23,143,152,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,0,-1,0
3675,creatinine,14,15,100,110,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0,-1,0
3676,hyperkalemia,3,4,36,48,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,1,1
3678,hyperprolactinemia,13,14,83,101,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,-1,1,1
3679,haloperidol,16,17,113,124,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,0,-1,0
3680,hyperprolactinemia,11,12,53,71,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,1,1
3681,haloperidol,15,16,84,95,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,0,-1,0
3682,testosterone,8,9,44,56,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,0,-1,0
3690,hyperemia,2,3,28,37,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,1,1
3692,hyperemia,25,26,126,135,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,1,1
3693,hyperemia,13,14,103,112,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,1,1
3695,reserpine,1,2,6,15,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,0,-1,0
3696,haloperidol,4,5,31,42,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,0,-1,0
3697,glutamate,9,10,80,89,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,0,-1,0
3698,dyskinesia,14,15,118,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,1,1
3699,dyskinesia,4,5,45,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,1,1
3701,dyskinesia,9,10,52,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,1,1
3702,reserpine,12,13,72,81,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,0,-1,0
3703,haloperidol,15,16,97,108,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,0,-1,0
3704,Reserpine,0,1,0,9,"Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days caused a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching, compared to the control.",15649445_3,0,-1,0
3705,Haloperidol,0,1,0,11,"Haloperidol administration (one dose of 12 mg/kg once a week s.c.) for 4 weeks caused an increase in vacuous chewing, tongue protrusion and duration of facial twitching observed in four weekly evaluations.",15649445_4,0,-1,0
3706,glutamate,7,8,49,58,"After the treatments and behavioral observation, glutamate uptake by segments of the brain was analyzed.",15649445_5,0,-1,0
3707,glutamate,2,3,12,21,"A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control.",15649445_6,0,-1,0
3708,reserpine,14,15,91,100,"A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control.",15649445_6,0,-1,0
3709,haloperidol,16,17,105,116,"A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control.",15649445_6,0,-1,0
3710,glutamate,5,6,27,36,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,0,-1,0
3711,glutamate,7,8,45,54,These results indicate that early changes in glutamate transport may be related to the development of vacuous chewing movements in rats.,15649445_8,0,-1,0
3712,morphine,17,18,132,140,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,0,-1,0
3715,morphine,21,22,154,162,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,0,-1,0
3717,morphine,20,21,73,81,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,0,-1,0
3719,morphine,43,44,165,173,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,0,-1,0
3723,morphine,2,3,9,17,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0,-1,0
3724,glutamate,10,11,49,58,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0,-1,0
3726,morphine,5,6,28,36,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0,-1,0
3727,glutamate,15,16,100,109,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0,-1,0
3729,neurotoxic,6,7,31,41,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,1,1
3733,amiodarone,8,9,57,67,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,0,-1,0
3734,Amiodarone,0,1,0,10,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,0,-1,0
3738,amiodarone,26,27,179,189,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,0,-1,0
3739,pseudolithiasis,2,3,31,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,-1,1,1
3740,ceftriaxone,5,6,22,33,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,0,-1,0
3741,pseudolithiasis,8,9,43,58,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,-1,1,1
3742,pseudolithiasis,24,25,152,167,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,1,1
3743,pseudolithiasis,13,14,83,98,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,-1,1,1
3744,ceftriaxone,19,20,141,152,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,0,-1,0
3745,ceftriaxone,5,6,30,41,"Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms. Of those, 13 (26%) developed biliary pathology.",15737522_4,0,-1,0
3746,pseudolithiasis,7,8,43,58,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,-1,1,1
3747,pseudolithiasis,6,7,34,49,"After cessation of the treatment, pseudolithiasis resolved spontaneously within a short period.",15737522_6,-1,1,1
3748,pseudolithiasis,3,4,17,32,The incidence of pseudolithiasis is not affected by fasting.,15737522_7,-1,1,1
3750,catecholamines,12,13,83,97,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,0,-1,0
3751,catecholamines,10,11,72,86,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0,-1,0
3752,psychotic symptoms,13,15,92,110,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,1,1
3753,psychiatric,20,21,135,146,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,1,1
3755,catecholamine,47,48,327,340,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0,-1,0
3756,Methamphetamine,0,1,0,15,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,0,-1,0
3757,amphetamine,2,3,19,30,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,0,-1,0
3759,psychotic symptoms,15,17,98,116,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,1,1
3762,aneurysm,35,36,222,230,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,1,1
3763,thrombosis,43,44,273,283,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,1,1
3765,aneurysm,6,7,37,45,The patient was asymptomatic and the aneurysm was detected in a routine control.,15804801_3,-1,1,1
3766,aneurysm,20,21,137,145,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,1,1
3767,hypertension,9,10,54,66,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,1,1
3768,headache,12,13,79,87,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,1,1
3769,vomiting,14,15,92,100,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,1,1
3770,verapamil,14,15,101,110,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,0,-1,0
3771,hypertensive,16,17,96,108,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,1,1
3772,hypertensive,19,20,104,116,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,1,1
3773,dexamethasone,19,20,112,125,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,0,-1,0
3774,dexamethasone,19,20,127,140,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,0,-1,0
3775,dexamethasone,3,4,28,41,Thirty-three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment.,15814210_2,0,-1,0
3776,dexamethasone,11,12,88,101,Thirty-three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment.,15814210_2,0,-1,0
3777,Dexamethasone,0,1,0,13,Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day.,15814210_4,0,-1,0
3778,dexamethasone,1,2,6,19,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,0,-1,0
3779,dexamethasone,13,14,86,99,Further long-term follow-up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development.,15814210_13,0,-1,0
3781,toxicity,12,13,69,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,1,1
3785,hepatotoxicity,13,14,99,113,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,1,1
3791,toxicity,1,2,6,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,-1,1,1
3792,hepatotoxicity,13,14,83,97,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1
3793,inflammation,21,22,138,150,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1
3794,necrosis,27,28,173,181,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1
3797,necrosis,25,26,149,157,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,1,1
3798,thrombotic microangiopathy,3,5,16,42,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,-1,1,1
3799,Thrombotic microangiopathy,2,4,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,-1,1,1
3800,thrombotic microangiopathy,4,6,30,56,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,-1,1,1
3801,hemolytic uremic syndrome,11,14,82,107,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,-1,1,1
3802,thrombotic microangiopathy,7,9,36,62,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,-1,1,1
3803,thrombotic microangiopathy,9,11,53,79,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,1,1
3804,thrombotic microangiopathy,5,7,23,49,RESULTS: Five cases of thrombotic microangiopathy were found.,15859940_6,-1,1,1
3805,cyclosporine,5,6,28,40,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0
3806,cyclosporine,14,15,75,87,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0
3807,tacrolimus,16,17,92,102,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0
3808,thrombotic microangiopathy,6,8,31,57,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,1,1
3810,hemolytic uremic syndrome,10,13,59,84,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,-1,1,1
3811,hemolytic uremic syndrome,22,25,150,175,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,-1,1,1
3812,cyclosporine,5,6,35,47,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0
3813,tacrolimus,7,8,49,59,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0
3814,toxicity,9,10,61,69,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,-1,1,1
3815,thrombotic microangiopathy,7,9,41,67,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,-1,1,1
3816,cyclosporine,16,17,106,118,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,0,-1,0
3817,thrombotic microangiopathy,8,10,39,65,"In the current study, the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature (20%).",15859940_13,-1,1,1
3818,toxicity,3,4,28,36,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,1,1
3820,piroxicam,17,18,133,142,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,0,-1,0
3821,toxicity,2,3,15,23,"Unlike general toxicity data, their prenatal toxic effects were not extensively studied before.",15863244_2,-1,1,1
3822,toxicity,10,11,60,68,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,1,1
3823,piroxicam,15,16,91,100,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,0,-1,0
3826,piroxicam,10,11,45,54,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,0,-1,0
3828,piroxicam,23,24,127,136,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,0,-1,0
3829,toxicity,3,4,18,26,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,1,1
3830,piroxicam,26,27,162,171,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,0,-1,0
3832,toxicity,12,13,69,77,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,1,1
3833,piroxicam,6,7,36,45,Lack of teratogenicity was found in piroxicam and DFU-exposed groups.,15863244_11,0,-1,0
3835,piroxicam,3,4,12,21,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,0,-1,0
3856,succinylcholine,17,18,81,96,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,0,-1,0
3857,propofol,5,6,43,51,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,0,-1,0
3859,etoposide,9,10,84,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0
3860,daunorubicin,11,12,98,110,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0
3861,doxorubicin,14,15,119,130,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0
3862,daunorubicin,4,5,28,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0,-1,0
3863,doxorubicin,6,7,45,56,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0,-1,0
3864,etoposide,10,11,84,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0,-1,0
3865,myelosuppression,26,27,186,202,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,1,1
3866,cardiac toxicity,28,30,207,223,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,1,1
3867,cardiotoxicity,10,11,83,97,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,1,1
3868,toxicity,11,12,70,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,1,1
3869,etoposide,36,37,259,268,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0
3870,daunorubicin,38,39,270,282,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0
3871,doxorubicin,41,42,288,299,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0
3872,etoposide,10,11,49,58,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0
3873,daunorubicin,12,13,60,72,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0
3874,doxorubicin,15,16,78,89,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0
3875,myelosuppression,7,8,47,63,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,1,1
3877,daunorubicin,12,13,85,97,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0
3878,etoposide,14,15,102,111,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0
3879,myelosuppression,32,33,226,242,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,1,1
3881,doxorubicin,43,44,292,303,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0
3882,doxorubicin,18,19,140,151,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0,-1,0
3883,daunorubicin,25,26,189,201,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0,-1,0
3884,etoposide,6,7,39,48,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0,-1,0
3885,etoposide,13,14,90,99,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0,-1,0
3886,toxicity,25,26,178,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,1,1
3888,creatine,5,6,41,49,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,0,-1,0
3891,arrhythmia,4,5,20,30,"Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved.",15899738_2,-1,1,1
3892,alcohol,11,12,60,67,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,0,-1,0
3894,fractures,9,10,55,64,"His medical history was unremarkable, except for minor fractures of the fingers and foot.",15899738_5,-1,1,1
3895,magnesium,3,4,29,38,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,0,-1,0
3896,potassium,6,7,44,53,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,0,-1,0
3897,alcohol,20,21,124,131,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,0,-1,0
3898,creatine,18,19,98,106,"However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed.",15899738_7,0,-1,0
3899,heparin,11,12,77,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0,-1,0
3900,diltiazem,16,17,108,117,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0,-1,0
3901,amiodarone,22,23,151,161,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0,-1,0
3902,metoprolol,11,12,59,69,"When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion.",15899738_9,0,-1,0
3903,aspirin,13,14,74,81,"When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion.",15899738_9,0,-1,0
3904,creatine,1,2,10,18,Exogenous creatine is used by athletes to theoretically improve exercise performance.,15899738_10,0,-1,0
3905,creatine,4,5,26,34,"Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products.",15899738_11,0,-1,0
3906,creatine,5,6,39,47,Previous anecdotal reports have linked creatine to the development of arrhythmia.,15899738_12,0,-1,0
3907,arrhythmia,10,11,70,80,Previous anecdotal reports have linked creatine to the development of arrhythmia.,15899738_12,-1,1,1
3908,Seizures,0,1,0,8,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,-1,1,1
3909,cocaine,4,5,24,31,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,0,-1,0
3910,benzoylecgonine,6,7,43,58,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,0,-1,0
3911,cocaine,6,7,24,31,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,0,-1,0
3912,seizures,22,23,102,110,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,-1,1,1
3913,strokes,24,25,115,122,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,-1,1,1
3914,cocaine,9,10,48,55,This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae.,1592014_2,0,-1,0
3915,cocaine,9,10,54,61,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0,-1,0
3916,benzoylecgonine,11,12,63,78,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0,-1,0
3917,seizures,18,19,94,102,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,-1,1,1
3918,cocaine,12,13,59,66,Two separate equimolar doses (0.2 and 0.4 mumol) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats.,1592014_4,0,-1,0
3919,seizure,11,12,61,68,"Treated rats were then evaluated for incidence, latency, and seizure pattern or for locomotor activity in animals without seizures.",1592014_5,-1,1,1
3920,seizures,20,21,122,130,"Treated rats were then evaluated for incidence, latency, and seizure pattern or for locomotor activity in animals without seizures.",1592014_5,-1,1,1
3921,seizures,1,2,11,19,BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.,1592014_6,-1,1,1
3922,cocaine,17,18,127,134,BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.,1592014_6,0,-1,0
3923,seizures,2,3,24,32,"Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.",1592014_7,-1,1,1
3924,death,16,17,106,111,"Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.",1592014_7,-1,1,1
3925,death,36,37,206,211,"Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.",1592014_7,-1,1,1
3926,seizure,16,17,116,123,Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression.,1592014_8,-1,1,1
3927,seizures,6,7,35,43,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,1,1
3928,seizures,16,17,124,132,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,1,1
3929,seizures,6,7,41,49,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,-1,1,1
3930,seizures,18,19,130,138,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,-1,1,1
3931,cocaine,25,26,174,181,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,0,-1,0
3932,amnesia,7,8,43,50,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,-1,1,1
3933,propofol,12,13,83,91,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0,-1,0
3934,propofol,20,21,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0,-1,0
3935,propofol,17,18,124,132,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,0,-1,0
3938,serotonin,2,3,15,24,Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.,15957009_1,0,-1,0
3939,acetylcholine,17,18,103,116,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,0,-1,0
3947,scopolamine,28,29,224,235,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0,-1,0
3950,scopolamine,31,32,142,153,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,0,-1,0
3954,Amiodarone,0,1,0,10,Amiodarone pulmonary toxicity.,1595783_0,0,-1,0
3955,toxicity,2,3,21,29,Amiodarone pulmonary toxicity.,1595783_0,-1,1,1
3956,Amiodarone,0,1,0,10,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,0,-1,0
3957,toxicity,2,3,14,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,1,1
3958,amiodarone,4,5,26,36,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,0,-1,0
3959,hypersensitivity,22,23,155,171,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,1,1
3960,toxicity,8,9,71,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,1,1
3962,infection,14,15,77,86,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,1,1
3963,malignancy,17,18,92,102,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,1,1
3964,amiodarone,3,4,20,30,"While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable.",1595783_5,0,-1,0
3965,steroid,4,5,30,37,Dose reduction or concomitant steroid therapy may have a role in selected patients.,1595783_6,0,-1,0
3967,pain,16,17,106,110,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,1,1
3969,glutamate,23,24,139,148,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0,-1,0
3970,pain,13,14,67,71,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1
3971,hyperalgesia,23,24,143,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1
3972,hyperalgesia,23,24,143,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1
3973,hyperalgesia,28,29,190,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1
3974,hyperalgesia,28,29,190,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1
3975,hiccups,2,3,33,40,Possible azithromycin-associated hiccups.,15985056_0,-1,1,1
3976,hiccups,8,9,42,49,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,-1,1,1
3977,azithromycin,11,12,64,76,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,0,-1,0
3978,hiccups,9,10,58,65,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,1,1
3979,azithromycin,12,13,82,94,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,0,-1,0
3980,Hiccups,0,1,0,7,Hiccups were persistent and exhausting.,15985056_3,-1,1,1
3981,azithromycin,2,3,19,31,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,0,-1,0
3982,hiccups,9,10,75,82,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,1,1
3983,hiccups,4,5,20,27,No organic cause of hiccups was identified despite extensive investigation.,15985056_5,-1,1,1
3984,hiccups,9,10,76,83,DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups.,15985056_6,-1,1,1
3985,Corticosteroids,0,1,0,15,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0
3986,dexamethasone,2,3,17,30,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0
3987,methylprednisolone,4,5,35,53,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0
3988,benzodiazepines,7,8,56,71,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0
3989,midazolam,9,10,73,82,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0
3990,hiccups,32,33,226,233,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,-1,1,1
3991,hiccups,4,5,26,33,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,1,1
3992,hiccups,45,46,275,282,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,1,1
3993,azithromycin,9,10,53,65,Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.,15985056_10,0,-1,0
3994,hiccups,15,16,95,102,Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.,15985056_10,-1,1,1
3995,hiccups,5,6,39,46,CONCLUSIONS: Diagnosis of drug-induced hiccups is difficult and often achieved only by a process of elimination.,15985056_11,-1,1,1
3996,hiccups,11,12,75,82,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,1,1
3999,cocaine,4,5,19,26,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,0,-1,0
4003,cocaine,21,22,129,136,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,0,-1,0
4006,cocaine,12,13,66,73,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,0,-1,0
4009,seizures,28,29,149,157,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,1,1
4010,death,34,35,172,177,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,1,1
4012,death,4,5,31,36,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,1,1
4016,hypercalcemia,9,10,65,78,OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.,16006300_1,-1,1,1
4017,hypercalcemia,16,17,92,105,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,-1,1,1
4018,calcium,20,21,123,130,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,0,-1,0
4022,furosemide,8,9,62,72,Treatment included aggressive hydration and varied amounts of furosemide.,16006300_5,0,-1,0
4023,calcium,7,8,37,44,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,0,-1,0
4024,hypocalcemia,24,25,145,157,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,1,1
4025,calcium,12,13,66,73,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,0,-1,0
4027,hypercalcemia,11,12,70,83,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,1,1
4029,furosemide,4,5,26,36,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,0,-1,0
4030,calcium,10,11,65,72,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,0,-1,0
4032,hypocalcemia,8,9,63,75,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,1,1
4033,hypercalcemia,16,17,111,124,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,-1,1,1
4034,myocardial injury,3,5,33,50,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,-1,1,1
4035,cocaine,8,9,83,90,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,0,-1,0
4036,schizophrenic,16,17,94,107,The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.,1601297_1,-1,1,1
4037,cocaine,3,4,14,21,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,0,-1,0
4038,myocardial injury,15,17,87,104,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1
4040,ischemia,22,23,139,147,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1
4041,vasculitis,2,3,34,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,1,1
4042,vasculitis,1,2,17,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,1,1
4043,vasculitis,11,12,71,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,1,1
4044,warfarin,10,11,56,64,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,0,-1,0
4045,warfarin,11,12,76,84,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,0,-1,0
4046,warfarin,21,22,129,137,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,0,-1,0
4047,warfarin,9,10,41,49,"In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.",16047871_6,0,-1,0
4048,warfarin,9,10,56,64,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,0,-1,0
4049,seizures,2,3,26,34,Cocaine-induced brainstem seizures and behavior.,1610717_0,-1,1,1
4050,cocaine,39,40,270,277,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,0,-1,0
4051,Cocaine,0,1,0,7,Cocaine (40 mg/kg) was injected subcutaneously for an acute experiment and subsequent 20 mg/kg doses twice daily for 3 days in a chronic study.,1610717_3,0,-1,0
4052,Cocaine,0,1,0,7,"Cocaine generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects.",1610717_4,0,-1,0
4053,hyperactivity,8,9,50,63,"The abnormal behaviors were yawning, retrocollis, hyperactivity, hypersensitivity, ""beating drum"" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.",1610717_5,-1,1,1
4054,hypersensitivity,10,11,65,81,"The abnormal behaviors were yawning, retrocollis, hyperactivity, hypersensitivity, ""beating drum"" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.",1610717_5,-1,1,1
4055,Hypersensitivity,0,1,0,16,"Hypersensitivity to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.",1610717_7,-1,1,1
4056,Cocaine,0,1,0,7,Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates.,1610717_9,0,-1,0
4057,dyskinesias,7,8,59,70,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,1,1
4059,dyskinesia,8,9,65,75,The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear.,16116131_1,-1,1,1
4061,apomorphine,46,47,291,302,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,0,-1,0
4062,dyskinesias,10,11,58,69,"rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.",16116131_3,-1,1,1
4063,glioblastoma,11,12,98,110,Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.,16132524_0,-1,1,1
4064,tumors,3,4,22,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,1,1
4067,glioblastoma,2,3,10,22,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,-1,1,1
4068,paclitaxel,19,20,127,137,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0
4069,carboplatin,21,22,142,153,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0
4071,paclitaxel,20,21,138,148,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0
4072,carboplatin,22,23,153,164,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0
4073,paclitaxel,9,10,45,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0
4075,paclitaxel,30,31,166,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0
4077,glioblastoma,4,5,40,52,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,1,1
4078,myoclonus,7,8,52,61,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,1,1
4079,myoclonic jerks,22,24,140,155,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,1,1
4081,hypertension,9,10,58,70,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,1,1
4082,bradycardia,11,12,75,86,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,1,1
4083,corticosterone,29,30,191,205,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,0,-1,0
4084,psychiatric,12,13,64,75,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,1,1
4085,amnesia,4,5,23,30,Learning of rats under amnesia caused by pentobarbital.,1616457_0,-1,1,1
4086,pentobarbital,7,8,41,54,Learning of rats under amnesia caused by pentobarbital.,1616457_0,0,-1,0
4087,amnesia,12,13,66,73,"Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.",1616457_1,-1,1,1
4088,pentobarbital,15,16,86,99,"Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.",1616457_1,0,-1,0
4089,pentobarbital,11,12,56,69,In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state.,1616457_3,0,-1,0
4090,pentobarbital,10,11,65,78,Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed.,1616457_6,0,-1,0
4091,pentobarbital,9,10,64,77,These findings show that the brain-dissociated state induced by pentobarbital is formed with the participation of the mechanisms of information perception.,1616457_7,0,-1,0
4096,osteoporosis,8,9,61,73,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,1,1
4098,calcium,11,12,71,78,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,0,-1,0
4099,calcium,10,11,46,53,Age-matched controls (n = 14) were given only calcium.,16167916_3,0,-1,0
4104,Cocaine,2,3,14,21,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,0,-1,0
4105,vasculitis,15,16,120,130,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,1,1
4106,cocaine,10,11,58,65,"However, there are few studies of angiographic effects of cocaine on human cerebral arteries.",16174948_2,0,-1,0
4108,cocaine,23,24,169,176,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,0,-1,0
4109,cocaine,16,17,111,118,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,0,-1,0
4110,cocaine,6,7,41,48,RESULTS: Thirteen patients with positive cocaine toxicology were compared to 26 controls.,16174948_7,0,-1,0
4111,vasculitis,19,20,139,149,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,1,1
4112,cocaine,33,34,240,247,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,0,-1,0
4113,encephalopathy,1,2,18,32,Valproate-induced encephalopathy.,16181582_0,-1,1,1
4114,encephalopathy,1,2,18,32,Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.,16181582_1,-1,1,1
4115,epileptic,12,13,90,99,Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.,16181582_1,-1,1,1
4116,hyperammonemia,8,9,50,64,It is usually but not necessarily associated with hyperammonemia.,16181582_3,-1,1,1
4117,encephalopathy,4,5,28,42,A case of valproate-induced encephalopathy is presented.,16181582_5,-1,1,1
4118,Methamphetamine,0,1,0,15,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,0,-1,0
4119,aggressiveness,16,17,115,129,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,1,1
4120,psychiatric,11,12,73,84,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,1,1
4121,methamphetamine,18,19,114,129,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,0,-1,0
4124,aggressiveness,16,17,92,106,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,1,1
4125,aggressiveness,3,4,17,31,This increase in aggressiveness was not secondary to METH-induced hyperactivity.,16192988_3,-1,1,1
4126,hyperactivity,9,10,66,79,This increase in aggressiveness was not secondary to METH-induced hyperactivity.,16192988_3,-1,1,1
4132,schizophrenic,7,8,55,68,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,1,1
4135,risperidone,11,12,76,87,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0,-1,0
4136,olanzapine,13,14,89,99,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0,-1,0
4137,clozapine,24,25,148,157,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,0,-1,0
4138,schizophrenic,5,6,30,43,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,1,1
4141,clozapine,27,28,197,206,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,0,-1,0
4143,chloroquine,9,10,52,63,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,0,-1,0
4144,dizziness,23,24,156,165,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,1,1
4149,chloroquine,15,16,106,117,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,0,-1,0
4152,gentamicin,24,25,145,155,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0,-1,0
4153,Aminoglycoside,0,1,0,14,Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.,16298782_2,0,-1,0
4154,ototoxicity,1,2,6,17,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1
4155,sensorineural hearing loss,33,36,198,224,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1
4156,gentamicin,14,15,75,85,"In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear.",16298782_4,0,-1,0
4159,nicotine,4,5,20,28,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,0,-1,0
4160,nicotine,10,11,59,67,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,0,-1,0
4161,Nicotine,2,3,12,20,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0,-1,0
4162,nicotine,12,13,65,73,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0,-1,0
4163,nicotine,18,19,108,116,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0,-1,0
4164,nicotine,2,3,14,22,The increased nicotine exposure from the lozenge has raised questions about the relative safety of the lozenge and gum.,16330293_2,0,-1,0
4165,nicotine,16,17,86,94,OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases.,16330293_3,0,-1,0
4166,nicotine,20,21,112,120,OBJECTIVE: The objective of this study was to compare the safety profiles of the 4-mg nicotine lozenge and 4-mg nicotine gum in smokers with selected label-restricted diseases.,16330293_3,0,-1,0
4168,hypertension,18,19,99,111,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,1,1
4170,nicotine,11,12,60,68,Patients were randomized in a 1:1 ratio to receive the 4-mg nicotine lozenge or 4-mg nicotine gum.,16330293_5,0,-1,0
4171,nicotine,15,16,85,93,Patients were randomized in a 1:1 ratio to receive the 4-mg nicotine lozenge or 4-mg nicotine gum.,16330293_5,0,-1,0
4172,nicotine,1,2,4,12,"The nicotine lozenge and nicotine gum were equally well tolerated, despite increased nicotine exposure from the lozenge.",16330293_11,0,-1,0
4173,nicotine,4,5,25,33,"The nicotine lozenge and nicotine gum were equally well tolerated, despite increased nicotine exposure from the lozenge.",16330293_11,0,-1,0
4174,nicotine,13,14,85,93,"The nicotine lozenge and nicotine gum were equally well tolerated, despite increased nicotine exposure from the lozenge.",16330293_11,0,-1,0
4175,smoking,11,12,61,68,"Stratification of patients by sex, age, extent of concurrent smoking, extent of product use, and severity of adverse events revealed no clinically significant differences between the lozenge and gum.",16330293_13,0,-1,0
4176,nausea,6,7,36,42,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,1,1
4177,hiccups,23,24,83,90,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,1,1
4178,headache,41,42,133,141,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,1,1
4179,nicotine,4,5,21,29,CONCLUSION: The 4-mg nicotine lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions.,16330293_18,0,-1,0
4180,nicotine,8,9,47,55,CONCLUSION: The 4-mg nicotine lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions.,16330293_18,0,-1,0
4181,pain,21,22,143,147,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,1,1
4182,secondary hyperalgesia,30,32,199,221,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,1,1
4183,Secondary hyperalgesia,0,2,0,22,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1
4185,neuropathic pain,11,13,101,117,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1
4186,hyperalgesia,12,13,83,95,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,-1,1,1
4187,gabapentin,11,12,51,61,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,0,-1,0
4188,neuropathic pain,17,19,83,99,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,1,1
4189,secondary hyperalgesia,31,33,223,245,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,-1,1,1
4190,gabapentin,3,4,12,22,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,0,-1,0
4191,gabapentin,6,7,18,28,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,0,-1,0
4192,gabapentin,27,28,155,165,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,0,-1,0
4193,gabapentin,43,44,248,258,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,0,-1,0
4194,gabapentin,4,5,29,39,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0
4195,gabapentin,29,30,209,219,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0
4196,epilepsy,9,10,72,80,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,-1,1,1
4197,pilocarpine,12,13,92,103,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,0,-1,0
4198,death,19,20,133,138,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,1,1
4200,pilocarpine,49,50,277,288,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,0,-1,0
4201,temporal lobe epilepsy,52,55,298,320,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,1,1
4203,nephrotoxic,2,3,11,22,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,1,1
4205,sodium,7,8,47,53,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,0,-1,0
4206,oxygen,10,11,65,71,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,0,-1,0
4212,amnesia,11,12,93,100,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,1,1
4213,scopolamine,9,10,47,58,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,0,-1,0
4214,amnesia,14,15,103,110,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,1,1
4215,scopolamine,16,17,79,90,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0
4217,scopolamine,46,47,230,241,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0,-1,0
4219,scopolamine,2,3,9,20,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,0,-1,0
4220,amnesia,17,18,124,131,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,1,1
4221,calcium,4,5,22,29,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,0,-1,0
4222,nitrendipine,7,8,46,58,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,0,-1,0
4223,hypertension,14,15,104,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,1,1
4224,calcium,8,9,42,49,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0
4225,nitrendipine,11,12,66,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0
4226,angiotensin,14,15,86,97,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0
4227,enalapril,18,19,126,135,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0
4228,albuminuria,23,24,155,166,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,1,1
4229,hypertension,44,45,287,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,1,1
4230,hypertensive,9,10,46,58,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,1,1
4231,hypertensive,27,28,132,144,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,1,1
4232,Enalapril,0,1,0,9,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,0,-1,0
4233,nitrendipine,3,4,18,30,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,0,-1,0
4234,glomerulosclerosis,9,10,55,73,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,-1,1,1
4235,enalapril,14,15,95,104,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,0,-1,0
4236,albuminuria,7,8,47,58,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,1,1
4237,hypertensive,30,31,154,166,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,1,1
4238,glomerulosclerosis,2,3,13,31,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,1,1
4239,hypertensive,14,15,118,130,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,1,1
4240,hypertensive,38,39,187,199,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,1,1
4241,Ketoconazole,0,1,0,12,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0,-1,0
4243,Ketoconazole,0,1,0,12,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,0,-1,0
4247,ketoconazole,24,25,137,149,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0,-1,0
4248,infection,29,30,174,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,1,1
4249,ketoconazole,9,10,54,66,Her QT interval returned to normal upon withdrawal of ketoconazole.,16403073_3,0,-1,0
4250,ketoconazole,13,14,66,78,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0,-1,0
4251,ketoconazole,27,28,155,167,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0,-1,0
4253,vasculitis,1,2,15,25,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,1,1
4256,vasculitis,5,6,27,37,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,-1,1,1
4259,propylthiouracil,3,4,17,33,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,0,-1,0
4260,vasculitis,5,6,51,61,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,1,1
4261,hyperthyroidism,4,5,35,50,"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.",16418614_5,-1,1,1
4262,vasculitis,15,16,111,121,"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.",16418614_5,-1,1,1
4263,vasculitis,1,2,9,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,-1,1,1
4264,methylphenidate,4,5,35,50,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,0,-1,0
4265,Methylphenidate,0,1,0,15,Methylphenidate is structurally and functionally similar to amphetamine.,16428221_1,0,-1,0
4266,amphetamine,7,8,60,71,Methylphenidate is structurally and functionally similar to amphetamine.,16428221_1,0,-1,0
4267,vasculitis,1,2,9,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,1,1
4268,amphetamine,4,5,36,47,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,0,-1,0
4269,stroke,15,16,102,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,1,1
4270,methylphenidate,20,21,133,148,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,0,-1,0
4271,methylphenidate,12,13,64,79,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,0,-1,0
4272,hyperactivity,15,16,87,100,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,1,1
4273,strokes,21,22,138,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,1,1
4274,vasculitis,4,5,34,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,1,1
4275,strokes,13,14,93,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,1,1
4276,methylphenidate,3,4,17,32,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,0,-1,0
4277,vasculitis,5,6,42,52,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,1,1
4278,methylphenidate,18,19,130,145,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,0,-1,0
4279,methylphenidate,20,21,110,125,"This potential side-effect, though very rare, represents one more reason to be very restrictive in the use of methylphenidate.",16428221_6,0,-1,0
4280,choline,2,3,19,26,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,0,-1,0
4281,amnesia,10,11,89,96,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,1,1
4282,choline,1,2,4,11,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0,-1,0
4283,acetylcholine,20,21,139,152,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0,-1,0
4288,amnesia,17,18,114,121,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,1,1
4289,scopolamine,2,3,14,25,Injections of scopolamine into mice resulted in impaired performance on Y-maze tests (a 37% decreases in alternation behavior).,16428827_6,0,-1,0
4290,scopolamine,12,13,60,71,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,0,-1,0
4291,acetylcholine,10,11,58,71,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,0,-1,0
4292,amnesia,23,24,155,162,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,1,1
4293,dry mouth,16,18,69,78,Only one case (3.3%) withdrew from the present study due to a severe dry mouth.,16471092_10,-1,1,1
4294,myoclonus,3,4,34,43,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,1,1
4295,myoclonus,28,29,155,164,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,1,1
4296,Myoclonus,2,3,14,23,MEASUREMENTS: Myoclonus was recorded with a scale of 0 to 3.,16563323_6,-1,1,1
4297,nausea,14,15,54,60,"The grade of sedation (none, mild, moderate, severe), nausea, pruritus, and apnea were recorded after injection of both drugs.",16563323_7,-1,1,1
4298,pruritus,16,17,62,70,"The grade of sedation (none, mild, moderate, severe), nausea, pruritus, and apnea were recorded after injection of both drugs.",16563323_7,-1,1,1
4299,apnea,19,20,76,81,"The grade of sedation (none, mild, moderate, severe), nausea, pruritus, and apnea were recorded after injection of both drugs.",16563323_7,-1,1,1
4300,myoclonus,6,7,31,40,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,1,1
4301,apnea,7,8,43,48,"None of the patients experienced sedation, apnea, nausea, or pruritus after injection of both drugs.",16563323_9,-1,1,1
4302,nausea,9,10,50,56,"None of the patients experienced sedation, apnea, nausea, or pruritus after injection of both drugs.",16563323_9,-1,1,1
4303,pruritus,12,13,61,69,"None of the patients experienced sedation, apnea, nausea, or pruritus after injection of both drugs.",16563323_9,-1,1,1
4304,myoclonus,14,15,94,103,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,1,1
4305,myoclonus,8,9,63,72,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1
4306,apnea,19,20,138,143,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1
4307,nausea,21,22,145,151,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1
4308,pruritus,24,25,156,164,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1
4309,myoclonus,5,6,38,47,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,1,1
4312,"3,4-methylenedioxymethamphetamine",14,15,77,110,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,0,-1,0
4313,ecstasy,16,17,112,119,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,0,-1,0
4315,ecstasy,2,3,17,24,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0,-1,0
4317,ecstasy,21,22,139,146,These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use.,16574712_6,0,-1,0
4318,serotonin,3,4,20,29,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,0,-1,0
4319,ecstasy,9,10,72,79,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,0,-1,0
4321,"3,4-methylenedioxymethamphetamine",1,2,9,42,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0,-1,0
4323,ecstasy,5,6,52,59,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0,-1,0
4324,serotonin,13,14,92,101,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0,-1,0
4335,memory impairment,6,8,28,45,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,1,1
4341,isoproterenol,23,24,125,138,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0,-1,0
4344,myocardial damage,21,23,108,125,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,1,1
4346,creatine,42,43,228,236,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0
4348,iron,56,57,316,320,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0,-1,0
4355,glutathione,34,35,237,248,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0
4359,stroke,26,27,212,218,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,1,1
4360,hypertension,28,29,220,232,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,1,1
4365,toxicity,34,35,232,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,1,1
4368,seizures,10,11,74,82,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,1,1
4371,pilocarpine,20,21,100,111,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0,-1,0
4372,Pilocarpine,0,1,0,11,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,0,-1,0
4375,seizures,19,20,122,130,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,1,1
4376,seizures,30,31,181,189,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,1,1
4381,prostaglandins,4,5,24,38,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,0,-1,0
4390,anemia,4,5,29,35,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,1,1
4392,infection,1,2,8,17,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1
4394,cirrhosis,12,13,63,72,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1
4395,hepatocellular carcinoma,14,16,74,98,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1
4396,liver disease,19,21,114,127,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1
4398,ribavirin,14,15,98,107,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,0,-1,0
4399,hemolytic anemia,25,27,156,172,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,1,1
4400,hemolysis,9,10,75,84,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,1,1
4401,anemia,13,14,95,101,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,1,1
4402,anemia,3,4,12,18,"In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.",16629641_5,-1,1,1
4403,anemia,2,3,30,36,"Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates.",16629641_6,-1,1,1
4404,anemia,9,10,78,84,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages.,16629641_7,-1,1,1
4405,ribavirin,6,7,41,50,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,0,-1,0
4406,ribavirin,17,18,108,117,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,0,-1,0
4407,hemolytic anemia,23,25,147,163,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,1,1
4409,alcohol,2,3,10,17,Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures.,16634859_0,0,-1,0
4410,alcohol,19,20,99,106,"BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by alcohol exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged.",16634859_1,0,-1,0
4411,alcohol,4,5,30,37,Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes.,16634859_2,0,-1,0
4413,alcohol,22,23,149,156,METHODS: We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study.,16634859_4,0,-1,0
4414,alcohol,3,4,21,28,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,0,-1,0
4415,alcohol,29,30,173,180,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,0,-1,0
4416,drug abuse,21,23,148,158,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,-1,1,1
4417,alcohol,1,2,4,11,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,0,-1,0
4418,Amphetamine,0,1,0,11,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,0,-1,0
4419,alcohol,32,33,207,214,"Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects.",16634859_14,0,-1,0
4420,cancer,16,17,84,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,1,1
4424,cancer,15,16,89,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,1,1
4426,carcinoma,4,5,33,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,1,1
4427,carcinoma,29,30,154,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,1,1
4428,Neutropenia,0,1,0,11,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,1,1
4429,infections,14,15,70,80,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,1,1
4430,seizures,23,24,115,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,1,1
4431,nausea,7,8,30,36,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,1,1
4432,vomiting,9,10,41,49,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,1,1
4433,carcinoma,5,6,29,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,1,1
4434,desipramine,2,3,20,31,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,0,-1,0
4435,cinacalcet,7,8,59,69,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,0,-1,0
4436,cinacalcet,8,9,47,57,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0,-1,0
4437,cinacalcet,11,12,56,66,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0,-1,0
4438,desipramine,17,18,93,104,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0,-1,0
4439,desipramine,28,29,175,186,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0,-1,0
4440,cinacalcet,46,47,266,276,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0,-1,0
4442,desipramine,2,3,12,23,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0,-1,0
4443,desipramine,11,12,54,65,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0,-1,0
4444,cinacalcet,19,20,119,129,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0,-1,0
4445,desipramine,6,7,17,28,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0
4446,desipramine,10,11,45,56,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0
4447,cinacalcet,14,15,81,91,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0
4448,desipramine,8,9,64,75,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0
4449,desipramine,13,14,102,113,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0
4450,cinacalcet,15,16,119,129,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0
4451,nausea,29,30,175,181,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,-1,1,1
4452,headache,31,32,186,194,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,-1,1,1
4453,desipramine,41,42,248,259,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0
4454,cinacalcet,43,44,263,273,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0
4455,cinacalcet,6,7,41,51,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,0,-1,0
4456,cinacalcet,8,9,58,68,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,0,-1,0
4457,neuropathy,2,3,28,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,1,1
4458,tuberculosis,9,10,53,65,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,1,1
4459,visual loss,25,27,148,159,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,1,1
4460,neuropathy,9,10,72,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,1,1
4461,visual loss,8,10,59,70,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,1,1
4463,paroxetine,9,10,78,88,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,0,-1,0
4464,alprazolam,11,12,93,103,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,0,-1,0
4465,depressive,4,5,23,33,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,1,1
4466,psychiatric,10,11,61,72,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,1,1
4467,agitation,23,24,133,142,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,1,1
4468,paroxetine,11,12,57,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,0,-1,0
4469,alprazolam,15,16,79,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,0,-1,0
4470,paroxetine,5,6,19,29,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0,-1,0
4471,alprazolam,7,8,34,44,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0,-1,0
4473,tremors,24,25,158,165,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,1,1
4474,fever,4,5,18,23,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,1,1
4475,extrapyramidal symptoms,26,28,118,141,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,1,1
4476,creatine,6,7,40,48,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0
4477,aspartate,13,14,76,85,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0
4478,alanine,20,21,115,122,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0
4479,bromocriptine,3,4,21,34,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0,-1,0
4480,diazepam,5,6,39,47,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0,-1,0
4481,fever,5,6,18,23,"7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).",16720068_7,-1,1,1
4483,paroxetine,22,23,145,155,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,0,-1,0
4484,alprazolam,24,25,160,170,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,0,-1,0
4485,depressive,10,11,56,66,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,1,1
4486,dehydration,16,17,105,116,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,1,1
4487,agitation,18,19,118,127,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,1,1
4488,depression,13,14,98,108,Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.,16720068_12,-1,1,1
4489,norepinephrine,2,3,19,33,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0,-1,0
4490,desipramine,10,11,92,103,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0,-1,0
4491,convulsions,19,20,174,185,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,-1,1,1
4492,norepinephrine,2,3,15,29,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0,-1,0
4493,seizures,18,19,118,126,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,-1,1,1
4494,cocaine,21,22,137,144,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0,-1,0
4495,desipramine,3,4,24,35,"Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.",16725121_2,0,-1,0
4496,lidocaine,2,3,21,30,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0
4497,bupivacaine,4,5,32,43,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0
4498,desipramine,8,9,61,72,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0
4499,cocaine,3,4,19,26,Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.,16725121_4,0,-1,0
4500,desipramine,3,4,24,35,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,0,-1,0
4501,convulsions,11,12,95,106,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,-1,1,1
4502,convulsions,17,18,145,156,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,-1,1,1
4503,lidocaine,2,3,21,30,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0
4504,desipramine,4,5,36,47,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0
4505,convulsive,9,10,72,82,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,-1,1,1
4506,lidocaine,12,13,95,104,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0
4507,cocaine,14,15,109,116,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0
4508,desipramine,20,21,155,166,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,0,-1,0
4509,desipramine,13,14,99,110,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,0,-1,0
4511,cocaine,3,4,27,34,Repeated administration of cocaine induces up-regulation of hippocampal NET function.,16725121_9,0,-1,0
4513,cocaine,17,18,142,149,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,0,-1,0
4514,carbachol,5,6,33,42,Case report: acute unintentional carbachol intoxication.,16740173_0,0,-1,0
4515,carbachol,4,5,33,42,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0,-1,0
4516,poisoning,11,12,59,68,We report an interesting case investigating a (near) fatal poisoning.,16740173_2,-1,1,1
4519,carbachol,22,23,106,115,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0,-1,0
4520,carbachol,5,6,18,27,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0,-1,0
4521,Carbachol,0,1,0,9,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,0,-1,0
4522,nausea,10,11,66,72,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,1,1
4523,hypotension,14,15,87,98,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,1,1
4524,Bradycardia,0,1,0,11,"Bradycardia, cholinergic symptoms and asystole occurred.",16740173_8,-1,1,1
4525,asystole,5,6,38,46,"Bradycardia, cholinergic symptoms and asystole occurred.",16740173_8,-1,1,1
4526,adrenaline,7,8,67,77,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,0,-1,0
4527,epinephrine,9,10,79,90,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,0,-1,0
4528,atropine,12,13,93,101,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,0,-1,0
4529,furosemide,14,15,106,116,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,0,-1,0
4530,atropine,3,4,14,22,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,0,-1,0
4531,adrenaline,14,15,51,61,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,0,-1,0
4532,dopamine,16,17,66,74,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,0,-1,0
4534,infection,8,9,68,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,1,1
4536,carbachol,13,14,72,81,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0,-1,0
4537,carbachol,12,13,66,75,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,0,-1,0
4538,carbachol,2,3,13,22,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0,-1,0
4540,cholesterol,19,20,116,127,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.",16755009_1,0,-1,0
4542,amnesia,5,6,43,50,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,-1,1,1
4543,amnesia,5,6,43,50,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,-1,1,1
4547,amnesia,5,6,30,37,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,1,1
4548,scopolamine,8,9,49,60,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,0,-1,0
4549,diazepam,17,18,83,91,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,0,-1,0
4550,cholesterol,19,20,111,122,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,0,-1,0
4552,cholesterol,7,8,42,53,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,0,-1,0
4556,cholesterol,30,31,178,189,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,0,-1,0
4560,bone marrow suppression,13,16,92,115,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1
4561,hepatotoxicity,18,19,129,143,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1
4562,encephalopathy,21,22,160,174,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1
4563,encephalopathy,5,6,33,47,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1
4564,seizure,17,18,127,134,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1
4565,hyperammonemia,23,24,162,176,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1
4567,encephalopathy,13,14,68,82,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,1,1
4568,encephalopathy,6,7,42,56,"We report 19 patients with VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of whom had been published previously.",16787750_5,-1,1,1
4569,hypertension,5,6,58,70,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,1,1
4570,dexamethasone,11,12,62,75,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0,-1,0
4571,hypertension,13,14,90,102,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,1,1
4572,Dex,0,1,0,3,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0
4573,superoxide,21,22,92,102,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0
4574,dex,34,35,147,150,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0
4575,dex,10,11,46,49,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0,-1,0
4576,hypertension,3,4,28,40,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,1,1
4577,superoxide,25,26,113,123,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,-1,0
4578,dex,31,32,140,143,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,-1,0
4579,dex,39,40,169,172,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,-1,0
4580,hypertension,7,8,64,76,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,1,1
4581,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,1,1
4582,toxicity,4,5,27,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,1,1
4583,toxicity,15,16,98,106,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,1,1
4584,peripheral neuropathy,5,7,51,72,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,-1,1,1
4585,neuropathy,1,2,5,15,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,-1,1,1
4586,methylprednisolone,34,35,234,252,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,0,-1,0
4587,peripheral neuropathy,4,6,27,48,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,1,1
4588,deferoxamine,4,5,31,43,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0,-1,0
4589,neurotoxicity,7,8,71,84,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,-1,1,1
4590,Methamphetamine,0,1,0,15,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,0,-1,0
4591,neurotoxicity,3,4,42,55,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,1,1
4594,deferoxamine,19,20,107,119,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0
4596,iron,25,26,130,134,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0
4597,neurotoxicity,31,32,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,1,1
4600,dopamine,3,4,22,30,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,0,-1,0
4602,serotonin,8,9,37,46,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,0,-1,0
4605,hyperthermia,6,7,43,55,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,1,1
4606,glutathione,10,11,59,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0,-1,0
4609,neuronal damage,9,11,62,77,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,1,1
4610,Cerebral haemorrhage,0,2,0,20,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,-1,1,1
4611,warfarin,4,5,32,40,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,0,-1,0
4612,warfarin,16,17,113,121,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,0,-1,0
4613,cerebral haemorrhage,40,42,251,271,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,1,1
4614,warfarin,8,9,65,73,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,0,-1,0
4615,cerebral haemorrhage,16,18,127,147,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,-1,1,1
4616,cerebral haemorrhage,6,8,33,53,"RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.",16858720_4,-1,1,1
4617,warfarin,19,20,92,100,"RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.",16858720_4,0,-1,0
4618,warfarin,17,18,89,97,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,0,-1,0
4619,bleeding,29,30,135,143,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,1,1
4620,warfarin,24,25,173,181,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,0,-1,0
4621,schizophrenia,16,17,107,120,Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia.,16867021_1,-1,1,1
4622,histamine,10,11,54,63,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,0,-1,0
4623,catalepsy,15,16,109,118,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,-1,1,1
4624,Catalepsy,0,1,0,9,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,-1,1,1
4625,haloperidol,4,5,25,36,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0,-1,0
4626,apomorphine,13,14,59,70,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0,-1,0
4627,amphetamine,21,22,92,103,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0,-1,0
4631,catalepsy,27,28,112,121,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,1,1
4634,haloperidol,17,18,65,76,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,0,-1,0
4635,catalepsy,25,26,122,131,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,1,1
4642,hyperactivity,2,3,23,36,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,1,1
4646,apomorphine,4,5,29,40,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,0,-1,0
4650,catalepsy,8,9,80,89,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,1,1
4651,hyperactivity,12,13,120,133,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,1,1
4654,histamine,12,13,72,81,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,0,-1,0
4655,schizophrenia,13,14,96,109,Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia.,16867021_14,-1,1,1
4656,dopamine,6,7,29,37,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,0,-1,0
4657,catalepsy,10,11,59,68,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,-1,1,1
4658,catalepsy,1,2,4,13,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,-1,1,1
4660,dopamine,12,13,79,87,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,0,-1,0
4661,catalepsy,16,17,109,118,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,-1,1,1
4662,Dopamine,2,3,3,11,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0
4664,sulpiride,13,14,80,89,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0
4665,catalepsy,15,16,98,107,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,1,1
4666,sulpiride,5,6,31,40,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,0,-1,0
4668,sulpiride,5,6,30,39,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0,-1,0
4669,catalepsy,9,10,55,64,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,1,1
4670,catalepsy,12,13,65,74,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,1,1
4672,sulpiride,20,21,113,122,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0,-1,0
4673,catalepsy,13,14,88,97,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,1,1
4675,catalepsy,12,13,73,82,"The data may indicate that although D-2 receptor blockade is involved in catalepsy, the D-1 receptor may plan a role.",1687392_9,-1,1,1
4676,steroid,5,6,37,44,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,0,-1,0
4677,steroid,13,14,102,109,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,0,-1,0
4679,bupivacaine,18,19,115,126,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,0,-1,0
4680,pain,12,13,67,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,1,1
4681,steroid,17,18,99,106,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,0,-1,0
4682,bupivacaine,6,7,36,47,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0,-1,0
4683,triamcinolone diacetate,8,10,52,75,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0,-1,0
4684,weakness,12,13,75,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,1,1
4685,steroid,6,7,51,58,CONCLUSION: Complications associated with epidural steroid injections are rare.,16904497_17,0,-1,0
4686,steroid,10,11,89,96,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,0,-1,0
4687,testosterone,1,2,10,22,High-dose testosterone is associated with atherosclerosis in postmenopausal women.,16938416_0,0,-1,0
4688,atherosclerosis,5,6,42,57,High-dose testosterone is associated with atherosclerosis in postmenopausal women.,16938416_0,-1,1,1
4689,atherosclerosis,11,12,68,83,OBJECTIVES: To study the long-term effects of androgen treatment on atherosclerosis in postmenopausal women.,16938416_1,-1,1,1
4690,testosterone,31,32,227,239,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,0,-1,0
4691,atherosclerosis,36,37,259,274,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,-1,1,1
4692,atherosclerosis,1,2,7,22,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,1,1
4693,atherosclerosis,22,23,149,164,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,-1,1,1
4694,atherosclerosis,7,8,37,52,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,1,1
4695,atherosclerosis,24,25,128,143,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,1,1
4696,smoking,55,56,253,260,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,0,-1,0
4698,diabetes,7,8,57,65,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,-1,1,1
4699,cholesterol,9,10,67,78,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,0,-1,0
4700,alcohol,17,18,114,121,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,0,-1,0
4701,testosterone,7,8,47,59,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,0,-1,0
4702,atherosclerosis,12,13,89,104,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,1,1
4704,cirrhosis,11,12,89,98,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,1,1
4705,lamivudine,15,16,120,130,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,0,-1,0
4707,infection,6,7,24,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1
4709,hepatocellular carcinoma,13,15,68,92,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1
4710,cirrhosis,11,12,72,81,"In this report, we encountered a patient with decompensated HBV-related cirrhosis who exhibited the dramatic improvements after antiviral therapy.",16960342_3,-1,1,1
4711,lamivudine,5,6,31,41,"However, the administration of lamivudine, a reverse transcriptase inhibitor, for 23 months dramatically improved her liver severity.",16960342_6,0,-1,0
4713,lamivudine,3,4,22,32,"The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.",16960342_10,0,-1,0
4714,cirrhosis,8,9,62,71,"The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.",16960342_10,-1,1,1
4715,ventricular arrhythmias,9,11,67,90,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,1,1
4716,arrhythmia,12,13,105,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,1,1
4717,arrhythmia,1,2,10,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,1,1
4718,ouabain,22,23,126,133,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0,-1,0
4721,adrenaline,14,15,82,92,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,0,-1,0
4722,arrhythmias,5,6,61,72,"(+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.",1700207_5,-1,1,1
4723,arrhythmias,11,12,101,112,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,1,1
4724,arrhythmia,13,14,81,91,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,-1,1,1
4725,arrhythmias,25,26,156,167,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,-1,1,1
4726,arrhythmia,11,12,101,111,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,1,1
4729,mannitol,2,3,11,19,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,0,-1,0
4730,mannitol,5,6,23,31,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,0,-1,0
4733,mannitol,2,3,11,19,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,0,-1,0
4734,mannitol,14,15,79,87,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,0,-1,0
4735,tumor,23,24,136,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,1,1
4736,Mannitol,2,3,9,17,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,0,-1,0
4737,Mannitol,0,1,0,8,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,0,-1,0
4738,mannitol,28,29,161,169,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,0,-1,0
4739,mannitol,8,9,63,71,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,0,-1,0
4740,mannitol,15,16,75,83,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,0,-1,0
4741,edema,34,35,211,216,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,1,1
4742,stroke,1,2,11,17,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,1,1
4745,warfarin,12,13,88,96,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,0,-1,0
4746,stroke,17,18,117,123,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,-1,1,1
4747,aspirin,24,25,141,148,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,0,-1,0
4748,warfarin,6,7,32,40,"Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.",17020434_3,0,-1,0
4749,aspirin,10,11,56,63,"Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.",17020434_3,0,-1,0
4750,strokes,13,14,78,85,"Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.",17020434_3,-1,1,1
4753,warfarin,19,20,131,139,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0,-1,0
4754,clopidogrel,26,27,173,184,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0,-1,0
4755,aspirin,28,29,190,197,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0,-1,0
4761,statins,4,5,33,40,Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion.,17020434_8,0,-1,0
4762,extrapyramidal symptoms,3,5,27,50,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,1,1
4765,extrapyramidal symptoms,4,6,24,47,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,1,1
4769,lithium,25,26,105,112,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,0,-1,0
4770,haloperidol,27,28,116,127,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,0,-1,0
4771,lithium,17,18,91,98,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0,-1,0
4773,Extrapyramidal symptoms,0,2,0,23,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,1,1
4777,haloperidol,13,14,73,84,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,0,-1,0
4778,lithium,28,29,146,153,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,0,-1,0
4781,Lithium,0,1,0,7,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0
4782,tremor,14,15,75,81,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,1,1
4783,tremor,27,28,125,131,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,1,1
4784,lithium,36,37,168,175,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0
4785,tremor,46,47,222,228,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,1,1
4786,lithium,50,51,251,258,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0,-1,0
4787,Haloperidol,0,1,0,11,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,0,-1,0
4789,tremor,21,22,99,105,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,1,1
4793,hypertension,6,7,62,74,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,1,1
4794,Dexamethasone,0,1,0,13,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,0,-1,0
4795,hypertension,2,3,28,40,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,1,1
4797,superoxide,18,19,144,154,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,0,-1,0
4799,hypertension,28,29,192,204,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,1,1
4803,Dexamethasone,0,1,0,13,"Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.",17042910_5,0,-1,0
4804,Dex,4,5,21,24,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0,-1,0
4806,Dex,4,5,13,16,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0
4807,Dex,45,46,181,184,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0
4808,Dex,10,11,78,81,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0
4810,Dex,17,18,106,109,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0
4811,superoxide,1,2,7,17,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0
4812,Dex,7,8,46,49,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0
4814,Dex,17,18,99,102,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0
4816,superoxide,8,9,58,68,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,0,-1,0
4817,phenytoin,1,2,3,12,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,0,-1,0
4818,phenytoin,1,2,12,21,Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.,17049862_2,0,-1,0
4819,seizure,12,13,80,87,Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.,17049862_2,-1,1,1
4820,phenytoin,1,2,10,19,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,0,-1,0
4821,bradycardia,9,10,71,82,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,-1,1,1
4822,atropine,13,14,98,106,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,0,-1,0
4823,adrenaline,15,16,111,121,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,0,-1,0
4824,phenytoin,5,6,34,43,The cardiac depressant actions of phenytoin and hypothermia can be additive.,17049862_4,0,-1,0
4825,hypothermia,7,8,48,59,The cardiac depressant actions of phenytoin and hypothermia can be additive.,17049862_4,-1,1,1
4826,phenytoin,2,3,18,27,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,0,-1,0
4827,hypothermia,7,8,47,58,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,1,1
4828,phenytoin,1,2,3,12,"As phenytoin is a commonly used drug, clinicians need to be aware of this interaction.",17049862_6,0,-1,0
4829,encephalopathy,3,4,29,43,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,1,1
4830,amino acid,6,8,44,54,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0,-1,0
4831,glycine,15,16,91,98,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0,-1,0
4832,glycine,23,24,143,150,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0,-1,0
4833,apnea,8,9,46,51,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,1,1
4834,seizures,11,12,65,73,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,1,1
4836,encephalopathy,25,26,168,182,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,1,1
4840,hypertension,6,7,40,52,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,1,1
4841,depression,11,12,74,84,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,1,1
4842,pravastatin,5,6,42,53,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0,-1,0
4843,paroxetine,8,9,59,69,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0,-1,0
4844,tetany,12,13,75,81,She then very rapidly developed acute onset of severe facial and extremity tetany.,17111419_6,-1,1,1
4846,calcium,9,10,52,59,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0,-1,0
4847,sodium citrate,12,14,73,87,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0,-1,0
4848,hypocalcemia,19,20,136,148,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,-1,1,1
4849,hypocalcemia,18,19,115,127,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,1,1
4850,hypocalcemia,12,13,93,105,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,1,1
4852,calcium,5,6,46,53,Laboratory measurement of pre-procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance.,17111419_11,0,-1,0
4853,hypertension,3,4,23,35,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,1,1
4856,hypertension,4,5,22,34,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,1,1
4858,isoflurane,1,2,6,16,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.",1711760_2,0,-1,0
4859,hypertensive,9,10,57,69,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.",1711760_2,-1,1,1
4860,hypertensive,2,3,7,19,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,1,1
4862,ischemia,11,12,76,84,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,1,1
4865,edema,16,17,79,84,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,1,1
4866,hypertensive,21,22,106,118,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,1,1
4867,hypertensive,21,22,110,122,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,1,1
4868,hypertension,5,6,45,57,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,1,1
4870,edema,14,15,103,108,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,1,1
4871,edema,23,24,148,153,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,1,1
4872,proteinuria,1,2,21,32,Sirolimus-associated proteinuria and renal dysfunction.,17147461_0,-1,1,1
4873,renal dysfunction,3,5,37,54,Sirolimus-associated proteinuria and renal dysfunction.,17147461_0,-1,1,1
4874,Sirolimus,0,1,0,9,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0,-1,0
4875,rapamycin,19,20,150,159,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0,-1,0
4876,Sirolimus,0,1,0,9,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0,-1,0
4877,nephropathy,17,18,124,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,1,1
4878,glomerulonephritis,6,7,27,45,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,1,1
4879,cancer,15,16,93,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,1,1
4880,sirolimus,1,2,8,17,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0,-1,0
4882,sirolimus,11,12,66,75,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,0,-1,0
4883,proteinuria,15,16,95,106,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,1,1
4886,proteinuria,4,5,39,50,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,-1,1,1
4887,sirolimus,6,7,32,41,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0,-1,0
4889,sirolimus,6,7,44,53,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,0,-1,0
4890,sirolimus,21,22,132,141,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0
4891,sirolimus,29,30,168,177,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0
4892,proteinuria,38,39,234,245,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,1,1
4895,proteinuria,54,55,353,364,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,-1,1,1
4896,sirolimus,8,9,60,69,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0,-1,0
4897,Proteinuria,0,1,0,11,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,-1,1,1
4898,sirolimus,4,5,32,41,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,0,-1,0
4899,Sirolimus,0,1,0,9,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0,-1,0
4901,proteinuria,3,4,15,26,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,-1,1,1
4902,sirolimus,11,12,65,74,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0,-1,0
4903,proteinuria,16,17,110,121,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,1,1
4906,nephropathy,22,23,107,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1
4908,cancers,43,44,181,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1
4909,tumors,47,48,205,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1
4910,nephropathy,57,58,250,261,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,1,1
4913,Proteinuria,0,1,0,11,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,1,1
4914,proteinuria,10,11,42,53,"Before conversion 8 (32%) patients had no proteinuria, whereas afterwards all patients had proteinuria.",17175308_8,-1,1,1
4915,proteinuria,17,18,91,102,"Before conversion 8 (32%) patients had no proteinuria, whereas afterwards all patients had proteinuria.",17175308_8,-1,1,1
4916,proteinuria,5,6,19,30,"In 28% of patients proteinuria remained unchanged, whereas it increased in 68% of patients.",17175308_9,-1,1,1
4917,proteinuria,6,7,50,61,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,-1,1,1
4918,nephrotic,9,10,69,78,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,-1,1,1
4919,interstitial nephritis,14,16,116,138,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,1,1
4920,creatinine,1,2,6,16,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,0,-1,0
4923,creatinine,2,3,11,21,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,0,-1,0
4924,proteinuria,1,2,6,17,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,1,1
4926,proteinuria,15,16,96,107,"Therefore, conversion should be considered for patients who have not developed advanced CAN and proteinuria.",17175308_21,-1,1,1
4928,steroid,6,7,51,58,Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.,17194457_0,0,-1,0
4929,serotonin,13,14,90,99,Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.,17194457_0,0,-1,0
4930,steroid,15,16,92,99,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0,-1,0
4931,serotonin,22,23,125,134,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0,-1,0
4932,5-hydroxytryptamine,24,25,136,155,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0,-1,0
4934,Serotonin,0,1,0,9,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,0,-1,0
4935,testosterone,18,19,99,111,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,0,-1,0
4936,irritability,5,6,41,53,"Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.",17194457_4,-1,1,1
4937,aggression,13,14,91,101,"Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.",17194457_4,-1,1,1
4938,aggression,4,5,24,34,"Animals were tested for aggression in their home cage, both with and without physical provocation (mild tail pinch).",17194457_5,-1,1,1
4942,irritability,11,12,88,100,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,1,1
4943,aggression,24,25,162,172,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,1,1
4944,irritability,8,9,37,49,"T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.",17194457_10,-1,1,1
4945,aggression,18,19,107,117,"T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.",17194457_10,-1,1,1
4947,aggressive behavior,23,25,123,142,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,1,1
4949,tumors,12,13,95,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,1,1
4951,ifosfamide,19,20,121,131,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0,-1,0
4953,ifosfamide,9,10,45,55,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0
4954,ifosfamide,16,17,77,87,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0
4955,vincristine,18,19,89,100,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0
4956,cisplatin,5,6,26,35,None of them had received cisplatin chemotherapy.,1720453_3,0,-1,0
4957,tumor,4,5,24,29,The most common primary tumor site was the head and neck.,1720453_5,-1,1,1
4958,proteinuria,13,14,90,101,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,1,1
4959,creatinine,22,23,142,152,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0
4960,phosphate,25,26,164,173,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0
4961,toxicity,27,28,146,154,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,1,1
4963,phosphate,51,52,286,295,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,0,-1,0
4964,toxicity,1,2,7,15,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,-1,1,1
4965,ifosfamide,13,14,77,87,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0,-1,0
4966,tumor,32,33,170,175,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,-1,1,1
4967,ifosfamide,18,19,83,93,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0,-1,0
4968,tumors,24,25,126,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,1,1
4969,cocaine,18,19,119,126,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,0,-1,0
4970,convulsive,11,12,85,95,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,-1,1,1
4971,cocaine,21,22,152,159,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,0,-1,0
4974,convulsions,17,18,125,136,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,1,1
4975,cocaine,20,21,126,133,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,0,-1,0
4976,myopathy,1,2,12,20,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,-1,1,1
4977,statin,8,9,65,71,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,0,-1,0
4978,Statins,0,1,0,7,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,0,-1,0
4979,myopathy,5,6,32,40,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,1,1
4980,statins,9,10,48,55,"What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.",17241784_2,0,-1,0
4981,myopathy,13,14,69,77,"What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.",17241784_2,-1,1,1
4982,necrosis,3,4,17,25,All had myofibre necrosis but only 3 had an inflammatory infiltrate.,17241784_4,-1,1,1
4983,prednisolone,9,10,66,78,"Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate, and in one case spontaneously.",17241784_6,0,-1,0
4984,methotrexate,11,12,83,95,"Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate, and in one case spontaneously.",17241784_6,0,-1,0
4985,statins,4,5,32,39,These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.,17241784_7,0,-1,0
4986,myopathy,9,10,72,80,These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.,17241784_7,-1,1,1
4987,myopathy,4,5,22,30,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,-1,1,1
4988,statins,13,14,77,84,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,0,-1,0
4989,seizure,7,8,51,58,Use of chromosome substitution strains to identify seizure susceptibility loci in mice.,17242861_0,-1,1,1
4990,Seizure,0,1,0,7,Seizure susceptibility varies among inbred mouse strains.,17242861_1,-1,1,1
4991,seizure,47,48,248,255,"Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility.",17242861_2,-1,1,1
4992,seizures,5,6,47,55,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,1,1
4993,temporal lobe epilepsy,10,13,68,90,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,1,1
4994,seizure,28,29,166,173,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,1,1
4995,seizures,25,26,136,144,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,1,1
4996,seizures,20,21,118,126,"Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.",17242861_5,-1,1,1
4997,seizures,5,6,26,34,B6 mice were resistant to seizures and slower to reach stages compared to A/J mice.,17242861_7,-1,1,1
4998,seizure,3,4,21,28,CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18.,17242861_10,-1,1,1
4999,temporal lobe epilepsy,14,17,106,128,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,-1,1,1
5000,cystitis,10,11,99,107,In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.,17244258_0,-1,1,1
5001,cystitis,2,3,28,36,"In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.",17244258_1,-1,1,1
5002,cystitis,10,11,60,68,Whether or not the neuronal transmission may be affected by cystitis was presently investigated.,17244258_2,-1,1,1
5003,atropine,2,3,11,19,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,0,-1,0
5004,atropine,4,5,36,44,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0,-1,0
5008,carbachol,3,4,22,31,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0,-1,0
5010,potassium,20,21,116,125,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0,-1,0
5011,cystitis,3,4,9,17,"Thus, in cystitis substantial changes of the efferent functional responses occur.",17244258_11,-1,1,1
5012,clonidine,10,11,103,112,Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.,17261653_0,0,-1,0
5014,arrhythmia,18,19,135,145,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,1,1
5017,clonidine,16,17,123,132,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0,-1,0
5018,clonidine,34,35,226,235,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0,-1,0
5019,clonidine,7,8,37,46,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,0,-1,0
5020,clonidine,12,13,88,97,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,0,-1,0
5021,clonidine,16,17,108,117,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,0,-1,0
5022,bradycardia,1,2,18,29,Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.,17261653_5,-1,1,1
5023,clonidine,5,6,32,41,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,0,-1,0
5024,Clonidine,0,1,0,9,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0,-1,0
5025,clonidine,8,9,35,44,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,0,-1,0
5026,clonidine,15,16,107,116,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0,-1,0
5027,Cardiac arrest,0,2,0,14,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,1,1
5029,sevoflurane,9,10,57,68,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0,-1,0
5030,clonidine,15,16,112,121,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0,-1,0
5031,Clonidine,0,1,0,9,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,0,-1,0
5033,seizure,12,13,64,71,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,1,1
5034,clonidine,16,17,92,101,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,0,-1,0
5036,clonidine,16,17,97,106,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,0,-1,0
5038,bradycardia,8,9,54,65,"During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation.",17263743_4,-1,1,1
5039,hypotension,10,11,70,81,"During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation.",17263743_4,-1,1,1
5040,cardiac arrest,7,9,54,68,There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.,17263743_5,-1,1,1
5041,angioedema,6,7,57,67,Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report.,17285209_0,-1,1,1
5042,hypertension,14,15,84,96,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,1,1
5045,angioedema,4,5,55,65,"Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.",17285209_8,-1,1,1
5046,ascites,27,28,161,168,"Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.",17285209_9,-1,1,1
5047,angiotensin,9,10,59,70,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,0,-1,0
5048,angioedema,16,17,105,115,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,1,1
5049,hepatitis,1,2,14,23,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,1,1
5050,amoxicillin,6,7,46,57,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,0,-1,0
5052,hepatitis,10,11,73,82,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,1,1
5053,liver injury,8,10,45,57,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,1,1
5054,eosinophilia,5,6,34,46,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,1,1
5055,penicillin,1,2,3,13,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0,-1,0
5056,amoxicillin,4,5,30,41,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0,-1,0
5057,amoxicillin,16,17,95,106,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0,-1,0
5059,cardiac dysfunction,1,3,22,41,Carbamazepine-induced cardiac dysfunction.,1728915_0,-1,1,1
5060,sinus bradycardia,3,5,15,32,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,1,1
5062,carbamazepine,11,12,72,85,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,0,-1,0
5063,cardiac dysfunction,12,14,81,100,"From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.",1728915_3,-1,1,1
5065,carbamazepine,26,27,217,230,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,0,-1,0
5066,carbamazepine,1,2,8,21,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,0,-1,0
5067,psychiatric,12,13,77,88,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,-1,1,1
5068,Dobutamine,0,1,0,10,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,0,-1,0
5069,cancer,18,19,161,167,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,-1,1,1
5070,Doxorubicin,0,1,0,11,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,0,-1,0
5071,cardiomyopathy,13,14,95,109,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,-1,1,1
5072,doxorubicin,13,14,87,98,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0
5073,dobutamine,21,22,135,145,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0
5074,cancer,30,31,218,224,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,1,1
5075,doxorubicin,33,34,238,249,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0
5076,doxorubicin,37,38,178,189,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,0,-1,0
5077,dobutamine,1,2,7,17,"Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered.",1732369_4,0,-1,0
5078,Dobutamine,0,1,0,10,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0,-1,0
5079,dobutamine,43,44,311,321,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,0,-1,0
5080,dobutamine,11,12,86,96,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,0,-1,0
5081,cardiomyopathy,9,10,79,93,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,1,1
5082,norepinephrine,9,10,58,72,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0,-1,0
5083,cardiomyopathy,6,7,40,54,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,1,1
5085,adriamycin,16,17,100,110,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0,-1,0
5086,adriamycin,10,11,58,68,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0,-1,0
5087,cardiomyopathy,35,36,245,259,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,1,1
5088,smoking,2,3,13,20,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,0,-1,0
5089,smoking,8,9,49,56,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,0,-1,0
5090,smoking,24,25,178,185,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,0,-1,0
5091,smoking,3,4,17,24,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,0,-1,0
5092,smoking,16,17,101,108,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,0,-1,0
5094,smoking,12,13,69,76,The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions (TEOAEs) of healthy neonates.,17343925_2,0,-1,0
5096,smoking,4,5,32,39,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,0,-1,0
5097,smoking,8,9,42,49,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,0,-1,0
5098,smoking,14,15,89,96,Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate's hearing acuity.,17343925_12,0,-1,0
5099,Syncope,0,1,0,7,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,1,1
5100,methadone,8,9,56,65,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,0,-1,0
5102,Methadone,2,3,12,21,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,0,-1,0
5105,methadone,21,22,106,115,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,0,-1,0
5106,syncope,17,18,106,113,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,1,1
5108,methadone,53,54,306,315,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,0,-1,0
5109,methadone,23,24,141,150,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,0,-1,0
5111,syncope,8,9,58,65,All participants were interviewed about any experience of syncope.,17344330_7,-1,1,1
5112,methadone,9,10,48,57,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,0,-1,0
5113,syncope,14,15,80,87,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,-1,1,1
5114,Methadone,2,3,9,18,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,0,-1,0
5115,methadone,5,6,32,41,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,0,-1,0
5116,methadone,4,5,15,24,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,0,-1,0
5117,syncope,23,24,98,105,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,1,1
5118,Methadone,2,3,13,22,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,0,-1,0
5119,syncope,12,13,82,89,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,1,1
5120,hypothyroidism,9,10,87,101,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,1,1
5121,hypothyroid,2,3,14,25,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,1,1
5122,thyroxine,5,6,38,47,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,0,-1,0
5123,simvastatin,7,8,52,63,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,0,-1,0
5124,simvastatin,15,16,102,113,Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin.,17344566_2,0,-1,0
5131,schizophrenia,10,11,52,65,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,1,1
5133,terbutaline,6,7,62,73,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,0,-1,0
5137,Terbutaline,0,1,0,11,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,0,-1,0
5139,terbutaline,5,6,26,37,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,0,-1,0
5140,terbutaline,4,5,24,35,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0,-1,0
5142,terbutaline,6,7,58,69,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0,-1,0
5143,terbutaline,8,9,48,59,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0,-1,0
5144,terbutaline,7,8,42,53,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,0,-1,0
5147,phenytoin,24,25,129,138,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0,-1,0
5148,seizures,12,13,85,93,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,1,1
5149,phenobarbital,8,9,62,75,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0,-1,0
5150,seizures,36,37,190,198,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,-1,1,1
5152,hypertension,6,7,50,62,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,1,1
5153,hypertension,1,2,23,35,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,1,1
5156,hypertension,26,27,140,152,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,1,1
5157,dexamethasone,16,17,93,106,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0
5158,dex,18,19,108,111,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0
5159,dex,28,29,160,163,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0
5161,Dex,0,1,0,3,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0,-1,0
5163,hypertension,15,16,114,126,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,1,1
5164,methylprednisolone,6,7,48,66,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0,-1,0
5165,gentamicin,8,9,71,81,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0,-1,0
5166,methylprednisolone,15,16,98,116,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0
5167,gentamicin,17,18,121,131,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0
5168,cataract,29,30,191,199,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,-1,1,1
5169,lignocaine,25,26,181,191,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,0,-1,0
5170,methylprednisolone,19,20,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0
5171,gentamicin,25,26,105,115,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0
5172,nausea,9,10,60,66,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,1,1
5173,vomiting,11,12,68,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,1,1
5174,headache,14,15,82,90,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,1,1
5175,headache,12,13,75,83,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,1,1
5176,methylprednisolone,5,6,35,53,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0,-1,0
5177,gentamicin,7,8,58,68,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0,-1,0
5178,nausea,24,25,162,168,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,1,1
5179,vomiting,26,27,170,178,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,1,1
5180,headache,29,30,184,192,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,1,1
5182,Iron,0,1,0,4,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,0,-1,0
5184,iron,6,7,51,55,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0
5186,iron,39,40,233,237,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0
5187,iron,57,58,381,385,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0
5190,iron,10,11,72,76,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,0,-1,0
5191,dopamine,4,5,13,21,"As a result, dopamine release and content, as well as its metabolites contents were decreased in caudate putamen.",17490790_4,0,-1,0
5193,iron,10,11,68,72,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0,-1,0
5194,iron,18,19,106,110,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0,-1,0
5197,corticosterone,13,14,115,129,Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.,17490864_0,0,-1,0
5198,schizophrenia,3,4,19,32,"The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.",17490864_1,-1,1,1
5199,corticosterone,26,27,150,164,"We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.",17490864_2,0,-1,0
5200,apomorphine,3,4,21,32,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0
5201,corticosterone,24,25,154,168,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0
5202,Amphetamine,0,1,0,11,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,0,-1,0
5203,locomotor hyperactivity,1,3,20,43,Amphetamine-induced locomotor hyperactivity was similar in all groups.,17490864_6,-1,1,1
5204,corticosterone,24,25,142,156,"These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.",17490864_7,0,-1,0
5205,apomorphine,4,5,23,34,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,0,-1,0
5206,amphetamine,6,7,39,50,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,0,-1,0
5207,dopamine,12,13,90,98,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,0,-1,0
5211,ischemia,58,59,375,383,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,1,1
5212,dobutamine,12,13,85,95,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,0,-1,0
5213,ischemia,10,11,59,67,In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT.,17491223_5,-1,1,1
5214,dobutamine,7,8,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0,-1,0
5217,cocaine,13,14,94,101,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,0,-1,0
5218,acute myocardial infarction,17,20,116,143,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,-1,1,1
5219,acute myocardial infarction,10,13,73,100,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,1,1
5220,oxygen,20,21,143,149,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,0,-1,0
5222,spasm,15,16,102,107,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,1,1
5223,spasm,3,4,15,20,"With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative.",1749407_4,-1,1,1
5224,spasm,10,11,80,85,"Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial, medium-size vessels, other data suggest intramural vasoconstriction.",1749407_5,-1,1,1
5225,infarction,12,13,90,100,"Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete infarction.",1749407_6,-1,1,1
5226,thrombotic,8,9,40,50,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,-1,1,1
5227,cocaine,11,12,61,68,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,0,-1,0
5230,ribavirin,18,19,123,132,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,0,-1,0
5232,ribavirin,10,11,69,78,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,0,-1,0
5233,depression,8,9,48,58,Twenty-three percent to 44% of patients develop depression.,17511042_2,-1,1,1
5237,ribavirin,18,19,133,142,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,0,-1,0
5238,dyskinesia,11,12,75,85,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,-1,1,1
5239,dyskinesia,1,2,15,25,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,1,1
5245,bromocriptine,32,33,204,217,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0,-1,0
5249,nephropathy,17,18,115,126,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,1,1
5251,iopamidol,15,16,104,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0,-1,0
5252,iodixanol,23,24,162,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0,-1,0
5253,iopamidol,16,17,96,105,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0
5254,iodixanol,18,19,110,119,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0
5256,creatinine,1,2,6,16,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0,-1,0
5258,iopamidol,18,19,74,83,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0
5259,iodixanol,29,30,120,129,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0
5260,diabetes,3,4,17,25,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,1,1
5261,iopamidol,22,23,92,101,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0
5262,iodixanol,33,34,137,146,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0
5263,iopamidol,7,8,53,62,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,0,-1,0
5264,diabetes,26,27,152,160,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,1,1
5265,nephropathy,6,7,42,53,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,1,1
5266,iopamidol,23,24,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0
5267,iodixanol,25,26,173,182,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0
5269,phenobarbital,6,7,52,65,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,0,-1,0
5270,Phenobarbital,0,1,0,13,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,0,-1,0
5271,liver disease,32,34,201,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,1,1
5272,epilepsy,12,13,60,68,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,1,1
5273,cardiac arrest,24,26,126,140,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,1,1
5274,necrosis,27,28,175,183,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,-1,1,1
5275,liver damage,10,12,63,75,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,1,1
5276,cognitive deficits,8,10,51,69,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,-1,1,1
5277,dementia,19,20,125,133,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,-1,1,1
5279,cognitive deficits,6,8,44,62,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,-1,1,1
5280,death,21,22,140,145,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,-1,1,1
5281,glutamate,17,18,95,104,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0,-1,0
5282,death,9,10,74,79,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,1,1
5286,death,32,33,208,213,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,1,1
5287,neurotoxicity,5,6,66,79,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,-1,1,1
5288,lipopolysaccharide,9,10,91,109,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,0,-1,0
5289,lipopolysaccharide,9,10,40,58,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0,-1,0
5291,Lipopolysaccharide,0,1,0,18,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,0,-1,0
5292,hyperthermia,11,12,102,114,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,-1,1,1
5293,lipopolysaccharide,2,3,14,32,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0
5294,dopamine,7,8,86,94,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0
5296,lipopolysaccharide,10,11,37,55,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0
5297,methamphetamine,22,23,112,127,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0
5298,dopamine,28,29,177,185,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0
5300,lipopolysaccharide,3,4,19,37,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0
5301,methamphetamine,11,12,78,93,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0
5302,dopamine,13,14,112,120,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0
5304,lipopolysaccharide,28,29,225,243,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0
5305,methamphetamine,40,41,319,334,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0
5306,lipopolysaccharide,8,9,49,67,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0,-1,0
5308,myocarditis,1,2,6,17,Acute myocarditis associated with clozapine.,17612891_0,-1,1,1
5309,clozapine,4,5,34,43,Acute myocarditis associated with clozapine.,17612891_0,0,-1,0
5310,myocarditis,6,7,27,38,"OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.",17612891_1,-1,1,1
5311,clozapine,12,13,75,84,"OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.",17612891_1,0,-1,0
5312,clozapine,14,15,88,97,There is an urgent need to raise awareness about this potentially fatal complication of clozapine use.,17612891_2,0,-1,0
5313,schizophrenia,6,7,33,46,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,-1,1,1
5314,myocarditis,12,13,75,86,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,-1,1,1
5315,clozapine,16,17,109,118,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,0,-1,0
5316,clozapine,8,9,52,61,The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting.,17612891_5,0,-1,0
5317,antidepressant,7,8,56,70,Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity.,17612891_6,0,-1,0
5318,Myocarditis,2,3,13,24,CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.,17612891_7,-1,1,1
5319,clozapine,13,14,95,104,CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.,17612891_7,0,-1,0
5320,clozapine,2,3,17,26,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,0,-1,0
5322,clozapine,12,13,85,94,There are also implications for recommendations and regulations regarding the use of clozapine.,17612891_10,0,-1,0
5323,rhabdomyolysis,1,2,7,21,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,1,1
5325,simvastatin,11,12,78,89,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,0,-1,0
5326,amiodarone,13,14,91,101,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,0,-1,0
5327,simvastatin,11,12,60,71,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,0,-1,0
5328,amiodarone,13,14,73,83,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,0,-1,0
5329,rhabdomyolysis,19,20,113,127,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,1,1
5333,pain,24,25,174,178,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1
5334,fatigue,26,27,180,187,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1
5335,simvastatin,6,7,29,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,0,-1,0
5336,amiodarone,16,17,81,91,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,0,-1,0
5338,blood urea nitrogen,10,13,68,87,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0
5339,creatinine,16,17,99,109,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0
5340,aspartate,20,21,120,129,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0
5341,alanine,26,27,160,167,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0
5342,Simvastatin,0,1,0,11,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,0,-1,0
5343,amiodarone,2,3,13,23,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,0,-1,0
5345,creatinine,14,15,74,84,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0,-1,0
5346,rhabdomyolysis,5,6,24,38,DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.,17615423_7,-1,1,1
5347,simvastatin,16,17,102,113,DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.,17615423_7,0,-1,0
5348,Simvastatin,0,1,0,11,Simvastatin is metabolized by CYP3A4.,17615423_8,0,-1,0
5349,Amiodarone,0,1,0,10,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,0,-1,0
5350,statins,5,6,44,51,CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions.,17615423_10,0,-1,0
5351,statins,7,8,44,51,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0
5352,pravastatin,12,13,75,86,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0
5354,simvastatin,32,33,206,217,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0
5355,lovastatin,34,35,222,232,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0,-1,0
5356,warfarin,2,3,20,28,Interaction between warfarin and levofloxacin: case series.,17639754_0,0,-1,0
5357,levofloxacin,4,5,33,45,Interaction between warfarin and levofloxacin: case series.,17639754_0,0,-1,0
5358,Warfarin,0,1,0,8,Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.,17639754_1,0,-1,0
5359,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0
5360,warfarin,12,13,96,104,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0
5361,levofloxacin,14,15,109,121,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0
5362,levofloxacin,22,23,164,176,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0
5363,warfarin,30,31,236,244,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0
5364,bleeding,6,7,29,37,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,-1,1,1
5365,warfarin,18,19,108,116,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0,-1,0
5366,levofloxacin,20,21,121,133,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0,-1,0
5367,levofloxacin,13,14,90,102,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0
5368,warfarin,17,18,122,130,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0
5369,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1
5370,leukoencephalopathy,4,5,24,43,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,1,1
5371,methotrexate,23,24,176,188,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,0,-1,0
5372,leukoencephalopathy,8,9,43,62,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,1,1
5373,methotrexate,13,14,88,100,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0
5374,5-fluorouracil,20,21,126,140,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0
5375,capecitabine,27,28,174,186,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0
5376,leukoencephalopathy,7,8,58,77,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,1,1
5377,fluoxetine,3,4,21,31,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,0,-1,0
5378,pulmonary hypertension,6,8,46,68,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,-1,1,1
5379,Fluoxetine,2,3,11,21,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,0,-1,0
5380,serotonin,6,7,37,46,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,0,-1,0
5381,antidepressant,9,10,66,80,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,0,-1,0
5382,fluoxetine,4,5,34,44,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,0,-1,0
5383,pulmonary hypertension,12,14,104,126,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,-1,1,1
5384,pulmonary hypertension,17,19,108,130,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,-1,1,1
5385,fluoxetine,20,21,142,152,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,0,-1,0
5386,fluoxetine,5,6,28,38,OBJECTIVES: To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate.,17702969_4,0,-1,0
5387,fluoxetine,7,8,41,51,METHODS: Pregnant rats were treated with fluoxetine (10 mg/kg) from Day 11 through Day 21 of gestation.,17702969_5,0,-1,0
5388,fluoxetine,5,6,27,37,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,0,-1,0
5390,oxygen,10,11,75,81,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,0,-1,0
5391,fluoxetine,3,4,10,20,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,0,-1,0
5392,fluoxetine,7,8,33,43,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,0,-1,0
5393,fluoxetine,8,9,39,49,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,0,-1,0
5394,pulmonary hypertension,13,15,76,98,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,1,1
5395,peripheral neuropathy,4,6,39,60,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,-1,1,1
5396,peripheral neuropathy,9,11,35,56,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,1,1
5397,disulfiram,15,16,78,88,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,0,-1,0
5398,alcohol,17,18,93,100,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,0,-1,0
5399,disulfiram,4,5,19,29,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,0,-1,0
5400,alcohol,6,7,34,41,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,0,-1,0
5401,Disulfiram,0,1,0,10,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,0,-1,0
5402,disulfiram,5,6,44,54,CONCLUSION: Physicians initiating long-term disulfiram therapy should be aware of these adverse effects.,17786501_10,0,-1,0
5407,antidepressant,3,4,17,31,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,0,-1,0
5408,antidepressants,23,24,146,161,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,0,-1,0
5410,Estrogen,0,1,0,8,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,0,-1,0
5413,ritonavir,18,19,111,120,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,0,-1,0
5414,atherosclerosis,13,14,82,97,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,-1,1,1
5415,ritonavir,5,6,37,46,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,0,-1,0
5416,atherosclerotic,8,9,67,82,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,1,1
5417,cholesterol,16,17,103,114,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,0,-1,0
5421,progesterone,32,33,163,175,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0
5422,ethanol,38,39,194,201,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0
5423,ritonavir,7,8,38,47,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,0,-1,0
5425,ritonavir,10,11,77,86,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,0,-1,0
5426,Ritonavir,0,1,0,9,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0,-1,0
5427,ritonavir,2,3,14,23,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,0,-1,0
5431,ritonavir,26,27,188,197,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0,-1,0
5432,hepatitis,1,2,6,15,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,1,1
5433,telithromycin,6,7,41,54,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0,-1,0
5434,hepatotoxicity,3,4,36,50,INTRODUCTION: Antibiotic-associated hepatotoxicity is rare.,17919553_1,-1,1,1
5435,hepatic injury,9,11,54,68,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,1,1
5437,jaundice,37,38,191,199,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,1,1
5438,nausea,41,42,210,216,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,1,1
5439,vomiting,44,45,222,230,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,1,1
5440,telithromycin,4,5,23,36,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,0,-1,0
5442,alanine,7,8,44,51,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0
5443,aspartate,22,23,107,116,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0
5445,bilirubin,69,70,279,288,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0
5446,bilirubin,81,82,325,334,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0
5447,alcohol,3,4,10,17,"No toxin, alcohol, or other drugs were reported.",17919553_6,0,-1,0
5448,hepatitis,10,11,54,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,1,1
5449,telithromycin,19,20,104,117,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,0,-1,0
5450,Telithromycin,2,3,12,25,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0,-1,0
5451,telithromycin,15,16,78,91,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,0,-1,0
5452,hepatitis,22,23,124,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,1,1
5453,hepatitis,33,34,206,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,1,1
5454,hepatitis,2,3,14,23,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,-1,1,1
5455,telithromycin,21,22,143,156,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,0,-1,0
5456,hepatitis,9,10,43,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,1,1
5457,telithromycin,16,17,100,113,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,0,-1,0
5460,heparin,10,11,54,61,A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.,17931375_0,0,-1,0
5461,bruising,13,14,75,83,A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.,17931375_0,-1,1,1
5462,pain,15,16,88,92,A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.,17931375_0,-1,1,1
5463,bruising,15,16,81,89,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,1,1
5464,pain,17,18,94,98,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,1,1
5465,heparin,26,27,161,168,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,0,-1,0
5466,bruising,7,8,50,58,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,1,1
5467,pain,9,10,63,67,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,1,1
5468,heparin,15,16,108,115,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,0,-1,0
5469,bruising,32,33,210,218,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,1,1
5470,pain,34,35,223,227,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,1,1
5471,heparin,14,15,79,86,METHOD: The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered.,17931375_4,0,-1,0
5472,Heparin,0,1,0,7,Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site.,17931375_5,0,-1,0
5473,bruising,8,9,51,59,Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection.,17931375_6,-1,1,1
5474,bruising,3,4,18,26,Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.,17931375_7,-1,1,1
5475,heparin,6,7,34,41,Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.,17931375_7,0,-1,0
5476,pain,11,12,50,54,The visual analog scale (VAS) was used to measure pain intensity and a stop-watch was used to time the pain period.,17931375_8,-1,1,1
5477,pain,21,22,103,107,The visual analog scale (VAS) was used to measure pain intensity and a stop-watch was used to time the pain period.,17931375_8,-1,1,1
5478,bruising,5,6,27,35,RESULTS: The percentage of bruising occurrence was 64% with the injection of 10 seconds duration and 42% in the 30-second injection.,17931375_10,-1,1,1
5479,bruising,8,9,39,47,It was determined that the size of the bruising was smaller in the 30-second injection.,17931375_11,-1,1,1
5480,Pain,0,1,0,4,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,-1,1,1
5481,pain,3,4,19,23,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,-1,1,1
5482,bruising,12,13,72,80,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,-1,1,1
5483,pain,14,15,85,89,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,-1,1,1
5484,heparin,20,21,135,142,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,0,-1,0
5485,heparin,8,9,64,71,"RELEVANCE TO CLINICAL PRACTICE: When administering subcutaneous heparin injections, it is important to extend the duration of the injection.",17931375_15,0,-1,0
5486,cardiomyopathy,8,9,73,87,Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.,17943461_0,-1,1,1
5487,Dilated cardiomyopathy,2,4,12,34,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,1,1
5488,myocarditis,8,9,45,56,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,1,1
5493,zidovudine,12,13,73,83,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,0,-1,0
5499,depressed,11,12,69,78,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,1,1
5502,cardiomyopathy,23,24,152,166,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,1,1
5504,rheumatoid arthritis,5,7,47,67,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1
5506,diclofenac,43,44,322,332,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0,-1,0
5507,rheumatoid arthritis,47,49,350,370,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1
5508,diclofenac,32,33,151,161,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0,-1,0
5509,aspirin,6,7,44,51,Use of gastroprotective agents and low-dose aspirin was allowed.,17965424_2,0,-1,0
5510,thrombotic,8,9,56,66,"General safety was also assessed, including adjudicated thrombotic cardiovascular event data.",17965424_4,-1,1,1
5511,diclofenac,30,31,123,133,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0,-1,0
5512,diclofenac,14,15,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0,-1,0
5513,diclofenac,24,25,167,177,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0,-1,0
5514,hypertension,35,36,219,231,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,1,1
5515,diclofenac,2,3,15,25,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0,-1,0
5516,diclofenac,19,20,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0,-1,0
5517,ciprofloxacin,3,4,24,37,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,0,-1,0
5518,ciprofloxacin,10,11,74,87,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,0,-1,0
5519,ciprofloxacin,13,14,107,120,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,0,-1,0
5520,Acute liver failure,0,3,0,19,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,-1,1,1
5521,alcohol,8,9,49,56,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0,-1,0
5522,paracetamol,11,12,79,90,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0,-1,0
5523,alcohol,6,7,33,40,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0,-1,0
5524,hepatotoxicity,11,12,63,77,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,-1,1,1
5525,paracetamol,17,18,115,126,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0,-1,0
5526,acetaminophen,19,20,128,141,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0,-1,0
5527,alcohol,12,13,66,73,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,0,-1,0
5529,alcohol,27,28,157,164,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,0,-1,0
5530,paracetamol,1,2,2,13,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0,-1,0
5531,hepatotoxicity,7,8,45,59,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,-1,1,1
5532,paracetamol,15,16,106,117,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0,-1,0
5533,alcohol,12,13,71,78,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,0,-1,0
5535,paracetamol,4,5,20,31,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0
5536,paracetamol,27,28,163,174,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0
5537,pain,2,3,13,17,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,1,1
5538,propofol,7,8,58,66,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0,-1,0
5539,Pain,2,3,12,16,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,-1,1,1
5540,propofol,6,7,33,41,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,0,-1,0
5541,propofol,3,4,21,29,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0
5542,pain,5,6,39,43,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,1,1
5543,propofol,15,16,108,116,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0
5544,pain,24,25,159,163,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,1,1
5545,propofol,10,11,50,58,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,0,-1,0
5546,pain,10,11,87,91,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,1,1
5547,propofol,13,14,102,110,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0
5548,propofol,22,23,161,169,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0
5549,pain,5,6,26,30,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,1,1
5550,Pain,0,1,0,4,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,1,1
5551,pain,7,8,40,44,"However, both incidence and severity of pain were not different between Groups R4 and R6.",18006530_9,-1,1,1
5552,propofol,9,10,57,65,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0
5553,propofol,17,18,111,119,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0
5554,pain,19,20,129,133,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,1,1
5555,benzodiazepines,4,5,28,43,"Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly.",18020536_0,0,-1,0
5556,benzodiazepines,9,10,55,70,"OBJECTIVE: To describe associations between the use of benzodiazepines or related drugs (BZDs/RDs) and health, functional abilities and cognitive function in the elderly.",18020536_1,0,-1,0
5558,dementia,31,32,161,169,"Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia.",18020536_13,-1,1,1
5559,dizziness,8,9,45,54,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,1,1
5560,depressive,31,32,181,191,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,1,1
5562,disulfiram,6,7,35,45,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,0,-1,0
5563,peripheral neuropathy,1,3,6,27,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,1,1
5566,pain,13,14,92,96,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,1,1
5567,disulfiram,12,13,58,68,"One month previously, she had taken a single high dose of disulfiram (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm.",18023325_3,0,-1,0
5568,ALCOHOL,17,18,85,92,"One month previously, she had taken a single high dose of disulfiram (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm.",18023325_3,0,-1,0
5569,ataxia,19,20,93,99,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,1,1
5570,hoarseness,2,3,12,22,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,-1,1,1
5571,polyneuropathy,10,11,72,86,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,-1,1,1
5572,weakness,4,5,21,29,Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer.,18023325_11,-1,1,1
5573,polyneuropathy,18,19,114,128,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,1,1
5574,disulfiram,22,23,149,159,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,0,-1,0
5575,Encephalopathy,0,1,0,14,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,1,1
5576,levetiracetam,3,4,26,39,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0,-1,0
5578,levetiracetam,9,10,48,61,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,0,-1,0
5579,encephalopathy,11,12,76,90,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,-1,1,1
5580,epilepsy,8,9,54,62,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,1,1
5581,seizures,11,12,80,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,1,1
5584,seizures,4,5,38,46,Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month.,18081909_3,-1,1,1
5585,seizure,13,14,92,99,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,1,1
5586,Norepinephrine,0,1,0,14,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,0,-1,0
5588,Cocaine,2,3,12,19,BACKGROUND: Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties.,18083142_1,0,-1,0
5589,cocaine,4,5,32,39,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,0,-1,0
5590,cocaine,25,26,167,174,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,0,-1,0
5592,dopamine,11,12,56,64,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0,-1,0
5593,norepinephrine,22,23,118,132,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0,-1,0
5595,cocaine,20,21,119,126,The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.,18083142_5,0,-1,0
5597,disulfiram,13,14,88,98,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,0,-1,0
5598,dopamine,16,17,102,110,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,0,-1,0
5600,propranolol,16,17,126,137,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0
5601,prazosin,35,36,254,262,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0
5602,yohimbine,41,42,291,300,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0
5605,hypotension,1,2,15,26,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1
5606,bradycardia,21,22,76,87,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1
5607,bradycardia,8,9,51,62,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,1,1
5621,Thrombosis,0,1,0,10,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,1,1
5624,estradiol,22,23,182,191,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,0,-1,0
5625,Hyperprolactinemia,0,1,0,18,Hyperprolactinemia can reduce fertility and libido.,18162529_1,-1,1,1
5626,hyperprolactinemia,5,6,32,50,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,-1,1,1
5627,hyperprolactinemia,1,2,8,26,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,1,1
5628,dopamine,5,6,42,50,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0
5629,sulpiride,7,8,62,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0
5630,estradiol,30,31,188,197,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0
5631,Sulpiride,0,1,0,9,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0,-1,0
5632,Estradiol,0,1,0,9,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,0,-1,0
5633,estrogen,5,6,28,36,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0,-1,0
5634,estradiol,18,19,120,129,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0,-1,0
5635,sulpiride,29,30,156,165,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0,-1,0
5636,estradiol,31,32,170,179,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0,-1,0
5637,Sulpiride,0,1,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0
5638,Estradiol,0,1,0,9,Estradiol enhanced these effects on SOCS-3 and CIS.,18162529_10,0,-1,0
5639,estradiol,2,3,15,24,"Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.",18162529_11,0,-1,0
5640,hyperprolactinemia,11,12,66,84,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,1,1
5643,amphetamine,21,22,134,145,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,0,-1,0
5647,amphetamine,26,27,152,163,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,0,-1,0
5648,Clonidine,0,1,0,9,Clonidine for attention-deficit/hyperactivity disorder: II.,18182964_0,0,-1,0
5649,clonidine,9,10,53,62,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,0,-1,0
5650,methylphenidate,14,15,82,97,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,0,-1,0
5651,clonidine,18,19,103,112,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0
5652,methylphenidate,25,26,123,138,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0
5653,clonidine,32,33,149,158,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0
5654,methylphenidate,34,35,163,178,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,0,-1,0
5655,clonidine,9,10,50,59,Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing).,18182964_4,0,-1,0
5656,methylphenidate,14,15,78,93,Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing).,18182964_4,0,-1,0
5657,bradycardia,7,8,38,49,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,1,1
5658,clonidine,12,13,75,84,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,0,-1,0
5659,clonidine,19,20,122,131,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,0,-1,0
5660,clonidine,7,8,50,59,There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes.,18182964_7,0,-1,0
5661,methylphenidate,9,10,64,79,There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes.,18182964_7,0,-1,0
5662,clonidine,11,12,66,75,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,0,-1,0
5663,clonidine,4,5,25,34,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,0,-1,0
5664,Clonidine,2,3,13,22,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,0,-1,0
5665,methylphenidate,8,9,43,58,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,0,-1,0
5666,clonidine,2,3,23,32,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,0,-1,0
5667,bradycardia,6,7,52,63,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,1,1
5669,myopathy,4,5,27,35,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,1,1
5671,Tacrolimus,0,1,0,10,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0,-1,0
5672,steroids,5,6,21,29,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0,-1,0
5673,Lamivudine,0,1,0,10,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,0,-1,0
5676,metabolic acidosis,11,13,80,98,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1
5677,tacrolimus,1,2,9,19,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0
5678,acidosis,12,13,80,88,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,-1,1,1
5679,sirolimus,17,18,109,118,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0
5680,acidosis,19,20,120,128,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,-1,1,1
5683,myopathy,6,7,29,37,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,1,1
5684,myopathy,9,10,54,62,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,1,1
5685,mitochondrial dysfunction,14,16,86,111,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,1,1
5686,tacrolimus,20,21,134,144,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0
5687,lamivudine,24,25,162,172,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0
5688,hypertension,40,41,260,272,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,1,1
5689,hypertension,48,49,247,259,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,1,1
5690,hypertension,32,33,183,195,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,-1,1,1
5692,headache,3,4,18,26,"The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.",18201582_11,-1,1,1
5693,dizziness,5,6,28,37,"The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.",18201582_11,-1,1,1
5694,diarrhea,8,9,43,51,"The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.",18201582_11,-1,1,1
5695,hypertension,9,10,55,67,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,-1,1,1
5696,thrombosis,8,9,52,62,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,1,1
5697,thrombocytopenia,13,14,96,112,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,1,1
5698,thrombocytopenia,13,14,94,110,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,1,1
5700,thrombosis,20,21,136,146,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,1,1
5701,heparin,31,32,213,220,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,0,-1,0
5702,thrombocytopenia,15,16,80,96,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,1,1
5703,heparin,25,26,132,139,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,0,-1,0
5704,heparin,50,51,256,263,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,0,-1,0
5706,thrombosis,8,9,38,48,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,1,1
5707,thrombosis,16,17,94,104,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,1,1
5708,thrombosis,6,7,45,55,"Eight of the isolated-HIT patients developed thrombosis within the next 30 d; thus, a total of 48 patients had thrombosis at day 30.",18208574_4,-1,1,1
5709,thrombosis,21,22,111,121,"Eight of the isolated-HIT patients developed thrombosis within the next 30 d; thus, a total of 48 patients had thrombosis at day 30.",18208574_4,-1,1,1
5711,thrombosis,13,14,81,91,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,1,1
5712,thrombosis,10,11,58,68,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1
5713,thrombosis,28,29,146,156,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1
5714,thrombosis,51,52,249,259,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,1,1
5715,thrombosis,21,22,139,149,The Receiver Operative Characteristic Curve showed that OD >1.27 in the isolated-HIT group had a significantly higher chance of developing thrombosis by day 30.,18208574_7,-1,1,1
5716,thrombosis,8,9,58,68,Multivariate analysis showed a 2.8-fold increased risk of thrombosis in females.,18208574_9,-1,1,1
5717,thrombotic,2,3,11,21,"Similarly, thrombotic risk increased with age and OD values.",18208574_10,-1,1,1
5718,thrombosis,11,12,72,82,"CONCLUSION: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated-HIT; percent inhibition, however, was not predictive.",18208574_11,-1,1,1
5719,Cancer,19,20,128,134,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,1,1
5721,thalidomide,14,15,99,110,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,0,-1,0
5722,myelosuppression,7,8,35,51,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1
5723,fatigue,9,10,53,60,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1
5724,neuropathy,14,15,89,99,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1
5726,thromboembolic,7,8,38,52,Of concern was the occurrence of four thromboembolic events.,18217897_7,-1,1,1
5727,thalidomide,12,13,77,88,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,0,-1,0
5729,morphine,7,8,50,58,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,0,-1,0
5730,capsaicin,11,12,81,90,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,0,-1,0
5731,pain,15,16,111,115,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,1,1
5735,morphine,15,16,101,109,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,0,-1,0
5736,pain,13,14,79,83,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,1,1
5738,hyperalgesia,5,6,24,36,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,-1,1,1
5739,capsaicin,11,12,70,79,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,0,-1,0
5743,morphine,18,19,128,136,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,0,-1,0
5744,morphine,2,3,15,23,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,0,-1,0
5747,morphine,10,11,89,97,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,0,-1,0
5748,pain,14,15,114,118,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,1,1
5750,trihexyphenidyl,10,11,72,87,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0,-1,0
5751,trihexyphenidyl,19,20,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0
5752,confusion,25,26,174,183,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,-1,1,1
5753,trihexyphenidyl,8,9,43,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,0,-1,0
5754,trihexyphenidyl,7,8,31,46,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0,-1,0
5755,trihexyphenidyl,10,11,63,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0,-1,0
5756,trihexyphenidyl,16,17,113,128,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0,-1,0
5757,proteinuria,2,3,15,26,Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.,18261172_0,-1,1,1
5758,renal dysfunction,5,7,42,59,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,1,1
5760,nephrotoxic,12,13,59,70,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,1,1
5761,proteinuria,17,18,89,100,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,1,1
5763,proteinuria,7,8,45,56,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,1,1
5765,cyclosporine,11,12,72,84,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0,-1,0
5766,steroids,8,9,54,62,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,0,-1,0
5767,Proteinuria,0,1,0,11,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,1,1
5768,proteinuria,10,11,52,63,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,1,1
5770,proteinuria,10,11,70,81,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,1,1
5771,proteinuria,2,3,17,28,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,1,1
5772,proteinuria,23,24,134,145,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,1,1
5773,proteinuria,2,3,6,17,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,1,1
5776,proteinuria,11,12,68,79,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,1,1
5777,renal dysfunction,14,16,94,111,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,1,1
5779,morphine,10,11,71,79,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,0,-1,0
5784,morphine,21,22,127,135,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,0,-1,0
5786,morphine,17,18,93,101,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,0,-1,0
5787,morphine,6,7,44,52,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,0,-1,0
5789,morphine,38,39,198,206,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,0,-1,0
5791,morphine,24,25,156,164,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,0,-1,0
5793,morphine,18,19,114,122,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0,-1,0
5797,morphine,14,15,96,104,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,0,-1,0
5799,adenosine,4,5,50,59,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,0,-1,0
5800,adenosine,4,5,45,54,A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described.,18329269_1,0,-1,0
5801,catalepsy,38,39,167,176,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,1,1
5803,dopamine,8,9,41,49,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,0,-1,0
5804,hyperactivity,13,14,90,103,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,-1,1,1
5805,nicotine,17,18,104,112,In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined.,1833784_2,0,-1,0
5806,dopamine,6,7,25,33,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0,-1,0
5807,dopamine,24,25,161,169,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0,-1,0
5808,nicotine,31,32,214,222,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0,-1,0
5809,Nicotine,0,1,0,8,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,0,-1,0
5810,nicotine,4,5,24,32,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0
5811,hexamethonium,20,21,138,151,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0
5812,hyperactivity,1,2,17,30,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,1,1
5814,hyperactivity,8,9,64,77,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,1,1
5815,nicotine,5,6,32,40,The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.,1833784_9,0,-1,0
5816,hyperactivity,10,11,72,85,The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.,1833784_9,-1,1,1
5817,nicotine,8,9,45,53,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0,-1,0
5818,dopamine,27,28,158,166,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0,-1,0
5828,thromboembolic,7,8,34,48,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,1,1
5834,theophylline,7,8,57,69,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,0,-1,0
5835,theophylline,17,18,108,120,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,0,-1,0
5836,theophylline,53,54,251,263,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,0,-1,0
5837,theophylline,18,19,100,112,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,0,-1,0
5838,theophylline,14,15,78,90,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,0,-1,0
5839,theophylline,9,10,54,66,"While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.",1835291_5,0,-1,0
5840,theophylline,12,13,78,90,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,0,-1,0
5842,Amikacin,0,1,0,8,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0
5843,aminoglycoside,3,4,15,29,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0
5845,infections,18,19,140,150,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,1,1
5846,nephrotoxicity,3,4,32,46,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,1,1
5847,aminoglycoside,15,16,113,127,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0
5848,amikacin,23,24,188,196,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0
5849,nephrotoxicity,3,4,18,32,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,-1,1,1
5850,creatinine,11,12,66,76,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0
5851,amikacin,17,18,108,116,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0
5852,nephrotoxicity,3,4,18,32,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,1,1
5853,nephrotoxicity,3,4,18,32,"The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.",18356633_8,-1,1,1
5854,pentobarbital,40,41,227,240,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0,-1,0
5855,bradycardia,11,12,73,84,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,1,1
5856,oxygen,28,29,181,187,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,0,-1,0
5857,Hepatotoxicity,0,1,0,14,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,1,1
5858,sulfasalazine,3,4,31,44,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,0,-1,0
5859,arthritis,6,7,61,70,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,1,1
5863,hepatotoxicity,5,6,19,33,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,1,1
5864,sulfasalazine,7,8,37,50,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0,-1,0
5866,hepatotoxicity,4,5,24,38,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,-1,1,1
5867,sulfasalazine,6,7,44,57,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,0,-1,0
5870,eosinophilia,8,9,38,50,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,1,1
5871,interstitial nephritis,11,13,59,81,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,1,1
5872,hepatotoxicity,1,2,13,27,Drug-related hepatotoxicity was judged probable or highly probable in 8 patients.,18405372_13,-1,1,1
5873,hepatotoxicity,5,6,32,46,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,-1,1,1
5874,sulfasalazine,7,8,52,65,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,0,-1,0
5875,hepatotoxicity,3,4,20,34,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,1,1
5876,sulfasalazine,6,7,51,64,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0,-1,0
5877,neurotoxicity,1,2,24,37,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,1,1
5878,Methamphetamine,0,1,0,15,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,0,-1,0
5880,dopamine,5,6,31,39,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,0,-1,0
5886,neurotoxicity,21,22,113,126,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1
5887,neurotoxicity,33,34,189,202,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1
5889,neurotoxicity,30,31,172,185,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,1,1
5897,nicotine,4,5,33,41,Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging (fMRI) experiment; eye movements were registered using video-oculography.,18417364_3,0,-1,0
5899,amino acid,6,8,58,68,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0,-1,0
5900,seizure,11,12,110,117,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,1,1
5901,amino acid,19,21,118,128,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0
5902,glutamate,23,24,148,157,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0
5903,aspartate,25,26,159,168,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0
5904,glycine,27,28,170,177,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0
5911,seizure,24,25,135,142,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,1,1
5913,pilocarpine,9,10,77,88,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0
5914,glutamate,16,17,135,144,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0
5915,aspartate,18,19,149,158,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0
5916,glycine,29,30,218,225,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0
5920,glutamate,24,25,142,151,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0,-1,0
5921,aspartate,26,27,156,165,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0,-1,0
5923,glycine,16,17,94,101,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0
5924,glutamate,24,25,139,148,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0
5925,aspartate,26,27,153,162,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0
5928,seizure,14,15,92,99,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,1,1
5929,amino acid,23,25,149,159,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0
5930,glutamate,36,37,242,251,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0
5931,aspartate,38,39,256,265,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0
5934,glutamate,15,16,100,109,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0,-1,0
5935,aspartate,17,18,114,123,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0,-1,0
5936,seizure,32,33,221,228,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,1,1
5938,lithium,5,6,45,52,Complete atrioventricular block secondary to lithium therapy.,18441470_0,0,-1,0
5939,lithium,14,15,101,108,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,0,-1,0
5941,lithium,17,18,103,110,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,0,-1,0
5942,lithium,1,2,6,13,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,0,-1,0
5943,Lithium,0,1,0,7,"Lithium should be used with extreme caution, especially in patients with mild disturbance of AV conduction.",18441470_4,0,-1,0
5944,verapamil,3,4,21,30,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,0,-1,0
5945,hemorrhagic,6,7,42,53,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,1,1
5946,atherosclerotic,10,11,71,86,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,1,1
5947,hemorrhage,6,7,48,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,1,1
5948,atherosclerotic,12,13,94,109,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,1,1
5949,histamine,17,18,87,96,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0,-1,0
5950,hemorrhage,33,34,199,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,1,1
5951,atherosclerosis,39,40,233,248,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,1,1
5953,cholesterol,47,48,295,306,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0,-1,0
5954,verapamil,6,7,39,48,"Additionally, the protective effect of verapamil on this ulcer model was evaluated.",18442015_3,0,-1,0
5957,cholesterol,21,22,125,136,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0,-1,0
5958,atherosclerosis,24,25,147,162,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,1,1
5961,histamine,8,9,53,62,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,0,-1,0
5962,ulcer,18,19,137,142,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,1,1
5963,atherosclerotic,1,2,9,24,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,-1,1,1
5964,calcium,7,8,51,58,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0,-1,0
5965,cholesterol,10,11,66,77,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0,-1,0
5966,atherosclerotic,18,19,137,152,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,-1,1,1
5967,histamine,14,15,109,118,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,0,-1,0
5968,histamine,6,7,36,45,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,0,-1,0
5969,hemorrhage,9,10,57,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,1,1
5970,atherosclerotic,17,18,100,115,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,1,1
5971,hemorrhagic,1,2,5,16,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,1,1
5972,verapamil,13,14,114,123,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,0,-1,0
5973,Atherosclerosis,0,1,0,15,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,1,1
5974,hemorrhagic,4,5,38,49,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,1,1
5975,histamine,16,17,120,129,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,0,-1,0
5976,verapamil,26,27,198,207,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,0,-1,0
5977,Lamivudine,0,1,0,10,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,0,-1,0
5980,cancer,17,18,116,122,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,1,1
5982,liver disease,14,16,62,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,1,1
5983,Cancer,0,1,0,6,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,1,1
5984,cancer,4,5,15,21,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,1,1
5985,malignancies,11,12,64,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,1,1
5986,infection,15,16,94,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,1,1
5987,lamivudine,20,21,133,143,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,0,-1,0
5988,lamivudine,34,35,223,233,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,0,-1,0
5989,lamivudine,8,9,46,56,"The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation, and diminishing morbidity and mortality during CT.",18464113_4,0,-1,0
5990,lamivudine,11,12,84,94,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,0,-1,0
5991,lamivudine,13,14,99,109,The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine.,18464113_7,0,-1,0
5992,hepatitis,17,18,65,74,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,1,1
5993,hepatitis,11,12,46,55,Twelve (24%) of them were evaluated as severe hepatitis.,18464113_11,-1,1,1
5994,lamivudine,3,4,20,30,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,0,-1,0
5995,hepatitis,6,7,44,53,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,1,1
5996,alanine,10,11,69,76,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0,-1,0
5997,lamivudine,23,24,150,160,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0,-1,0
5998,lamivudine,5,6,37,47,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,0,-1,0
5999,cancer,17,18,131,137,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,1,1
6000,cyclophosphamide,15,16,114,130,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0,-1,0
6001,cystitis,17,18,145,153,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,-1,1,1
6002,cyclophosphamide,14,15,106,122,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,0,-1,0
6003,cystitis,16,17,137,145,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,-1,1,1
6004,cystitis,22,23,148,156,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,-1,1,1
6005,cystitis,33,34,193,201,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,1,1
6011,inflammation,10,11,52,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,1,1
6012,inflammation,16,17,100,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,1,1
6013,metoprolol,10,11,88,98,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0,-1,0
6014,metoprolol,6,7,51,61,The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type.,1848636_1,0,-1,0
6015,metoprolol,31,32,199,209,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,0,-1,0
6016,metoprolol,13,14,84,94,We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol.,1848636_3,0,-1,0
6017,metoprolol,8,9,46,56,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,0,-1,0
6018,metoprolol,9,10,82,92,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0,-1,0
6019,metoprolol,28,29,188,198,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0,-1,0
6020,terbutaline,6,7,27,38,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,0,-1,0
6021,metoprolol,32,33,142,152,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,0,-1,0
6022,terbutaline,14,15,74,85,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,0,-1,0
6023,potassium,7,8,41,50,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0
6024,terbutaline,9,10,52,63,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0
6025,metoprolol,11,12,65,75,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0
6026,metoprolol,34,35,203,213,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0
6027,metoprolol,3,4,8,18,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0,-1,0
6028,terbutaline,6,7,33,44,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0,-1,0
6029,metoprolol,5,6,26,36,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0
6030,metoprolol,10,11,65,75,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0
6031,everolimus,8,9,72,82,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0,-1,0
6033,Neurotoxicity,0,1,0,13,Neurotoxicity is a potentially serious toxic effect.,18503483_2,-1,1,1
6034,encephalopathy,4,5,23,37,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,1,1
6035,seizures,8,9,50,58,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,1,1
6037,methylprednisolone,17,18,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0
6039,everolimus,16,17,122,132,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0,-1,0
6040,oxytocin,3,4,20,28,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,0,-1,0
6041,Oxytocin,0,1,0,8,"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.",18513945_1,0,-1,0
6042,hypotension,13,14,81,92,"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.",18513945_1,-1,1,1
6043,hypotension,2,3,14,25,The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return.,18513945_2,-1,1,1
6044,hypotension,16,17,105,116,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,-1,1,1
6045,stroke,25,26,164,170,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,-1,1,1
6046,hypotension,1,2,17,28,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,1,1
6047,Hypotension,0,1,0,11,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,1,1
6048,oxytocin,4,5,27,35,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,0,-1,0
6049,stroke,19,20,130,136,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,1,1
6050,hypotension,13,14,80,91,Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia.,18513945_8,-1,1,1
6054,nephrosis,19,20,135,144,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,1,1
6059,renal dysfunction,2,4,34,51,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,1,1
6060,renal damage,4,6,46,58,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,1,1
6064,fentanyl,1,2,9,17,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0
6065,nausea,3,4,26,32,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,1,1
6066,vomiting,5,6,37,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,1,1
6067,pain,9,10,66,70,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,-1,1,1
6068,sevoflurane,12,13,78,89,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0
6069,sevoflurane,13,14,94,105,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,0,-1,0
6071,Fentanyl,0,1,0,8,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,0,-1,0
6073,pain,16,17,110,114,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,1,1
6075,sevoflurane,23,24,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0,-1,0
6076,fentanyl,12,13,70,78,"Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.",18544179_4,0,-1,0
6077,dexamethasone,19,20,109,122,"Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.",18544179_4,0,-1,0
6078,fentanyl,23,24,138,146,"Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.",18544179_4,0,-1,0
6079,fentanyl,4,5,21,29,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,0,-1,0
6081,vomiting,23,24,137,145,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,1,1
6082,nausea,28,29,172,178,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,1,1
6083,fentanyl,39,40,220,228,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,0,-1,0
6084,Dexamethasone,0,1,0,13,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,0,-1,0
6086,fentanyl,3,4,18,26,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,0,-1,0
6088,nausea,21,22,150,156,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,1,1
6089,nausea,50,51,255,261,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,1,1
6091,Pain,0,1,0,4,Pain severity and analgesic requirements were unaffected by the omission of fentanyl.,18544179_9,-1,1,1
6092,fentanyl,11,12,76,84,Pain severity and analgesic requirements were unaffected by the omission of fentanyl.,18544179_9,0,-1,0
6093,Fentanyl,0,1,0,8,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,0,-1,0
6095,hypotension,16,17,126,137,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1
6096,bradycardia,18,19,142,153,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,1,1
6097,fentanyl,3,4,15,23,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0,-1,0
6099,pain,14,15,110,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,1,1
6100,sevoflurane,33,34,234,245,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0,-1,0
6101,Valvular heart disease,0,3,0,22,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,1,1
6103,pergolide,11,12,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0,-1,0
6106,pergolide,17,18,103,112,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,0,-1,0
6108,pergolide,11,12,57,66,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0,-1,0
6110,pergolide,13,14,75,84,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0,-1,0
6113,pergolide,28,29,150,159,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,0,-1,0
6114,pergolide,7,8,50,59,Severity of regurgitation was not correlated with pergolide cumulative dose.,18560792_11,0,-1,0
6115,pergolide,12,13,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0,-1,0
6117,Pergolide,0,1,0,9,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,0,-1,0
6118,valvular heart disease,7,10,47,69,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,1,1
6121,pergolide,15,16,102,111,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0,-1,0
6123,thrombocytopenia,1,2,16,32,Heparin-induced thrombocytopenia after liver transplantation.,18589141_0,-1,1,1
6125,heparin,11,12,72,79,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0,-1,0
6126,thrombosis,25,26,157,167,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,1,1
6127,thrombocytopenia,1,2,16,32,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,1,1
6129,heparin,11,12,81,88,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,0,-1,0
6133,thrombosis,5,6,38,48,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,1,1
6135,platelet aggregation,2,4,20,40,The heparin-induced platelet aggregation test was negative in these patients.,18589141_12,-1,1,1
6139,death,3,4,44,49,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,1,1
6142,adriamycin,9,10,63,73,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,0,-1,0
6144,adriamycin,20,21,119,129,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,0,-1,0
6146,3-methyladenine,2,3,9,24,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0,-1,0
6149,adriamycin,23,24,119,129,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0,-1,0
6152,adriamycin,2,3,13,23,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0,-1,0
6154,death,4,5,37,42,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,1,1
6156,adriamycin,19,20,123,133,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,0,-1,0
6158,adriamycin,13,14,83,93,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,0,-1,0
6159,Doxorubicin,0,1,0,11,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,0,-1,0
6160,inflammation,2,3,35,47,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,-1,1,1
6163,cardiotoxic,13,14,70,81,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,1,1
6165,inflammation,32,33,173,185,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,1,1
6166,cardiomyopathy,39,40,231,245,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,1,1
6168,cardiac dysfunction,4,6,24,43,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,1,1
6170,cardiac dysfunction,6,8,22,41,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,1,1
6174,proteinuria,2,3,24,35,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management.",18631865_0,-1,1,1
6176,rapamycin,16,17,120,129,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0
6177,sirolimus,23,24,160,169,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0
6178,nephropathy,32,33,225,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,1,1
6179,proteinuria,1,2,8,19,"Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years.",18631865_2,-1,1,1
6180,proteinuria,1,2,8,19,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,1,1
6181,sirolimus,5,6,31,40,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0
6183,proteinuria,19,20,135,146,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,1,1
6184,sirolimus,24,25,172,181,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0
6185,sirolimus,34,35,244,253,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0
6187,proteinuria,12,13,88,99,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,-1,1,1
6188,Penicillin,0,1,0,10,Penicillin model is a widely used experimental model for epilepsy research.,18657397_1,0,-1,0
6189,epilepsy,9,10,57,65,Penicillin model is a widely used experimental model for epilepsy research.,18657397_1,-1,1,1
6190,epileptic,9,10,50,59,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,-1,1,1
6191,potassium,18,19,119,128,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,0,-1,0
6192,mefloquine,7,8,47,57,Neuropsychiatric side effects after the use of mefloquine.,1867351_0,0,-1,0
6193,mefloquine,11,12,84,94,This study describes neuropsychiatric side effects in patients after treatment with mefloquine.,1867351_1,0,-1,0
6194,seizures,4,5,30,38,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,1,1
6197,mefloquine,18,19,98,108,"In a risk analysis of neuropsychiatric side effects in Germany, it is estimated that one of 8,000 mefloquine users suffers from such reactions.",1867351_4,0,-1,0
6198,mefloquine,30,31,190,200,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,0,-1,0
6199,mefloquine,10,11,74,84,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,0,-1,0
6200,cardiotoxicity,10,11,73,87,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,1,1
6201,doxorubicin,4,5,23,34,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0,-1,0
6202,Adriamycin,6,7,36,46,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0,-1,0
6203,cardiotoxicity,14,15,83,97,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,-1,1,1
6204,cardiotoxicity,13,14,103,117,"Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.",18674790_2,-1,1,1
6206,cardiotoxicity,39,40,208,222,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,1,1
6207,cardiotoxicity,23,24,104,118,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,1,1
6208,cardiac dysfunction,25,27,120,139,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,1,1
6209,toxicity,51,52,253,261,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,1,1
6210,Doxorubicin,0,1,0,11,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0,-1,0
6211,doxorubicin,9,10,73,84,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0,-1,0
6215,doxorubicin,93,94,536,547,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0,-1,0
6216,cardiotoxicity,11,12,83,97,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,1,1
6218,schizophrenia,12,13,98,111,Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia.,18703024_1,-1,1,1
6219,schizophrenia,27,28,160,173,The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia.,18703024_2,-1,1,1
6221,apomorphine,17,18,104,115,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,0,-1,0
6222,amphetamine,24,25,155,166,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,0,-1,0
6223,catalepsy,4,5,34,43,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,1,1
6227,dopamine,10,11,76,84,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,0,-1,0
6229,schizophrenia,18,19,117,130,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,1,1
6230,papaverine,4,5,27,37,Adverse effects of topical papaverine on auditory nerve function.,18726058_0,0,-1,0
6231,Papaverine,2,3,12,22,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,0,-1,0
6232,vasospasm,11,12,83,92,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,1,1
6233,papaverine,13,14,83,93,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,0,-1,0
6234,papaverine,20,21,150,160,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,0,-1,0
6235,vasospasm,22,23,165,174,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,-1,1,1
6236,papaverine,1,2,8,18,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,0,-1,0
6237,vasospasm,11,12,69,78,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,-1,1,1
6238,papaverine,3,4,14,24,The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings.,18726058_6,0,-1,0
6239,papaverine,9,10,60,70,FINDINGS: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss.,18726058_8,0,-1,0
6240,papaverine,5,6,35,45,The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min.,18726058_9,0,-1,0
6241,papaverine,17,18,90,100,"In 10 of 11 patients, BAEP waves II/III-V completely disappeared within 2 to 25 min after papaverine.",18726058_10,0,-1,0
6242,sensorineural hearing loss,12,15,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,-1,1,1
6243,papaverine,3,4,21,31,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,0,-1,0
6244,vasospasm,8,9,53,62,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,-1,1,1
6245,papaverine,8,9,63,73,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,0,-1,0
6248,statin,17,18,141,147,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,0,-1,0
6249,hepatotoxic,2,3,9,20,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,1,1
6251,fulminant hepatic failure,8,11,55,80,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,-1,1,1
6252,simvastatin,19,20,148,159,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,0,-1,0
6253,simvastatin,23,24,173,184,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,0,-1,0
6254,simvastatin,9,10,51,62,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,0,-1,0
6255,hepatotoxicity,19,20,119,133,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,-1,1,1
6256,depression,9,10,64,74,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,1,1
6257,hepatotoxicity,19,20,125,139,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,1,1
6258,toxicity,18,19,135,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,1,1
6262,simvastatin,30,31,222,233,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0,-1,0
6263,hepatotoxicity,34,35,258,272,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,1,1
6265,hepatotoxicity,8,9,68,82,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,1,1
6266,simvastatin,12,13,100,111,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,0,-1,0
6268,hepatotoxicity,6,7,40,54,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,-1,1,1
6269,proteinuria,1,2,8,19,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,1,1
6274,steroid,17,18,126,133,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,0,-1,0
6275,sodium,21,22,121,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,0,-1,0
6277,creatinine,4,5,25,35,"Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.",18754075_4,0,-1,0
6278,proteinuria,14,15,96,107,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,1,1
6281,nephropathy,1,2,20,31,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,1,1
6282,sodium,5,6,52,58,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,0,-1,0
6283,fibrosis,12,13,111,119,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,1,1
6284,fibrosis,21,22,152,160,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,-1,1,1
6285,salt,25,26,193,197,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0,-1,0
6286,fibrosis,16,17,90,98,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,1,1
6288,doxorubicin,4,5,13,24,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,0,-1,0
6289,Doxorubicin,0,1,0,11,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,0,-1,0
6290,proteinuria,5,6,40,51,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,1,1
6292,ascites,30,31,170,177,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,1,1
6293,aldosterone,1,2,7,18,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,0,-1,0
6294,nephrotic,5,6,39,48,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,1,1
6295,sodium,1,2,8,14,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,0,-1,0
6298,urea,8,9,47,51,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,0,-1,0
6299,fibrosis,18,19,117,125,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,1,1
6301,thrombocytopenia,1,2,7,23,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,1,1
6302,ciprofloxacin,7,8,63,76,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,0,-1,0
6303,ciprofloxacin,12,13,94,107,Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin.,18791946_1,0,-1,0
6305,jaundice,10,11,61,69,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,1,1
6306,ciprofloxacin,16,17,105,118,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,0,-1,0
6308,thrombocytopenia,8,9,62,78,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,1,1
6309,depression,5,6,24,34,No signs of bone marrow depression were found.,18791946_7,-1,1,1
6310,ciprofloxacin,5,6,28,41,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,0,-1,0
6311,thrombocytopenia,9,10,75,91,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,1,1
6312,Isoproterenol,0,1,0,13,Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.,18808529_0,0,-1,0
6313,myocardial injury,12,14,81,98,Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.,18808529_0,-1,1,1
6314,myocardial damage,4,6,39,56,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,1,1
6315,oxygen,13,14,87,93,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,0,-1,0
6316,hypotension,19,20,131,142,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,1,1
6318,isoproterenol,18,19,122,135,Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.,18808529_2,0,-1,0
6319,isoproterenol,37,38,247,260,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0,-1,0
6320,isoproterenol,10,11,58,71,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,0,-1,0
6321,isoproterenol,5,6,33,46,"In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",18808529_8,0,-1,0
6322,isoproterenol,29,30,191,204,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,0,-1,0
6323,neurotoxicity,6,7,52,65,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,1,1
6324,neuropathy,10,11,95,105,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,1,1
6325,neurotoxicity,11,12,92,105,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,1,1
6327,peripheral neuropathy,9,11,50,71,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,1,1
6328,paclitaxel,32,33,191,201,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0
6329,cisplatin,34,35,206,215,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0
6330,cisplatin,5,6,34,43,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0
6331,paclitaxel,7,8,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0
6332,neurotoxicity,8,9,78,91,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,1,1
6333,toxicity,17,18,141,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,1,1
6334,toxicity,3,4,28,36,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,1,1
6335,paclitaxel,11,12,70,80,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0
6336,cisplatin,13,14,85,94,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0
6337,neurotoxicity,15,16,103,116,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,1,1
6338,toxicity,14,15,99,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,1,1
6339,Toxicity,0,1,0,8,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,1,1
6341,8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline,9,11,76,152,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0,-1,0
6346,toxicity,27,28,257,265,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,-1,1,1
6347,poisoning,10,11,64,73,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,1,1
6353,toxicity,12,13,77,85,"Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity, with greater severity in the orally-treated animal.",18821488_8,-1,1,1
6354,toxicity,9,10,72,80,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,-1,1,1
6356,poisoning,14,15,77,86,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,1,1
6357,toxicity,30,31,204,212,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,1,1
6358,tumors,7,8,47,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,1,1
6359,oral contraceptives,10,12,70,89,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,0,-1,0
6360,tumors,9,10,53,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,1,1
6362,Tumors,4,5,23,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,1,1
6363,Oral Contraceptives,7,9,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0,-1,0
6366,deaths,1,2,6,12,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,1,1
6368,dyskinesias,6,7,66,77,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,1,1
6370,dyskinesias,35,36,185,196,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,1,1
6374,dyskinesias,6,7,35,46,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,1,1
6375,dyskinesia,14,15,108,118,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,-1,1,1
6376,dyskinesia,12,13,80,90,"However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo.",18951540_4,-1,1,1
6377,dystonia,5,6,24,32,The major effect was on dystonia subscore.,18951540_5,-1,1,1
6378,dyskinesia,13,14,87,97,"Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.",18951540_6,-1,1,1
6380,dyskinesias,18,19,138,149,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,1,1
6382,Ifosfamide,0,1,0,10,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0
6383,mesna,4,5,39,44,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0
6384,ifosfamide,6,7,39,49,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0
6385,Mesna,17,18,116,121,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0
6386,ifosfamide,16,17,78,88,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0
6387,Mesna,29,30,174,179,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0
6388,hematuria,5,6,46,55,"Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d.",1899352_5,-1,1,1
6389,hematuria,6,7,39,48,There were no instances of macroscopic hematuria.,1899352_6,-1,1,1
6390,toxicity,8,9,55,63,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1
6391,confusion,10,11,65,74,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1
6392,nausea,15,16,80,86,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1
6393,leukopenia,23,24,104,114,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,-1,1,1
6394,hematuria,5,6,36,45,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,-1,1,1
6395,Mesna,22,23,132,137,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0,-1,0
6396,hematuria,30,31,182,191,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,-1,1,1
6397,ifosfamide,5,6,37,47,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0
6398,Mesna,11,12,101,106,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0
6399,epinephrine,1,2,15,26,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,0,-1,0
6400,cocaine,7,8,40,47,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,0,-1,0
6401,cocaine,28,29,156,163,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,0,-1,0
6402,epinephrine,26,27,152,163,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,0,-1,0
6403,ventricular tachycardia,3,5,10,33,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,-1,1,1
6404,caffeine,7,8,45,53,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,0,-1,0
6405,seizure,1,2,11,18,"Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice, especially in older patients with higher seizure thresholds.",18997632_1,-1,1,1
6406,seizure,17,18,132,139,"Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice, especially in older patients with higher seizure thresholds.",18997632_1,-1,1,1
6407,caffeine,1,2,12,20,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,0,-1,0
6408,seizure,7,8,49,56,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,1,1
6410,arrhythmia,12,13,69,79,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,1,1
6411,ventricular tachycardia,22,24,133,156,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,1,1
6412,caffeine,25,26,163,171,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,0,-1,0
6413,caffeine,2,3,21,29,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,0,-1,0
6414,ventricular arrhythmias,20,22,136,159,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,-1,1,1
6415,lamivudine,3,4,20,30,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,0,-1,0
6416,lamivudine,18,19,124,134,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,0,-1,0
6418,lamivudine,23,24,141,151,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,0,-1,0
6420,Lamivudine,0,1,0,10,Lamivudine therapy was started 3-7 days prior to immunosuppressive therapy in all patients.,19037603_5,0,-1,0
6421,Lamivudine,0,1,0,10,Lamivudine was well tolerated and was continued in all patients.,19037603_12,0,-1,0
6422,lamivudine,3,4,31,41,"Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe, well tolerated and effective in preventing HBV reactivation.",19037603_13,0,-1,0
6423,green tea,2,4,10,19,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0,-1,0
6425,isoproterenol,9,10,49,62,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0,-1,0
6427,green tea,11,13,67,76,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0
6430,isoproterenol,37,38,217,230,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0
6435,green tea,2,4,18,27,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0
6440,green tea,81,83,422,431,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0
6442,green tea,8,10,61,70,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0,-1,0
6447,warfarin,13,14,108,116,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,0,-1,0
6448,warfarin,26,27,151,159,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,0,-1,0
6449,warfarin,22,23,129,137,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,0,-1,0
6450,warfarin,31,32,192,200,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,0,-1,0
6451,bupropion,7,8,55,64,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,0,-1,0
6452,seizures,9,10,87,95,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,-1,1,1
6453,seizures,18,19,109,117,BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion-induced seizures.,19105845_1,-1,1,1
6454,bupropion,10,11,70,79,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0,-1,0
6455,bupropion,13,14,85,94,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,0,-1,0
6456,convulsive,20,21,118,128,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,1,1
6457,convulsions,34,35,196,207,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,1,1
6458,bupropion,22,23,104,113,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,0,-1,0
6459,Bupropion,0,1,0,9,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,0,-1,0
6460,convulsions,13,14,61,72,"The number, time of onset, duration and the intensity of the convulsions or absence of convulsions were recorded.",19105845_6,-1,1,1
6461,convulsions,17,18,87,98,"The number, time of onset, duration and the intensity of the convulsions or absence of convulsions were recorded.",19105845_6,-1,1,1
6462,bupropion,9,10,54,63,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,0,-1,0
6463,convulsions,17,18,105,116,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,1,1
6464,bupropion,26,27,145,154,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,0,-1,0
6465,convulsions,39,40,211,222,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,1,1
6466,convulsions,13,14,79,90,Further increase in infusion time resulted in further reduction in the odds of convulsions to 99.8% reduction at 240 min.,19105845_9,-1,1,1
6467,convulsive,18,19,109,119,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,-1,1,1
6468,bupropion,21,22,128,137,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0,-1,0
6469,convulsions,26,27,154,165,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,-1,1,1
6470,everolimus,4,5,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0
6471,tacrolimus,6,7,58,68,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0
6473,methotrexate,5,6,38,50,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,0,-1,0
6474,Everolimus,0,1,0,10,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0
6475,sirolimus,5,6,28,37,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0
6476,everolimus,6,7,30,40,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0
6477,tacrolimus,8,9,45,55,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0
6478,mucositis,11,12,64,73,"All patients engrafted, and only 1 patient experienced grade IV mucositis.",19135948_4,-1,1,1
6482,sulindac,15,16,114,122,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,0,-1,0
6483,sulindac,22,23,144,152,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,0,-1,0
6485,toxicity,6,7,34,42,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,1,1
6486,sulindac,19,20,106,114,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,0,-1,0
6487,sulindac,13,14,45,53,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,0,-1,0
6488,sulindac,14,15,83,91,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,0,-1,0
6490,ototoxicity,5,6,35,46,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,1,1
6491,sulindac,16,17,82,90,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,0,-1,0
6492,nephropathy,9,10,76,87,Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats.,1919871_0,-1,1,1
6493,Renal papillary necrosis,0,3,0,24,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,1,1
6495,aspirin,18,19,130,137,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0,-1,0
6496,paracetamol,20,21,142,153,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0,-1,0
6498,glomerulonephritis,7,8,81,99,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,-1,1,1
6499,sulphasalazine,10,11,117,131,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0,-1,0
6501,eosinophilia,13,14,82,94,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,1,1
6502,sulphasalazine,20,21,141,155,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0,-1,0
6503,glomerulonephritis,9,10,67,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,1,1
6505,sulphasalazine,3,4,22,36,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0,-1,0
6506,fever,9,10,75,80,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,1,1
6510,steroid,30,31,182,189,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0,-1,0
6512,steroid,3,4,16,23,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,0,-1,0
6514,sulphasalazine,4,5,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0,-1,0
6515,glomerulonephritis,9,10,80,98,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,-1,1,1
6516,hypertension,1,2,23,35,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,-1,1,1
6517,salt,7,8,28,32,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,0,-1,0
6518,testosterone,22,23,144,156,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,0,-1,0
6519,renal injury,30,32,194,206,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,1,1
6520,Testosterone,0,1,0,12,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,0,-1,0
6521,renal injury,9,11,60,72,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,1,1
6522,Testosterone,0,1,0,12,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,0,-1,0
6523,hypertension,6,7,47,59,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1
6524,renal injury,8,10,64,76,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1
6528,dyskinesias,56,57,262,273,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,1,1
6529,levodopa,7,8,46,54,All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.,19234905_3,0,-1,0
6532,parkinsonian,9,10,75,87,There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.,19234905_6,-1,1,1
6533,Levodopa,0,1,0,8,Levodopa equivalent daily intake was significantly reduced in the STN group.,19234905_7,0,-1,0
6537,pain,8,9,84,88,Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.,19269743_0,-1,1,1
6538,Pain,0,1,0,4,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1
6539,pain,7,8,40,44,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1
6540,pain,14,15,89,93,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,-1,1,1
6541,pain,12,13,93,97,Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse.,19269743_2,-1,1,1
6542,pain,5,6,30,34,"In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.",19269743_3,-1,1,1
6543,capsaicin,19,20,122,131,"In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.",19269743_3,0,-1,0
6544,Pain,0,1,0,4,"Pain rating was performed using a computerized visual analogue scale (0-100) digitized at 1/s, either immediately online or one hour or one day after injection.",19269743_4,-1,1,1
6545,Capsaicin,0,1,0,9,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,0,-1,0
6546,pain,3,4,19,23,The strong burning pain decayed exponentially within a few minutes.,19269743_7,-1,1,1
6547,pain,6,7,44,48,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,1,1
6548,capsaicin,11,12,79,88,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,0,-1,0
6549,Pain,0,1,0,4,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,1,1
6550,pain,13,14,94,98,These results indicate a reliable memory for magnitude and duration of experimentally induced pain.,19269743_11,-1,1,1
6551,cyclophosphamide,8,9,47,63,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0,-1,0
6552,cyclophosphamide,11,12,67,83,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0,-1,0
6553,dexamethasone,17,18,119,132,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0,-1,0
6555,dexamethasone,24,25,109,122,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0,-1,0
6556,cyclophosphamide,38,39,187,203,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0,-1,0
6557,cyclophosphamide,5,6,30,46,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,0,-1,0
6560,toxicities,9,10,73,83,The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy.,19274460_7,-1,1,1
6561,neuropathy,13,14,95,105,The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy.,19274460_7,-1,1,1
6562,cyclophosphamide,8,9,56,72,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0,-1,0
6563,dexamethasone,14,15,92,105,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0,-1,0
6564,Naloxone,0,1,0,8,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,0,-1,0
6565,hypotension,3,4,21,32,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,1,1
6567,captopril,4,5,27,36,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,0,-1,0
6569,naloxone,3,4,22,30,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0,-1,0
6570,hypotensive,12,13,70,81,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,-1,1,1
6571,captopril,15,16,93,102,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0,-1,0
6573,hypotension,13,14,76,87,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,1,1
6574,naloxone,22,23,139,147,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,0,-1,0
6575,hypotension,12,13,71,82,"To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.",1928887_4,-1,1,1
6576,naloxone,15,16,96,104,"To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.",1928887_4,0,-1,0
6577,naloxone,7,8,47,55,Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.,1928887_5,0,-1,0
6578,hypotension,12,13,75,86,Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.,1928887_5,-1,1,1
6579,captopril,15,16,102,111,Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.,1928887_5,0,-1,0
6580,heparin,16,17,116,123,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,0,-1,0
6581,Heparin,0,1,0,7,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,0,-1,0
6582,heparin,8,9,41,48,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,0,-1,0
6583,hypotensive,28,29,167,178,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,1,1
6584,heparin,3,4,24,31,"Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.",19289093_3,0,-1,0
6585,hypotension,18,19,132,143,"Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.",19289093_3,-1,1,1
6586,heparin,9,10,52,59,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,0,-1,0
6587,heparin,19,20,121,128,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,0,-1,0
6588,heparin,9,10,45,52,This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.,19289093_6,0,-1,0
6589,cholestasis,4,5,24,35,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,1,1
6590,infection,9,10,53,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,1,1
6591,cholestasis,15,16,112,123,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,1,1
6598,Cardiotoxicity,0,1,0,14,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,-1,1,1
6599,cancer,15,16,93,99,We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer.,19300240_4,-1,1,1
6601,cancer,9,10,78,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,1,1
6602,akinetic,13,14,112,120,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,-1,1,1
6603,cancer,6,7,52,58,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,1,1
6605,catecholamines,9,10,55,69,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,0,-1,0
6606,cancer,16,17,113,119,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,1,1
6607,Bradykinin,0,1,0,10,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0
6609,vincristine,9,10,73,84,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0
6610,streptozotocin,11,12,89,103,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0
6611,hyperalgesia,13,14,112,124,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,1,1
6613,bradykinin,66,67,373,383,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0
6615,diabetic,90,91,472,480,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,1,1
6616,neuropathy,99,100,538,548,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,1,1
6617,pain,5,6,24,28,METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.,19300402_2,-1,1,1
6618,bradykinin,11,12,62,72,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0
6621,bradykinin,19,20,109,119,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0
6622,hyperalgesia,23,24,136,148,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,-1,1,1
6623,vincristine,26,27,161,172,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0
6624,neuropathy,19,20,117,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,1,1
6625,diabetic,21,22,130,138,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,1,1
6626,neuropathy,24,25,149,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,1,1
6627,hyperalgesia,2,3,26,38,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,1,1
6628,bradykinin,12,13,105,115,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0,-1,0
6631,neuropathic pain,21,23,150,166,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,1,1
6632,Confusion,0,1,0,9,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,1,1
6634,Confusion,2,3,14,23,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,1,1
6636,confusion,13,14,79,88,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,1,1
6638,confusion,5,6,22,31,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,1,1
6640,Confusion,0,1,0,9,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,1,1
6643,confusion,6,7,33,42,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,1,1
6645,hemorrhage,5,6,42,52,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,1,1
6648,stroke,11,12,73,79,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,1,1
6650,hemorrhagic,23,24,138,149,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,1,1
6651,warfarin,6,7,33,41,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,0,-1,0
6653,hemorrhage,11,12,75,85,"Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum.",19319147_6,-1,1,1
6654,hemorrhage,3,4,24,34,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,-1,1,1
6655,hemorrhagic,6,7,46,57,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,-1,1,1
6656,hemorrhagic,2,3,9,20,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,1,1
6657,hemorrhagic,18,19,110,121,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,1,1
6658,encephalopathy,6,7,63,77,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,1,1
6659,encephalopathy,12,13,94,108,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,1,1
6660,encephalopathy,25,26,139,153,"MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).",19346865_2,-1,1,1
6661,metronidazole,4,5,21,34,"They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.",19346865_3,0,-1,0
6662,infection,25,26,104,113,"They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.",19346865_3,-1,1,1
6663,metronidazole,15,16,93,106,Follow-up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration.,19346865_5,0,-1,0
6664,encephalopathy,14,15,120,134,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,1,1
6665,proteinuria,2,3,23,34,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,-1,1,1
6666,sirolimus,7,8,67,76,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,0,-1,0
6667,Sirolimus,2,3,12,21,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0,-1,0
6668,nephrotoxicity,17,18,105,119,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,1,1
6669,proteinuria,10,11,70,81,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,-1,1,1
6670,sirolimus,16,17,105,114,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,0,-1,0
6671,proteinuria,8,9,63,74,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,-1,1,1
6672,sirolimus,11,12,91,100,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,0,-1,0
6673,sirolimus,12,13,76,85,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0
6674,proteinuria,15,16,98,109,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,-1,1,1
6675,sirolimus,17,18,121,130,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0
6676,proteinuria,25,26,166,177,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,-1,1,1
6677,sirolimus,26,27,166,175,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0,-1,0
6678,proteinuria,7,8,36,47,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,1,1
6679,sirolimus,10,11,69,78,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0,-1,0
6680,proteinuria,10,11,57,68,RESULTS: Twenty-eight patients (24%) developed increased proteinuria from baseline during their post-transplantation course.,19356053_8,-1,1,1
6681,proteinuria,7,8,39,50,In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive.,19356053_9,-1,1,1
6682,sirolimus,16,17,92,101,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,0,-1,0
6683,proteinuria,22,23,141,152,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,-1,1,1
6684,Proteinuria,0,1,0,11,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,-1,1,1
6685,sirolimus,5,6,42,51,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,0,-1,0
6686,sirolimus,6,7,37,46,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,0,-1,0
6687,proteinuria,17,18,94,105,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,-1,1,1
6688,Sirolimus,2,3,13,22,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,0,-1,0
6689,proteinuria,7,8,58,69,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,-1,1,1
6690,Proteinuria,0,1,0,11,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,-1,1,1
6691,sirolimus,10,11,52,61,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,0,-1,0
6692,dementia,6,7,44,52,Components of lemon essential oil attenuate dementia induced by scopolamine.,19356307_0,-1,1,1
6693,scopolamine,9,10,64,75,Components of lemon essential oil attenuate dementia induced by scopolamine.,19356307_0,0,-1,0
6694,alcohol,7,8,55,62,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,0,-1,0
6695,scopolamine,12,13,79,90,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,0,-1,0
6696,alcohol,17,18,112,119,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,0,-1,0
6697,dopamine,14,15,93,101,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0,-1,0
6698,alcohol,39,40,276,283,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0,-1,0
6699,scopolamine,46,47,326,337,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0,-1,0
6701,osteoporosis,28,29,168,180,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,1,1
6702,dementia,30,31,185,193,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,1,1
6703,cancer,15,16,88,94,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1
6704,gallbladder disease,17,19,96,115,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1
6705,fractures,22,23,128,137,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1
6706,stroke,26,27,154,160,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1
6707,breast cancer,33,35,182,195,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1
6708,gallbladder disease,36,38,200,219,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1
6709,gallbladder disease,13,15,100,119,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1
6710,breast cancer,40,42,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1
6711,fractures,12,13,80,89,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,1,1
6713,dementia,34,35,199,207,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,1,1
6716,pain,4,5,36,40,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,-1,1,1
6717,secondary hyperalgesia,8,10,72,94,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,-1,1,1
6718,hyperalgesia,9,10,82,94,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,-1,1,1
6719,pain,1,2,10,14,Perceived pain intensity is modulated by attention.,19387625_1,-1,1,1
6720,pain,8,9,34,38,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,-1,1,1
6721,secondary hyperalgesia,17,19,104,126,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,-1,1,1
6722,pain,5,6,28,32,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,1,1
6723,secondary hyperalgesia,8,10,46,68,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,1,1
6724,secondary hyperalgesia,12,14,74,96,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,1,1
6725,capsaicin,7,8,45,54,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,0,-1,0
6726,secondary hyperalgesia,15,17,123,145,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,1,1
6727,pain,22,23,184,188,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,1,1
6733,aspartate,12,13,96,105,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0
6735,malondialdehyde,18,19,140,155,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0
6739,cardiac dysfunction,14,16,107,126,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,1,1
6740,myocardial injury,17,19,131,148,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,1,1
6742,myocardial damage,9,11,72,89,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,1,1
6745,glutamate,1,2,10,19,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0
6746,neurotoxicity,8,9,73,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,-1,1,1
6747,paclitaxel,10,11,90,100,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0
6748,peripheral neuropathy,1,3,6,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,1,1
6749,paclitaxel,12,13,89,99,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0
6751,glutamate,18,19,116,125,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0
6752,amino acid,23,25,150,160,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0
6754,glutamate,9,10,47,56,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,0,-1,0
6755,peripheral neuropathy,14,16,100,121,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,1,1
6756,ovarian cancer,1,3,12,26,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,1,1
6757,glutamate,22,23,149,158,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,0,-1,0
6758,neurotoxicity,17,18,106,119,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1
6759,pain,41,42,275,279,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1
6760,glutamate,8,9,46,55,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,0,-1,0
6761,neurotoxicity,19,20,130,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,1,1
6762,ribavirin,8,9,65,74,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,0,-1,0
6764,ribavirin,32,33,231,240,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,0,-1,0
6767,acetylcholine,1,2,4,17,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,0,-1,0
6769,ribavirin,16,17,117,126,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,0,-1,0
6770,ribavirin,12,13,88,97,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,0,-1,0
6771,ecstasy,5,6,32,39,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,0,-1,0
6772,ecstasy,6,7,36,43,It has been consistently shown that ecstasy users display impairments in learning and memory performance.,19631624_1,0,-1,0
6773,ecstasy,7,8,42,49,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,0,-1,0
6774,ecstasy,28,29,195,202,"Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.",19631624_3,0,-1,0
6775,cannabis,8,9,52,60,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,0,-1,0
6776,ecstasy,12,13,72,79,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,0,-1,0
6777,cannabis,23,24,141,149,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,0,-1,0
6778,hyperactivity,7,8,49,62,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,1,1
6779,cannabis,12,13,98,106,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,0,-1,0
6780,Ecstasy,0,1,0,7,Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.,19631624_7,0,-1,0
6781,cannabis,13,14,92,100,Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.,19631624_7,0,-1,0
6782,hyperactivity,14,15,93,106,"A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",19631624_8,-1,1,1
6783,ecstasy,2,3,8,15,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,0,-1,0
6784,cannabis,4,5,20,28,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,0,-1,0
6785,cannabis,14,15,93,101,"These results elucidated ecstasy-related deficits, only some of which might be attributed to cannabis use.",19631624_11,0,-1,0
6786,neurotoxic,16,17,114,124,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,-1,1,1
6787,ecstasy,19,20,136,143,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,0,-1,0
6789,vancomycin,12,13,81,91,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,0,-1,0
6791,vancomycin,8,9,52,62,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,0,-1,0
6795,nephrotoxic,11,12,84,95,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,1,1
6797,vancomycin,17,18,113,123,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,0,-1,0
6798,alcohol,24,25,162,169,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,0,-1,0
6799,alcohol,24,25,147,154,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,0,-1,0
6800,alcohol,9,10,43,50,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,0,-1,0
6801,tachycardia,20,21,100,111,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,1,1
6802,tachycardia,12,13,80,91,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,1,1
6803,hypotension,16,17,106,117,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,1,1
6804,alcohol,7,8,46,53,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,0,-1,0
6805,toxicity,8,9,54,62,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,1,1
6807,Sulpiride,0,1,0,9,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0,-1,0
6808,antidepressant,9,10,71,85,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0,-1,0
6810,parkinsonism,15,16,111,123,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,1,1
6811,dystonia,9,10,64,72,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,-1,1,1
6812,sulpiride,15,16,104,113,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,0,-1,0
6814,polyuria,7,8,54,62,Mice lacking mPGES-1 are resistant to lithium-induced polyuria.,19692487_0,-1,1,1
6815,polyuria,9,10,77,85,Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.,19692487_1,-1,1,1
6818,polyuria,8,9,59,67,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,1,1
6820,polyuria,20,21,93,101,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,1,1
6821,polyuria,11,12,72,80,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,1,1
6822,lithium,30,31,159,166,"Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.",19692487_10,0,-1,0
6823,polyuria,8,9,65,73,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,1,1
6824,hypotension,6,7,40,51,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,1,1
6825,hypotension,7,8,44,55,The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy.,1969772_1,-1,1,1
6826,hypotension,9,10,55,66,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,1,1
6827,sodium nitroprusside,36,38,244,264,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0,-1,0
6828,halothane,42,43,283,292,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0,-1,0
6829,sodium nitroprusside,34,36,171,191,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,-1,0
6830,hypotension,9,10,59,70,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,1,1
6831,hypotension,27,28,157,168,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,1,1
6832,Sodium nitroprusside,0,2,0,20,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,0,-1,0
6833,hypotension,22,23,156,167,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,-1,1,1
6834,hypotension,31,32,191,202,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,1,1
6835,Seizures,0,1,0,8,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,-1,1,1
6836,levofloxacin,3,4,25,37,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0,-1,0
6837,seizures,11,12,54,62,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,-1,1,1
6838,levofloxacin,17,18,103,115,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0,-1,0
6839,seizures,49,50,288,296,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,-1,1,1
6840,levofloxacin,9,10,52,64,The main search terms utilized were case report and levofloxacin.,19707748_3,0,-1,0
6841,seizures,6,7,43,51,RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.,19707748_5,-1,1,1
6842,levofloxacin,9,10,62,74,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0,-1,0
6843,levofloxacin,11,12,76,88,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0,-1,0
6844,dextran,3,4,24,31,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0,-1,0
6845,dextran,19,20,118,125,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0,-1,0
6847,edema,20,21,145,150,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,1,1
6848,pilocarpine,8,9,59,70,The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models.,19721134_0,0,-1,0
6849,pilocarpine,9,10,51,62,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,0,-1,0
6850,arrhythmia,25,26,171,181,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,-1,1,1
6851,pilocarpine,5,6,29,40,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,0,-1,0
6852,arrhythmias,10,11,72,83,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,1,1
6854,arrhythmia,23,24,164,174,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,1,1
6855,ouabain,7,8,45,52,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0,-1,0
6856,pilocarpine,15,16,102,113,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0,-1,0
6857,acetylcholine,3,4,26,39,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0,-1,0
6860,pilocarpine,19,20,171,182,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0,-1,0
6861,pilocarpine,4,5,24,35,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0,-1,0
6862,ouabain,19,20,132,139,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0,-1,0
6863,oxycodone,8,9,71,80,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,0,-1,0
6864,oxycodone,16,17,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0,-1,0
6865,pain,45,46,255,259,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,-1,1,1
6866,oxycodone,17,18,112,121,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0,-1,0
6867,oxycodone,1,2,7,16,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0,-1,0
6869,oxycodone,28,29,183,192,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,0,-1,0
6870,oxycodone,18,19,116,125,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0,-1,0
6871,glycine,1,2,4,11,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,0,-1,0
6873,Schizophrenia,0,1,0,13,Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.,19759529_1,-1,1,1
6874,dopamine,8,9,64,72,Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.,19759529_1,0,-1,0
6875,glutamate,8,9,49,58,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0,-1,0
6879,glycine,3,4,15,22,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0,-1,0
6882,glycine,22,23,141,148,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0,-1,0
6885,hyperactivity,19,20,129,142,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,1,1
6886,amphetamine,28,29,181,192,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,0,-1,0
6890,hyperactivity,13,14,57,70,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,1,1
6893,hyperactivity,27,28,170,183,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,1,1
6896,hyperactivity,7,8,40,53,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,1,1
6897,amphetamine,10,11,65,76,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0,-1,0
6898,dopamine,15,16,102,110,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0,-1,0
6899,haloperidol,5,6,29,40,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0
6900,olanzapine,10,11,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0
6901,clozapine,12,13,68,77,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0
6903,hyperactivity,24,25,149,162,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,1,1
6905,catalepsy,10,11,56,65,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,1,1
6907,dyskinesia,19,20,114,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,1,1
6908,reserpine,6,7,43,52,"The rats were treated with intraperitoneal reserpine (1 mg/kg, ip) for 3 days every other day.",19761039_2,0,-1,0
6909,Reserpine,0,1,0,9,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,0,-1,0
6910,reserpine,7,8,48,57,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0,-1,0
6915,dyskinesia,18,19,129,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,1,1
6919,neuronal damage,18,20,110,125,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,1,1
6921,pilocarpine,21,22,139,150,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,0,-1,0
6927,neuronal damage,8,10,62,77,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,1,1
6932,neuronal damage,22,24,149,164,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,1,1
6934,spasm,5,6,35,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,1,1
6937,spasm,20,21,142,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,1,1
6938,suxamethonium,27,28,189,202,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,0,-1,0
6939,cardiac toxicity,4,6,27,43,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,-1,1,1
6940,infection,20,21,121,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,1,1
6942,dilated cardiomyopathy,9,11,52,74,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1
6943,bradycardia,27,28,187,198,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1
6945,catecholamines,3,4,20,34,"Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective.",19843802_2,0,-1,0
6946,epinephrine,5,6,20,31,"However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.",19843802_3,0,-1,0
6947,hypertensive,13,14,84,96,"However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.",19843802_3,-1,1,1
6948,catecholamine,10,11,65,78,"The catheters were changed, and hemodynamics stabilized at lower catecholamine doses.",19843802_5,0,-1,0
6949,lithium,2,3,14,21,Less frequent lithium administration and lower urine volume.,1987816_0,0,-1,0
6950,lithium,15,16,92,99,OBJECTIVE: This study was designed to determine whether patients maintained on a regimen of lithium on a once-per-day schedule have lower urine volumes than do patients receiving multiple doses per day.,1987816_1,0,-1,0
6951,lithium,12,13,63,70,METHOD: This was a cross-sectional study of 85 patients from a lithium clinic who received different dose schedules.,1987816_2,0,-1,0
6952,lithium,9,10,58,65,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0
6953,creatinine,12,13,73,83,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0
6954,lithium,6,7,33,40,RESULTS: Multiple daily doses of lithium were associated with higher urine volumes.,1987816_4,0,-1,0
6955,lithium,6,7,33,40,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0,-1,0
6956,lithium,13,14,70,77,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0,-1,0
6957,creatinine,20,21,115,125,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0,-1,0
6958,lithium,9,10,51,58,CONCLUSIONS: Urine volume can be reduced by giving lithium once daily and/or by lowering the total daily dose.,1987816_6,0,-1,0
6959,polyuria,1,2,16,24,Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.,1987816_7,-1,1,1
6966,anencephaly,4,5,34,45,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,1,1
6972,cephalosporins,19,20,112,126,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0,-1,0
6973,cephalosporins,9,10,59,73,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,0,-1,0
6974,cephalosporins,9,10,59,73,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,0,-1,0
6979,lamivudine,38,39,262,272,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0,-1,0
6989,gentamicin,12,13,71,81,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,0,-1,0
6990,urea,19,20,130,134,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0
6991,creatinine,21,22,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0
6992,potassium,26,27,170,179,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0
6994,hypertrophy,2,3,22,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,1,1
6995,tacrolimus,5,6,45,55,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0,-1,0
6996,Tacrolimus,0,1,0,10,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,0,-1,0
6997,cardiac toxicity,5,7,33,49,"However, adverse effects include cardiac toxicity.",19917396_2,-1,1,1
6998,hypertrophy,5,6,40,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,1,1
6999,tacrolimus,8,9,63,73,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,0,-1,0
7000,hypertrophy,1,2,4,15,The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.,19917396_4,-1,1,1
7001,edema,15,16,105,110,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,1,1
7002,hypertrophy,19,20,131,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,1,1
7003,tacrolimus,2,3,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0
7004,tacrolimus,14,15,77,87,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0
7005,hypertrophy,1,2,11,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,-1,1,1
7006,tacrolimus,10,11,85,95,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,0,-1,0
7007,tacrolimus,5,6,23,33,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0,-1,0
7008,hypertrophy,9,10,64,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,-1,1,1
7009,tacrolimus,3,4,22,32,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,0,-1,0
7010,Nimodipine,0,1,0,10,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,0,-1,0
7011,memory impairment,2,4,20,37,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,-1,1,1
7012,hypotension,7,8,70,81,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,-1,1,1
7013,Hypotension,2,3,12,23,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,1,1
7015,nimodipine,5,6,30,40,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0,-1,0
7016,nitroglycerin,14,15,77,90,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0,-1,0
7017,hypotension,16,17,105,116,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,1,1
7018,shock,22,23,117,122,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,1,1
7021,hypotension,3,4,14,25,The extent of hypotension and changes in brain tissue oxygenation (PbtO(2)) and in cerebral blood flow were studied in a separate group of animals.,19923525_7,-1,1,1
7022,hypotensive,3,4,18,29,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,1,1
7024,hypotension,29,30,187,198,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,1,1
7025,hypotension,21,22,128,139,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,1,1
7026,calcium,13,14,78,85,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,0,-1,0
7027,hypotension,16,17,105,116,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,1,1
7028,Hemolytic anemia,0,2,0,16,Hemolytic anemia associated with the use of omeprazole.,1992636_0,-1,1,1
7029,omeprazole,7,8,44,54,Hemolytic anemia associated with the use of omeprazole.,1992636_0,0,-1,0
7030,Omeprazole,0,1,0,10,Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell.,1992636_1,0,-1,0
7032,omeprazole,4,5,34,44,"Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug.",1992636_3,0,-1,0
7033,omeprazole,15,16,82,92,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,0,-1,0
7034,hemolytic anemia,17,19,94,110,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,-1,1,1
7035,weakness,3,4,22,30,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,1,1
7036,omeprazole,17,18,101,111,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,0,-1,0
7037,bilirubin,32,33,173,182,"Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin.",1992636_6,0,-1,0
7039,omeprazole,4,5,23,33,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,0,-1,0
7040,hemolytic anemia,9,11,55,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,-1,1,1
7041,glutamate,1,2,13,22,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,0,-1,0
7043,glutamate,1,2,13,22,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,0,-1,0
7048,catalepsy,23,24,124,133,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,1,1
7049,6-hydroxydopamine,12,13,77,94,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,0,-1,0
7050,akinetic,10,11,55,63,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,1,1
7052,catalepsy,9,10,64,73,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,1,1
7054,dopamine,15,16,116,124,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,0,-1,0
7055,acute myocardial infarction,1,4,18,45,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,1,1
7056,spasm,8,9,69,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,1,1
7057,carcinoma,7,8,43,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,1,1
7059,sorafenib,6,7,32,41,"Two weeks before his admission, sorafenib had been started.",19944333_2,0,-1,0
7061,infarction,8,9,69,79,Enhanced heart magnetic resonance imaging also showed subendocardial infarction.,19944333_4,-1,1,1
7062,spasm,2,3,16,21,Coronary artery spasm was induced by a provocative test.,19944333_6,-1,1,1
7063,sorafenib,2,3,13,22,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0,-1,0
7064,sorafenib,20,21,144,153,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0,-1,0
7065,spasm,9,10,62,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,1,1
7066,Sorafenib,0,1,0,9,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0,-1,0
7067,spasm,18,19,101,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,1,1
7068,sorafenib,12,13,65,74,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,0,-1,0
7070,seizures,10,11,78,86,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,1,1
7071,epileptic,17,18,114,123,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,-1,1,1
7072,epilepsy,21,22,147,155,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,1,1
7073,Phenylephrine,0,1,0,13,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,0,-1,0
7074,ephedrine,3,4,22,31,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,0,-1,0
7075,hypotension,10,11,94,105,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,-1,1,1
7076,hypotension,9,10,70,81,BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension.,19957053_1,-1,1,1
7077,phenylephrine,5,6,26,39,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,0,-1,0
7078,ephedrine,7,8,44,53,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,0,-1,0
7079,hypotension,18,19,122,133,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,-1,1,1
7080,fentanyl,7,8,46,54,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0
7081,propofol,15,16,76,84,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0
7082,phenylephrine,26,27,123,136,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0
7083,ephedrine,36,37,174,183,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0
7084,stroke,8,9,22,28,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,1,1
7087,phenylephrine,3,4,24,37,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,0,-1,0
7089,ephedrine,3,4,22,31,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,0,-1,0
7091,phenylephrine,5,6,32,45,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,0,-1,0
7092,hypotension,8,9,57,68,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,1,1
7093,ephedrine,20,21,131,140,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,0,-1,0
7096,seizures,8,9,66,74,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,1,1
7099,seizures,22,23,129,137,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,1,1
7100,seizures,15,16,96,104,METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.,19996135_4,-1,1,1
7101,seizures,18,19,98,106,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,1,1
7102,seizures,3,4,18,26,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,1,1
7103,seizures,4,5,21,29,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,1,1
7104,seizures,13,14,83,91,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,1,1
7105,seizures,26,27,180,188,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,1,1
7106,argatroban,4,5,30,40,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,0,-1,0
7107,thrombocytopenia,16,17,117,133,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,-1,1,1
7108,thrombosis,18,19,139,149,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,-1,1,1
7109,thrombocytopenia,21,22,142,158,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,1,1
7112,thrombosis,28,29,177,187,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,1,1
7115,argatroban,18,19,112,122,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,0,-1,0
7117,bleeding,43,44,252,260,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,1,1
7118,argatroban,16,17,101,111,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0,-1,0
7119,argatroban,6,7,45,55,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0,-1,0
7120,argatroban,25,26,135,145,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0,-1,0
7121,argatroban,5,6,35,45,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0,-1,0
7122,argatroban,23,24,172,182,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0,-1,0
7123,coagulopathy,32,33,230,242,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,-1,1,1
7124,argatroban,8,9,43,53,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,0,-1,0
7125,coagulopathy,17,18,103,115,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,-1,1,1
7126,cardiac arrhythmias,3,5,33,52,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,1,1
7129,antidepressants,19,20,145,160,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,0,-1,0
7130,ventricular tachycardia,20,22,122,145,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,1,1
7131,tachycardia,1,2,17,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,1,1
7132,chlorpromazine,9,10,75,89,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,0,-1,0
7133,amitriptyline,7,8,36,49,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,0,-1,0
7134,ventricular arrhythmias,1,3,4,27,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,1,1
7135,lidocaine,8,9,71,80,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0,-1,0
7136,shock,14,15,112,117,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,1,1
7137,propranolol,27,28,203,214,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0,-1,0
7139,cardiac arrhythmias,1,3,6,25,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,1,1
7142,antidepressant,19,20,138,152,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,0,-1,0
7143,azidothymidine,8,9,66,80,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0,-1,0
7145,infection,9,10,37,46,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,1,1
7154,delirium,10,11,77,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,1,1
7155,delirium,25,26,185,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,1,1
7156,delirium,27,28,165,173,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,1,1
7157,dementia,30,31,184,192,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,1,1
7158,propofol,40,41,256,264,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,0,-1,0
7159,delirium,1,2,14,22,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,1,1
7161,Confusion,22,23,147,156,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,1,1
7162,delirium,4,5,32,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,1,1
7163,delirium,39,40,187,195,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,1,1
7164,delirium,9,10,34,42,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,1,1
7165,propofol,6,7,29,37,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0,-1,0
7166,delirium,13,14,89,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,1,1
7167,delirium,19,20,132,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,1,1
7168,bupropion,5,6,30,39,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0,-1,0
7170,serotonin,14,15,90,99,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0,-1,0
7171,bupropion,10,11,62,71,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0
7172,sexual dysfunction,17,19,103,121,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,1,1
7173,serotonin,26,27,150,159,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0
7174,bupropion,6,7,34,43,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0,-1,0
7176,bupropion,26,27,124,133,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0,-1,0
7177,bupropion,3,4,17,26,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0,-1,0
7178,bupropion,14,15,80,89,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,0,-1,0
7179,bupropion,10,11,42,51,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,0,-1,0
7180,Bupropion,2,3,13,22,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,0,-1,0
7181,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0
7182,seizures,2,3,14,22,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,-1,1,1
7183,epilepsy,20,21,142,150,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,-1,1,1
7184,epilepsy,21,22,111,119,"In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.",20080419_1,-1,1,1
7185,pilocarpine,24,25,131,142,"In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.",20080419_1,0,-1,0
7188,seizures,2,3,22,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,1,1
7189,seizure,11,12,67,74,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,1,1
7190,epileptic,7,8,38,47,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1
7191,epileptic,18,19,109,118,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1
7192,seizures,21,22,131,139,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,1,1
7193,epileptic,17,18,91,100,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,1,1
7194,seizures,20,21,113,121,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,1,1
7195,epileptic,32,33,179,188,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,-1,1,1
7197,epileptic,15,16,124,133,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,1,1
7198,epileptic,13,14,79,88,The donor-derived GFP(+) cells were rarely found in the brains of transplanted epileptic rats.,20080419_8,-1,1,1
7199,seizures,12,13,74,82,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,-1,1,1
7200,modafinil,3,4,23,32,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0,-1,0
7201,cocaine,8,9,53,60,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0,-1,0
7202,modafinil,15,16,89,98,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0,-1,0
7203,cocaine,23,24,142,149,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0,-1,0
7204,modafinil,10,11,80,89,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,0,-1,0
7205,cocaine,5,6,37,44,RESULTS: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes.,20080983_6,0,-1,0
7206,modafinil,4,5,23,32,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0,-1,0
7207,modafinil,3,4,14,23,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,0,-1,0
7208,modafinil,23,24,151,160,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0,-1,0
7209,Modafinil,0,1,0,9,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,0,-1,0
7210,modafinil,3,4,27,36,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0,-1,0
7211,cocaine,18,19,140,147,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0,-1,0
7212,cocaine,9,10,50,57,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,0,-1,0
7217,stroke,19,20,100,106,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,1,1
7218,mitral regurgitation,31,33,151,171,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,1,1
7222,hypoxia,1,2,5,12,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1
7223,hypoxia,24,25,100,107,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1
7225,hypoxia,41,42,182,189,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1
7227,hypotension,1,2,10,21,Transient hypotension (SAP<90mmHg) occurred in 1 patient (0.7%).,20084309_10,-1,1,1
7231,variant angina,12,14,95,109,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,1,1
7232,variant angina,13,15,97,111,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,1,1
7235,variant angina,4,6,21,35,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,1,1
7236,coronary spasm,7,9,37,51,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,1,1
7237,spasm,10,11,62,67,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,1,1
7238,spasm,4,5,27,32,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,1,1
7239,variant angina,26,28,162,176,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,1,1
7240,meth mouth,4,6,24,34,"Oral manifestations of ""meth mouth"": a case report.",20098969_0,-1,1,1
7241,meth mouth,18,20,88,98,"AIM: The aim of the documentation of this clinical case is to make clinicians aware of ""meth mouth"" and the medical risks associated with this serious condition.",20098969_1,-1,1,1
7242,Methamphetamine,2,3,12,27,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,0,-1,0
7243,hypertension,26,27,177,189,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,1,1
7244,hallucinations,28,29,191,205,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,1,1
7245,methamphetamine,3,4,24,39,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,0,-1,0
7246,meth mouth,17,19,105,115,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,1,1
7248,methamphetamine,5,6,38,53,Oral rehabilitation of patients using methamphetamine can be challenging.,20098969_4,0,-1,0
7249,pain,10,11,70,74,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,1,1
7250,methamphetamine,5,6,24,39,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,0,-1,0
7251,meth mouth,21,23,122,132,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,1,1
7252,meth mouth,10,12,73,83,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,1,1
7253,diabetic nephropathy,7,9,54,74,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,-1,1,1
7254,Diabetic nephropathy,2,4,11,31,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,1,1
7257,diabetic nephropathy,13,15,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,-1,1,1
7258,diabetic nephropathy,13,15,76,96,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1
7259,diabetic nephropathy,21,23,136,156,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1
7260,diabetic nephropathy,27,29,192,212,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1
7261,diabetic nephropathy,6,8,32,52,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,-1,1,1
7262,renal damage,14,16,96,108,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,-1,1,1
7263,renal injury,19,21,115,127,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,1,1
7264,diabetic nephropathy,16,18,106,126,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,1,1
7265,glucose,7,8,37,44,"In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes.",20103708_9,0,-1,0
7266,diabetic nephropathy,12,14,70,90,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1
7267,diabetic nephropathy,37,39,221,241,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1
7268,nephropathy,4,5,51,62,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,1,1
7271,gentamicin,26,27,165,175,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,0,-1,0
7273,gentamicin,11,12,74,84,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,0,-1,0
7274,gentamicin,3,4,14,24,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0,-1,0
7277,nephropathy,2,3,8,19,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,1,1
7278,nephropathy,7,8,62,73,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,1,1
7282,sodium,1,2,6,12,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0
7284,potassium,6,7,19,28,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0
7286,creatinine,12,13,38,48,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0
7293,renal damage,22,24,112,124,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,1,1
7294,renal injury,27,29,114,126,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1
7295,renal injury,43,45,182,194,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1
7300,acute liver failure,2,5,33,52,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,1,1
7301,acute liver failure,3,6,42,61,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,1,1
7304,hepatitis,10,11,43,52,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,1,1
7305,infection,12,13,59,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,1,1
7306,tuberculosis,16,17,86,98,"In 44 (62.8%) patients, ATT was prescribed empirically without definitive evidence of tuberculosis.",20196116_6,-1,1,1
7307,encephalopathy,8,9,53,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,1,1
7309,encephalopathy,4,5,26,40,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,1,1
7311,seizures,3,4,24,32,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,1,1
7312,infection,5,6,34,43,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,1,1
7316,bilirubin,11,12,81,90,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,0,-1,0
7317,encephalopathy,33,34,179,193,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,-1,1,1
7319,hypotension,7,8,68,79,Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.,2021202_0,-1,1,1
7320,hypotension,4,5,33,44,The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.,2021202_1,-1,1,1
7321,fentanyl,4,5,31,39,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,0,-1,0
7323,oxygen,9,10,56,62,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,0,-1,0
7324,isoflurane,12,13,68,78,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,0,-1,0
7325,Hypotension,0,1,0,11,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,-1,1,1
7326,isoflurane,12,13,65,75,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,0,-1,0
7327,hypotension,14,15,90,101,GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension.,2021202_5,-1,1,1
7328,hypotension,9,10,73,84,"Renal vascular resistance increased during anesthesia but decreased when hypotension was induced, allowing the maintenance of renal blood flow.",2021202_7,-1,1,1
7329,hypotension,10,11,87,98,We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.,2021202_8,-1,1,1
7330,enalapril,9,10,51,60,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,0,-1,0
7331,prazosin,11,12,65,73,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,0,-1,0
7333,angiotensin,4,5,26,37,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,0,-1,0
7335,hypotension,25,26,162,173,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,1,1
7337,hypotension,26,27,174,185,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,1,1
7338,enalapril,5,6,28,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,0,-1,0
7339,prazosin,8,9,45,53,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,0,-1,0
7341,enalapril,3,4,22,31,Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).,2024540_5,0,-1,0
7342,hypotension,11,12,104,115,Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).,2024540_5,-1,1,1
7343,prazosin,21,22,154,162,Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).,2024540_5,0,-1,0
7344,enalapril,6,7,37,46,"It was concluded that treatment with enalapril was well tolerated and it is, therefore, unreasonable to restrict the initiation of treatment with enalapril to inpatients.",2024540_7,0,-1,0
7345,enalapril,24,25,146,155,"It was concluded that treatment with enalapril was well tolerated and it is, therefore, unreasonable to restrict the initiation of treatment with enalapril to inpatients.",2024540_7,0,-1,0
7346,cocaine,8,9,56,63,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,0,-1,0
7347,cocaine,10,11,60,67,Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.,20304337_1,0,-1,0
7348,risperidone,7,8,46,57,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0,-1,0
7349,serotonin,10,11,72,81,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0,-1,0
7350,hyperprolactinemia,15,16,93,111,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,-1,1,1
7351,risperidone,17,18,103,114,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,0,-1,0
7352,Hyperprolactinemia,2,3,9,27,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,1,1
7353,risperidone,18,19,80,91,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,0,-1,0
7354,testosterone,1,2,6,18,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,0,-1,0
7355,hyperprolactinemia,12,13,88,106,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,-1,1,1
7356,serotonin,11,12,76,85,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,0,-1,0
7357,fractures,3,4,17,26,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,1,1
7358,risperidone,8,9,45,56,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,0,-1,0
7359,hyperprolactinemia,20,21,116,134,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,1,1
7360,hyperprolactinemia,10,11,65,83,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,1,1
7362,yohimbine,12,13,85,94,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0,-1,0
7366,yohimbine,15,16,83,92,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0,-1,0
7367,yohimbine,2,3,13,22,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0,-1,0
7369,dermatitis,1,2,12,22,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,-1,1,1
7370,tacrolimus,5,6,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0,-1,0
7371,dermatitis,8,9,57,67,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,1,1
7372,tacrolimus,17,18,104,114,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,0,-1,0
7373,dermatitis,21,22,135,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,1,1
7374,tacrolimus,7,8,51,61,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0,-1,0
7375,dermatitis,19,20,133,143,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,1,1
7376,acute lymphoblastic leukemia,7,10,57,85,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,1,1
7377,acute lymphoblastic leukemia,11,14,73,101,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,1,1
7379,peripheral neuropathy,10,12,84,105,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,1,1
7380,encephalopathy,14,15,118,132,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,1,1
7381,leukoencephalopathy,5,6,48,67,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1
7382,stroke,13,14,87,93,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1
7383,temporal lobe epilepsy,20,23,103,125,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1
7385,Cocaine,0,1,0,7,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0,-1,0
7387,cocaine,24,25,166,173,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,0,-1,0
7388,toxicity,24,25,134,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,1,1
7390,cocaine,33,34,194,201,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0,-1,0
7391,cocaine,43,44,256,263,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0,-1,0
7392,cocaine,9,10,57,64,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0,-1,0
7395,cocaine,7,8,50,57,Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.,20477932_5,0,-1,0
7397,cocaine,21,22,142,149,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,0,-1,0
7402,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0
7404,cisplatin,21,22,102,111,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0,-1,0
7406,blood urea nitrogen,4,7,35,54,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0
7407,creatinine,9,10,65,75,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0
7408,cisplatin,15,16,107,116,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0
7410,glutathione,12,13,95,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0
7414,cisplatin,53,54,368,377,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0
7415,cisplatin,8,9,56,65,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0,-1,0
7421,cholestasis,1,2,11,22,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,1,1
7422,azathioprine,7,8,55,67,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,0,-1,0
7423,liver disease,12,14,82,95,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,1,1
7424,cholestasis,22,23,151,162,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,1,1
7425,azathioprine,28,29,192,204,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,0,-1,0
7426,cholestasis,3,4,20,31,Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.,2051906_3,-1,1,1
7427,Azathioprine,0,1,0,12,Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities.,2051906_4,0,-1,0
7428,cholestasis,13,14,87,98,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,1,1
7429,asenapine,4,5,23,32,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,0,-1,0
7430,schizophrenia,17,18,119,132,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,-1,1,1
7431,Asenapine,0,1,0,9,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,0,-1,0
7432,schizophrenia,15,16,92,105,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,1,1
7433,manic,18,19,112,117,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,1,1
7435,schizophrenia,10,11,56,69,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,1,1
7436,asenapine,18,19,122,131,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0
7437,asenapine,28,29,159,168,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0
7438,haloperidol,37,38,195,206,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0
7439,asenapine,26,27,170,179,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0
7440,haloperidol,35,36,204,215,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0
7441,asenapine,68,69,359,368,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0
7442,haloperidol,83,84,424,435,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0
7443,asenapine,21,22,123,132,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0,-1,0
7444,asenapine,22,23,84,93,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,0,-1,0
7445,haloperidol,30,31,114,125,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,0,-1,0
7446,Extrapyramidal symptoms,0,2,0,23,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,1,1
7447,asenapine,21,22,85,94,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0,-1,0
7448,haloperidol,29,30,115,126,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0,-1,0
7449,asenapine,9,10,59,68,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0,-1,0
7450,haloperidol,11,12,73,84,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0,-1,0
7451,extrapyramidal symptoms,21,23,133,156,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,-1,1,1
7452,nelarabine,3,4,21,31,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0
7453,etoposide,5,6,33,42,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0
7454,cyclophosphamide,8,9,48,64,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0
7455,nelarabine,6,7,24,34,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0
7457,etoposide,14,15,54,63,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0
7458,cyclophosphamide,19,20,73,89,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0
7460,neuropathy,17,18,95,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,1,1
7462,toxicity,1,2,15,23,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,1,1
7465,etoposide,14,15,87,96,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0,-1,0
7466,cyclophosphamide,16,17,101,117,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0,-1,0
7467,toxicity,20,21,141,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,1,1
7468,Dopamine,0,1,0,8,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,0,-1,0
7469,neurotoxicity,9,10,73,86,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,-1,1,1
7470,dopamine,5,6,27,35,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,0,-1,0
7472,methamphetamine,10,11,50,65,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,0,-1,0
7473,toxicity,12,13,81,89,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,1,1
7475,toxicity,26,27,185,193,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,1,1
7477,toxicity,35,36,252,260,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,1,1
7485,neurotoxicity,17,18,117,130,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,1,1
7487,adriamycin,2,3,10,20,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,0,-1,0
7488,hyperthermia,7,8,46,58,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,-1,1,1
7489,tumor,9,10,62,67,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,-1,1,1
7490,toxicities,9,10,80,90,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,1,1
7491,hyperthermia,13,14,105,117,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,1,1
7492,tumor,6,7,39,44,Antitumor activity was studied using a tumor growth delay assay.,2054792_2,-1,1,1
7493,toxicities,3,4,20,30,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1
7494,leukopenia,7,8,38,48,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1
7495,thrombocytopenia,9,10,53,69,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1
7496,toxicities,15,16,94,104,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1
7497,hyperthermia,2,3,11,23,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,1,1
7498,hyperthermia,5,6,23,35,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,-1,1,1
7499,toxicity,13,14,97,105,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,-1,1,1
7500,salbutamol,5,6,55,65,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,0,-1,0
7501,arrhythmia,1,2,4,14,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,1,1
7502,salbutamol,14,15,81,91,The patient noticed that before these episodes he had been using an inhalator of salbutamol.,20552622_4,0,-1,0
7503,arrhythmia,14,15,73,83,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,1,1
7504,arrhythmia,9,10,65,75,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,1,1
7505,Salbutamol,2,3,12,22,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0,-1,0
7506,salbutamol,21,22,111,121,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0,-1,0
7507,tachycardia,26,27,139,150,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,1,1
7509,Diabetes,2,3,3,11,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,1,1
7511,diabetic,16,17,103,111,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,1,1
7513,Diabetes,0,1,0,8,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,1,1
7515,diabetic,13,14,94,102,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,1,1
7517,diabetes,8,9,61,69,The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.,2055425_9,-1,1,1
7519,catalepsy,13,14,119,128,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,1,1
7520,amino acid,22,24,153,163,"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing, escape-like behavior, and immobility.",20558148_2,0,-1,0
7521,catalepsy,16,17,103,112,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,-1,1,1
7522,dopamine,20,21,128,136,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0,-1,0
7523,haloperidol,23,24,154,165,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0,-1,0
7524,catalepsy,1,2,20,29,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,1,1
7532,haloperidol,15,16,108,119,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,0,-1,0
7533,catalepsy,19,20,149,158,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,1,1
7535,catalepsy,16,17,127,136,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,-1,1,1
7537,proteinuria,12,13,73,84,BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when proteinuria starts.,20588063_1,-1,1,1
7540,proteinuria,14,15,63,74,"RESULTS: By day 2, some patchy foot process effacement, but no proteinuria, appeared.",20588063_6,-1,1,1
7541,proteinuria,10,11,51,62,"By day 4, foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage.",20588063_9,-1,1,1
7543,proteinuria,15,16,98,109,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,1,1
7548,Clomipramine,2,3,9,21,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,0,-1,0
7552,Dopamine,0,1,0,8,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,0,-1,0
7554,serotonin,15,16,83,92,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,0,-1,0
7557,psychiatric,33,34,223,234,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,1,1
7565,Suxamethonium,0,1,0,13,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,0,-1,0
7566,apnea,3,4,32,37,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,-1,1,1
7567,Suxamethonium,0,1,0,13,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0
7568,apnea,3,4,31,36,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,1,1
7569,depressed,10,11,50,59,"Here, we present a similar incident in a severely depressed patient who received electroconvulsive therapy (ECT).",20633755_2,-1,1,1
7570,apnea,1,2,10,15,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,1,1
7572,amiodarone,6,7,43,53,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,0,-1,0
7573,coma,10,11,80,84,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,1,1
7574,coma,7,8,34,38,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,1,1
7575,hypothyroidism,11,12,71,85,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,1,1
7578,coma,15,16,89,93,To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.,20635749_2,-1,1,1
7579,amiodarone,19,20,111,121,To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.,20635749_2,0,-1,0
7580,coma,1,2,9,13,Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment.,20635749_3,-1,1,1
7581,thyroxine,6,7,42,51,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0,-1,0
7583,amiodarone,4,5,21,31,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,0,-1,0
7584,hypothyroidism,12,13,80,94,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,1,1
7586,amiodarone,13,14,87,97,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,0,-1,0
7588,coma,6,7,45,49,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,1,1
7590,hypotension,26,27,177,188,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,1,1
7591,weakness,28,29,190,198,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,1,1
7592,Curcumin,0,1,0,8,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0
7594,phenobarbitone,8,9,67,81,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0
7595,carbamazepine,10,11,86,99,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0
7596,phenobarbitone,4,5,25,39,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0,-1,0
7597,carbamazepine,6,7,44,57,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0,-1,0
7600,Curcumin,0,1,0,8,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0,-1,0
7601,curcumin,14,15,82,90,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0,-1,0
7603,curcumin,3,4,32,40,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0
7604,phenobarbitone,5,6,46,60,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0
7605,phenobarbitone,5,6,46,60,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0
7606,carbamazepine,7,8,65,78,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0
7608,carbamazepine,10,11,53,66,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0
7609,malondialdehyde,14,15,80,95,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0
7610,glutathione,17,18,108,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0
7611,phenobarbitone,3,4,22,36,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0,-1,0
7612,carbamazepine,5,6,41,54,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0,-1,0
7613,curcumin,1,2,12,20,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0,-1,0
7615,Curcumin,0,1,0,8,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0
7616,phenobarbitone,14,15,104,118,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0
7617,carbamazepine,18,19,130,143,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0
7618,curcumin,4,5,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0
7619,phenobarbitone,22,23,152,166,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0
7620,carbamazepine,24,25,171,184,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0
7621,curcumin,4,5,26,34,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0
7622,phenobarbitone,16,17,99,113,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0
7623,carbamazepine,18,19,118,131,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0
7628,memory impairment,13,15,86,103,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,1,1
7629,cognitive deficits,18,20,108,126,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,1,1
7632,ribavirin,8,9,46,55,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0
7634,ribavirin,14,15,110,119,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0
7637,sorafenib,31,32,221,230,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0
7638,hemolysis,38,39,262,271,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,1,1
7639,anemia,27,28,184,190,"We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia.",20698227_1,-1,1,1
7641,ribavirin,18,19,121,130,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,0,-1,0
7643,ribavirin,19,20,127,136,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,0,-1,0
7644,ribavirin,18,19,116,125,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,0,-1,0
7645,anemia,20,21,134,140,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,1,1
7647,ribavirin,20,21,120,129,Future research with larger number of patients is needed to find out modifiable factors that will improve the safety of ribavirin therapy.,20698227_9,0,-1,0
7648,pain,3,4,23,27,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,-1,1,1
7649,lidocaine,6,7,43,52,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,0,-1,0
7650,pain,5,6,37,41,Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.,2070391_1,-1,1,1
7651,lidocaine,11,12,75,84,Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.,2070391_1,0,-1,0
7652,lidocaine,14,15,73,82,"To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.",2070391_2,0,-1,0
7653,pain,21,22,123,127,"To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.",2070391_2,-1,1,1
7654,pain,9,10,55,59,Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.,2070391_3,-1,1,1
7655,lidocaine,13,14,85,94,Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.,2070391_3,0,-1,0
7656,lidocaine,20,21,128,137,Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.,2070391_3,0,-1,0
7657,pain,2,3,9,13,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,1,1
7658,lidocaine,6,7,33,42,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,-1,0
7659,lidocaine,16,17,100,109,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,0,-1,0
7660,lidocaine,5,6,30,39,The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues.,2070391_5,0,-1,0
7661,pain,23,24,152,156,The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues.,2070391_5,-1,1,1
7665,schizophrenia,18,19,131,144,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,1,1
7666,serotonin,1,2,4,13,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0
7668,clozapine,18,19,114,123,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0
7669,olanzapine,20,21,128,138,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0
7670,hyperactivity,24,25,166,179,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,1,1
7671,schizophrenia,11,12,72,85,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,1,1
7673,methamphetamine,3,4,16,31,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,0,-1,0
7675,schizophrenia,13,14,95,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,1,1
7678,methamphetamine,15,16,73,88,The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients.,20705401_8,0,-1,0
7682,amnesia,4,5,48,55,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,-1,1,1
7683,amnesia,4,5,48,55,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,-1,1,1
7684,scopolamine,7,8,66,77,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,0,-1,0
7685,memory impairment,16,18,108,125,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,-1,1,1
7686,scopolamine,20,21,137,148,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,0,-1,0
7687,scopolamine,22,23,112,123,"They were given a ten day pretreatment with either L-alpha-GFC or placebo, p.o., and on the eleventh day either scopolamine or placebo, i.m.",2071257_3,0,-1,0
7689,scopolamine,20,21,118,129,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,0,-1,0
7690,capecitabine,2,3,10,22,Safety of capecitabine: a review.,20722491_0,0,-1,0
7691,5-fluorouracil,9,10,58,72,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0,-1,0
7693,tumors,23,24,135,141,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,1,1
7694,cancers,33,34,190,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,1,1
7695,capecitabine,14,15,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0,-1,0
7696,capecitabine,16,17,82,94,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,0,-1,0
7698,capecitabine,8,9,50,62,We also explore different dosing and schedules of capecitabine administration.,20722491_4,0,-1,0
7699,Capecitabine,4,5,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0,-1,0
7701,cancers,28,29,171,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,1,1
7702,capecitabine,7,8,44,56,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,0,-1,0
7703,diarrhea,9,10,61,69,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1
7704,nausea,11,12,71,77,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1
7705,vomiting,13,14,79,87,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1
7706,Capecitabine,0,1,0,12,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,0,-1,0
7709,schizophrenia,14,15,101,114,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,1,1
7711,ketamine,14,15,105,113,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,0,-1,0
7712,schizophrenia,24,25,180,193,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,1,1
7713,schizophrenia,3,4,17,30,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,1,1
7714,ketamine,5,6,32,40,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,0,-1,0
7716,Ketamine,0,1,0,8,Ketamine elicited psychosis like psychopathology.,20727411_7,0,-1,0
7718,ketamine,8,9,70,78,"Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.",20727411_8,0,-1,0
7719,Ketamine,0,1,0,8,"Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency, but not for semantic verbal fluency.",20727411_9,0,-1,0
7720,Ketamine,0,1,0,8,"Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.",20727411_10,0,-1,0
7721,schizophrenia,14,15,99,112,"Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.",20727411_10,-1,1,1
7723,schizophrenia,17,18,113,126,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,1,1
7724,acute liver failure,7,10,73,92,Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.,20735774_0,-1,1,1
7725,acute liver failure,9,12,79,98,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,-1,1,1
7726,acute liver failure,6,9,44,63,AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.,20735774_2,-1,1,1
7728,liver injury,16,18,107,119,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1
7729,acute liver failure,21,24,130,149,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1
7730,liver injury,15,17,109,121,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1
7731,acute liver failure,20,23,136,155,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1
7732,acute liver failure,49,52,273,292,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1
7733,liver disease,54,56,301,314,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1
7734,acute liver failure,7,10,54,73,These observations speak against long-term effects of acute liver failure.,20735774_7,-1,1,1
7735,acute liver failure,22,25,148,167,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,1,1
7736,acute liver failure,3,6,33,52,CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.,20735774_9,-1,1,1
7739,dyskinesias,1,2,17,28,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,1,1
7741,Levodopa,0,1,0,8,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,0,-1,0
7743,dopamine,7,8,35,43,"However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.",20880751_2,0,-1,0
7744,dyskinesias,16,17,106,117,"However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.",20880751_2,-1,1,1
7745,dyskinesias,18,19,155,166,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,-1,1,1
7747,dopamine,21,22,148,156,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0,-1,0
7748,glutamate,28,29,204,213,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0,-1,0
7749,dyskinesias,40,41,314,325,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,1,1
7750,neurotensin,3,4,20,31,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,0,-1,0
7752,neurotensin,20,21,147,158,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,0,-1,0
7753,neurotensin,10,11,63,74,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,0,-1,0
7754,parkinsonian,13,14,98,110,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,1,1
7755,neurotensin,5,6,32,43,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,0,-1,0
7757,neurotensin,6,7,62,73,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0,-1,0
7758,haloperidol,17,18,141,152,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0,-1,0
7759,neurotensin,1,2,4,15,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0
7760,neurotensin,16,17,127,138,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0
7761,neurotensin,5,6,35,46,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0,-1,0
7764,leukoencephalopathy,18,19,122,141,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,1,1
7765,leukoencephalopathy,3,4,31,50,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,1,1
7766,adenosine,6,7,35,44,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,0,-1,0
7768,adenosine,7,8,39,48,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,0,-1,0
7771,catalepsy,54,55,272,281,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,1,1
7772,6-hydroxydopamine,63,64,330,347,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0,-1,0
7775,apnea,7,8,64,69,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,-1,1,1
7776,succinylcholine,9,10,76,91,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,0,-1,0
7777,succinylcholine,11,12,78,93,BACKGROUND: patients undergoing electroconvulsive therapy (ECT) often receive succinylcholine as part of the anesthetic procedure.,21029050_1,0,-1,0
7778,succinylcholine,30,31,179,194,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,0,-1,0
7779,apnea,17,18,103,108,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,1,1
7780,apnea,3,4,16,21,The duration of apnea was compared with published data on normal subjects.,21029050_6,-1,1,1
7781,apnea,3,4,16,21,The duration of apnea was 5-15 min compared with 3-5.3 min from the literature.,21029050_8,-1,1,1
7782,succinylcholine,13,14,73,88,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,0,-1,0
7783,apnea,31,32,182,187,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,-1,1,1
7784,epileptic,9,10,62,71,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,-1,1,1
7785,epilepsy,15,16,107,115,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,-1,1,1
7786,epileptic,13,14,86,95,"AIM: Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity, but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined.",21294084_1,-1,1,1
7787,epileptic,14,15,90,99,The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.,21294084_2,-1,1,1
7788,epilepsy,18,19,131,139,The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.,21294084_2,-1,1,1
7790,epileptic,11,12,89,98,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,-1,1,1
7791,epileptic,16,17,121,130,CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges.,21294084_9,-1,1,1
7792,epileptic,22,23,178,187,CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges.,21294084_9,-1,1,1
7793,epilepsy,17,18,108,116,These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy.,21294084_10,-1,1,1
7794,toxicity,4,5,17,25,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,1,1
7795,toxicities,27,28,159,169,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,1,1
7797,toxicity,21,22,101,109,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,1,1
7798,neutropenia,8,9,48,59,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,1,1
7799,thrombocytopenia,18,19,109,125,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,1,1
7800,vomiting,17,18,92,100,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,1,1
7801,renal toxicity,1,3,10,24,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,-1,1,1
7802,alanine,5,6,38,45,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,0,-1,0
7804,toxicity,3,4,29,37,"CONCLUSIONS: CCNU-associated toxicity in dogs is common, but is usually not life threatening.",21418164_8,-1,1,1
7805,Perhexiline maleate,0,2,0,19,Perhexiline maleate and peripheral neuropathy.,220563_0,0,-1,0
7806,peripheral neuropathy,3,5,24,45,Perhexiline maleate and peripheral neuropathy.,220563_0,-1,1,1
7807,Peripheral neuropathy,0,2,0,21,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,1,1
7808,perhexiline maleate,11,13,71,90,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,0,-1,0
7810,neuropathy,5,6,37,47,"The underlying mechanism causing the neuropathy is not yet fully known, although some evidence indicates that it may be a lipid storage process.",220563_5,-1,1,1
7811,thrombosis,2,3,13,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,1,1
7812,epinephrine,6,7,46,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,0,-1,0
7813,thrombosis,12,13,69,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,1,1
7814,epinephrine,26,27,161,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,0,-1,0
7815,glaucoma,29,30,186,194,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,1,1
7816,4'-0-tetrahydropyranyladriamycin,5,6,19,51,A phase I study of 4'-0-tetrahydropyranyladriamycin.,2224762_0,0,-1,0
7817,4'-0-tetrahydropyranyladriamycin,5,6,19,51,A phase I study of 4'-0-tetrahydropyranyladriamycin.,2224762_0,0,-1,0
7818,4'-0-tetrahydropyranyladriamycin,10,11,42,74,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,0,-1,0
7819,tumors,25,26,156,162,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,1,1
7820,thrombocytopenia,5,6,37,53,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1
7821,anemia,7,8,55,61,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1
7822,nausea,9,10,63,69,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1
7823,mucositis,17,18,101,110,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1
7824,Myelosuppression,0,1,0,16,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,1,1
7826,doxorubicin,2,3,14,25,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0,-1,0
7827,doxorubicin,18,19,134,145,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0,-1,0
7828,carcinoma,11,12,67,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,1,1
7829,toxicity,3,4,20,28,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,-1,1,1
7830,desferrioxamine,8,9,64,79,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0,-1,0
7831,desferrioxamine,10,11,70,85,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,0,-1,0
7832,toxicity,30,31,181,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,1,1
7833,toxicity,9,10,61,69,6 patients presented clinical symptoms of visual or auditory toxicity.,2234245_2,-1,1,1
7834,toxicity,1,2,7,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,1,1
7835,toxicity,1,2,9,17,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,1,1
7837,Desferrioxamine,0,1,0,15,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,0,-1,0
7839,toxicity,1,2,5,13,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,1,1
7840,desferrioxamine,10,11,65,80,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0,-1,0
7841,toxicity,5,6,35,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,1,1
7842,desferrioxamine,15,16,113,128,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0,-1,0
7843,azidothymidine,17,18,96,110,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0,-1,0
7844,toxicities,4,5,24,34,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,1,1
7845,anemia,25,26,152,158,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,1,1
7846,leukopenia,27,28,163,173,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,1,1
7847,toxicity,23,24,139,147,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,1,1
7851,anemia,39,40,213,219,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,1,1
7852,leukopenia,41,42,224,234,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,1,1
7854,toxicity,15,16,99,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,1,1
7856,epilepsy,1,2,7,15,Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.,2265898_0,-1,1,1
7857,chronic renal failure,12,15,77,98,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,1,1
7858,seizures,46,47,286,294,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,1,1
7860,mazindol,5,6,34,42,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,0,-1,0
7862,weakness,13,14,75,83,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,1,1
7863,mazindol,7,8,44,52,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0,-1,0
7865,mazindol,23,24,139,147,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,0,-1,0
7866,weakness,26,27,126,134,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,1,1
7867,Mazindol,0,1,0,8,Mazindol did not benefit strength at any point in the study.,2266990_5,0,-1,0
7868,mazindol,4,5,29,37,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0
7869,dry mouth,13,15,73,82,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,1,1
7870,mazindol,35,36,152,160,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0
7871,mazindol,3,4,14,22,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0
7872,mazindol,29,30,158,166,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0
7873,Mazindol,0,1,0,8,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,0,-1,0
7874,weakness,7,8,43,51,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,1,1
7875,morphine,6,7,45,53,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,0,-1,0
7876,Amnesia,0,1,0,7,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,1,1
7877,scopolamine,3,4,20,31,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0
7878,cycloheximide,5,6,36,49,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0
7879,morphine,9,10,67,75,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0
7880,morphine,23,24,136,144,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0
7881,naloxone,33,34,211,219,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0
7882,scopolamine,3,4,20,31,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0
7883,amnesia,8,9,75,82,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,-1,1,1
7884,amnesia,8,9,75,82,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,-1,1,1
7885,cycloheximide,16,17,120,133,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0
7886,amnesia,22,23,178,185,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,-1,1,1
7887,morphine,11,12,76,84,These results suggest that the facilitation of memory retrieval by pre-test morphine might be the direct action of morphine rather than a state dependent effect.,2273650_3,0,-1,0
7888,morphine,18,19,115,123,These results suggest that the facilitation of memory retrieval by pre-test morphine might be the direct action of morphine rather than a state dependent effect.,2273650_3,0,-1,0
7889,Naloxone,0,1,0,8,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0
7890,clonidine,6,7,49,58,Naloxone reverses the antihypertensive effect of clonidine.,227508_0,0,-1,0
7891,hypertensive,4,5,33,45,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,1,1
7892,clonidine,17,18,121,130,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,0,-1,0
7893,hypotensive,1,2,4,15,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,-1,1,1
7894,naloxone,12,13,84,92,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,0,-1,0
7895,Naloxone,0,1,0,8,Naloxone alone did not affect either blood pressure or heart rate.,227508_3,0,-1,0
7896,hypertensive,5,6,38,50,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,1,1
7897,clonidine,7,8,56,65,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0,-1,0
7898,naloxone,29,30,158,166,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0,-1,0
7899,hypertensive,6,7,46,58,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,-1,1,1
7900,naloxone,1,2,3,11,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0
7901,clonidine,3,4,16,25,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0
7902,clonidine,27,28,164,173,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0
7903,Neurotoxicity,0,1,0,13,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,1,1
7904,neurotoxic,9,10,50,60,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,1,1
7905,encephalopathy,14,15,91,105,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,1,1
7908,peripheral neuropathy,14,16,77,98,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,1,1
7909,peripheral neuropathy,3,5,23,44,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,1,1
7910,encephalopathy,8,9,46,60,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,-1,1,1
7911,neuropathy,6,7,42,52,"The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken greater quantities of the drug.",230316_11,-1,1,1
7912,stress incontinence,1,3,17,36,Prazosin-induced stress incontinence.,2304736_0,-1,1,1
7913,stress incontinence,4,6,18,37,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,-1,1,1
7914,prazosin,8,9,45,53,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,0,-1,0
7915,Prazosin,0,1,0,8,Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha-1 adrenergic receptors.,2304736_2,0,-1,0
7916,prazosin,15,16,99,107,The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil.,2304736_4,0,-1,0
7917,verapamil,21,22,144,153,The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil.,2304736_4,0,-1,0
7918,incontinence,1,2,4,16,Her incontinence resolved with the change of medication.,2304736_5,-1,1,1
7919,stress incontinence,4,6,26,45,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,-1,1,1
7920,prazosin,8,9,59,67,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,0,-1,0
7921,incontinence,20,21,158,170,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,-1,1,1
7924,necrosis,5,6,33,41,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,1,1
7927,coronary spasm,13,15,73,87,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,1,1
7929,anuria,1,2,7,13,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,1,1
7930,ifosfamide,5,6,37,47,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0,-1,0
7931,breast cancer,9,11,66,79,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,1,1
7932,breast cancer,5,7,37,50,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1
7933,cisplatin,11,12,76,85,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0
7935,anuria,20,21,139,145,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1
7936,ifosfamide,28,29,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0
7938,hypotension,13,14,84,95,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,1,1
7939,anuria,24,25,149,155,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,1,1
7940,Ifosfamide,0,1,0,10,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,0,-1,0
7941,nephrotoxic,4,5,22,33,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,1,1
7942,anuria,6,7,37,43,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,-1,1,1
7943,ifosfamide,11,12,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0
7944,cisplatin,20,21,122,131,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0
7945,hypotension,30,31,193,204,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,-1,1,1
7946,ifosfamide,5,6,28,38,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0,-1,0
7947,nephrotoxic,10,11,67,78,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,-1,1,1
7950,prostaglandins,6,7,45,59,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,0,-1,0
7951,pain,8,9,63,67,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,1,1
7961,hyperalgesia,4,5,37,49,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,1,1
7963,pain,7,8,44,48,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,1,1
7966,hyperalgesia,11,12,80,92,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,1,1
7968,proteinuria,10,11,77,88,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,1,1
7970,morphine,2,3,13,21,infusions of morphine and regional analgesia by extradural block.,2334618_1,0,-1,0
7972,morphine,2,3,12,20,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0,-1,0
7973,bupivacaine,19,20,106,117,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0,-1,0
7975,apnoea,10,11,48,54,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,1,1
7976,morphine,25,26,121,129,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,0,-1,0
7977,morphine,26,27,129,137,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,0,-1,0
7978,thrombosis,2,3,15,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,1,1
7979,thrombosis,13,14,90,100,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,1,1
7980,thromboembolic,4,5,27,41,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,1,1
7981,thrombosis,17,18,132,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,1,1
7982,Seizure,0,1,0,7,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,1,1
7983,seizures,24,25,137,145,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,1,1
7984,seizures,5,6,38,46,Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.,2343592_2,-1,1,1
7985,seizures,1,2,4,12,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,-1,1,1
7986,phenytoin,8,9,55,64,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,0,-1,0
7987,seizure,13,14,94,101,Both patients had received maximum doses of other beta-lactam antibiotics without evidence of seizure activity.,2343592_4,-1,1,1
7988,aminophylline,2,3,11,24,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,0,-1,0
7991,Cardiac arrhythmias,0,2,0,19,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,1,1
7994,aminophylline,3,4,15,28,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,0,-1,0
7998,aminophylline,4,5,23,36,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,0,-1,0
8000,oxygen,26,27,157,163,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,0,-1,0
8004,aminophylline,30,31,130,143,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,0,-1,0
8006,ventricular arrhythmias,14,16,98,121,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,1,1
8008,aminophylline,24,25,181,194,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,0,-1,0
8009,Pentoxifylline,0,1,0,14,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,0,-1,0
8010,hyperemia,9,10,72,81,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,1,1
8011,pentoxifylline,6,7,34,48,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,0,-1,0
8013,pentoxifylline,1,2,8,22,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,0,-1,0
8014,hyperemia,5,6,62,71,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,1,1
8015,theophylline,11,12,107,119,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,0,-1,0
8016,dipyridamole,8,9,48,60,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0,-1,0
8017,pentoxifylline,18,19,130,144,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0,-1,0
8018,theophylline,31,32,175,187,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0,-1,0
8019,Dipyridamole,0,1,0,12,Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v.,2348231_6,0,-1,0
8020,pentoxifylline,0,1,0,14,pentoxifylline (p less than 0.002).,2348231_7,0,-1,0
8021,pentoxifylline,3,4,16,30,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,0,-1,0
8022,hyperemia,8,9,80,89,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,1,1
8023,theophylline,19,20,152,164,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,0,-1,0
8024,hyperemia,9,10,80,89,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,1,1
8025,death,2,3,9,14,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,1,1
8027,cerebral haemorrhage,15,17,80,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,1,1
8028,death,2,3,10,15,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,1,1
8029,cerebral haemorrhage,8,10,43,63,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,1,1
8031,death,4,5,22,27,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,1,1
8034,Cerebral haemorrhage,0,2,0,20,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1
8035,death,9,10,57,62,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1
8036,deaths,17,18,92,98,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1
8037,death,31,32,163,168,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1
8038,cerebral haemorrhage,4,6,21,41,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1
8039,death,10,11,56,61,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1
8041,hypotensive,20,21,115,126,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1
8042,levodopa,23,24,137,145,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,0,-1,0
8043,hypotensive,26,27,152,163,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1
8044,noradrenaline,31,32,189,202,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,0,-1,0
8045,parkinsonian,35,36,217,229,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1
8046,death,6,7,73,78,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,1,1
8047,Midazolam,0,1,0,9,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,0,-1,0
8048,depression,17,18,138,148,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,1,1
8049,death,11,12,79,84,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,1,1
8050,midazolam,17,18,133,142,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,0,-1,0
8051,midazolam,2,3,22,31,Information regarding midazolam use is reviewed to provide recommendation for safe administration.,2375138_4,0,-1,0
8053,weakness,4,5,32,40,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,-1,1,1
8054,magnesium,6,7,47,56,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,0,-1,0
8055,magnesium,17,18,119,128,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,0,-1,0
8056,magnesium,2,3,10,19,"The serum magnesium concentration was 3.0 mEq/L, which is usually well tolerated.",2385256_2,0,-1,0
8057,magnesium,1,2,4,13,The magnesium was stopped and she recovered over a few days.,2385256_3,0,-1,0
8058,acetylcholine,1,2,4,17,Her acetylcholine receptor antibody level was markedly elevated.,2385256_6,0,-1,0
8059,paralysis,1,2,9,18,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,1,1
8060,magnesium,3,4,25,34,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,0,-1,0
8062,magnesium,10,11,69,78,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,0,-1,0
8063,phenobarbital,3,4,18,31,No enhancement by phenobarbital of the hepatocarcinogenicity of a choline-devoid diet in the rat.,2396046_0,0,-1,0
8064,phenobarbital,9,10,57,70,An experiment was performed to test whether inclusion of phenobarbital in a choline-devoid diet would increase the hepatocarcinogenicity of the diet.,2396046_1,0,-1,0
8065,phenobarbital,25,26,151,164,"Groups of 5-week old male Fischer-344 rats were fed for 7-25 months semipurified choline-devoid or choline-supplemented diets, containing or not 0.06% phenobarbital.",2396046_2,0,-1,0
8066,hepatocellular carcinoma,22,24,160,184,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,1,1
8067,phenobarbital,33,34,236,249,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,0,-1,0
8068,phenobarbital,13,14,94,107,The results evinced no enhancement of the hepatocarcinogenicity of the choline-devoid diet by phenobarbital.,2396046_5,0,-1,0
8069,serotonin,2,3,11,20,Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.,2422478_0,0,-1,0
8070,hypotensive,10,11,59,70,Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.,2422478_0,-1,1,1
8071,methyldopa,13,14,81,91,Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.,2422478_0,0,-1,0
8072,methyldopa,10,11,74,84,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,0,-1,0
8073,serotonin,18,19,124,133,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,0,-1,0
8074,hypotensive,25,26,167,178,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,1,1
8075,serotonin,16,17,93,102,"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.",2422478_2,0,-1,0
8076,hypertensive,2,3,17,29,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,1,1
8077,methyldopa,9,10,68,78,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0,-1,0
8078,serotonin,17,18,111,120,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0,-1,0
8079,hypotension,27,28,171,182,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,1,1
8081,serotonin,49,50,269,278,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0,-1,0
8082,serotonin,15,16,96,105,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,0,-1,0
8083,hypotension,25,26,157,168,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,1,1
8084,serotonin,5,6,27,36,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,0,-1,0
8085,serotonin,23,24,134,143,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,0,-1,0
8087,hypotension,15,16,101,112,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,-1,1,1
8088,serotonin,22,23,153,162,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,0,-1,0
8089,hypotensive,31,32,205,216,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,-1,1,1
8090,methyldopa,34,35,227,237,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,0,-1,0
8091,prednisolone,5,6,35,47,"On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.",2425813_0,0,-1,0
8092,prednisolone,14,15,106,118,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,0,-1,0
8093,prednisolone,14,15,85,97,This view supports the contention that the liver and muscle are independent sites of prednisolone action.,2425813_4,0,-1,0
8094,ventricular arrhythmias,7,9,62,85,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,1,1
8095,ventricular arrhythmias,10,12,78,101,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1
8096,arrhythmia,27,28,211,221,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1
8097,arrhythmias,4,5,31,42,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,1,1
8098,arrhythmias,13,14,96,107,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,1,1
8099,adrenaline,27,28,182,192,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,0,-1,0
8100,arrhythmia,4,5,41,51,The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.,2435991_3,-1,1,1
8101,arrhythmias,15,16,111,122,The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.,2435991_3,-1,1,1
8102,mexiletine,8,9,52,62,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,0,-1,0
8103,hypotensive,5,6,34,45,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,1,1
8104,depressive,9,10,61,71,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,1,1
8105,lindane,5,6,53,60,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,0,-1,0
8106,seizures,9,10,91,99,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,-1,1,1
8107,lindane,11,12,82,89,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0,-1,0
8108,seizure,18,19,118,125,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,1,1
8111,seizures,37,38,242,250,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,1,1
8115,Seizure,0,1,0,7,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,1,1
8117,picrotoxin,6,7,32,42,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0,-1,0
8118,seizure,16,17,87,94,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,1,1
8120,bicuculline,26,27,143,154,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0,-1,0
8122,picrotoxin,7,8,43,53,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0,-1,0
8123,seizure,10,11,71,78,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,1,1
8126,seizure,13,14,72,79,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,1,1
8128,ribavirin,5,6,34,43,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,0,-1,0
8130,ribavirin,5,6,34,43,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,0,-1,0
8132,ribavirin,2,3,18,27,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,0,-1,0
8133,death,4,5,20,25,The average time of death was delayed.,2445283_3,-1,1,1
8134,anemia,2,3,13,19,A reversible anemia was the only adverse effect observed.,2445283_4,-1,1,1
8135,ribavirin,7,8,37,46,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,0,-1,0
8136,anemia,20,21,106,112,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,1,1
8137,ribavirin,5,6,34,43,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,0,-1,0
8138,cardiac toxicity,7,9,46,62,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,1,1
8141,tumors,17,18,127,133,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,1,1
8152,death,6,7,31,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,1,1
8154,ischemia,18,19,118,126,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,1,1
8156,lindane,17,18,121,128,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,0,-1,0
8157,Lindane,0,1,0,7,"Lindane is also widely used as an agricultural and industrial pesticide, and as a result the toxic profile of this insecticide is well understood.",2476560_1,0,-1,0
8158,lindane,4,5,30,37,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,0,-1,0
8159,lindane,2,3,24,31,Preparations containing lindane continue to be sold over the counter and may represent a hazard to poorly informed patients.,2476560_3,0,-1,0
8160,toxicity,24,25,185,193,"This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at-risk groups, and give adequate warnings regarding potential toxicity.",2476560_4,-1,1,1
8161,amantadine,4,5,33,43,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0,-1,0
8163,amantadine,3,4,14,24,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0,-1,0
8165,Amantadine,0,1,0,10,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0,-1,0
8167,amantadine,1,2,11,21,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0,-1,0
8168,amantadine,27,28,172,182,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0,-1,0
8169,amantadine,2,3,20,30,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,0,-1,0
8170,amantadine,2,3,15,25,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0,-1,0
8171,dopamine,8,9,52,60,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0,-1,0
8173,amantadine,11,12,85,95,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0,-1,0
8174,amantadine,7,8,49,59,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,0,-1,0
8175,amantadine,22,23,122,132,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,0,-1,0
8177,catecholamine,16,17,103,116,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0
8179,norepinephrine,31,32,215,229,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0
8180,depression,38,39,265,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,1,1
8181,amantadine,41,42,286,296,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0
8182,cyclophosphamide,9,10,77,93,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0,-1,0
8183,ifosfamide,11,12,97,107,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0,-1,0
8189,mesna,21,22,122,127,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0,-1,0
8190,pain,2,3,10,14,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,1,1
8191,migraine,7,8,44,52,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,1,1
8193,nitroglycerin,22,23,155,168,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,0,-1,0
8194,migraine,2,3,12,20,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,-1,1,1
8195,nitroglycerin,7,8,45,58,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,0,-1,0
8196,migraine,2,3,16,24,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,-1,1,1
8197,nitroglycerin,13,14,91,104,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,0,-1,0
8198,migraine,3,4,15,23,No early onset migraine was observed.,2515254_3,-1,1,1
8199,nitroglycerin,5,6,37,50,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,0,-1,0
8200,pain,17,18,113,117,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,1,1
8201,migraine,33,34,210,218,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,-1,1,1
8202,migraine,9,10,44,52,This is not consistent with a CNS origin of migraine attack.,2515254_5,-1,1,1
8203,Hypersensitivity,0,1,0,16,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,1,1
8204,carbamazepine,2,3,20,33,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,0,-1,0
8206,eosinophilia,9,10,72,84,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,1,1
8208,hypersensitivity,6,7,28,44,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1
8209,carbamazepine,8,9,48,61,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,0,-1,0
8211,eosinophilia,19,20,132,144,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1
8212,hyponatremia,21,22,146,158,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,1,1
8214,carbamazepine,11,12,56,69,This is the first report of such an unusual reaction to carbamazepine.,2522601_2,0,-1,0
8215,Azidothymidine,17,18,114,128,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,0,-1,0
8216,zidovudine,10,11,68,78,"Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.",2528969_2,0,-1,0
8217,nausea,13,14,75,81,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1
8218,fatigue,19,20,89,96,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1
8219,headache,25,26,107,115,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1
8233,fluoxetine,3,4,24,34,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,0,-1,0
8234,major depression,12,14,89,105,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,1,1
8242,fluoxetine,9,10,49,59,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0,-1,0
8243,propranolol,20,21,138,149,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0,-1,0
8246,morphine,6,7,33,41,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0,-1,0
8250,hyperalgesia,20,21,141,153,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,1,1
8251,morphine,6,7,39,47,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,0,-1,0
8252,naloxone,11,12,84,92,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,0,-1,0
8254,Morphine,0,1,0,8,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,0,-1,0
8255,hyperalgesia,8,9,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,1,1
8258,nephropathy,10,11,75,86,Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy.,2559236_0,-1,1,1
8259,enalapril,10,11,52,61,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0,-1,0
8261,adriamycin,7,8,33,43,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0,-1,0
8262,albuminuria,18,19,101,112,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,-1,1,1
8263,enalapril,12,13,64,73,Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril.,2559236_3,0,-1,0
8264,enalapril,5,6,37,46,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0,-1,0
8265,albuminuria,57,58,243,254,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,1,1
8266,enalapril,17,18,78,87,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,0,-1,0
8267,renal injury,21,23,106,118,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,1,1
8269,enalapril,1,2,8,17,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,0,-1,0
8270,albuminuria,8,9,68,79,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,-1,1,1
8271,Enalapril,0,1,0,9,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0,-1,0
8274,fentanyl,13,14,88,96,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,0,-1,0
8276,ketamine,24,25,154,162,"We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon, using male Sprague-Dawley rats anesthetized with ketamine.",2564649_2,0,-1,0
8278,fentanyl,15,16,103,111,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,0,-1,0
8280,prazosin,30,31,208,216,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,0,-1,0
8281,fentanyl,2,3,18,26,"Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.",2564649_5,0,-1,0
8283,fentanyl,10,11,60,68,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,0,-1,0
8287,rigidity,5,6,46,54,"Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism.",2569282_3,-1,1,1
8289,alfentanil,19,20,118,128,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0,-1,0
8290,alfentanil,6,7,32,42,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0,-1,0
8294,akinetic,7,8,42,50,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,1,1
8295,hepatitis,2,3,26,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,1,1
8296,hepatitis,10,11,52,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,1,1
8297,necrosis,14,15,92,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,1,1
8298,benzodiazepines,4,5,30,45,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,0,-1,0
8299,hepatitis,23,24,148,157,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,1,1
8300,hepatitis,8,9,57,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,1,1
8301,hepatotoxicity,16,17,103,117,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,1,1
8302,benzodiazepines,21,22,150,165,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,0,-1,0
8303,serotonin,12,13,79,88,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0,-1,0
8304,hyperactivity,23,24,129,142,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,1,1
8305,hyperactivity,1,2,4,17,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,1,1
8306,citalopram,10,11,77,87,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0
8307,serotonin,14,15,107,116,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0
8308,antidepressant,23,24,163,177,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0
8309,5-azacytidine,0,1,0,13,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,0,-1,0
8310,5-azacytidine,22,23,134,147,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0,-1,0
8312,"1,2-dimethylhydrazine",65,66,357,378,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0,-1,0
8314,2-acetylaminofluorene,27,28,182,203,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0,-1,0
8321,bupivacaine,5,6,40,51,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,0,-1,0
8322,death,37,38,179,184,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,-1,1,1
8323,bupivacaine,21,22,117,128,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0
8324,bupivacaine,2,3,13,24,injection of bupivacaine were ineffective.,2594614_4,0,-1,0
8325,bupivacaine,13,14,61,72,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0,-1,0
8326,toxicity,46,47,256,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,1,1
8330,alcohol,83,84,338,345,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,0,-1,0
8331,ibuprofen,15,16,95,104,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,0,-1,0
8334,depression,3,4,27,37,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,1,1
8335,hypertensive,3,4,25,37,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,1,1
8336,depression,7,8,40,50,"The results showed a high prevalence of depression in both groups of patients, with no preponderance in the hypertensive group.",26094_2,-1,1,1
8337,hypertensive,19,20,108,120,"The results showed a high prevalence of depression in both groups of patients, with no preponderance in the hypertensive group.",26094_2,-1,1,1
8338,Hypertensive,0,1,0,12,Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients.,26094_3,-1,1,1
8339,psychiatric,3,4,27,38,Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients.,26094_3,-1,1,1
8340,depression,10,11,76,86,Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients.,26094_3,-1,1,1
8341,methyl dopa,12,14,75,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0,-1,0
8342,psychiatric,17,18,109,120,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,1,1
8343,hepatitis,2,3,15,24,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,1,1
8346,phenylacetic acid,14,16,103,120,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0,-1,0
8347,hepatitis,18,19,126,135,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,1,1
8348,diclofenac,21,22,147,157,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,0,-1,0
8349,hepatitis,6,7,47,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,1,1
8352,ketoconazole,7,8,53,65,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,0,-1,0
8353,ketoconazole,14,15,77,89,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,0,-1,0
8354,hypertension,17,18,110,122,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,1,1
8355,cortisol,8,9,45,53,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0,-1,0
8356,ketoconazole,14,15,89,101,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0,-1,0
8357,hypertension,23,24,165,177,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,-1,1,1
8358,aldosterone,17,18,105,116,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,0,-1,0
8359,ketoconazole,10,11,62,74,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0,-1,0
8360,hypertension,18,19,139,151,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,-1,1,1
8361,angiotensin,5,6,27,38,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0,-1,0
8362,Captopril,9,10,58,67,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0,-1,0
8367,sepsis,34,35,223,229,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,1,1
8368,Captopril,2,3,13,22,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0,-1,0
8369,angiotensin,11,12,50,61,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0,-1,0
8371,Captopril,13,14,71,80,"The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein.",2670794_4,0,-1,0
8372,Renal damage,0,2,0,12,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,1,1
8373,urea,9,10,50,54,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,0,-1,0
8374,Captopril,17,18,93,102,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,0,-1,0
8376,Captopril,7,8,36,45,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0,-1,0
8377,bradykinin,40,41,228,238,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0,-1,0
8378,Captopril,0,1,0,9,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,0,-1,0
8379,Stroke,0,1,0,6,Stroke associated with cocaine use.,2673163_0,-1,1,1
8380,cocaine,3,4,23,30,Stroke associated with cocaine use.,2673163_0,0,-1,0
8381,cocaine,6,7,35,42,We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature.,2673163_1,0,-1,0
8382,stroke,11,12,62,68,We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature.,2673163_1,-1,1,1
8383,Stroke,0,1,0,6,"Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.",2673163_3,-1,1,1
8384,cocaine,2,3,16,23,"Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.",2673163_3,0,-1,0
8385,aneurysms,1,2,13,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,1,1
8386,vasculitis,19,20,137,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,1,1
8390,stroke,11,12,55,61,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8391,cocaine,14,15,73,80,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0
8392,stroke,23,24,123,129,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8393,stroke,33,34,168,174,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8394,cocaine,39,40,199,206,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0
8395,stroke,45,46,227,233,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8396,cocaine,47,48,240,247,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0
8397,aneurysms,54,55,295,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8399,stroke,65,66,368,374,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8400,hemorrhage,71,72,406,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,1,1
8402,labetalol,4,5,27,36,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0,-1,0
8403,nitroprusside,6,7,41,54,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0,-1,0
8404,hypotension,9,10,67,78,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,-1,1,1
8405,hypotension,6,7,41,52,"In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.",2696505_1,-1,1,1
8406,hypotension,9,10,79,90,"In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.",2696505_1,-1,1,1
8407,Nitroprusside,0,1,0,13,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0
8408,hypertension,22,23,127,139,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,1,1
8409,nitroprusside,31,32,196,209,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0
8410,Labetalol,0,1,0,9,Labetalol administration was not associated with any of these findings.,2696505_4,0,-1,0
8411,labetalol,4,5,22,31,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0,-1,0
8412,nitroprusside,8,9,55,68,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0,-1,0
8413,glycosuria,1,2,18,28,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,1,1
8417,glycosuria,15,16,93,103,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,1,1
8420,glucose,19,20,139,146,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,0,-1,0
8423,glycosuria,4,5,18,28,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,1,1
8424,gentamicin,27,28,93,103,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0,-1,0
8426,gentamicin,37,38,135,145,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0,-1,0
8427,Nephrotoxic,0,1,0,11,Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.,2709684_6,-1,1,1
8428,gentamicin,9,10,44,54,Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.,2709684_6,0,-1,0
8429,glycosuria,10,11,44,54,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1
8431,renal dysfunction,28,30,125,142,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1
8432,tubular necrosis,45,47,214,230,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1
8433,tubular necrosis,34,36,155,171,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,1,1
8434,tubular necrosis,32,34,148,164,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,1,1
8435,Catalepsy,0,1,0,9,"Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.",2716967_0,-1,1,1
8436,ketamine,5,6,37,45,"Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.",2716967_0,0,-1,0
8437,morphine,7,8,50,58,"Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.",2716967_0,0,-1,0
8438,ketamine,5,6,40,48,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,0,-1,0
8439,morphine,7,8,53,61,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,0,-1,0
8440,catalepsy,11,12,84,93,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,1,1
8441,ketamine,2,3,19,27,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0
8442,morphine,6,7,56,64,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0
8443,morphine,11,12,92,100,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0
8444,ketamine,17,18,135,143,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0
8445,morphine,31,32,235,243,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,0,-1,0
8446,ketamine,17,18,107,115,"The present studies explored the duration of the loss of righting reflex induced by sub-effective doses of ketamine and morphine, administered simultaneously.",2716967_3,0,-1,0
8447,morphine,19,20,120,128,"The present studies explored the duration of the loss of righting reflex induced by sub-effective doses of ketamine and morphine, administered simultaneously.",2716967_3,0,-1,0
8448,ketamine,8,9,61,69,"There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of morphine.",2716967_4,0,-1,0
8449,morphine,10,11,74,82,"There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of morphine.",2716967_4,0,-1,0
8450,ketamine,16,17,111,119,"There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of morphine.",2716967_4,0,-1,0
8451,morphine,22,23,164,172,"There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of morphine.",2716967_4,0,-1,0
8452,rigidity,8,9,40,48,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,-1,1,1
8453,ketamine,19,20,114,122,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,0,-1,0
8454,morphine,21,22,126,134,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,0,-1,0
8455,Naloxone,0,1,0,8,Naloxone inhibited the induced cataleptic effects.,2716967_6,0,-1,0
8456,ketamine,17,18,117,125,The degree and time course of development of tolerance to daily administration of sub-effective dose combinations of ketamine and morphine were similar.,2716967_7,0,-1,0
8457,morphine,19,20,130,138,The degree and time course of development of tolerance to daily administration of sub-effective dose combinations of ketamine and morphine were similar.,2716967_7,0,-1,0
8458,morphine,22,23,163,171,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,0,-1,0
8459,ketamine,33,34,237,245,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,0,-1,0
8460,catalepsy,14,15,98,107,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,-1,1,1
8461,rigidity,20,21,133,141,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,-1,1,1
8462,naloxone,32,33,217,225,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,0,-1,0
8463,hypertension,1,2,23,35,Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.,2722224_0,-1,1,1
8464,hydrocortisone,1,2,5,19,Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects.,2722224_1,0,-1,0
8465,hydrocortisone,9,10,41,55,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,0,-1,0
8466,norepinephrine,30,31,166,180,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,0,-1,0
8467,norepinephrine,8,9,68,82,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0
8468,hydrocortisone,23,24,145,159,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0
8469,hydrocortisone,46,47,259,273,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,0,-1,0
8470,norepinephrine,17,18,107,121,A shift to the left in the dose-response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment.,2722224_7,0,-1,0
8471,norepinephrine,3,4,23,37,Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased.,2722224_8,0,-1,0
8472,norepinephrine,9,10,67,81,Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased.,2722224_8,0,-1,0
8473,hydrocortisone,7,8,40,54,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,0,-1,0
8475,nifedipine,6,7,50,60,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,0,-1,0
8476,nifedipine,6,7,38,48,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,0,-1,0
8478,nifedipine,4,5,32,42,This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium.,2750819_2,0,-1,0
8479,toxicity,9,10,72,80,This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium.,2750819_2,-1,1,1
8480,magnesium,11,12,84,93,This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium.,2750819_2,0,-1,0
8481,carbamazepine,1,2,8,21,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0
8482,seizures,8,9,67,75,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,-1,1,1
8483,cocaine,11,12,87,94,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0
8484,lidocaine,13,14,99,108,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0
8485,carbamazepine,3,4,15,28,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0,-1,0
8487,seizures,11,12,73,81,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,1,1
8490,seizures,11,12,82,90,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,1,1
8491,seizures,23,24,154,162,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,1,1
8494,seizures,22,23,116,124,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,1,1
8496,seizures,18,19,104,112,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,1,1
8498,seizure,9,10,56,63,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,1,1
8499,seizures,23,24,181,189,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,1,1
8502,cocaine,16,17,97,104,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,0,-1,0
8503,Sodium,0,1,0,6,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,0,-1,0
8505,nephrotoxic,1,2,4,15,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,1,1
8508,creatinine,7,8,48,58,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0,-1,0
8509,creatinine,6,7,33,43,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0
8510,creatinine,25,26,132,142,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0
8513,creatinine,5,6,29,39,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0
8516,salt,20,21,149,153,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0
8517,sodium,25,26,182,188,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0
8520,oral contraceptive,9,11,42,60,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0,-1,0
8521,terbutaline,11,12,62,73,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0,-1,0
8522,terbutaline,5,6,27,38,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0,-1,0
8523,potassium,16,17,109,118,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0,-1,0
8524,terbutaline,12,13,74,85,The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects.,2826064_5,0,-1,0
8525,potassium,15,16,105,114,The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects.,2826064_5,0,-1,0
8526,terbutaline,10,11,46,57,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,0,-1,0
8527,terbutaline,4,5,19,30,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0,-1,0
8529,dystonia,15,16,102,110,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,1,1
8530,depression,56,57,298,308,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,1,1
8532,Flestolol,0,1,0,9,Flestolol: an ultra-short-acting beta-adrenergic blocking agent.,2870085_0,0,-1,0
8533,Flestolol,0,1,0,9,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,0,-1,0
8534,Flestolol,0,1,0,9,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0,-1,0
8535,flestolol,5,6,31,40,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,0,-1,0
8536,Flestolol,0,1,0,9,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0,-1,0
8537,flestolol,16,17,131,140,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0,-1,0
8538,Flestolol,0,1,0,9,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,0,-1,0
8539,tachycardia,7,8,73,84,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,-1,1,1
8540,flestolol,5,6,46,55,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,0,-1,0
8541,Flestolol,0,1,0,9,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,0,-1,0
8542,flestolol,6,7,34,43,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,0,-1,0
8544,flestolol,4,5,21,30,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0,-1,0
8545,flestolol,2,3,7,16,Use of flestolol in the critical care setting is currently undergoing investigation.,2870085_12,0,-1,0
8546,hypertensive,6,7,75,87,Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.,2886572_0,-1,1,1
8547,epinephrine,8,9,47,58,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,0,-1,0
8549,catecholamine,1,2,6,19,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,0,-1,0
8550,norepinephrine,12,13,99,113,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,0,-1,0
8551,epinephrine,2,3,9,20,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8552,epinephrine,9,10,64,75,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8553,catecholamine,12,13,87,100,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8554,catecholamine,21,22,143,156,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8555,epinephrine,24,25,169,180,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8556,norepinephrine,27,28,191,205,"However, epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40% of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree.",2886572_3,0,-1,0
8557,catecholamine,2,3,13,26,Total tissue catecholamine content of the kidney on a molar basis was unchanged.,2886572_4,0,-1,0
8558,norepinephrine,17,18,147,161,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,0,-1,0
8559,epinephrine,19,20,166,177,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,0,-1,0
8560,Propranolol,0,1,0,11,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,0,-1,0
8561,epinephrine,4,5,23,34,"In conclusion, chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow.",2886572_9,0,-1,0
8562,epinephrine,21,22,162,173,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,0,-1,0
8563,bromocriptine,12,13,111,124,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0,-1,0
8564,bromocriptine,5,6,26,39,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0,-1,0
8565,prolactinoma,7,8,43,55,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1
8566,prolactinoma,23,24,173,185,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1
8569,bromocriptine,33,34,223,236,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0,-1,0
8572,prolactinoma,20,21,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,1,1
8573,bromocriptine,13,14,81,94,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,0,-1,0
8575,prolactinoma,1,2,4,16,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,1,1
8576,prolactinoma,23,24,177,189,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,1,1
8578,bromocriptine,15,16,95,108,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0,-1,0
8579,bromocriptine,30,31,200,213,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0,-1,0
8581,naloxone,3,4,20,28,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,0,-1,0
8585,naloxone,3,4,14,22,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,0,-1,0
8588,glutamate,17,18,107,116,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0
8589,aspartate,24,25,139,148,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0
8590,glycine,26,27,152,159,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0
8592,glutamate,17,18,100,109,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,0,-1,0
8594,Naloxone,0,1,0,8,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,0,-1,0
8596,glutamate,12,13,59,68,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,0,-1,0
8598,naloxone,3,4,19,27,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,0,-1,0
8601,Diazepam,0,1,0,8,Diazepam facilitates reflex bradycardia in conscious rats.,2894433_0,0,-1,0
8602,bradycardia,3,4,28,39,Diazepam facilitates reflex bradycardia in conscious rats.,2894433_0,-1,1,1
8603,diazepam,3,4,15,23,The effects of diazepam on cardiovascular function were assessed in conscious rats.,2894433_1,0,-1,0
8604,diazepam,3,4,30,38,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,0,-1,0
8606,adrenaline,12,13,73,83,"Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).",2894433_3,0,-1,0
8607,diazepam,6,7,42,50,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,0,-1,0
8608,bradycardia,23,24,163,174,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,-1,1,1
8609,diazepam,3,4,13,21,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0,-1,0
8610,bradycardia,8,9,63,74,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,1,1
8611,picrotoxin,20,21,143,153,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0,-1,0
8613,diazepam,4,5,23,31,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,0,-1,0
8614,bradycardia,20,21,164,175,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,-1,1,1
8617,sulfasalazine,25,26,179,192,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,0,-1,0
8618,sulfasalazine,4,5,23,36,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0,-1,0
8619,corticosteroids,12,13,76,91,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0,-1,0
8621,sulfasalazine,3,4,19,32,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,0,-1,0
8622,potassium,1,2,8,17,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,0,-1,0
8624,sodium,18,19,143,149,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,0,-1,0
8625,potassium,4,5,27,36,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,0,-1,0
8627,potassium,8,9,45,54,All patients had a normal initial total body potassium (40K).,28952_4,0,-1,0
8629,aldosterone,14,15,76,87,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,0,-1,0
8630,potassium,4,5,17,26,"In both groups a potassium deficit developed, with proportionally larger losses from the extracellular than from the intracellular compartment.",28952_6,0,-1,0
8631,potassium,7,8,44,53,"In the normal-sodium group the highest mean potassium deficit was 176 mmol on day 9, after which some potassium was regained; in the low-sodium group the highest deficit was 276 mmol on day 13.",28952_7,0,-1,0
8632,potassium,19,20,102,111,"In the normal-sodium group the highest mean potassium deficit was 176 mmol on day 9, after which some potassium was regained; in the low-sodium group the highest deficit was 276 mmol on day 13.",28952_7,0,-1,0
8633,aldosterone,13,14,80,91,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0,-1,0
8634,aldosterone,22,23,134,145,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0,-1,0
8635,sodium,5,6,29,35,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0,-1,0
8636,potassium,9,10,75,84,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0,-1,0
8637,sodium,23,24,178,184,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0,-1,0
8638,potassium,36,37,267,276,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0,-1,0
8639,catalepsy,3,4,32,41,Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs.,2907585_0,-1,1,1
8640,catalepsy,8,9,47,56,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,1,1
8641,haloperidol,11,12,68,79,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,0,-1,0
8642,haloperidol,18,19,135,146,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,0,-1,0
8643,catalepsy,20,21,155,164,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,1,1
8644,catalepsy,12,13,90,99,Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.,2907585_3,-1,1,1
8647,catalepsy,13,14,97,106,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,1,1
8648,carbamazepine,1,2,8,21,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,0,-1,0
8649,toxicity,9,10,54,62,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,1,1
8652,Carbamazepine,0,1,0,13,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0,-1,0
8657,seizures,29,30,160,168,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,1,1
8659,Seizures,0,1,0,8,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,1,1
8661,seizures,22,23,124,132,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,1,1
8664,seizures,22,23,134,142,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,1,1
8671,dipyridamole,10,11,87,99,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,0,-1,0
8672,dipyridamole,16,17,89,101,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,0,-1,0
8675,ischemia,24,25,158,166,"Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary ""steal"" phenomenon may be the mechanism of the dipyridamole-induced ischemia observed.",2950248_3,-1,1,1
8677,sodium,11,12,55,61,"In six conscious, trained dogs, maintained on a normal sodium intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v.",2951327_1,0,-1,0
8678,norepinephrine,28,29,148,162,"In six conscious, trained dogs, maintained on a normal sodium intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v.",2951327_1,0,-1,0
8679,epinephrine,30,31,167,178,"In six conscious, trained dogs, maintained on a normal sodium intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v.",2951327_1,0,-1,0
8680,tachycardia,71,72,258,269,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,1,1
8681,norepinephrine,77,78,297,311,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0,-1,0
8682,hypotension,95,96,404,415,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,1,1
8683,nitroglycerin,100,101,442,455,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0,-1,0
8684,epinephrine,4,5,20,31,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0,-1,0
8689,lithium,6,7,56,63,Thyroid function and urine-concentrating ability during lithium treatment.,3001299_0,0,-1,0
8691,hypothyroidism,20,21,135,149,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,1,1
8692,lithium,22,23,157,164,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,0,-1,0
8693,thyroxine,3,4,18,27,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0,-1,0
8694,lithium,21,22,128,135,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0,-1,0
8695,Hypothyroidism,0,1,0,14,Hypothyroidism developed in eight patients while they were taking lithium.,3001299_3,-1,1,1
8696,lithium,9,10,66,73,Hypothyroidism developed in eight patients while they were taking lithium.,3001299_3,0,-1,0
8697,lithium,9,10,54,61,It is concluded that the dominant mechanisms by which lithium exerts these two effects are different.,3001299_5,0,-1,0
8699,neuropathy,1,2,4,14,The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.,3015327_1,-1,1,1
8700,isoniazid,8,9,42,51,The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.,3015327_1,0,-1,0
8701,hypotension,1,2,22,33,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,-1,1,1
8703,oxytocin,8,9,65,73,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,0,-1,0
8704,corticosterone,14,15,72,86,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0
8706,oxytocin,37,38,256,264,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0
8707,corticosterone,40,41,272,286,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0,-1,0
8708,corticosterone,9,10,56,70,"Resting irCRF levels are suppressed only at the highest corticosterone infusion rate, which resulted in systemic corticosterone levels of 40 micrograms/dl.",3015567_4,0,-1,0
8709,corticosterone,17,18,113,127,"Resting irCRF levels are suppressed only at the highest corticosterone infusion rate, which resulted in systemic corticosterone levels of 40 micrograms/dl.",3015567_4,0,-1,0
8710,hypotension,8,9,68,79,Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.,3015567_5,-1,1,1
8711,corticosterone,16,17,115,129,Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.,3015567_5,0,-1,0
8712,catalepsy,3,4,29,38,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,1,1
8713,6-hydroxydopamine,26,27,163,180,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0,-1,0
8715,desipramine,32,33,198,209,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0,-1,0
8718,desipramine,28,29,164,175,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,0,-1,0
8720,haloperidol,8,9,46,57,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0,-1,0
8721,desipramine,16,17,105,116,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0,-1,0
8724,catalepsy,14,15,97,106,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,1,1
8725,catalepsy,25,26,169,178,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,1,1
8726,haloperidol,28,29,190,201,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,0,-1,0
8729,hypertension,14,15,110,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,1,1
8730,hypertension,6,7,27,39,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,1,1
8732,captopril,27,28,170,179,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,0,-1,0
8733,captopril,13,14,79,88,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,0,-1,0
8736,Lovastatin,0,1,0,10,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,0,-1,0
8737,simvastatin,2,3,15,26,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,0,-1,0
8738,lovastatin,3,4,25,35,"Clinical experience with lovastatin includes over 5000 patients, 700 of whom have been treated for 2 years or more, and experience with simvastatin includes over 3500 patients, of whom 350 have been treated for 18 months or more.",3076126_3,0,-1,0
8739,simvastatin,24,25,136,147,"Clinical experience with lovastatin includes over 5000 patients, 700 of whom have been treated for 2 years or more, and experience with simvastatin includes over 3500 patients, of whom 350 have been treated for 18 months or more.",3076126_3,0,-1,0
8740,Lovastatin,0,1,0,10,Lovastatin has been marketed in the United States for over 6 months.,3076126_4,0,-1,0
8741,cholesterol,11,12,73,84,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,0,-1,0
8743,Myopathy,0,1,0,8,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,1,1
8745,lovastatin,23,24,130,140,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,0,-1,0
8746,Lovastatin,0,1,0,10,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,0,-1,0
8747,simvastatin,2,3,15,26,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,0,-1,0
8748,cholesterol,15,16,110,121,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,0,-1,0
8749,Toxicity,0,1,0,8,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,1,1
8750,rheumatoid arthritis,7,9,44,64,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,1,1
8751,rheumatoid arthritis,3,5,26,46,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1
8752,toxicity,10,11,66,74,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1
8753,toxicity,19,20,128,136,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1
8754,dermatitis,9,10,58,68,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,1,1
8755,dermatitis,27,28,162,172,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,1,1
8756,amphetamine,17,18,147,158,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,0,-1,0
8760,amphetamine,10,11,72,83,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,0,-1,0
8761,amphetamine,16,17,91,102,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,0,-1,0
8762,amphetamine,51,52,325,336,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,0,-1,0
8763,amphetamine,4,5,28,39,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,0,-1,0
8764,ketoconazole,4,5,34,46,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,0,-1,0
8765,Ketoconazole,0,1,0,12,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,0,-1,0
8766,hepatotoxicity,15,16,90,104,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,1,1
8767,deaths,23,24,146,152,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,1,1
8768,deaths,18,19,100,106,"An analysis of the 75 cases that had been adequately followed up suggested that 16, including three deaths, were probably related to treatment with the drug.",3101906_3,-1,1,1
8769,hepatotoxicity,14,15,65,79,"The mean age of patients in the 16 probable cases was 57.9, with hepatotoxicity being more common in women.",3101906_5,-1,1,1
8770,jaundice,9,10,54,62,The average duration of treatment before the onset of jaundice was 61 days.,3101906_6,-1,1,1
8771,cholestasis,15,16,91,102,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,1,1
8772,rash,4,5,32,36,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,1,1
8773,eosinophilia,6,7,41,53,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,1,1
8774,Hepatitis,0,1,0,9,"Hepatitis was usually reversible when treatment was stopped, with the results of liver function tests returning to normal after an average of 3.1 months.",3101906_12,-1,1,1
8775,deaths,5,6,20,26,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,1,1
8776,ketoconazole,9,10,52,64,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,0,-1,0
8777,jaundice,20,21,122,130,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,1,1
8778,hepatitis,25,26,153,162,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,1,1
8779,hepatitis,10,11,73,82,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,1,1
8780,ketoconazole,18,19,126,138,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,0,-1,0
8781,hepatic injury,23,25,167,181,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,1,1
8782,hepatitis,1,2,18,27,Glyburide-induced hepatitis.,3107448_0,-1,1,1
8783,hepatotoxicity,1,2,13,27,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,1,1
8784,hepatotoxicity,12,13,75,89,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,1,1
8786,infection,7,8,41,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,1,1
8787,hepatitis,21,22,135,144,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,1,1
8788,hemolytic uremic syndrome,3,6,23,48,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,1,1
8789,Hemolytic Uremic Syndrome,3,6,23,48,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,1,1
8791,hemolytic anemia,4,6,32,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,1,1
8792,thrombocytopenia,7,8,50,66,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,1,1
8799,thrombocytopenia,21,22,137,153,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,1,1
8802,serotonin,9,10,68,77,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0,-1,0
8804,alfentanil,27,28,203,213,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0,-1,0
8805,rigidity,13,14,91,99,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,1,1
8806,rigidity,12,13,79,87,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,1,1
8807,alfentanil,15,16,100,110,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,0,-1,0
8808,rigidity,4,5,23,31,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,1,1
8809,alfentanil,20,21,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0
8810,alfentanil,36,37,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0
8811,alfentanil,5,6,34,44,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0
8814,rigidity,12,13,102,110,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,1,1
8816,diazepam,5,6,39,47,Fifty-seven patients were sedated with diazepam for surgery under epidural anaesthesia.,3120485_3,0,-1,0
8817,amnesia,18,19,97,104,"The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.",3120485_5,-1,1,1
8818,amnesia,13,14,81,88,"No significant differences between the two groups were observed for mood rating, amnesia, or vital signs.",3120485_6,-1,1,1
8819,oral contraceptives,6,8,48,67,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0,-1,0
8821,rigidity,5,6,58,66,Intracranial pressure increases during alfentanil-induced rigidity.,3125768_0,-1,1,1
8822,rigidity,9,10,67,75,Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.,3125768_1,-1,1,1
8823,halothane,16,17,82,91,"Ten rats had arterial, central venous (CVP), and subdural cannulae inserted under halothane anesthesia.",3125768_2,0,-1,0
8825,halothane,3,4,27,36,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0
8826,alfentanil,7,8,58,68,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0
8827,halothane,17,18,119,128,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0
8828,rigidity,7,8,40,48,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,1,1
8829,rigidity,6,7,42,50,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,1,1
8830,alfentanil,16,17,77,87,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,0,-1,0
8831,rigidity,4,5,32,40,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,-1,1,1
8832,alfentanil,9,10,66,76,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,0,-1,0
8833,carcinogenesis,7,8,57,71,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,1,1
8839,tumors,38,39,223,229,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1
8840,carcinoma,44,45,259,268,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1
8841,carcinoma,55,56,296,305,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1
8842,carcinoma,66,67,336,345,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,1,1
8844,Tumors,0,1,0,6,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,1,1
8846,carcinogenesis,13,14,80,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,1,1
8847,cardiotoxicity,8,9,46,60,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,1,1
8848,cardiotoxic,24,25,138,149,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,1,1
8849,doxorubicin,33,34,200,211,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,0,-1,0
8851,doxorubicin,17,18,86,97,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,0,-1,0
8853,cardiotoxicity,7,8,46,60,"None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.",3137399_8,-1,1,1
8854,cardiotoxicity,17,18,98,112,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,1,1
8855,doxorubicin,45,46,258,269,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,0,-1,0
8856,Verapamil,0,1,0,9,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,0,-1,0
8858,hypertensive,11,12,71,83,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,1,1
8859,Verapamil,0,1,0,9,Verapamil is an effective and relatively-safe antihypertensive drug.,3173179_1,0,-1,0
8860,depression,12,13,73,83,"Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents.",3173179_2,-1,1,1
8862,captopril,13,14,83,92,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,0,-1,0
8863,verapamil,18,19,115,124,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,0,-1,0
8864,hypertension,26,27,172,184,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,1,1
8865,catecholamines,15,16,126,140,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,0,-1,0
8866,metronidazole,5,6,49,62,Haemolytic-uraemic syndrome after treatment with metronidazole.,3173180_0,0,-1,0
8867,metronidazole,17,18,126,139,This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.,3173180_1,0,-1,0
8868,metronidazole,4,5,25,38,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,0,-1,0
8869,metronidazole,44,45,299,312,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,0,-1,0
8874,5-fluorouracil,10,11,84,98,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0,-1,0
8875,carcinoma,8,9,50,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,1,1
8876,carcinoma,11,12,75,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,1,1
8879,cardiotoxicity,3,4,17,31,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,1,1
8881,cardiotoxicity,5,6,25,39,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,1,1
8885,death,11,12,72,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,1,1
8888,Death,0,1,0,5,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,1,1
8890,Etoposide,7,8,39,48,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0
8891,Methotrexate,10,11,57,69,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0
8892,Cyclophosphamide,12,13,71,87,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0
8893,Cisplatin,17,18,106,115,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0
8894,Methotrexate,12,13,57,69,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0
8895,Etoposide,14,15,71,80,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0
8896,Cyclophosphamide,16,17,85,101,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0
8898,tumor,30,31,162,167,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1
8899,tumor,39,40,210,215,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1
8900,tumor,53,54,308,313,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,1,1
8901,necrosis,25,26,152,160,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,1,1
8902,tumor,4,5,27,32,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,-1,1,1
8903,locomotor hyperactivity,4,6,40,63,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,1,1
8904,nicotine,6,7,36,44,"Rats were pretreated with saline or nicotine (1.5 mg/kg per day) by subcutaneously implanting each animal with an Alzet osmotic mini-pump which continuously released saline or nicotine for 1, 5 and 14 days.",3220106_1,0,-1,0
8905,nicotine,28,29,176,184,"Rats were pretreated with saline or nicotine (1.5 mg/kg per day) by subcutaneously implanting each animal with an Alzet osmotic mini-pump which continuously released saline or nicotine for 1, 5 and 14 days.",3220106_1,0,-1,0
8906,nicotine,22,23,123,131,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,0,-1,0
8907,nicotine,19,20,144,152,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,0,-1,0
8908,nicotine,6,7,35,43,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,0,-1,0
8909,dopamine,39,40,245,253,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,0,-1,0
8911,nicotine,4,5,27,35,"In animals pretreated with nicotine for 14 days, the nicotine-induced locomotor response remained to be potentiated.",3220106_6,0,-1,0
8913,locomotor hyperactivity,8,10,65,88,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,1,1
8914,nicotine,13,14,104,112,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,0,-1,0
8917,hypotension,9,10,82,93,Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.,322550_0,-1,1,1
8918,sodium nitroprusside,27,29,160,180,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0,-1,0
8919,nitroprusside,1,2,7,20,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0,-1,0
8922,nitroprusside,5,6,23,36,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0,-1,0
8923,Nitroprusside,0,1,0,13,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,0,-1,0
8925,nitroprusside,5,6,24,37,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0,-1,0
8927,nitroprusside,4,5,25,38,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0,-1,0
8928,nitroprusside,1,2,7,20,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0,-1,0
8931,timolol,5,6,54,61,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,0,-1,0
8932,timolol,6,7,35,42,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,0,-1,0
8933,Timolol,0,1,0,7,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0,-1,0
8934,aldosterone,7,8,40,51,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0,-1,0
8935,potassium,10,11,62,71,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0,-1,0
8936,potassium,8,9,36,45,There was no evidence of a shift of potassium from the intracellular to the extracellular space.,326460_3,0,-1,0
8937,vasospasm,5,6,22,31,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,1,1
8940,migraine,20,21,132,140,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,1,1
8941,cyclosporine,4,5,12,24,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0,-1,0
8942,cyclosporine,4,5,13,25,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0
8943,azathioprine,19,20,105,117,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0
8944,blood urea nitrogen,12,15,77,96,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0,-1,0
8945,creatinine,17,18,107,117,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0,-1,0
8946,nephrotoxicity,9,10,55,69,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,-1,1,1
8947,cyclosporine,15,16,106,118,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0,-1,0
8948,creatinine,17,18,91,101,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0,-1,0
8949,cyclosporine,8,9,42,54,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,0,-1,0
8950,nephrotoxicity,12,13,73,87,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,-1,1,1
8951,hemorrhage,6,7,46,56,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,-1,1,1
8952,sodium,9,10,69,75,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,0,-1,0
8953,hypotension,11,12,98,109,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,-1,1,1
8954,hypotension,38,39,219,230,"The systolic pressure variation (SPV), which is the difference between the maximal and minimal values of the systolic blood pressure (SBP) after one positive-pressure breath, was studied in ventilated dogs subjected to hypotension.",3341566_1,-1,1,1
8955,hemorrhage,14,15,74,84,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,1,1
8956,sodium nitroprusside,27,29,127,147,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,0,-1,0
8958,hypotension,2,3,19,30,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,1,1
8960,hypotension,3,4,15,26,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,1,1
8963,hypotension,39,40,171,182,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,1,1
8964,hypotensive,16,17,85,96,It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload.,3341566_8,-1,1,1
8965,hypotension,11,12,80,91,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,1,1
8966,potassium,9,10,72,81,Preoperative assessment should focus on cardiovascular status and serum potassium level.,3358181_3,0,-1,0
8967,ephedrine,10,11,67,76,Careful fluid administration and cautious use of titrated doses of ephedrine are advised.,3358181_5,0,-1,0
8968,phenylephrine,20,21,120,133,"After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.",3358181_6,0,-1,0
8969,hypotensive,23,24,143,154,"After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.",3358181_6,-1,1,1
8970,tachycardia,26,27,169,180,"After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.",3358181_6,-1,1,1
8973,verapamil,11,12,85,94,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,0,-1,0
8974,calcium,19,20,149,156,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,0,-1,0
8975,verapamil,2,3,7,16,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0
8976,carbamazepine,6,7,37,50,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0
8977,carbamazepine,19,20,130,143,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0
8978,carbamazepine,26,27,175,188,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0
8979,parkinsonism,5,6,53,65,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,1,1
8980,parkinsonism,14,15,92,104,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,1,1
8981,fluphenazine enanthate,17,19,116,138,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0,-1,0
8982,schizophrenic,21,22,145,158,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,1,1
8983,parkinsonian,11,12,80,92,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,1,1
8986,depression,25,26,182,192,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,1,1
8987,parkinsonian,16,17,113,125,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,1,1
8988,coma,1,2,23,27,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,1,1
8989,metabolic acidosis,3,5,29,47,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,1,1
8991,metabolic acidosis,3,5,10,28,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,1,1
8993,paracetamol,13,14,80,91,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,0,-1,0
8994,Sexual dysfunction,0,2,0,18,Sexual dysfunction among patients with arthritis.,3409645_0,-1,1,1
8995,arthritis,5,6,39,48,Sexual dysfunction among patients with arthritis.,3409645_0,-1,1,1
8996,arthritis,3,4,20,29,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1
8997,sexual dysfunction,5,7,34,52,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1
8998,rheumatoid arthritis,13,15,94,114,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1
8999,depressed,5,6,37,46,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,-1,1,1
9001,methotrexate,21,22,127,139,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,0,-1,0
9002,Depressed,0,1,0,9,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,1,1
9004,arthritis,13,14,74,83,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,1,1
9005,sexual dysfunction,18,20,108,126,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,1,1
9006,hepatitis,3,4,51,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,1,1
9008,hepatitis,9,10,76,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,1,1
9009,paracetamol,1,2,5,16,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0
9010,cancer,4,5,34,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1
9012,renal papillary necrosis,12,15,92,116,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1
9013,cancer,16,17,120,126,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1
9014,phenacetin,30,31,204,214,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0
9015,paracetamol,32,33,218,229,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0
9016,renal papillary necrosis,3,6,12,36,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1
9017,phenacetin,13,14,84,94,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,0,-1,0
9018,cancer,21,22,130,136,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1
9019,cancer,32,33,190,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1
9020,paracetamol,12,13,67,78,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,0,-1,0
9021,renal papillary necrosis,15,18,95,119,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1
9022,cancers,22,23,136,143,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1
9023,cancer,32,33,199,205,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1
9025,epinephrine,6,7,45,56,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,0,-1,0
9026,ischemia,11,12,91,99,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,1,1
9027,epinephrine,3,4,12,23,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,0,-1,0
9030,ischemia,3,4,19,27,Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.,3413271_2,-1,1,1
9031,oxygen,8,9,62,68,Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.,3413271_2,0,-1,0
9032,epinephrine,13,14,102,113,Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.,3413271_2,0,-1,0
9033,epinephrine,1,2,5,16,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,0,-1,0
9035,depression,12,13,86,96,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,1,1
9037,epinephrine,9,10,58,69,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,0,-1,0
9039,ischemia,23,24,189,197,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,1,1
9040,ischemia,4,5,29,37,"These findings indicate that ischemia produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.",3413271_6,-1,1,1
9041,epinephrine,7,8,50,61,"These findings indicate that ischemia produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.",3413271_6,0,-1,0
9042,hemolytic anemia,3,5,30,46,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,1,1
9045,hemolytic anemia,16,18,82,98,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,1,1
9046,dapsone,23,24,122,129,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,0,-1,0
9047,hemolysis,33,34,179,188,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,1,1
9048,glutathione,16,17,91,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0,-1,0
9052,dapsone,9,10,51,58,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0,-1,0
9056,dapsone,21,22,105,112,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,0,-1,0
9057,hemolytic anemia,25,27,128,144,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,1,1
9058,infection,22,23,127,136,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,1,1
9069,breast cancer,13,15,66,79,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1
9070,ovarian cancer,16,18,81,95,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1
9071,Toxicities,0,1,0,10,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1
9072,hepatotoxicity,2,3,20,34,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1
9073,nephrotoxicity,8,9,63,77,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1
9076,nephrotoxicity,12,13,69,83,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1
9077,renal toxicity,22,24,131,145,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1
9078,Hepatotoxicity,0,1,0,14,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,1,1
9080,hepatitis,2,3,7,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,1,1
9083,hepatitis,31,32,174,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,1,1
9085,hepatitis,1,2,9,18,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,1,1
9089,hepatitis,13,14,88,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,1,1
9090,hepatitis,8,9,41,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,1,1
9091,metoprolol,15,16,98,108,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0
9092,diltiazem,19,20,123,132,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0
9093,sparteine,22,23,138,147,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0
9095,shock,14,15,88,93,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,1,1
9097,hypotension,4,5,17,28,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,1,1
9098,metoprolol,11,12,61,71,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,0,-1,0
9099,diltiazem,4,5,26,35,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,0,-1,0
9100,metoprolol,11,12,76,86,Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol (greater than 3000 ng/ml) and diltiazem (526 ng/ml).,3437726_5,0,-1,0
9101,diltiazem,19,20,117,126,Analyses of a blood sample revealed unusually high plasma concentrations of metoprolol (greater than 3000 ng/ml) and diltiazem (526 ng/ml).,3437726_5,0,-1,0
9102,metoprolol,12,13,63,73,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0
9103,diltiazem,14,15,75,84,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0
9104,sparteine,30,31,149,158,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0
9105,prostate cancer,3,5,28,43,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,-1,1,1
9106,testosterone,13,14,112,124,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,0,-1,0
9108,tumor,8,9,27,32,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,1,1
9109,prostate cancer,19,21,96,111,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,1,1
9110,haloperidol,29,30,143,154,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,0,-1,0
9111,haloperidol,6,7,31,42,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,0,-1,0
9112,schizophrenia,26,27,165,178,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,1,1
9113,cholestasis,1,2,10,21,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,1,1
9114,hepatitis,5,6,57,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,1,1
9115,hepatitis,10,11,63,72,We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.,3496378_1,-1,1,1
9116,cholestasis,16,17,109,120,We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.,3496378_1,-1,1,1
9117,Jaundice,0,1,0,8,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,1,1
9118,Jaundice,0,1,0,8,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,1,1
9119,cholestasis,11,12,77,88,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,1,1
9120,pruritus,14,15,99,107,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,1,1
9122,pruritus,2,3,9,17,"Finally, pruritus disappeared within 19 months, and liver tests returned to normal 27 months after the onset of hepatitis.",3496378_4,-1,1,1
9123,hepatitis,20,21,112,121,"Finally, pruritus disappeared within 19 months, and liver tests returned to normal 27 months after the onset of hepatitis.",3496378_4,-1,1,1
9124,cholestasis,5,6,45,56,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,1,1
9125,hepatitis,10,11,97,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,1,1
9126,neurotoxicity,4,5,27,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,1,1
9127,deferoxamine,8,9,63,75,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,0,-1,0
9128,neurotoxicity,3,4,20,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,1,1
9129,anemia,14,15,108,114,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,1,1
9130,iron,18,19,134,138,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0,-1,0
9131,deferoxamine,24,25,181,193,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0,-1,0
9132,deferoxamine,1,2,5,17,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0,-1,0
9134,deferoxamine,9,10,53,65,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0,-1,0
9135,toxicity,53,54,299,307,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,1,1
9136,deferoxamine,14,15,113,125,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0
9137,deferoxamine,26,27,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0
9138,ototoxicity,29,30,242,253,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,-1,1,1
9139,deferoxamine,18,19,105,117,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0,-1,0
9140,toxicity,2,3,10,18,"With mild toxicity, a reduction to 30 or 40 mg/kg per dose should result in a reversal of the abnormal results to normal within four weeks.",3503576_9,-1,1,1
9141,deferoxamine,6,7,46,58,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,0,-1,0
9143,toxicity,3,4,22,30,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,1,1
9144,tobramycin,7,8,49,59,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,0,-1,0
9145,tobramycin,11,12,75,85,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0,-1,0
9146,infections,25,26,189,199,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,1,1
9147,Nephrotoxicity,0,1,0,14,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,1,1
9148,tobramycin,12,13,88,98,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,0,-1,0
9149,Ototoxicity,0,1,0,11,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,1,1
9150,tobramycin,22,23,92,102,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,0,-1,0
9151,tobramycin,25,26,176,186,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,0,-1,0
9152,tobramycin,38,39,226,236,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,0,-1,0
9153,ototoxicity,4,5,43,54,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,1,1
9154,tobramycin,16,17,123,133,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,0,-1,0
9156,lidocaine,8,9,54,63,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,0,-1,0
9157,depression,16,17,106,116,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,-1,1,1
9158,lidocaine,29,30,183,192,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,0,-1,0
9159,rheumatoid arthritis,6,8,42,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,1,1
9160,rheumatoid arthritis,4,6,35,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,1,1
9161,arthritis,28,29,185,194,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,1,1
9162,bleeding,29,30,145,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,1,1
9163,headache,10,11,67,75,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,1,1
9165,Hyperkalemia,0,1,0,12,Hyperkalemia associated with sulindac therapy.,3560096_0,-1,1,1
9166,sulindac,3,4,29,37,Hyperkalemia associated with sulindac therapy.,3560096_0,0,-1,0
9167,Hyperkalemia,0,1,0,12,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,1,1
9168,indomethacin,17,18,116,128,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,0,-1,0
9169,sulindac,10,11,67,75,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,0,-1,0
9170,hyperkalemia,6,7,31,43,We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.,3560096_3,-1,1,1
9171,sulindac,20,21,106,114,We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.,3560096_3,0,-1,0
9172,potassium,6,7,28,37,In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac.,3560096_4,0,-1,0
9173,sulindac,16,17,84,92,In all of them normal serum potassium levels reached within 2 to 4 days of stopping sulindac.,3560096_4,0,-1,0
9174,potassium,8,9,46,55,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,0,-1,0
9175,sulindac,25,26,165,173,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,0,-1,0
9176,hyperkalemia,27,28,178,190,"As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.",3560096_5,-1,1,1
9177,sulindac,7,8,52,60,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,0,-1,0
9178,spasm,2,3,22,27,Drug-induced arterial spasm relieved by lidocaine.,3564823_0,-1,1,1
9179,lidocaine,5,6,40,49,Drug-induced arterial spasm relieved by lidocaine.,3564823_0,0,-1,0
9180,vasospasm,1,2,8,17,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,1,1
9181,lidocaine,11,12,65,74,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,0,-1,0
9182,vasospasm,24,25,161,170,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,-1,1,1
9183,hyperactivity,7,8,63,76,Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.,3615541_0,-1,1,1
9185,calcitonin,10,11,94,104,Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.,3615541_0,0,-1,0
9186,Calcitonin,0,1,0,10,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,0,-1,0
9187,calcitonin,12,13,76,86,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,0,-1,0
9188,calcitonin,16,17,103,113,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,0,-1,0
9189,calcitonin,4,5,26,36,In the present experiment calcitonin decreased locomotor activity when locally injected into the same sites where it decreases food intake.,3615541_4,0,-1,0
9190,calcitonin,3,4,16,26,"The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.",3615541_5,0,-1,0
9191,calcitonin,31,32,194,204,"The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.",3615541_5,0,-1,0
9192,cefonicid,4,5,27,36,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0
9193,cefazedone,6,7,41,51,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0
9194,toxicity,3,4,17,25,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,1,1
9195,cefonicid,10,11,69,78,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0
9196,cefazedone,12,13,82,92,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0
9197,anemia,21,22,145,151,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,1,1
9198,neutropenia,23,24,153,164,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,1,1
9199,thrombocytopenia,26,27,170,186,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,1,1
9200,anemia,2,3,18,24,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,1,1
9201,cefonicid,23,24,135,144,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0,-1,0
9202,cefazedone,29,30,162,172,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0,-1,0
9203,cefonicid,16,17,105,114,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0,-1,0
9204,cefonicid,9,10,53,62,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0,-1,0
9205,cefazedone,11,12,66,76,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0,-1,0
9208,nephrotoxicity,4,5,30,44,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,1,1
9213,glucose,3,4,25,32,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,0,-1,0
9214,renal damage,28,30,178,190,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,-1,1,1
9217,Aspirin,0,1,0,7,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0
9219,paracetamol,19,20,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0
9220,acetaminophen,21,22,96,109,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0
9225,aspirin,7,8,37,44,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0
9226,paracetamol,30,31,138,149,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0
9227,acetaminophen,32,33,151,164,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0
9229,aspirin,16,17,105,112,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,0,-1,0
9230,hypotension,7,8,61,72,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,1,1
9231,aneurysms,15,16,119,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,1,1
9232,oxygen,8,9,52,58,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,0,-1,0
9233,hypotension,13,14,99,110,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,1,1
9234,aneurysm,25,26,177,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,1,1
9235,isoflurane,6,7,44,54,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0,-1,0
9237,oxygen,18,19,105,111,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0,-1,0
9238,hypotension,1,2,11,22,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,1,1
9239,isoflurane,19,20,94,104,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,0,-1,0
9240,aneurysm,5,6,26,34,After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%.,3676049_6,-1,1,1
9241,isoflurane,7,8,39,49,After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%.,3676049_6,0,-1,0
9242,hypotension,12,13,79,90,These changes might offer protection to brain tissue during periods of induced hypotension.,3676049_8,-1,1,1
9244,bromocriptine,4,5,32,45,Postpartum psychosis induced by bromocriptine.,3686155_0,0,-1,0
9245,psychiatric,6,7,40,51,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,1,1
9247,bromocriptine,16,17,113,126,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,0,-1,0
9248,Bromocriptine,0,1,0,13,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0,-1,0
9251,bromocriptine,4,5,29,42,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0,-1,0
9254,depressed,8,9,57,66,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,1,1
9256,depressed,12,13,73,82,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,1,1
9258,delirium,6,7,37,45,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,1,1
9259,Manic,0,1,0,5,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,1,1
9260,coma,2,3,23,27,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,1,1
9261,death,4,5,32,37,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,1,1
9262,prednisone,5,6,33,43,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,0,-1,0
9263,somnolence,13,14,86,96,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,1,1
9264,polydipsia,15,16,98,108,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,1,1
9265,polyuria,20,21,126,134,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,1,1
9266,coma,8,9,51,55,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,1,1
9267,hypotension,10,11,57,68,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,1,1
9268,acidosis,16,17,96,104,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,1,1
9273,cyclosporine,3,4,12,24,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0,-1,0
9275,toxicity,19,20,114,122,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,1,1
9278,nephrotoxic,11,12,77,88,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,1,1
9279,gentamicin,16,17,108,118,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0,-1,0
9280,ketoconazole,26,27,163,175,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0,-1,0
9282,toxicity,42,43,267,275,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,1,1
9283,Gentamicin,0,1,0,10,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,0,-1,0
9285,nephrotoxicity,3,4,10,24,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,1,1
9287,neurotoxic,3,4,24,34,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,1,1
9288,neurotoxic,8,9,61,71,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,1,1
9289,neuropathy,11,12,84,94,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,1,1
9290,neurotoxic,32,33,212,222,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,1,1
9291,Allergic reaction,0,2,0,17,Allergic reaction to 5-fluorouracil infusion.,3719553_0,-1,1,1
9292,5-fluorouracil,3,4,21,35,Allergic reaction to 5-fluorouracil infusion.,3719553_0,0,-1,0
9293,allergic reaction,1,3,3,20,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1
9294,edema,6,7,49,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1
9295,5-fluorouracil,11,12,88,102,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,0,-1,0
9296,carcinoma,18,19,140,149,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1
9297,cirrhosis,24,25,170,179,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1
9298,prednisone,3,4,25,35,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,0,-1,0
9299,allergic reaction,12,14,89,106,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,1,1
9301,potassium,2,3,11,20,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,0,-1,0
9302,arrhythmias,4,5,25,36,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,1,1
9304,potassium,9,10,51,60,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,0,-1,0
9305,cardiac arrhythmias,15,17,92,111,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,-1,1,1
9309,amiloride,28,29,198,207,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0,-1,0
9310,potassium,1,2,7,16,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0,-1,0
9311,amiloride,15,16,107,116,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0,-1,0
9312,noradrenaline,13,14,77,90,"Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline (norepinephrine) concentrations were similar on the 2 regimens.",3732088_5,0,-1,0
9313,norepinephrine,15,16,92,106,"Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline (norepinephrine) concentrations were similar on the 2 regimens.",3732088_5,0,-1,0
9314,amiloride,2,3,12,21,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0,-1,0
9316,potassium,26,27,191,200,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,0,-1,0
9318,penicillamine,4,5,28,41,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,0,-1,0
9319,chloroquine,6,7,46,57,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,0,-1,0
9320,rheumatoid arthritis,9,11,70,90,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,1,1
9322,penicillamine,14,15,95,108,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,0,-1,0
9323,chloroquine,16,17,113,124,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,0,-1,0
9324,rheumatoid arthritis,19,21,137,157,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,1,1
9325,acetylcholine,1,2,9,22,"Although acetylcholine receptor antibodies were not detectable, the time course was consistent with an autoimmune process.",3750012_2,0,-1,0
9326,encephalopathy,6,7,59,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,1,1
9327,diabetic,12,13,77,85,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,1,1
9328,encephalopathy,18,19,119,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,1,1
9331,diabetic,13,14,68,76,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,1,1
9332,encephalopathy,21,22,120,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,1,1
9333,diabetic,10,11,57,65,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,1,1
9334,encephalopathy,18,19,105,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,1,1
9336,encephalopathy,16,17,133,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,1,1
9337,Bradycardia,0,1,0,11,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,1,1
9338,trihexyphenidyl,3,4,19,34,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,0,-1,0
9339,schizophrenic,2,3,10,23,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,1,1
9340,trihexyphenidyl,11,12,74,89,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,0,-1,0
9341,sinus bradycardia,6,8,38,55,"The patient developed, paradoxically, sinus bradycardia.",3769769_2,-1,1,1
9342,trihexyphenidyl,5,6,29,44,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0,-1,0
9343,psychiatric,8,9,52,63,This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.,3769769_4,-1,1,1
9344,rigidity,1,2,15,23,Post-operative rigidity after fentanyl administration.,3780697_0,-1,1,1
9345,fentanyl,3,4,30,38,Post-operative rigidity after fentanyl administration.,3780697_0,0,-1,0
9346,rigidity,4,5,28,36,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,1,1
9348,fentanyl,25,26,164,172,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,0,-1,0
9349,naloxone,5,6,34,42,This was successfully reversed by naloxone.,3780697_2,0,-1,0
9350,phenobarbital,3,4,28,41,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,0,-1,0
9351,phenobarbital,13,14,70,83,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,0,-1,0
9352,tumor,13,14,61,66,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,1,1
9354,morphine,14,15,87,95,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,0,-1,0
9356,morphine,10,11,66,74,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,0,-1,0
9357,morphine,7,8,48,56,Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.,3780846_2,0,-1,0
9358,rigidity,17,18,93,101,Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.,3780846_2,-1,1,1
9359,morphine,6,7,30,38,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,0,-1,0
9361,rigidity,29,30,152,160,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,1,1
9362,morphine,35,36,184,192,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,0,-1,0
9363,akinetic,47,48,255,263,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,1,1
9364,rigidity,9,10,47,55,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,1,1
9365,akinetic,24,25,132,140,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,1,1
9367,rigidity,1,2,4,12,The rigidity was considerably decreased in both groups after 20 days' treatment.,3780846_5,-1,1,1
9368,haloperidol,7,8,36,47,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,0,-1,0
9369,rigidity,34,35,176,184,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,-1,1,1
9370,Haloperidol,0,1,0,11,Haloperidol enhanced the rigidity in the A group.,3780846_7,0,-1,0
9371,rigidity,3,4,25,33,Haloperidol enhanced the rigidity in the A group.,3780846_7,-1,1,1
9372,rigidity,4,5,25,33,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,-1,1,1
9373,morphine,16,17,78,86,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,0,-1,0
9374,rigidity,4,5,26,34,The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS/KS group might be due to rapid shifts in the predominance of various DA-innervated structures.,3780846_11,-1,1,1
9375,rhabdomyolysis,4,5,18,32,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,1,1
9376,Rhabdomyolysis,0,1,0,14,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,-1,1,1
9377,psychiatric,7,8,53,64,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,-1,1,1
9379,rhabdomyolysis,13,14,83,97,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,1,1
9380,schizophrenic,4,5,14,27,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,1,1
9381,rhabdomyolysis,11,12,70,84,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,1,1
9383,neuropathy,1,2,12,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,1,1
9384,myopathy,10,11,78,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,1,1
9385,myopathy,1,2,8,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,1,1
9386,pentazocine,11,12,65,76,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,0,-1,0
9387,neuropathy,3,4,21,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,1,1
9388,myopathy,11,12,87,95,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,1,1
9389,myopathy,8,9,67,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,1,1
9390,myopathy,50,51,322,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,1,1
9393,cirrhosis,4,5,27,36,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,1,1
9397,renal dysfunction,20,22,124,141,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,1,1
9404,amphetamine,13,14,87,98,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,0,-1,0
9405,seizures,9,10,54,62,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,1,1
9410,neuropathy,2,3,16,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,1,1
9411,isoniazid,8,9,58,67,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,0,-1,0
9412,isoniazid,19,20,131,140,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,0,-1,0
9413,neuropathy,3,4,24,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,1,1
9414,Isoniazid,0,1,0,9,"Isoniazid was discontinued later, followed by a dramatic improvement in the visual acuity.",384871_4,0,-1,0
9415,toxicity,5,6,27,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,1,1
9416,isoniazid,11,12,63,72,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,0,-1,0
9417,methotrexate,8,9,69,81,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,0,-1,0
9418,acute lymphoblastic leukemia,3,6,21,49,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,1,1
9419,methotrexate,16,17,124,136,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,0,-1,0
9420,methotrexate,26,27,191,203,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,0,-1,0
9421,methotrexate,1,2,4,16,"The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours.",3856631_2,0,-1,0
9422,methotrexate,37,38,199,211,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0,-1,0
9423,methotrexate,54,55,296,308,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0,-1,0
9424,toxicities,3,4,16,26,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1
9425,bilirubin,10,11,77,86,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,0,-1,0
9426,neutropenia,13,14,99,110,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1
9427,mucositis,16,17,116,125,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1
9428,seizures,4,5,22,30,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,1,1
9429,methotrexate,2,3,22,34,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,0,-1,0
9432,etoposide,4,5,24,33,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0,-1,0
9434,etoposide,4,5,34,43,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0,-1,0
9437,confusion,7,8,39,48,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,1,1
9438,toxicity,26,27,165,173,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,1,1
9440,vancomycin,8,9,57,67,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,0,-1,0
9441,vancomycin,9,10,55,65,A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16-month period.,3934126_1,0,-1,0
9442,Vancomycin,0,1,0,10,Vancomycin was curative in 95% of 43 patients with proven infection.,3934126_2,0,-1,0
9443,infection,11,12,58,67,Vancomycin was curative in 95% of 43 patients with proven infection.,3934126_2,-1,1,1
9444,vancomycin,15,16,82,92,Drugs were ceased in six patients because of adverse reactions; in three of these vancomycin was considered the likely cause.,3934126_3,0,-1,0
9445,rash,10,11,57,61,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1
9446,nephrotoxicity,17,18,73,87,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1
9447,proteinuria,24,25,99,110,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1
9448,ototoxicity,31,32,125,136,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1
9449,nephrotoxicity,9,10,74,88,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1
9450,ototoxicity,11,12,93,104,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1
9451,aminoglycoside,18,19,144,158,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0,-1,0
9452,vancomycin,20,21,164,174,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0,-1,0
9453,vancomycin,3,4,17,27,"We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.",3934126_6,0,-1,0
9454,infections,14,15,97,107,"We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for infections caused by susceptible bacteria.",3934126_6,-1,1,1
9455,nephrotoxicity,3,4,24,38,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,-1,1,1
9456,amikacin,10,11,82,90,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0,-1,0
9457,amikacin,6,7,35,43,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0,-1,0
9458,nephrotoxicity,13,14,86,100,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,-1,1,1
9459,creatinine,11,12,61,71,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0
9460,creatinine,14,15,79,89,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0
9461,nephrotoxicity,22,23,130,144,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,1,1
9462,nephrotoxic,16,17,83,94,"Based on this model and on Bayes' theorem, the predictive accuracy of identifying ""nephrotoxic"" patients increased from 0.17 to 0.39.",3950060_7,-1,1,1
9463,Cardiac toxicity,0,2,0,16,Cardiac toxicity of 5-fluorouracil.,3952818_0,-1,1,1
9464,5-fluorouracil,3,4,20,34,Cardiac toxicity of 5-fluorouracil.,3952818_0,0,-1,0
9466,5-fluorouracil,18,19,103,117,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0,-1,0
9469,nifedipine,19,20,131,141,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,0,-1,0
9470,coronary spasm,4,6,24,38,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,1,1
9471,cardiotoxicity,11,12,59,73,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,1,1
9475,corticosterone,7,8,55,69,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,0,-1,0
9476,neuropathy,11,12,106,116,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,-1,1,1
9477,phosphate,1,2,16,25,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0,-1,0
9479,corticosterone,42,43,221,235,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0,-1,0
9480,neuropathy,11,12,78,88,Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared.,3961813_2,-1,1,1
9481,corticosterone,13,14,62,76,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,0,-1,0
9482,neuropathy,19,20,116,126,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,1,1
9484,Neurotoxic,0,1,0,10,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,1,1
9486,corticosterone,4,5,23,37,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0,-1,0
9489,Hepatotoxicity,0,1,0,14,Hepatotoxicity of amiodarone.,3962737_0,-1,1,1
9490,amiodarone,2,3,18,28,Hepatotoxicity of amiodarone.,3962737_0,0,-1,0
9491,Amiodarone,0,1,0,10,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,0,-1,0
9492,amiodarone,3,4,11,21,"The use of amiodarone has, however, been limited due to its serious side-effects.",3962737_2,0,-1,0
9493,hepatitis,4,5,27,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,1,1
9494,amiodarone,7,8,44,54,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,0,-1,0
9495,hepatotoxicity,17,18,104,118,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,1,1
9496,amiodarone,19,20,122,132,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,0,-1,0
9497,hepatic injury,8,10,46,60,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1
9498,amiodarone,12,13,68,78,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,0,-1,0
9499,hepatitis,21,22,144,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1
9500,hepatitis,24,25,167,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1
9501,cirrhosis,27,28,194,203,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1
9502,amiodarone,2,3,19,29,Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.,3962737_5,0,-1,0
9503,hepatomegaly,11,12,73,85,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,1,1
9504,testosterone,3,4,23,35,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,0,-1,0
9505,testosterone,6,7,37,49,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,0,-1,0
9506,prostate cancer,17,19,99,114,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1
9507,tumors,32,33,179,185,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1
9508,tumors,41,42,224,230,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1
9510,prostate cancer,27,29,154,169,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,1,1
9511,prostate cancer,10,12,52,67,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,1,1
9512,testosterone,9,10,53,65,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,0,-1,0
9513,prostate cancer,14,16,112,127,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,-1,1,1
9514,rheumatoid arthritis,6,8,40,60,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,1,1
9515,rheumatoid arthritis,16,18,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,1,1
9516,cyclophosphamide,5,6,28,44,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0,-1,0
9518,azathioprine,13,14,83,95,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0,-1,0
9519,methotrexate,20,21,119,131,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0,-1,0
9523,azathioprine,21,22,143,155,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,0,-1,0
9524,Cyclophosphamide,0,1,0,16,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,0,-1,0
9525,carcinoma,6,7,47,56,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,-1,1,1
9526,rheumatoid arthritis,9,11,59,79,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1
9527,azathioprine,13,14,93,105,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0,-1,0
9528,cyclophosphamide,15,16,110,126,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0,-1,0
9529,cancers,24,25,167,174,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1
9530,malignancy,7,8,39,49,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1
9531,rheumatoid arthritis,9,11,53,73,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1
9533,rheumatoid arthritis,37,39,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1
9534,hypotension,14,15,93,104,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,1,1
9535,hemorrhage,2,3,27,37,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,1,1
9536,warfarin,10,11,52,60,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,0,-1,0
9537,pain,21,22,128,132,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,1,1
9538,hematoma,5,6,43,51,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,1,1
9539,peripheral neuropathy,11,13,94,115,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1
9540,pain,19,20,147,151,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1
9542,neuropathy,7,8,54,64,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,1,1
9543,amiodarone,9,10,72,82,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,0,-1,0
9545,amiodarone,11,12,75,85,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,0,-1,0
9547,neuropathy,14,15,96,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,1,1
9548,amiodarone,7,8,57,67,Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone.,3997294_3,0,-1,0
9549,prednisolone,11,12,87,99,Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone.,3997294_3,0,-1,0
9550,amiodarone,14,15,87,97,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,0,-1,0
9551,amiodarone,20,21,135,145,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,0,-1,0
9552,steroid,26,27,172,179,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,0,-1,0
9555,amiodarone,7,8,44,54,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,0,-1,0
9558,amiodarone,5,6,27,37,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,0,-1,0
9560,sinus bradycardia,19,21,128,145,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,1,1
9561,delirium,1,2,20,28,"Desipramine-induced delirium at ""subtherapeutic"" concentrations: a case report.",4027862_0,-1,1,1
9562,Desipramine,7,8,41,52,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,0,-1,0
9563,delirium,10,11,65,73,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,-1,1,1
9564,Delirium,0,1,0,8,"Delirium, which may be induced by tricyclic drug therapy in the elderly, can be caused by tricyclics with low anticholinergic potency.",4027862_2,-1,1,1
9565,antidepressants,3,4,23,38,Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly.,4027862_3,0,-1,0
9566,bupivacaine,12,13,70,81,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0
9567,lidocaine,23,24,138,147,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0
9568,epinephrine,27,28,177,188,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0
9569,lidocaine,21,22,124,133,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,0,-1,0
9570,epinephrine,23,24,139,150,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,0,-1,0
9573,gentamicin,18,19,105,115,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,0,-1,0
9574,penicillin,24,25,134,144,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,0,-1,0
9575,gentamicin,2,3,10,20,The serum gentamicin concentration had reached toxic levels when anuria developed.,4069770_2,0,-1,0
9576,anuria,9,10,65,71,The serum gentamicin concentration had reached toxic levels when anuria developed.,4069770_2,-1,1,1
9578,gentamicin,5,6,36,46,The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported.,4069770_4,0,-1,0
9581,hyperkalemia,11,12,61,73,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1
9582,cirrhosis,16,17,92,101,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1
9583,ascites,18,19,103,110,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1
9584,indomethacin,24,25,136,148,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,0,-1,0
9585,indomethacin,16,17,101,113,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,0,-1,0
9586,prostaglandins,8,9,55,69,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,0,-1,0
9588,paracetamol,2,3,13,24,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,0,-1,0
9589,paracetamol,19,20,97,108,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0,-1,0
9590,paracetamol,12,13,67,78,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0,-1,0
9591,hepatic injury,2,4,12,26,Patterns of hepatic injury induced by methyldopa.,424937_0,-1,1,1
9592,liver disease,3,5,21,34,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,-1,1,1
9593,Jaundice,0,1,0,8,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,1,1
9594,hepatomegaly,3,4,21,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,1,1
9597,necrosis,6,7,58,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1
9598,hepatic injury,13,15,117,131,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1
9599,necrosis,27,28,205,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1
9601,hepatitis,7,8,46,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,1,1
9602,hepatitis,11,12,74,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,1,1
9603,cholestasis,14,15,100,111,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,1,1
9605,methyldopa,17,18,88,98,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,0,-1,0
9606,hepatitis,8,9,56,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,1,1
9607,hepatitis,23,24,160,169,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,1,1
9608,methyldopa,14,15,73,83,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,0,-1,0
9609,hepatitis,24,25,142,151,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,1,1
9610,toxicity,8,9,65,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,1,1
9611,overdose,10,11,57,65,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,1,1
9612,overdose,11,12,75,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,1,1
9613,toxicity,14,15,81,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,1,1
9614,Suxamethonium,0,1,0,13,Suxamethonium infusion rate and observed fasciculations.,435349_0,0,-1,0
9616,fasciculation,18,19,88,101,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,1,1
9617,fasciculation,4,5,19,32,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,1,1
9618,fasciculation,8,9,46,59,Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion.,435349_8,-1,1,1
9619,fasciculation,1,2,6,19,Total fasciculation scores in the 30-mg bolus group and the 5-mg s-1 and 20-mg s-1 infusion groups were not significantly different.,435349_9,-1,1,1
9620,metoclopramide,9,10,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0
9622,Parkinsonism,8,9,53,65,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,1,1
9623,dystonia,13,14,83,91,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,1,1
9624,dyskinesias,9,10,63,74,These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.,458486_4,-1,1,1
9625,dopamine,19,20,128,136,These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.,458486_4,0,-1,0
9626,psoriasis,2,3,13,22,Treatment of psoriasis with azathioprine.,4812392_0,-1,1,1
9627,azathioprine,4,5,28,40,Treatment of psoriasis with azathioprine.,4812392_0,0,-1,0
9628,Azathioprine,0,1,0,12,Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from severe psoriasis.,4812392_1,0,-1,0
9629,psoriasis,15,16,83,92,Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from severe psoriasis.,4812392_1,-1,1,1
9630,cholestasis,1,2,8,19,Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight.,4812392_3,-1,1,1
9631,fibrosis,9,10,53,61,Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight.,4812392_3,-1,1,1
9632,azathioprine,9,10,60,72,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,0,-1,0
9633,liver damage,16,18,113,125,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,-1,1,1
9634,hepatitis,1,2,10,19,Quinidine hepatitis.,48362_0,-1,1,1
9637,hepatitis,4,5,27,36,Liver biopsy showed active hepatitis.,48362_2,-1,1,1
9640,hepatotoxicity,7,8,45,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,1,1
9641,toxicity,13,14,81,89,"This report also suggests that, even after long-term administration, the hepatic toxicity is reversible.",48362_6,-1,1,1
9642,diethylstilbestrol,6,7,42,60,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,0,-1,0
9643,diethylstilbestrol,21,22,136,154,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,0,-1,0
9644,tumors,10,11,83,89,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,1,1
9645,heparin,6,7,56,63,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,0,-1,0
9646,thrombocytopenia,14,15,120,136,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,1,1
9647,heparin,8,9,66,73,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,0,-1,0
9648,ischemia,12,13,90,98,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,1,1
9649,heparin,22,23,153,160,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,0,-1,0
9650,thrombocytopenia,28,29,191,207,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,1,1
9651,heparin,14,15,79,86,Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.,591536_4,0,-1,0
9652,thrombocytopenia,6,7,47,63,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,1,1
9653,platelet aggregation,9,11,83,103,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,1,1
9654,heparin,6,7,53,60,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,0,-1,0
9656,scopolamine,17,18,111,122,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0,-1,0
9657,scopolamine,40,41,291,302,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0,-1,0
9658,scopolamine,9,10,54,65,"However, studies into the dose necessary to combating scopolamine intoxication are indicated.",603022_2,0,-1,0
9659,Dizziness,0,1,0,9,"Dizziness was less marked than sedation, but increased with the dose.",6103707_7,-1,1,1
9660,pain,2,3,10,14,There was pain on i.m.,6103707_8,-1,1,1
9662,propranolol,18,19,89,100,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0,-1,0
9663,propranolol,6,7,51,62,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0,-1,0
9665,propranolol,5,6,40,51,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0,-1,0
9666,hypertension,11,12,78,90,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,1,1
9667,Hypertension,11,12,69,81,Report of Medical Research Council Working Party on Mild to Moderate Hypertension.,6115999_1,-1,1,1
9668,hypertension,10,11,70,82,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,1,1
9669,propranolol,23,24,155,166,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0,-1,0
9672,propranolol,20,21,143,154,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0,-1,0
9673,glucose,10,11,80,87,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0
9674,propranolol,37,38,236,247,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0
9675,propranolol,10,11,52,63,No corneal disease is known to have occurred in the propranolol group.,6115999_7,0,-1,0
9676,potassium,2,3,11,20,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0
9677,urea,7,8,37,41,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0
9679,propranolol,2,3,7,18,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0
9680,potassium,6,7,32,41,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0
9682,urea,18,19,91,95,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0
9683,benzodiazepines,3,4,20,35,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0,-1,0
9684,myoclonic jerks,8,10,72,87,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,1,1
9685,myoclonic jerks,7,9,38,53,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,1,1
9686,serotonin,3,4,21,30,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0,-1,0
9687,5-hydroxytryptophan,9,10,63,82,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0,-1,0
9688,serotonin,9,10,28,37,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,0,-1,0
9689,benzodiazepines,2,3,7,22,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0
9690,diazepam,20,21,97,105,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0,-1,0
9691,myoclonic jerks,30,32,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,1,1
9694,benzodiazepines,7,8,40,55,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,0,-1,0
9695,myoclonus,19,20,119,128,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,1,1
9696,myoclonus,23,24,151,160,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,1,1
9697,myoclonus,16,17,104,113,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,1,1
9698,verapamil,7,8,63,72,Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.,6127992_0,0,-1,0
9701,hypotension,11,12,80,91,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,1,1
9702,bradycardia,13,14,96,107,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,1,1
9703,verapamil,18,19,137,146,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,0,-1,0
9704,verapamil,7,8,68,77,Simultaneously administration of beta-adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution.,6127992_4,0,-1,0
9705,sulphasalazine,3,4,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0,-1,0
9706,sulphasalazine,15,16,95,109,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,0,-1,0
9708,sulphasalazine,10,11,54,68,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,0,-1,0
9709,ranitidine,5,6,35,45,Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.,6150641_0,0,-1,0
9710,cimetidine,7,8,50,60,Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.,6150641_0,0,-1,0
9711,ranitidine,4,5,38,48,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,0,-1,0
9712,cimetidine,6,7,53,63,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,0,-1,0
9713,cimetidine,8,9,36,46,The rates of onset of the action of cimetidine and ranitidine were the same.,6150641_3,0,-1,0
9714,ranitidine,10,11,51,61,The rates of onset of the action of cimetidine and ranitidine were the same.,6150641_3,0,-1,0
9715,ranitidine,2,3,9,19,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,0,-1,0
9716,cimetidine,8,9,51,61,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,0,-1,0
9717,ranitidine,27,28,156,166,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,0,-1,0
9718,cimetidine,34,35,189,199,"However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine).",6150641_5,0,-1,0
9720,cimetidine,12,13,78,88,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,0,-1,0
9721,cimetidine,21,22,137,147,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,0,-1,0
9722,ranitidine,25,26,164,174,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,0,-1,0
9723,cimetidine,5,6,29,39,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0
9724,ranitidine,18,19,81,91,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0
9725,toxicity,37,38,177,185,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,1,1
9727,ranitidine,46,47,238,248,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0
9728,creatinine,55,56,305,315,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0
9729,cimetidine,60,61,337,347,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0
9730,ranitidine,8,9,33,43,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0,-1,0
9731,cimetidine,27,28,153,163,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0,-1,0
9732,enflurane,3,4,28,37,Epileptogenic properties of enflurane and their clinical interpretation.,6153967_0,0,-1,0
9733,enflurane,10,11,57,66,Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported.,6153967_1,0,-1,0
9734,enflurane,4,5,16,25,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,0,-1,0
9735,seizures,15,16,103,111,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,-1,1,1
9736,seizures,5,6,23,31,"Until the cause of the seizures was correctly identified, the patient was inappropriately treated with anticonvulsants.",6153967_3,-1,1,1
9737,seizures,10,11,66,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,-1,1,1
9738,Epileptic,0,1,0,9,Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.,6153967_5,-1,1,1
9739,enflurane,6,7,43,52,Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.,6153967_5,0,-1,0
9740,enflurane,3,4,22,31,Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG.,6153967_6,0,-1,0
9741,enflurane,5,6,19,28,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,0,-1,0
9742,epileptic,16,17,77,86,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,1,1
9743,Thrombotic microangiopathy,0,2,0,26,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,1,1
9745,carcinoma,3,4,19,28,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1
9746,thrombotic microangiopathy,5,7,39,65,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1
9748,hemolytic anemia,14,16,122,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1
9749,thrombocytopenia,19,20,152,168,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1
9750,cisplatin,24,25,191,200,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0,-1,0
9751,thrombotic,3,4,16,26,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,1,1
9752,tumor,10,11,56,61,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1
9753,thrombotic microangiopathy,19,21,97,123,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1
9756,anemia,34,35,211,217,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1
9757,thrombocytopenia,36,37,222,238,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1
9758,bone marrow suppression,39,42,255,278,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1
9759,cardiac hypertrophy,3,5,37,56,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,-1,1,1
9760,cardiac hypertrophy,3,5,19,38,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,1,1
9761,isoproterenol,17,18,122,135,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,0,-1,0
9765,hypertrophy,18,19,134,145,Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy.,6203632_8,-1,1,1
9767,hypertrophy,19,20,103,114,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,1,1
9768,mexiletine,1,2,14,24,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,0,-1,0
9769,arrhythmia,11,12,81,91,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,1,1
9770,mexiletine,9,10,60,70,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,0,-1,0
9772,mexiletine,10,11,70,80,"Large differences, regarded as statistically significant, between the mexiletine and placebo groups were noted in that end point at months 1 and 4, but only trends were observed at month 12.",6209318_4,0,-1,0
9773,mexiletine,8,9,54,64,These differences were observed even though the serum mexiletine levels obtained in this study were generally lower than those observed in studies that have used the regular form of the drug.,6209318_5,0,-1,0
9774,deaths,3,4,16,22,There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.,6209318_6,-1,1,1
9775,mexiletine,6,7,30,40,There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.,6209318_6,0,-1,0
9776,tremor,6,7,49,55,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,1,1
9777,mexiletine,16,17,113,123,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,0,-1,0
9778,penicillamine,4,5,25,38,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,0,-1,0
9779,rheumatoid arthritis,10,12,67,87,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,-1,1,1
9780,proteinuria,3,4,13,24,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1
9782,penicillamine,20,21,134,147,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,0,-1,0
9783,rheumatoid arthritis,25,27,173,193,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1
9786,rheumatoid arthritis,28,30,164,184,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1
9787,penicillamine,32,33,198,211,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,0,-1,0
9788,timolol,6,7,39,46,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,0,-1,0
9790,timolol,4,5,24,31,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,0,-1,0
9792,timolol,27,28,168,175,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,0,-1,0
9793,bradycardia,7,8,51,62,These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume.,6229975_4,-1,1,1
9794,timolol,15,16,93,100,"After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.",6229975_7,0,-1,0
9795,nephrolithiasis,9,10,54,69,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,1,1
9796,calcium,21,22,139,146,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,0,-1,0
9800,hypercalcemia,21,22,103,116,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,1,1
9802,Calcium,0,1,0,7,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,0,-1,0
9805,milk fever,11,13,57,67,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,1,1
9806,milk fever,30,32,159,169,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,1,1
9809,calcification,4,5,32,45,There was widespread metastatic calcification in the cows that died.,6286738_5,-1,1,1
9810,toxicity,4,5,23,31,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1
9813,milk fever,25,27,140,150,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1
9814,milk fever,31,33,173,183,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1
9816,milk fever,46,48,252,262,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1
9817,neuropathy,1,2,14,24,Sensori-motor neuropathy was the commonest presentation (50%).,6287825_3,-1,1,1
9818,neuropathy,21,22,115,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,1,1
9819,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,1,1
9820,neuropathy,23,24,148,158,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,1,1
9822,autonomic neuropathy,7,9,41,61,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,1,1
9823,Isoniazid,0,1,0,9,Isoniazid was the most frequent agent in drug-induced neuropathy.,6287825_7,0,-1,0
9824,neuropathy,8,9,54,64,Isoniazid was the most frequent agent in drug-induced neuropathy.,6287825_7,-1,1,1
9825,Migraine,0,1,0,8,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1
9826,neuropathy,12,13,52,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1
9827,malignancies,14,15,72,84,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,1,1
9828,neuropathy,12,13,48,58,"In 26.5% of all the cases, the aetiology of the neuropathy was undetermined.",6287825_9,-1,1,1
9833,tumor,17,18,122,127,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,1,1
9834,doxorubicin,23,24,159,170,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,0,-1,0
9835,cardiomyopathy,1,2,4,18,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,1,1
9837,doxorubicin,30,31,159,170,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,0,-1,0
9838,doxorubicin,4,5,23,34,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,0,-1,0
9840,calcitonin,2,3,11,21,Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.,6293644_0,0,-1,0
9841,salmon calcitonin,4,6,23,40,"injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats.",6293644_2,0,-1,0
9842,Calcitonin,0,1,0,10,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,0,-1,0
9843,catalepsy,8,9,71,80,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,-1,1,1
9844,hyperactivity,15,16,129,142,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,-1,1,1
9845,calcitonin,1,2,9,19,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,0,-1,0
9848,calcitonin,11,12,57,67,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,0,-1,0
9850,acetaminophen,5,6,34,47,Reduction in caffeine toxicity by acetaminophen.,6308277_0,0,-1,0
9851,sodium,12,13,89,95,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0
9852,caffeine,15,16,114,122,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0
9853,acetaminophen,18,19,128,141,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0
9854,caffeine,31,32,225,233,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0,-1,0
9855,caffeine,11,12,77,85,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0
9856,acetaminophen,26,27,160,173,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0
9857,toxicity,34,35,209,217,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,1,1
9858,caffeine,36,37,221,229,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0,-1,0
9859,acetaminophen,11,12,57,70,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,0,-1,0
9860,caffeine,23,24,136,144,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,0,-1,0
9861,convulsions,36,37,190,201,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,1,1
9862,acetaminophen,49,50,253,266,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,0,-1,0
9863,seizures,59,60,314,322,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,1,1
9864,caffeine,65,66,351,359,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,0,-1,0
9865,seizures,4,5,31,39,The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.,6308277_4,-1,1,1
9866,caffeine,10,11,63,71,The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.,6308277_4,0,-1,0
9867,acetaminophen,19,20,101,114,The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.,6308277_4,0,-1,0
9868,caffeine,4,5,18,26,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,0,-1,0
9869,acetaminophen,6,7,28,41,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,0,-1,0
9870,seizures,17,18,79,87,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,1,1
9871,Acetaminophen,0,1,0,13,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,0,-1,0
9872,adenosine,14,15,88,97,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,0,-1,0
9874,acetaminophen,5,6,28,41,Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown.,6308277_7,0,-1,0
9875,caffeine,10,11,69,77,Thus the mechanism by which acetaminophen antagonizes the actions of caffeine in the CNS remains unknown.,6308277_7,0,-1,0
9876,morphine,11,12,91,99,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,0,-1,0
9877,morphine,9,10,63,71,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0,-1,0
9878,morphine,5,6,51,59,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,0,-1,0
9879,catalepsy,8,9,71,80,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,1,1
9880,hypotension,7,8,67,78,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1
9882,bradycardia,14,15,132,143,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1
9883,morphine,15,16,121,129,Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine.,6308526_4,0,-1,0
9884,hyperammonemia,5,6,31,45,Modification of drug action by hyperammonemia.,6323692_0,-1,1,1
9885,ammonium acetate,2,4,18,34,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0,-1,0
9886,diazepam,30,31,190,198,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0,-1,0
9887,hyperammonemia,2,3,6,20,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1
9888,liver disease,24,26,158,171,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1
9889,catecholamine,6,7,55,68,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,0,-1,0
9890,depressed,13,14,108,117,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,1,1
9891,calcium,3,4,19,26,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,0,-1,0
9892,depression,6,7,40,50,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,1,1
9893,catecholamine,13,14,92,105,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,0,-1,0
9895,calcium,8,9,42,49,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0,-1,0
9896,verapamil,11,12,66,75,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0,-1,0
9897,verapamil,1,2,5,14,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0
9898,morphine,12,13,63,71,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0
9899,verapamil,26,27,192,201,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0,-1,0
9900,hyperammonemia,4,5,22,36,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,1,1
9901,calcium,7,8,46,53,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0,-1,0
9903,dyskinesia,1,2,17,27,Levodopa-induced dyskinesia and thalamotomy.,6381653_0,-1,1,1
9904,dyskinesia,1,2,17,27,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,1,1
9905,Parkinsonism,9,10,62,74,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,1,1
9906,dyskinesias,3,4,28,39,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,1,1
9907,Parkinsonism,14,15,98,110,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,1,1
9909,amitriptyline,10,11,65,78,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,0,-1,0
9910,depressed,20,21,127,136,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,1,1
9911,amitriptyline,2,3,14,27,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,0,-1,0
9912,depressive,11,12,82,92,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,1,1
9913,dry mouth,15,17,88,97,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,1,1
9914,amitriptyline,27,28,163,176,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,0,-1,0
9915,antidepressant,8,9,44,58,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0,-1,0
9916,amitriptyline,16,17,104,117,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0,-1,0
9917,depressed,21,22,138,147,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,1,1
9918,diazepam,3,4,22,30,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0
9919,propranolol,5,6,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0
9921,agoraphobia,12,13,83,94,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,1,1
9922,diazepam,6,7,29,37,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0,-1,0
9923,propranolol,25,26,108,119,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0,-1,0
9925,agoraphobia,52,53,253,264,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,1,1
9926,diazepam,12,13,75,83,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0
9927,propranolol,14,15,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0
9928,propranolol,4,5,29,40,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0
9929,diazepam,6,7,46,54,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0
9930,diazepam,13,14,88,96,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0
9931,propranolol,15,16,102,113,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0
9933,toxicity,4,5,43,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,1,1
9934,sodium,9,10,78,84,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0
9936,MESNA,13,14,114,119,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0
9937,cancer,20,21,154,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,1,1
9938,sodium,10,11,67,73,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0
9939,MESNA,14,15,103,108,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0
9940,toxicity,18,19,129,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,1,1
9941,ifosfamide,21,22,149,159,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0
9943,MESNA,0,1,0,5,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0,-1,0
9944,MESNA,9,10,51,56,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,0,-1,0
9945,MESNA,7,8,50,55,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0,-1,0
9946,toxicity,21,22,153,161,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,-1,1,1
9947,MESNA,6,7,34,39,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0,-1,0
9948,MESNA,3,4,21,26,Protection with oral MESNA is particularly suitable for outpatients.,6402369_9,0,-1,0
9949,seizures,6,7,31,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,1,1
9950,carbamazepine,10,11,65,78,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,0,-1,0
9951,carbamazepine,11,12,48,61,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,0,-1,0
9952,epilepsy,13,14,66,74,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,-1,1,1
9953,seizures,35,36,193,201,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,-1,1,1
9954,carbamazepine,2,3,9,22,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,0,-1,0
9955,seizures,23,24,130,138,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,-1,1,1
9956,seizures,35,36,182,190,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,-1,1,1
9957,seizures,5,6,22,30,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,1,1
9958,convulsions,8,9,72,83,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,1,1
9959,prostaglandins,5,6,35,49,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0
9961,seizure,10,11,59,66,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,1,1
9963,convulsions,21,22,125,136,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,1,1
9964,picrotoxin,26,27,159,169,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0
9966,bicuculline,35,36,206,217,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0
9967,Ibuprofen,0,1,0,9,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0
9968,sulindac,2,3,11,19,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0
9972,picrotoxin,25,26,153,163,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0
9973,bicuculline,27,28,168,179,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0
9974,convulsions,15,16,102,113,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,1,1
9975,convulsions,25,26,174,185,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,1,1
9979,epileptic,9,10,36,45,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,1,1
9983,captopril,2,3,10,19,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,0,-1,0
9984,proteinuria,7,8,64,75,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,-1,1,1
9985,hypertensive,10,11,93,105,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,-1,1,1
9986,Proteinuria,0,1,0,11,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,-1,1,1
9987,captopril,6,7,32,41,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,0,-1,0
9988,hypertensive,9,10,55,67,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,-1,1,1
9989,captopril,9,10,63,72,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,0,-1,0
9990,captopril,3,4,23,32,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,0,-1,0
9991,proteinuria,13,14,78,89,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,-1,1,1
9992,captopril,2,3,6,15,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,0,-1,0
9993,proteinuria,12,13,84,95,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,1,1
9995,Captopril,0,1,0,9,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0
9996,sodium,16,17,105,111,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0
9997,potassium,18,19,116,125,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0
9998,creatinine,21,22,138,148,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0
10001,captopril,17,18,117,126,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,0,-1,0
10002,glycopyrrolate,0,1,0,14,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0
10003,atropine,2,3,19,27,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0
10004,bradycardia,7,8,49,60,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,-1,1,1
10005,arrhythmias,9,10,65,76,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,-1,1,1
10006,suxamethonium,14,15,105,118,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0
10007,glycopyrrolate,5,6,39,53,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0,-1,0
10008,atropine,12,13,83,91,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0,-1,0
10009,arrhythmia,9,10,60,70,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,-1,1,1
10010,bradycardia,11,12,75,86,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,-1,1,1
10011,suxamethonium,16,17,115,128,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,0,-1,0
10012,glycopyrrolate,13,14,73,87,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0,-1,0
10013,atropine,15,16,92,100,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0,-1,0
10014,bradycardia,3,4,15,26,"A frequency of bradycardia of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs.",6466532_5,-1,1,1
10015,Bradycardia,0,1,0,11,Bradycardia (defined as a decrease in heart rate to less than 50 beat min-1) was prevented when the larger dose of either active drug was used.,6466532_6,-1,1,1
10016,glycopyrrolate,5,6,30,44,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0
10017,atropine,10,11,67,75,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0
10018,suxamethonium,31,32,200,213,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0
10021,liver disease,1,3,15,28,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,1,1
10022,death,11,12,67,72,There was a fulminant clinical course from start of symptoms until death.,6503301_2,-1,1,1
10023,thrombosis,8,9,54,64,Small- and medium-sized hepatic veins were blocked by thrombosis.,6503301_4,-1,1,1
10024,dyskinesia,1,2,22,32,Phenobarbital-induced dyskinesia in a neurologically-impaired child.,6504332_0,-1,1,1
10025,dyskinesia,9,10,64,74,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,1,1
10026,phenobarbital,13,14,95,108,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,0,-1,0
10027,seizures,16,17,121,129,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,1,1
10029,phenobarbital,4,5,25,38,"On repeat challenge with phenobarbital, the dyskinesia recurred.",6504332_3,0,-1,0
10030,dyskinesia,7,8,44,54,"On repeat challenge with phenobarbital, the dyskinesia recurred.",6504332_3,-1,1,1
10031,Phenobarbital,0,1,0,13,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,0,-1,0
10033,lithium,1,2,9,16,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,0,-1,0
10035,lithium,11,12,90,97,Cross-sectional echocardiography was used to evaluate two neonates whose mothers ingested lithium during pregnancy.,6518066_1,0,-1,0
10038,lithium,7,8,67,74,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,0,-1,0
10042,polyethylene glycol 400,2,5,10,33,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,0,-1,0
10044,polyethylene glycol 400,9,12,45,68,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0
10046,adriamycin,28,29,138,148,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0
10051,ketamine,5,6,33,41,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,0,-1,0
10052,catecholamines,10,11,57,71,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,0,-1,0
10053,dopamine,7,8,48,56,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,0,-1,0
10054,ketamine,17,18,105,113,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,0,-1,0
10055,norepinephrine,22,23,137,151,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,0,-1,0
10056,Serotonin,0,1,0,9,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0
10057,serotonin,3,4,23,32,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0
10058,ketamine,6,7,49,57,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0
10059,ketamine,25,26,147,155,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0
10060,Ketamine,0,1,0,8,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,0,-1,0
10061,ketamine,27,28,162,170,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,0,-1,0
10062,dopamine,30,31,183,191,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,0,-1,0
10063,ketamine,16,17,87,95,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,0,-1,0
10064,dopamine,2,3,13,21,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,0,-1,0
10065,ketamine,15,16,93,101,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,0,-1,0
10066,thrombocytopenia,1,2,16,32,"Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.",6615052_0,-1,1,1
10067,thrombosis,3,4,34,44,"Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.",6615052_0,-1,1,1
10068,hemorrhage,6,7,50,60,"Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.",6615052_0,-1,1,1
10069,thrombocytopenia,5,6,42,58,Sixty-two patients with a heparin-induced thrombocytopenia are reported.,6615052_1,-1,1,1
10070,hemorrhage,6,7,49,59,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,-1,1,1
10071,thromboembolic,12,13,81,95,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,-1,1,1
10072,heparin,17,18,125,132,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,0,-1,0
10073,heparin,12,13,82,89,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,0,-1,0
10074,heparin,24,25,149,156,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,0,-1,0
10075,deaths,2,3,7,13,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,-1,1,1
10076,hemorrhagic,5,6,18,29,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,-1,1,1
10077,thromboembolic,7,8,34,48,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,-1,1,1
10078,heparin,13,14,82,89,"Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored.",6615052_6,0,-1,0
10079,heparin,15,16,85,92,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,0,-1,0
10080,platelet aggregation,17,19,94,114,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,-1,1,1
10081,heparin,5,6,36,43,"Management consists of cessation of heparin, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.",6615052_8,0,-1,0
10084,toxicity,1,2,4,12,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,1,1
10086,calcium,14,15,101,108,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0
10087,sodium citrate,19,21,133,147,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0
10090,toxicity,15,16,123,131,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,1,1
10091,ventricular tachycardia,3,5,28,51,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,1,1
10092,toxicity,3,4,23,31,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,1,1
10093,amiodarone,6,7,45,55,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,0,-1,0
10094,ventricular tachycardia,9,11,68,91,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,1,1
10096,Amiodarone,0,1,0,10,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,0,-1,0
10097,ventricular tachycardia,11,13,75,98,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1
10098,cardiac arrest,23,25,119,133,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1
10099,amiodarone,7,8,56,66,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,0,-1,0
10101,amiodarone,17,18,104,114,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,0,-1,0
10102,amiodarone,9,10,50,60,Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of amiodarone in 10% of patients.,6637851_6,0,-1,0
10103,amiodarone,16,17,91,101,Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of amiodarone in 10% of patients.,6637851_6,0,-1,0
10104,tremor,7,8,51,57,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1
10105,ataxia,9,10,61,67,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1
10106,nausea,15,16,75,81,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,1,1
10107,amiodarone,2,3,20,30,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,0,-1,0
10108,toxicity,23,24,161,169,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,1,1
10109,amiodarone,31,32,164,174,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,0,-1,0
10110,adriamycin,2,3,15,25,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,0,-1,0
10111,carcinoma,6,7,49,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,-1,1,1
10112,carcinoma,12,13,85,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,-1,1,1
10113,Adriamycin,0,1,0,10,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0,-1,0
10115,tumors,21,22,122,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,1,1
10116,cystitis,6,7,33,41,In 24 of these patients chemical cystitis was severe enough for them to drop out of the study.,6640832_5,-1,1,1
10117,tumors,7,8,33,39,"Of these recurrences, 27 were T1 tumors while five progressed to more highly invasive lesions.",6640832_10,-1,1,1
10118,Adriamycin,4,5,25,35,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,0,-1,0
10121,myopathy,8,9,48,56,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,1,1
10122,myopathy,4,5,22,30,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,1,1
10123,aspirin,2,3,10,17,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,0,-1,0
10124,aspirin,3,4,25,32,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,0,-1,0
10126,tumors,26,27,211,217,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,1,1
10128,aspirin,20,21,111,118,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0,-1,0
10129,aspirin,32,33,164,171,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0,-1,0
10131,aspirin,10,11,80,87,FANFT-induced cell proliferation in the bladder was significantly suppressed by aspirin co-administration after 4 weeks but not after 12 weeks.,6692345_3,0,-1,0
10132,aspirin,10,11,43,50,"In the forestomach, and also in the liver, aspirin did not affect the FANFT-induced increase in labeling index.",6692345_4,0,-1,0
10134,aspirin,26,27,186,193,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,0,-1,0
10136,aspirin,16,17,80,87,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,0,-1,0
10139,caffeine,8,9,76,84,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,0,-1,0
10142,stroke,16,17,97,103,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,1,1
10143,caffeine,5,6,26,34,"It is often combined with caffeine in diet preparations and ""look-alike"" pills.",6695415_2,0,-1,0
10144,stroke,9,10,50,56,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,1,1
10145,hypertensive,13,14,80,92,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,1,1
10147,hypertensive,11,12,61,73,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,1,1
10148,hypertension,11,12,63,75,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,1,1
10149,hypertensive,17,18,105,117,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,1,1
10151,hypertensive,12,13,86,98,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,1,1
10152,Renal papillary necrosis,0,3,0,24,Renal papillary necrosis due to naproxen.,6699841_0,-1,1,1
10153,rheumatoid arthritis,4,6,23,43,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,1,1
10154,sulindac,13,14,82,90,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0,-1,0
10155,calcium,16,17,103,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0,-1,0
10156,renal papillary necrosis,26,29,160,184,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,1,1
10159,Sulindac,0,1,0,8,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,0,-1,0
10161,sulindac,15,16,103,111,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,0,-1,0
10162,renal toxicity,21,23,145,159,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,1,1
10164,metoclopramide,7,8,39,53,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,0,-1,0
10165,metoclopramide,21,22,123,137,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0,-1,0
10166,metoclopramide,2,3,9,23,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0,-1,0
10168,Nephrotoxic,0,1,0,11,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,-1,1,1
10169,aminoglycoside,3,4,23,37,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0,-1,0
10170,gentamicin,5,6,27,37,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0,-1,0
10171,kanamycin,7,8,39,48,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0,-1,0
10172,sodium,11,12,83,89,"Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v.",6728084_2,0,-1,0
10173,potassium,13,14,91,100,"Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v.",6728084_2,0,-1,0
10174,Gentamicin,0,1,0,10,"Gentamicin administration decreased diameter, density and shape of endothelial fenestrae.",6728084_4,0,-1,0
10175,Kanamycin,0,1,0,9,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,0,-1,0
10176,aminoglycosides,2,3,10,25,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0,-1,0
10177,sodium,10,11,75,81,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0,-1,0
10178,potassium,12,13,86,95,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0,-1,0
10179,gentamicin,1,2,6,16,While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.,6728084_7,0,-1,0
10180,kanamycin,3,4,21,30,While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.,6728084_7,0,-1,0
10181,kanamycin,15,16,98,107,"Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin.",6728084_9,0,-1,0
10182,gentamicin,17,18,112,122,"Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin.",6728084_9,0,-1,0
10183,aminoglycosides,2,3,6,21,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,0,-1,0
10185,apnea,29,30,197,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,1,1
10186,apnea,9,10,67,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,1,1
10187,apnea,13,14,79,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,1,1
10190,"1,3-bis-(2-chloroethyl)-1-nitrosourea",9,10,49,86,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,0,-1,0
10192,tumor,15,16,94,99,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,1,1
10193,tumor,14,15,78,83,"After two to seven cycles of chemotherapy, nine patients showed a decrease in tumor size and surrounding edema on contrast-enhanced computerized tomography scans.",6747681_4,-1,1,1
10194,edema,18,19,105,110,"After two to seven cycles of chemotherapy, nine patients showed a decrease in tumor size and surrounding edema on contrast-enhanced computerized tomography scans.",6747681_4,-1,1,1
10197,vasculitis,16,17,98,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,1,1
10198,visual loss,3,5,17,28,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,-1,1,1
10199,ethanol,11,12,70,77,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,0,-1,0
10200,Cardiotoxic,0,1,0,11,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,-1,1,1
10201,adriamycin,6,7,49,59,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0,-1,0
10202,adriamycin,15,16,112,122,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0,-1,0
10204,adriamycin,13,14,80,90,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0,-1,0
10205,cardiomyopathy,11,12,92,106,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,1,1
10206,adriamycin,14,15,87,97,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0,-1,0
10207,adriamycin,4,5,25,35,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0,-1,0
10208,hypotension,3,4,24,35,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1
10209,nitroglycerin,5,6,39,52,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,0,-1,0
10211,nitroglycerin,12,13,100,113,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,0,-1,0
10212,diabetic,28,29,194,202,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1
10213,autonomic neuropathy,31,33,220,240,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1
10214,diabetic,36,37,248,256,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1
10215,autonomic neuropathy,39,41,271,291,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1
10216,nitroglycerin,19,20,110,123,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,0,-1,0
10217,diabetic,26,27,155,163,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1
10218,autonomic neuropathy,29,31,181,201,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1
10219,diabetic,50,51,309,317,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1
10220,autonomic neuropathy,53,55,332,352,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1
10222,diabetic,14,15,97,105,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,1,1
10223,autonomic neuropathy,20,22,140,160,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,1,1
10227,lithium,18,19,107,114,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,0,-1,0
10233,depression,4,5,26,36,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,1,1
10236,amnesia,79,80,467,474,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,1,1
10237,amnesia,92,93,537,544,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,1,1
10238,shock,103,104,613,618,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,1,1
10239,cycloheximide,132,133,800,813,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0
10241,cycloheximide,169,170,1012,1025,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0
10243,noradrenaline,7,8,55,68,Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats.,6861444_0,0,-1,0
10245,noradrenaline,8,9,35,48,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,0,-1,0
10246,noradrenaline,3,4,23,36,Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.,6861444_2,0,-1,0
10247,hypertension,5,6,44,56,Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.,6861444_2,-1,1,1
10248,noradrenaline,6,7,49,62,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,0,-1,0
10249,noradrenaline,10,11,84,97,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,0,-1,0
10250,noradrenaline,18,19,139,152,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,0,-1,0
10251,noradrenaline,26,27,216,229,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,0,-1,0
10252,hypertension,4,5,27,39,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,-1,1,1
10253,noradrenaline,8,9,65,78,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,0,-1,0
10254,noradrenaline,18,19,143,156,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,0,-1,0
10255,tumors,4,5,54,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,1,1
10256,tumors,1,2,10,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,1,1
10257,diethylstilbestrol,12,13,76,94,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,0,-1,0
10263,tumor,13,14,90,95,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,1,1
10265,carbachol,10,11,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0,-1,0
10267,tremor,43,44,244,250,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,1,1
10268,convulsions,46,47,268,279,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,1,1
10269,carbachol,49,50,292,301,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0,-1,0
10271,carbachol,13,14,95,104,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0,-1,0
10272,tremor,7,8,30,36,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,1,1
10273,convulsions,10,11,54,65,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,1,1
10274,carbachol,13,14,76,85,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0,-1,0
10277,tremor,22,23,134,140,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,1,1
10278,convulsions,25,26,158,169,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,1,1
10279,carbachol,28,29,180,189,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0,-1,0
10281,carbachol,9,10,69,78,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0,-1,0
10282,calcium,7,8,44,51,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,0,-1,0
10283,cardiac arrhythmias,5,7,36,55,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,1,1
10284,hypertension,16,17,79,91,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,1,1
10287,potassium,13,14,87,96,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,0,-1,0
10288,necrosis,6,7,48,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,1,1
10290,fulminant hepatic failure,24,27,157,182,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,1,1
10292,fulminant hepatic failure,22,25,128,153,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,1,1
10294,fulminant hepatic failure,37,40,241,266,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,1,1
10295,hepatitis,43,44,280,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,1,1
10297,aspartate,27,28,170,179,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0,-1,0
10298,cimetidine,5,6,27,37,Age and renal clearance of cimetidine.,7053303_0,0,-1,0
10299,cimetidine,11,12,44,54,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0
10300,cimetidine,28,29,156,166,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0
10301,creatinine,35,36,214,224,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0
10302,Cimetidine,0,1,0,10,Cimetidine clearance decreased with age.,7053303_2,0,-1,0
10303,cimetidine,6,7,45,55,"The extrapolated 6-hr serum concentration of cimetidine per unit dose, after intravenous cimetidine, increased with age of the patients.",7053303_3,0,-1,0
10304,cimetidine,13,14,89,99,"The extrapolated 6-hr serum concentration of cimetidine per unit dose, after intravenous cimetidine, increased with age of the patients.",7053303_3,0,-1,0
10305,cimetidine,3,4,13,23,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0
10306,creatinine,6,7,37,47,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0
10307,cimetidine,22,23,122,132,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0
10308,cimetidine,14,15,88,98,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,0,-1,0
10309,cimetidine,20,21,129,139,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,0,-1,0
10310,dementia,6,7,27,35,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,1,1
10311,cimetidine,10,11,52,62,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,0,-1,0
10312,cimetidine,38,39,187,197,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,0,-1,0
10313,cimetidine,3,4,11,21,"Thus, high cimetidine levels alone do not always induce dementia.",7053303_7,0,-1,0
10314,dementia,10,11,56,64,"Thus, high cimetidine levels alone do not always induce dementia.",7053303_7,-1,1,1
10315,fibrosis,9,10,65,73,"Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted.",7053705_3,-1,1,1
10316,neuropathy,2,3,29,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,1,1
10317,diabetes,5,6,37,45,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,1,1
10318,neuropathy,16,17,104,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,1,1
10319,Visual loss,0,2,0,11,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,1,1
10320,neuropathy,6,7,40,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,1,1
10321,visual loss,15,17,105,116,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,1,1
10331,albuminuria,2,3,14,25,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,1,1
10332,nephrotic,28,29,147,156,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,1,1
10334,nephrotic,4,5,20,29,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,-1,1,1
10335,nephrotic,12,13,78,87,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,1,1
10337,nephrotic,14,15,73,82,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,-1,1,1
10338,aplastic anemia,1,3,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,1,1
10339,aplastic anemia,5,7,28,43,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,1,1
10340,cataract,13,14,82,90,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,1,1
10341,aplastic anemia,4,6,19,34,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,1,1
10342,aplastic anemia,7,9,36,51,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,1,1
10343,toxicity,6,7,36,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,1,1
10344,amiodarone,8,9,63,73,Further observations on the electrophysiologic effects of oral amiodarone therapy.,7083920_0,0,-1,0
10345,amiodarone,11,12,71,81,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,0,-1,0
10346,tachycardia,15,16,103,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,1,1
10347,tachycardia,6,7,39,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,1,1
10348,amiodarone,3,4,18,28,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,0,-1,0
10350,Amiodarone,0,1,0,10,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,0,-1,0
10351,diethylstilbestrol,19,20,110,128,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,0,-1,0
10352,carcinoma,13,14,59,68,"One patient, aged 23, had been followed for 2 years before carcinoma was diagnosed; the second patient, aged 22, had been seen on a regular basis for 5 years, 8 months.",7088431_2,-1,1,1
10353,carcinoma,9,10,48,57,"In both instances, suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix.",7088431_3,-1,1,1
10354,Midazolam,0,1,0,9,Midazolam compared with thiopentone as an induction agent.,7102237_0,0,-1,0
10355,thiopentone,3,4,24,35,Midazolam compared with thiopentone as an induction agent.,7102237_0,0,-1,0
10356,scopolamine,4,5,30,41,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0
10357,morphine,6,7,44,52,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0
10358,midazolam,22,23,129,138,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0
10359,thiopentone,35,36,196,207,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0
10360,thiopentone,35,36,196,207,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0
10361,midazolam,10,11,67,76,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,0,-1,0
10362,apnoea,16,17,98,104,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,-1,1,1
10363,midazolam,22,23,132,141,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,0,-1,0
10364,midazolam,7,8,38,47,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0,-1,0
10365,thiopentone,9,10,52,63,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0,-1,0
10366,Midazolam,0,1,0,9,Midazolam is a new alternative agent for induction in combination anaesthesia.,7102237_4,0,-1,0
10367,haloperidol,5,6,37,48,Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.,7161250_0,0,-1,0
10369,haloperidol,16,17,93,104,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,0,-1,0
10370,parkinsonism,3,4,17,29,The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.,7161250_2,-1,1,1
10371,haloperidol,10,11,60,71,The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.,7161250_2,0,-1,0
10372,parkinsonism,16,17,95,107,"However, these medications were more effective in both young and old patients when given after parkinsonism developed.",7161250_4,-1,1,1
10374,benzodiazepine,5,6,32,46,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,0,-1,0
10376,haloperidol,19,20,113,124,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,0,-1,0
10377,Deaths,0,1,0,6,Deaths from local anesthetic-induced convulsions in mice.,7189975_0,-1,1,1
10378,convulsions,4,5,37,48,Deaths from local anesthetic-induced convulsions in mice.,7189975_0,-1,1,1
10379,convulsions,31,32,187,198,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,-1,1,1
10380,bupivacaine,13,14,62,73,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0
10381,lidocaine,20,21,101,110,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0
10382,bupivacaine,4,5,30,41,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0,-1,0
10383,lidocaine,13,14,80,89,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0,-1,0
10384,Convulsions,0,1,0,11,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,1,1
10385,death,3,4,28,33,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,1,1
10386,convulsions,8,9,41,52,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,1,1
10387,seizures,22,23,109,117,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,1,1
10388,lidocaine,38,39,172,181,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,0,-1,0
10389,convulsions,14,15,97,108,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,-1,1,1
10391,aggressiveness,11,12,67,81,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,1,1
10392,aggressiveness,6,7,53,67,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,1,1
10393,bupivacaine,8,9,74,85,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0,-1,0
10394,neurotoxicity,16,17,84,97,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,1,1
10395,bupivacaine,20,21,96,107,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0,-1,0
10396,paralysis,17,18,110,119,Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.,7199841_4,-1,1,1
10397,bupivacaine,6,7,34,45,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0,-1,0
10398,paralysis,21,22,120,129,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,-1,1,1
10399,necrosis,15,16,91,99,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,-1,1,1
10400,bupivacaine,8,9,46,57,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0,-1,0
10401,ventricular tachycardia,2,4,34,57,Procainamide-induced polymorphous ventricular tachycardia.,7234705_0,-1,1,1
10402,ventricular tachycardia,5,7,49,72,Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.,7234705_1,-1,1,1
10403,ventricular tachycardia,5,7,31,54,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,1,1
10404,procainamide,17,18,117,129,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,0,-1,0
10405,ventricular tachycardia,23,25,161,184,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,1,1
10406,procainamide,6,7,33,45,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0,-1,0
10408,syncope,7,8,50,57,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,-1,1,1
10409,ventricular tachycardia,11,13,78,101,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,-1,1,1
10410,arrhythmia,5,6,22,32,"In four patients, the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia.",7234705_5,-1,1,1
10411,arrhythmia,18,19,113,123,"In four patients, the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia.",7234705_5,-1,1,1
10412,arrhythmia,5,6,21,31,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,1,1
10414,procainamide,16,17,100,112,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0,-1,0
10415,ventricular tachycardia,20,22,135,158,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,-1,1,1
10416,procainamide,5,6,35,47,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,0,-1,0
10417,ventricular tachycardia,15,17,113,136,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,-1,1,1
10418,cirrhosis,14,15,109,118,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,1,1
10419,cirrhosis,4,5,20,29,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,1,1
10420,ascites,20,21,116,123,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,1,1
10423,phenobarbitone,6,7,30,44,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,0,-1,0
10426,phenobarbitone,15,16,83,97,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,0,-1,0
10427,aplastic anemia,1,3,6,21,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,-1,1,1
10428,indomethacin,5,6,29,41,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,0,-1,0
10429,indomethacin,1,2,9,21,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,0,-1,0
10430,aplastic anemia,10,12,65,80,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,-1,1,1
10431,aplastic anemia,4,6,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,1,1
10432,indomethacin,16,17,90,102,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,0,-1,0
10433,Indomethacin,0,1,0,12,Indomethacin was first given four weeks prior to the onset of symptoms.,7263204_3,0,-1,0
10434,indomethacin,6,7,47,59,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,0,-1,0
10435,aplastic anemia,19,21,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,1,1
10436,nephrolithiasis,1,2,12,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,1,1
10437,nephrolithiasis,4,5,22,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,1,1
10438,hypertension,17,18,120,132,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,1,1
10440,nephrolithiasis,3,4,30,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,1,1
10444,cystitis,14,15,119,127,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,1,1
10445,busulfan,7,8,33,41,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,0,-1,0
10446,carcinoma,13,14,72,81,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,-1,1,1
10448,cardiomyopathy,1,2,4,18,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,1,1
10450,doxorubicin,10,11,56,67,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0,-1,0
10451,Adriamycin,15,16,75,85,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0,-1,0
10452,myocardial damage,2,4,10,27,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,1,1
10453,ventricular tachycardia,1,3,8,31,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,1,1
10455,ventricular tachycardia,6,8,28,51,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,1,1
10457,arrhythmia,4,5,24,34,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,1,1
10458,ventricular tachycardia,3,5,23,46,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1
10459,ventricular tachycardia,14,16,105,128,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1
10461,fulminant hepatic failure,5,8,39,64,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,1,1
10464,fulminant hepatic failure,7,10,44,69,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,1,1
10465,fulminant hepatic failure,7,10,54,79,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1
10468,hypertensive,1,2,8,20,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,-1,1,1
10469,sodium nitroprusside,3,5,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0
10470,saralasin,7,8,61,70,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0
10471,halothane,15,16,86,95,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0,-1,0
10472,sodium nitroprusside,18,20,111,131,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0,-1,0
10473,hypotension,21,22,146,157,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,-1,1,1
10474,halothane,3,4,22,31,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,0,-1,0
10476,saralasin,17,18,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0
10481,halothane,6,7,38,47,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0
10483,saralasin,30,31,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0
10484,hypotensive,14,15,98,109,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,1,1
10485,halothane,17,18,121,130,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,0,-1,0
10487,sexual dysfunction,3,5,25,43,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,1,1
10488,estrogen,19,20,117,125,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0,-1,0
10489,testosterone,25,26,157,169,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0,-1,0
10491,estradiol,28,29,174,183,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,0,-1,0
10492,testosterone,30,31,185,197,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,0,-1,0
10494,estradiol,10,11,69,78,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,0,-1,0
10495,testosterone,12,13,80,92,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,0,-1,0
10496,nephrotoxicity,1,2,9,23,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,-1,1,1
10497,tobramycin,3,4,27,37,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,0,-1,0
10498,gentamicin,5,6,42,52,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,0,-1,0
10499,aminoglycoside,8,9,50,64,Nearly 3.2 million people in this country receive aminoglycoside antibiotics annually.,7420681_2,0,-1,0
10500,Gentamicin,0,1,0,10,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0,-1,0
10501,tobramycin,3,4,23,33,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0,-1,0
10502,ototoxicity,8,9,66,77,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1
10503,nephrotoxicity,10,11,82,96,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1
10504,gentamicin,20,21,109,119,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0,-1,0
10505,tobramycin,23,24,131,141,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0,-1,0
10509,gentamicin,2,3,6,16,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,0,-1,0
10511,tobramycin,16,17,89,99,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,0,-1,0
10512,carcinoma,1,2,12,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,1,1
10514,carcinoma,6,7,53,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,1,1
10517,endometrial cancer,25,27,169,187,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,1,1
10518,cancer,9,10,63,69,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,1,1
10519,carcinoma,18,19,122,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,1,1
10521,cardiotoxic,1,2,4,15,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,-1,1,1
10522,adriamycin,4,5,27,37,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,0,-1,0
10523,Adriamycin,0,1,0,10,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0,-1,0
10524,creatine,6,7,41,49,Such disparity suggests an inhibition of creatine phosphokinase.,7423039_5,0,-1,0
10525,adenosine,5,6,21,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,0,-1,0
10528,adenosine,8,9,49,58,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,0,-1,0
10529,lithium,1,2,10,17,Long-term lithium treatment and the kidney.,7437994_0,0,-1,0
10530,lithium,16,17,76,83,This is a report on the first part of our study of the effects of long-term lithium treatment on the kidney.,7437994_2,0,-1,0
10531,Creatinine,0,1,0,10,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0,-1,0
10532,lithium,24,25,149,156,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0,-1,0
10533,lithium,18,19,103,110,"These findings have been compared with norms and with values of the same tests from screening prior to lithium, available for most of our patients.",7437994_4,0,-1,0
10534,lithium,11,12,72,79,No evidence was found for any reduction of glomerular filtration during lithium treatment.,7437994_5,0,-1,0
10535,Polyuria,0,1,0,8,Polyuria above 3 litres/24 hours was found in 10% of patients.,7437994_9,-1,1,1
10536,neurotoxic,6,7,40,50,Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.,7444978_0,-1,1,1
10537,streptomycin,9,10,62,74,Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.,7444978_0,0,-1,0
10539,streptomycin,48,49,275,287,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,0,-1,0
10540,dyskinesias,60,61,346,357,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,1,1
10542,Cardiac toxicity,0,2,0,16,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,-1,1,1
10543,adriamycin,11,12,65,75,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,0,-1,0
10544,Cardiomyopathy,0,1,0,14,Cardiomyopathy is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy.,7449470_2,-1,1,1
10545,cardiomyopathy,7,8,48,62,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,-1,1,1
10546,cardiotoxicity,22,23,151,165,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,-1,1,1
10547,amiloride,7,8,71,80,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,0,-1,0
10548,amiloride,3,4,14,23,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0,-1,0
10549,polydipsia,6,7,43,53,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,1,1
10550,polyuria,8,9,58,66,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,1,1
10551,lithium,12,13,78,85,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0,-1,0
10553,Amiloride,0,1,0,9,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0,-1,0
10556,amiloride,6,7,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0
10557,lithium,14,15,75,82,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0
10559,lithium,12,13,53,60,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,0,-1,0
10560,lithium,14,15,76,83,"After 3 days of combined treatment, a marked elevation in plasma and tissue lithium levels accompanied a reduction in water intake.",7453952_5,0,-1,0
10561,amiloride,13,14,99,108,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0
10562,lithium,24,25,165,172,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0
10563,potassium,42,43,267,276,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0
10564,amiloride,5,6,27,36,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0
10565,polydipsia,12,13,95,105,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,-1,1,1
10566,polyuria,14,15,110,118,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,-1,1,1
10567,amiloride,21,22,162,171,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0
10568,lithium,27,28,213,220,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0
10569,terbutaline,4,5,45,56,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,0,-1,0
10570,terbutaline,11,12,83,94,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,0,-1,0
10571,hepatitis,1,2,6,15,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,1,1
10573,carbimazole,14,15,101,112,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0,-1,0
10575,hyperthyroidism,11,12,70,85,METHODS: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department (in- or out-patients) from 1986 to 1992.,7504976_2,-1,1,1
10576,hepatitis,12,13,57,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,1,1
10577,hepatitis,5,6,31,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,1,1
10578,carbimazole,8,9,52,63,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,0,-1,0
10579,hepatitis,10,11,51,60,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,1,1
10580,carbimazole,12,13,71,82,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,0,-1,0
10581,hepatitis,10,11,63,72,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,1,1
10582,carbimazole,22,23,135,146,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,0,-1,0
10583,hepatitis,3,4,23,32,"Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug, while biliary, viral and immunological searches were negative.",7504976_7,-1,1,1
10584,neutropenia,12,13,72,83,Only 2 patients of our retrospective study experienced a mild or severe neutropenia.,7504976_8,-1,1,1
10585,hepatitis,3,4,18,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,1,1
10587,hepatotoxicity,2,3,10,24,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,1,1
10590,verapamil,28,29,160,169,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,0,-1,0
10593,bradycardia,1,2,15,26,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,-1,1,1
10594,verapamil,4,5,38,47,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,0,-1,0
10597,verapamil,4,5,24,33,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,0,-1,0
10598,Nephrotoxicity,0,1,0,14,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,1,1
10604,rapamycin,23,24,111,120,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0,-1,0
10605,hypertrophy,45,46,239,250,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,1,1
10614,rapamycin,27,28,166,175,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0,-1,0
10617,rapamycin,17,18,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0
10618,nephrotoxic,5,6,31,42,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,1,1
10622,carboplatin,6,7,33,44,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,0,-1,0
10623,Carboplatin,0,1,0,11,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0,-1,0
10625,carboplatin,11,12,63,74,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,0,-1,0
10627,corticosteroids,3,4,29,44,Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.,7582165_0,0,-1,0
10628,dexamethasone,10,11,65,78,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0,-1,0
10629,urticaria,11,12,64,73,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,1,1
10630,corticosteroids,11,12,78,93,"Clinical examinations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed.",7582165_4,0,-1,0
10631,paramethasone,10,11,47,60,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0,-1,0
10632,corticosteroids,10,11,62,77,We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them.,7582165_7,0,-1,0
10633,paramethasone,4,5,27,40,These results suggest that paramethasone caused pseudoallergic reactions in our patients.,7582165_8,0,-1,0
10634,Corticosteroids,0,1,0,15,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0,-1,0
10635,paramethasone,3,4,31,44,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0,-1,0
10636,hypersensitivity,6,7,59,75,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,-1,1,1
10637,paramethasone,14,15,73,86,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,0,-1,0
10638,adenosine,41,42,263,272,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0,-1,0
10639,platelet aggregation,13,15,81,101,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,1,1
10640,headache,6,7,37,45,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,1,1
10641,nausea,17,18,103,109,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,1,1
10642,myopathy,1,2,23,31,Pravastatin-associated myopathy.,7604176_0,-1,1,1
10643,myopathy,5,6,29,37,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,1,1
10644,pravastatin,11,12,65,76,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,0,-1,0
10647,hypertension,13,14,91,103,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,1,1
10648,pravastatin,2,3,11,22,He assumed pravastatin (20 mg/day) because of hypercholesterolemia.,7604176_4,0,-1,0
10649,hypercholesterolemia,9,10,46,66,He assumed pravastatin (20 mg/day) because of hypercholesterolemia.,7604176_4,-1,1,1
10650,myopathy,5,6,27,35,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,-1,1,1
10651,pravastatin,17,18,90,101,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,0,-1,0
10652,hypothyroidism,3,4,21,35,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,1,1
10653,lovastatin,1,2,6,16,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,0,-1,0
10654,simvastatin,3,4,21,32,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,0,-1,0
10655,myopathy,9,10,65,73,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,1,1
10656,myopathy,12,13,98,106,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,-1,1,1
10657,coma,3,4,20,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,1,1
10658,coma,1,2,8,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,1,1
10659,coma,1,2,5,9,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,1,1
10661,dopamine,19,20,101,109,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,0,-1,0
10662,urea,30,31,161,165,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,0,-1,0
10663,dopamine,3,4,29,37,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,0,-1,0
10664,dopamine,9,10,68,76,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,0,-1,0
10665,coma,19,20,124,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,1,1
10666,coma,16,17,108,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,1,1
10667,coma,14,15,77,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,1,1
10668,dopamine,27,28,145,153,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,0,-1,0
10671,etoposide,11,12,84,93,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0,-1,0
10674,folinic acid,8,10,37,49,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0
10675,toxicity,14,15,92,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,1,1
10676,zidovudine,16,17,104,114,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0
10678,folinic acid,15,17,86,98,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0
10679,zidovudine,20,21,129,139,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0
10680,bone marrow suppression,22,25,154,177,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,1,1
10681,folinic acid,37,39,198,210,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0,-1,0
10683,death,13,14,69,74,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,-1,1,1
10686,toxicity,2,3,19,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,1,1
10689,myelosuppression,13,14,81,97,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,1,1
10691,folinic acid,3,5,16,28,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0,-1,0
10692,enflurane,4,5,29,38,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,0,-1,0
10693,isoflurane,6,7,43,53,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,0,-1,0
10694,hepatic injury,14,16,98,112,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,-1,1,1
10695,halothane,23,24,159,168,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,0,-1,0
10698,enflurane,8,9,63,72,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,0,-1,0
10699,isoflurane,10,11,77,87,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,0,-1,0
10700,hypersensitivity,13,14,97,113,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,-1,1,1
10701,halothane,16,17,125,134,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,0,-1,0
10702,enflurane,13,14,115,124,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,0,-1,0
10703,isoflurane,15,16,129,139,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,0,-1,0
10704,Enflurane,0,1,0,9,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,0,-1,0
10705,enflurane,11,12,69,78,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0
10706,isoflurane,13,14,86,96,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0
10707,hypersensitivity,17,18,113,129,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,-1,1,1
10708,halothane,23,24,159,168,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0
10709,halothane,30,31,209,218,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0
10710,toxicity,1,2,12,20,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,1,1
10715,depressed,9,10,61,70,Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.,7650771_2,-1,1,1
10716,Seizure,0,1,0,7,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,1,1
10719,benzodiazepine,3,4,16,30,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0,-1,0
10721,benzodiazepines,15,16,114,129,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0,-1,0
10722,Seizures,0,1,0,8,Seizures and cardiac arrhythmias have complicated its use in adult patients.,7651879_2,-1,1,1
10723,cardiac arrhythmias,2,4,13,32,Seizures and cardiac arrhythmias have complicated its use in adult patients.,7651879_2,-1,1,1
10724,Overdose,0,1,0,8,Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.,7651879_3,-1,1,1
10725,antidepressants,6,7,48,63,Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.,7651879_3,0,-1,0
10727,seizure,8,9,55,62,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,1,1
10729,toxicities,15,16,81,91,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,1,1
10730,toxicity,11,12,67,75,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,1,1
10731,toxicities,1,2,14,24,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,1,1
10732,hypercalcemia,11,12,73,86,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,1,1
10733,rash,18,19,96,100,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,1,1
10734,toxicities,1,2,4,14,All toxicities resolved after cis-RA was discontinued.,7707116_9,-1,1,1
10735,hypercalcemia,3,4,17,30,"The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.",7707116_14,-1,1,1
10736,calcium,3,4,20,27,Monitoring of serum calcium and cis-RA levels is indicated in future trials.,7707116_15,0,-1,0
10737,malondialdehyde,4,5,26,41,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0,-1,0
10738,ischemia,13,14,98,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,1,1
10739,ischemia,2,3,20,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,1,1
10740,ischemia,19,20,106,114,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,1,1
10741,ischemia,33,34,152,160,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,1,1
10742,malondialdehyde,17,18,131,146,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0,-1,0
10743,ischemia,1,2,7,15,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,1,1
10744,malondialdehyde,1,2,7,22,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,0,-1,0
10745,ischemia,26,27,136,144,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,1,1
10746,malondialdehyde,2,3,17,32,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0
10747,ischemia,33,34,234,242,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1
10748,hypotensive,44,45,294,305,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1
10749,nitroprusside,46,47,311,324,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0
10750,ischemia,56,57,384,392,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,1,1
10751,malondialdehyde,63,64,424,439,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0
10752,malondialdehyde,8,9,52,67,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0,-1,0
10753,toxicity,2,3,12,20,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,1,1
10754,doxorubicin,4,5,24,35,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,0,-1,0
10755,renal toxicity,6,8,45,59,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,-1,1,1
10756,glomerulonephritis,18,19,120,138,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,-1,1,1
10757,doxorubicin,8,9,36,47,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,0,-1,0
10758,proteinuria,4,5,17,28,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,1,1
10759,proteinuria,6,7,28,39,Free NP did not provoke any proteinuria.,7724492_4,-1,1,1
10760,glomerulonephritis,5,6,33,51,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,1,1
10761,Proteinuria,0,1,0,11,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,1,1
10762,doxorubicin,22,23,99,110,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,0,-1,0
10763,toxicity,23,24,134,142,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,1,1
10764,hyperactivity,3,4,33,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,1,1
10769,hyperactivity,14,15,81,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,1,1
10770,shock,2,3,23,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,1,1
10773,metoprolol,11,12,77,87,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,0,-1,0
10775,hypotension,10,11,82,93,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,1,1
10776,verapamil,19,20,149,158,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0,-1,0
10777,metoprolol,24,25,183,193,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0,-1,0
10778,hypotensive,5,6,32,43,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,1,1
10780,atropine,17,18,110,118,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0
10781,dopamine,28,29,167,175,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0
10782,dobutamine,30,31,180,190,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0
10784,hypotension,13,14,79,90,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,1,1
10786,indomethacin,5,6,36,48,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,0,-1,0
10787,renal dysfunction,7,9,57,74,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,1,1
10788,indomethacin,19,20,134,146,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,0,-1,0
10789,indomethacin,28,29,178,190,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0,-1,0
10790,indomethacin,38,39,217,229,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0,-1,0
10791,creatinine,7,8,46,56,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0
10792,blood urea nitrogen,9,12,58,77,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0
10793,pain,13,14,79,83,Response to treatment was estimated by the visual analog scale for severity of pain.,7791169_4,-1,1,1
10794,creatinine,19,20,90,100,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0,-1,0
10795,Potassium,0,1,0,9,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,0,-1,0
10797,creatinine,6,7,28,38,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0,-1,0
10799,indomethacin,10,11,69,81,CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.,7791169_8,0,-1,0
10800,renal dysfunction,12,14,90,107,CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.,7791169_8,-1,1,1
10801,pain,10,11,77,81,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,1,1
10802,alprazolam,4,5,27,37,Safety and side-effects of alprazolam.,7802851_0,0,-1,0
10803,agoraphobia,3,4,20,31,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,1,1
10805,benzodiazepines,6,7,34,49,BACKGROUND: The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects.,7802851_2,0,-1,0
10806,alprazolam,3,4,16,26,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,0,-1,0
10808,agoraphobia,10,11,62,73,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,1,1
10810,agoraphobia,16,17,92,103,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,1,1
10811,alprazolam,20,21,123,133,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,0,-1,0
10812,alprazolam,3,4,14,24,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,0,-1,0
10813,alprazolam,5,6,32,42,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,0,-1,0
10814,depression,19,20,100,110,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1
10815,aggression,25,26,140,150,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1
10816,irritability,34,35,198,210,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1
10818,ataxia,42,43,245,251,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,1,1
10819,Alprazolam,2,3,13,23,CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.,7802851_11,0,-1,0
10821,nausea,15,16,74,80,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,1,1
10823,ataxia,21,22,106,112,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,1,1
10824,aggressive behavior,38,40,216,235,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,1,1
10827,ouabain,2,3,11,18,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0,-1,0
10828,oxygen,5,6,33,39,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0,-1,0
10832,oxygen,7,8,50,56,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,0,-1,0
10834,ouabain,5,6,27,34,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,0,-1,0
10838,ouabain,26,27,169,176,"Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted.",783197_4,0,-1,0
10839,ouabain,14,15,109,116,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,0,-1,0
10842,ouabain,40,41,219,226,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,0,-1,0
10843,oxygen,5,6,36,42,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0
10844,ouabain,9,10,70,77,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0
10845,ouabain,26,27,172,179,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0
10848,ouabain,24,25,165,172,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,0,-1,0
10849,oxygen,19,20,100,106,"Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption.",783197_11,0,-1,0
10850,oxygen,36,37,198,204,"Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption.",783197_11,0,-1,0
10852,rifampin,6,7,70,78,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,0,-1,0
10853,tuberculosis,10,11,101,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,1,1
10854,glomerulonephritis,11,12,79,97,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,-1,1,1
10855,rifampin,17,18,124,132,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,0,-1,0
10856,rifampin,7,8,45,53,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,0,-1,0
10857,isoniazid,9,10,58,67,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,0,-1,0
10858,tuberculosis,12,13,82,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,1,1
10860,glomerulonephritis,4,5,29,47,"Renal biopsy revealed severe glomerulonephritis with crescents, electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate.",7834920_3,-1,1,1
10861,glomerulonephritis,6,7,45,63,Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out.,7834920_4,-1,1,1
10862,glomerulonephritis,9,10,68,86,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,1,1
10863,glomerulonephritis,14,15,116,134,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,1,1
10864,rifampin,20,21,161,169,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,0,-1,0
10867,glaucoma,14,15,109,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,1,1
10868,dexamethasone,13,14,71,84,Paired eyes were perfused in serum-free media with or without 10(-7) M dexamethasone for 12 days.,7843916_4,0,-1,0
10869,dexamethasone,19,20,110,123,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,0,-1,0
10870,dexamethasone,36,37,193,206,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,0,-1,0
10871,dexamethasone,9,10,54,67,"The contralateral control eyes, which did not receive dexamethasone, maintained a stable intraocular pressure during the same period.",7843916_8,0,-1,0
10872,hypertensive,5,6,39,51,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,1,1
10873,Dexamethasone,2,3,12,25,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,0,-1,0
10875,Steroid,0,1,0,7,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,0,-1,0
10876,glaucoma,16,17,122,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,1,1
10877,glaucoma,20,21,146,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,1,1
10880,glaucoma,22,23,135,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,1,1
10881,confusion,1,2,6,15,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,-1,1,1
10882,5-fluorouracil,8,9,51,65,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0
10883,folinic acid,10,12,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0
10884,etoposide,11,12,87,96,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0
10885,5-fluorouracil,14,15,108,122,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0
10886,folinic acid,21,23,150,162,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0
10887,confusion,7,8,49,58,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,1,1
10888,irritability,11,12,79,91,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,1,1
10889,coma,19,20,121,125,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,1,1
10890,5-fluorouracil,35,36,195,209,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0
10891,folinic acid,37,39,214,226,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0
10892,5-fluorouracil,11,12,65,79,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0
10893,folinic acid,13,15,84,96,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0
10894,folinic acid,1,3,8,20,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0
10895,neurotoxicity,12,13,72,85,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,-1,1,1
10896,5-fluorouracil,16,17,103,117,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0
10899,cancers,13,14,105,112,High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.,7858459_6,-1,1,1
10900,carbamazepine,3,4,20,33,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0,-1,0
10902,Carbamazepine,0,1,0,13,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0
10903,schizophrenic,11,12,94,107,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,1,1
10904,haloperidol,18,19,158,169,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0
10905,chlorpromazine,20,21,171,185,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0
10906,clozapine,22,23,189,198,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0
10908,extrapyramidal symptoms,26,28,127,150,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,1,1
10909,carbamazepine,13,14,71,84,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,0,-1,0
10911,Bupivacaine,0,1,0,11,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0
10912,adrenaline,4,5,23,33,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0
10913,bupivacaine,16,17,93,104,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0
10916,bupivacaine,20,21,101,112,The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine.,7880714_6,0,-1,0
10917,nephropathy,8,9,71,82,Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.,7881871_0,-1,1,1
10920,nephropathy,14,15,114,125,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,1,1
10921,proteinuria,21,22,172,183,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,1,1
10922,proteinuria,10,11,71,82,The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study.,7881871_2,-1,1,1
10926,Proteinuria,0,1,0,11,"Proteinuria was evident at day 5, peaked at day 7 and persisted to day 27.",7881871_7,-1,1,1
10928,octreotide,7,8,51,61,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0,-1,0
10930,Octreotide,0,1,0,10,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,0,-1,0
10931,octreotide,28,29,173,183,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0,-1,0
10932,cholesterol,21,22,120,131,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,0,-1,0
10933,cholesterol,34,35,195,206,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,0,-1,0
10934,cholesterol,11,12,53,64,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0,-1,0
10935,cholesterol,31,32,145,156,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0,-1,0
10936,cholesterol,54,55,246,257,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0,-1,0
10938,cholesterol,36,37,173,184,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,0,-1,0
10939,octreotide,3,4,15,25,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0,-1,0
10940,cholesterol,14,15,81,92,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0,-1,0
10941,calcium,41,42,249,256,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0,-1,0
10942,zidovudine,11,12,79,89,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0,-1,0
10943,zidovudine,52,53,343,353,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0,-1,0
10944,zidovudine,54,55,361,371,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0,-1,0
10945,zidovudine,16,17,78,88,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0,-1,0
10947,zidovudine,28,29,139,149,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0,-1,0
10949,zidovudine,37,38,172,182,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0,-1,0
10950,zidovudine,8,9,52,62,"Sixty patients received combination therapy and 58, zidovudine and placebo.",7905523_2,0,-1,0
10951,zidovudine,17,18,65,75,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,0,-1,0
10952,zidovudine,19,20,103,113,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,0,-1,0
10953,zidovudine,4,5,24,34,"For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively.",7905523_6,0,-1,0
10954,zidovudine,17,18,96,106,"For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively.",7905523_6,0,-1,0
10955,zidovudine,14,15,86,96,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,0,-1,0
10956,Diarrhea,0,1,0,8,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,1,1
10959,paralysis,1,2,10,19,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,1,1
10961,corticosteroids,9,10,77,92,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,0,-1,0
10965,weakness,18,19,100,108,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,1,1
10966,corticosteroids,5,6,39,54,Two patients also received intravenous corticosteroids.,7910951_3,0,-1,0
10967,acidosis,16,17,89,97,"Renal function was normal but hepatic function was impaired in all patients, and all had acidosis.",7910951_4,-1,1,1
10968,weakness,1,2,4,12,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,1,1
10969,corticosteroids,28,29,146,161,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,0,-1,0
10970,acidosis,3,4,24,32,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,-1,1,1
10973,ampicillin,7,8,63,73,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,0,-1,0
10976,ampicillin,14,15,94,104,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,0,-1,0
10977,ampicillin,9,10,49,59,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,0,-1,0
10978,gentamicin,11,12,64,74,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,0,-1,0
10981,myocarditis,12,13,94,105,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,1,1
10982,methylprednisolone,5,6,29,47,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0,-1,0
10983,ampicillin,7,8,48,58,Macrophage-migration inhibition (MIF) test with ampicillin was positive.,7919560_5,0,-1,0
10984,infections,4,5,23,33,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,1,1
10986,myocarditis,9,10,66,77,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,1,1
10987,allergic reaction,16,18,109,126,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,1,1
10988,ampicillin,4,5,22,32,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,0,-1,0
10989,ampicillin,13,14,86,96,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,0,-1,0
10991,clomipramine,15,16,86,98,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,0,-1,0
10992,clomipramine,9,10,45,57,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,0,-1,0
10993,clomipramine,3,4,17,29,During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness.,7930386_6,0,-1,0
10995,clomipramine,35,36,191,203,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,0,-1,0
11003,nausea,20,21,91,97,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,1,1
11004,pain,6,7,31,35,"Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension.",7977601_8,-1,1,1
11005,hypotension,19,20,92,103,"Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension.",7977601_8,-1,1,1
11006,hypotensive,2,3,8,19,The two hypotensive patients required treatment for shock.,7977601_9,-1,1,1
11007,shock,7,8,52,57,The two hypotensive patients required treatment for shock.,7977601_9,-1,1,1
11011,fluorescein,31,32,206,217,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0,-1,0
11012,Angioedema,0,1,0,10,Angioedema following the intravenous administration of metoprolol.,7988234_0,-1,1,1
11013,metoprolol,6,7,55,65,Angioedema following the intravenous administration of metoprolol.,7988234_0,0,-1,0
11018,hypertension,12,13,91,103,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,1,1
11020,angioedema,3,4,13,23,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,1,1
11022,metoprolol,12,13,71,81,"During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.",7988234_6,0,-1,0
11023,angioedema,19,20,113,123,"During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.",7988234_6,-1,1,1
11024,angioedema,1,2,4,14,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,1,1
11025,steroids,7,8,55,63,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,0,-1,0
11026,thrombosis,9,10,63,73,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,-1,1,1
11027,thrombosis,7,8,60,70,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,-1,1,1
11028,thrombosis,10,11,73,83,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1
11029,heparin,14,15,101,108,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0,-1,0
11030,platelet aggregation,16,18,117,137,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1
11031,heparin,23,24,170,177,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0,-1,0
11032,thrombosis,34,35,230,240,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1
11033,thrombosis,15,16,92,102,The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.,8012887_3,-1,1,1
11035,oxytocin,4,5,35,43,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,0,-1,0
11037,oxytocin,8,9,52,60,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,0,-1,0
11039,Oxytocin,0,1,0,8,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,0,-1,0
11042,oxytocin,1,2,4,12,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,0,-1,0
11045,oxytocin,8,9,47,55,The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.,803783_5,0,-1,0
11046,oxytocin,1,2,4,12,The oxytocin should not be administered in excess of 36 hours.,803783_6,0,-1,0
11047,oxytocin,9,10,43,51,If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance.,803783_7,0,-1,0
11048,proteinuria,2,3,12,23,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,-1,1,1
11049,rifampin,8,9,58,66,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,0,-1,0
11050,tuberculosis,12,13,89,101,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,-1,1,1
11051,proteinuria,2,3,12,23,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,-1,1,1
11052,tuberculosis,9,10,45,57,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,-1,1,1
11053,rifampin,13,14,80,88,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,0,-1,0
11054,tuberculosis,11,12,66,78,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,-1,1,1
11055,rifampin,15,16,87,95,This last finding may be related to time of testing and/or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte.,804391_5,0,-1,0
11056,adenosine,5,6,27,36,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,0,-1,0
11057,adenosine,5,6,29,38,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,0,-1,0
11058,adenosine,23,24,165,174,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,0,-1,0
11059,catalepsy,4,5,25,34,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,-1,1,1
11060,haloperidol,7,8,46,57,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0,-1,0
11061,reserpine,16,17,80,89,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0,-1,0
11062,adenosine,9,10,59,68,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0
11063,adenosine,25,26,175,184,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0,-1,0
11064,parkinsonism,12,13,62,74,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,1,1
11065,coniine,2,3,10,17,Effect of coniine on the developing chick embryo.,8073369_0,0,-1,0
11066,Coniine,0,1,0,7,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,0,-1,0
11067,coniine,2,3,9,16,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,0,-1,0
11068,coniine,13,14,69,76,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0,-1,0
11069,nicotine,15,16,81,89,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0,-1,0
11070,coniine,2,3,18,25,"Concentrations of coniine and nicotine sulfate were 0.015%, 0.03%, 0.075%, 0.15%, 0.75%, 1.5%, 3%, and 6% and 1%, 5%, and 10%, respectively.",8073369_5,0,-1,0
11071,nicotine,4,5,30,38,"Concentrations of coniine and nicotine sulfate were 0.015%, 0.03%, 0.075%, 0.15%, 0.75%, 1.5%, 3%, and 6% and 1%, 5%, and 10%, respectively.",8073369_5,0,-1,0
11072,nicotine,3,4,22,30,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0,-1,0
11073,coniine,14,15,87,94,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0,-1,0
11074,coniine,5,6,32,39,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0,-1,0
11075,nicotine,7,8,44,52,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0,-1,0
11076,hemorrhage,26,27,154,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,1,1
11077,nicotine,30,31,181,189,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,0,-1,0
11078,coniine,16,17,78,85,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,0,-1,0
11079,nicotine,18,19,90,98,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,0,-1,0
11080,nicotine,33,34,170,178,"Control chicks were in motion an average of 33.67% of the time, while coniine-treated chicks were only moving 8.95% of a 5-min interval, and no movement was observed for nicotine sulfate treated chicks.",8073369_11,0,-1,0
11081,allergic reactions,1,3,10,28,Immediate allergic reactions to amoxicillin.,8092427_0,-1,1,1
11082,amoxicillin,4,5,32,43,Immediate allergic reactions to amoxicillin.,8092427_0,0,-1,0
11083,allergic reactions,7,9,41,59,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,-1,1,1
11084,amoxicillin,37,38,241,252,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0,-1,0
11086,penicillin,46,47,292,302,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0,-1,0
11089,ampicillin,17,18,117,127,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,0,-1,0
11096,Anaphylaxis,0,1,0,11,"Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema.",8092427_8,-1,1,1
11097,urticaria,19,20,69,78,"Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema.",8092427_8,-1,1,1
11098,angioedema,21,22,86,96,"Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema.",8092427_8,-1,1,1
11104,allergic reaction,19,21,100,117,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,1,1
11109,phenylephrine,2,3,12,25,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,0,-1,0
11110,nitroglycerin,9,10,67,80,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,0,-1,0
11111,acute myocardial infarction,13,16,98,125,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,-1,1,1
11112,Nitroglycerin,0,1,0,13,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,0,-1,0
11113,acute myocardial infarction,9,12,67,94,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,-1,1,1
11114,hypotension,24,25,174,185,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,-1,1,1
11115,nitroglycerin,10,11,60,73,Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy.,809711_2,0,-1,0
11116,phenylephrine,12,13,78,91,Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy.,809711_2,0,-1,0
11118,nitroglycerin,9,10,79,92,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,0,-1,0
11119,nitroglycerin,21,22,112,125,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,0,-1,0
11120,phenylephrine,3,4,23,36,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,0,-1,0
11121,phenylephrine,6,7,37,50,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,0,-1,0
11122,nitroglycerin,8,9,54,67,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,0,-1,0
11123,acute myocardial infarction,18,21,120,147,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,-1,1,1
11124,dyskinesias,6,7,50,61,Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.,8106150_0,-1,1,1
11125,parkinsonian,7,8,37,49,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,1,1
11127,dyskinesia,12,13,82,92,"This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.",8106150_3,-1,1,1
11128,dopamine,10,11,68,76,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,0,-1,0
11129,clonidine,4,5,25,34,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0
11130,propranolol,12,13,73,84,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0
11132,parkinsonian,30,31,171,183,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,1,1
11133,yohimbine,2,3,9,18,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,0,-1,0
11134,dyskinesia,13,14,71,81,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,1,1
11135,Atropine,0,1,0,8,Atropine converted the dystonic movements into chorea.,8106150_8,0,-1,0
11136,Hallucinations,0,1,0,14,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,-1,1,1
11137,neurotoxicity,3,4,38,51,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,-1,1,1
11138,Hallucinations,2,3,12,26,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1
11139,neurotoxicity,8,9,51,64,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1
11140,ifosfamide,18,19,113,123,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,0,-1,0
11141,hallucinations,4,5,33,47,Most cases of ifosfamide-induced hallucinations have been reported with other mental status changes.,8111719_2,-1,1,1
11142,hallucinations,9,10,69,83,METHODS: The authors interviewed six persons with ifosfamide-induced hallucinations in the presence of a clear sensorium.,8111719_3,-1,1,1
11143,ifosfamide,5,6,38,48,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,0,-1,0
11144,Hallucinations,2,3,9,23,"RESULTS: Hallucinations occurred only when the patient's eyes were closed and, in all but one case, were reported as disturbing or frightening.",8111719_5,-1,1,1
11145,hallucinations,3,4,24,38,Underreporting of these hallucinations by patients is likely.,8111719_6,-1,1,1
11146,Hallucinations,2,3,13,27,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,-1,1,1
11147,neurotoxicity,11,12,70,83,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,-1,1,1
11148,hallucinations,8,9,64,78,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,1,1
11149,neurotoxicity,17,18,119,132,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,1,1
11150,agitation,1,2,3,12,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,1,1
11152,haloperidol,10,11,62,73,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,0,-1,0
11153,nephrolithiasis,1,2,22,37,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,1,1
11155,nephrolithiasis,5,6,40,55,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,-1,1,1
11156,paralysis,12,13,95,104,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,1,1
11157,Nephrolithiasis,0,1,0,15,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,1,1
11159,toxicity,7,8,59,67,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,1,1
11161,toxicity,17,18,116,124,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,1,1
11163,diltiazem,10,11,55,64,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0
11164,verapamil,12,13,66,75,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0
11165,bepridil,14,15,80,88,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0
11166,bupivacaine,2,3,8,19,dose of bupivacaine.,8231633_3,0,-1,0
11168,bupivacaine,4,5,27,38,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0
11170,convulsions,21,22,159,170,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,1,1
11171,bepridil,29,30,209,217,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0
11172,nifedipine,4,5,27,37,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,0,-1,0
11173,glomerulonephritis,3,4,42,60,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,1,1
11174,rheumatoid arthritis,8,10,79,99,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,1,1
11175,rheumatoid arthritis,4,6,25,45,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,1,1
11176,glomerulonephritis,9,10,76,94,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,1,1
11177,glomerulonephritis,5,6,37,55,Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.,8267029_2,-1,1,1
11178,steroid,5,6,29,36,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0,-1,0
11179,cyclophosphamide,10,11,60,76,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0,-1,0
11180,proteinuria,26,27,166,177,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,1,1
11182,toxicity,10,11,72,80,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,1,1
11184,Hyperalgesia,0,1,0,12,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1
11185,myoclonus,2,3,17,26,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1
11186,cancer,5,6,39,45,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1
11187,morphine,11,12,91,99,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,0,-1,0
11188,cancer,1,2,6,12,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,-1,1,1
11189,morphine,16,17,99,107,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,0,-1,0
11190,hyperalgesia,18,19,118,130,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,-1,1,1
11191,hyperalgesia,4,5,34,46,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1
11192,myoclonus,14,15,102,111,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1
11193,myoclonus,16,17,99,108,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,-1,1,1
11194,morphine,14,15,109,117,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,0,-1,0
11195,morphine,25,26,189,197,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,0,-1,0
11197,hypotension,9,10,68,79,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,1,1
11201,hypotension,16,17,80,91,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,1,1
11202,isoflurane,45,46,261,271,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0,-1,0
11205,hypotensive,1,2,4,15,The hypotensive drug was discontinued at the completion of the operative procedure.,8302922_3,-1,1,1
11208,hypotension,30,31,151,162,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,1,1
11215,hypotensive,11,12,61,72,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,1,1
11217,daunorubicin,1,2,10,22,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,0,-1,0
11219,daunorubicin,16,17,98,110,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,0,-1,0
11223,toxicities,5,6,41,51,"Clinical, biochemical and haematological toxicities were assessed.",8305357_4,-1,1,1
11225,toxicity,12,13,65,73,"The drug was generally well tolerated, with few mild symptoms of toxicity.",8305357_8,-1,1,1
11226,toxicity,6,7,48,56,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,1,1
11227,neutropenia,13,14,98,109,"The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).",8305357_9,-1,1,1
11228,cardiotoxicity,5,6,25,39,There was no evidence of cardiotoxicity.,8305357_10,-1,1,1
11229,daunorubicin,7,8,40,52,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0,-1,0
11232,nephrosis,8,9,70,79,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,1,1
11233,nephrotic,3,4,18,27,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,1,1
11234,proteinuria,7,8,46,57,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,1,1
11235,hypercholesterolemia,11,12,76,96,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,1,1
11239,losartan,37,38,250,258,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0
11241,nephrosis,16,17,131,140,The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.,8319760_2,-1,1,1
11244,kanamycin,12,13,85,94,"Following recovery, the monkeys were selectively deafened for high frequencies using kanamycin and furosemide.",8372922_5,0,-1,0
11245,furosemide,14,15,99,109,"Following recovery, the monkeys were selectively deafened for high frequencies using kanamycin and furosemide.",8372922_5,0,-1,0
11248,vincristine,3,4,21,32,Long-term effects of vincristine on the peripheral nervous system.,8384253_0,0,-1,0
11249,vincristine,8,9,56,67,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0
11250,vincristine,35,36,193,204,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0
11251,vincristine,27,28,186,197,"Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment.",8384253_3,0,-1,0
11253,vincristine,8,9,46,57,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,0,-1,0
11257,penile pain,3,5,30,41,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,1,1
11259,penile pain,6,8,35,46,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,1,1
11260,penile pain,31,33,195,206,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,1,1
11263,papaverine,0,1,0,10,"papaverine, 100 micrograms.",8386779_4,0,-1,0
11267,penile pain,18,20,93,104,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,1,1
11269,penile pain,42,44,206,217,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,1,1
11270,penile pain,7,9,37,48,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,-1,1,1
11271,toxicity,3,4,12,20,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,1,1
11272,didanosine,5,6,24,34,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,0,-1,0
11273,zidovudine,15,16,92,102,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,0,-1,0
11275,zidovudine,23,24,157,167,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,0,-1,0
11277,didanosine,28,29,183,193,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,0,-1,0
11281,didanosine,5,6,43,53,Adverse reactions possibly attributable to didanosine were common.,8387218_7,0,-1,0
11282,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,1,1
11284,glucose,3,4,25,32,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,0,-1,0
11285,diabetes,8,9,68,76,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,-1,1,1
11286,didanosine,24,25,158,168,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,0,-1,0
11288,oral contraceptives,13,15,78,97,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0,-1,0
11290,oral contraceptives,17,19,104,123,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0,-1,0
11296,glutamate,2,3,8,17,Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.,8410199_0,0,-1,0
11297,seizures,13,14,111,119,Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.,8410199_0,-1,1,1
11299,seizures,34,35,215,223,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,1,1
11300,pilocarpine,6,7,57,68,"Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.",8410199_2,0,-1,0
11301,seizures,28,29,186,194,"Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.",8410199_2,-1,1,1
11303,cresyl violet,5,7,47,60,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,0,-1,0
11307,confusion,14,15,134,143,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,1,1
11308,cimetidine,36,37,205,215,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,0,-1,0
11309,cimetidine,19,20,85,95,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,0,-1,0
11310,cimetidine,7,8,40,50,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0,-1,0
11311,cimetidine,14,15,96,106,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0,-1,0
11312,histamine,33,34,211,220,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0,-1,0
11313,confusion,9,10,69,78,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,1,1
11314,cimetidine,12,13,69,79,They should be closely observed and should be given reduced doses of cimetidine.,84204_6,0,-1,0
11315,octreotide,10,11,67,77,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0,-1,0
11316,octreotide,26,27,184,194,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,0,-1,0
11317,octreotide,3,4,22,32,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0,-1,0
11318,depressed,11,12,72,81,"In 8 patients followed for 24 weeks, gallbladder contractility remained depressed throughout therapy.",8421099_4,-1,1,1
11319,octreotide,3,4,20,30,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,0,-1,0
11320,depressed,35,36,203,212,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,1,1
11321,octreotide,25,26,164,174,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,0,-1,0
11322,octreotide,14,15,94,104,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,0,-1,0
11323,fluoxetine,5,6,39,49,Increase of Parkinson disability after fluoxetine medication.,8423889_0,0,-1,0
11324,Depression,0,1,0,10,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,1,1
11326,motor disability,6,8,34,50,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,1,1
11329,fluoxetine,9,10,75,85,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,0,-1,0
11331,hypotension,3,4,22,33,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,-1,1,1
11332,labetalol,6,7,45,54,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,0,-1,0
11333,isoflurane,8,9,60,70,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,0,-1,0
11334,hypotension,4,5,25,36,The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients.,8424298_1,-1,1,1
11335,hypotension,9,10,79,90,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,-1,1,1
11336,labetalol,12,13,102,111,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,0,-1,0
11337,isoflurane,14,15,117,127,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,0,-1,0
11338,hypotensive,16,17,129,140,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,-1,1,1
11339,hypotension,3,4,27,38,Seventeen patients without hypotension served as a control group.,8424298_3,-1,1,1
11340,hypotension,18,19,71,82,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,1,1
11341,hypotension,33,34,126,137,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,1,1
11342,hypotensive,36,37,145,156,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,1,1
11344,depression,41,42,244,254,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,1,1
11345,hypotension,4,5,26,37,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,-1,1,1
11346,labetalol,7,8,49,58,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,0,-1,0
11347,isoflurane,9,10,64,74,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,0,-1,0
11348,cimetidine,5,6,49,59,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,0,-1,0
11349,cimetidine,7,8,60,70,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,0,-1,0
11351,cimetidine,23,24,163,173,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,0,-1,0
11352,arrhythmias,1,2,4,15,"The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.",8437969_3,-1,1,1
11353,cimetidine,6,7,43,53,"The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.",8437969_3,0,-1,0
11354,ranitidine,18,19,126,136,"The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.",8437969_3,0,-1,0
11355,cimetidine,12,13,84,94,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,0,-1,0
11356,rheumatoid arthritis,3,5,17,37,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,-1,1,1
11357,rheumatoid arthritis,13,15,86,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,1,1
11358,aplastic anemia,6,8,29,44,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,1,1
11359,Seizures,0,1,0,8,Seizures induced by combined levomepromazine-fluvoxamine treatment.,8473723_0,-1,1,1
11360,seizures,8,9,75,83,We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.,8473723_1,-1,1,1
11361,ventricular tachycardia,6,8,41,64,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,1,1
11364,magnesium,9,10,63,72,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,0,-1,0
11368,magnesium,8,9,50,59,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,0,-1,0
11369,lovastatin,4,5,29,39,Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.,8480959_0,0,-1,0
11370,hypercholesterolemia,10,11,68,88,Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.,8480959_0,-1,1,1
11371,lovastatin,9,10,50,60,OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.,8480959_1,0,-1,0
11372,hypercholesterolemia,14,15,84,104,OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.,8480959_1,-1,1,1
11373,Lovastatin,7,8,44,54,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,0,-1,0
11374,lovastatin,33,34,202,212,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,0,-1,0
11375,cholesterol,17,18,94,105,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,0,-1,0
11376,lovastatin,5,6,22,32,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0
11377,cholesterol,30,31,137,148,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0
11378,cholesterol,52,53,214,225,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0
11379,Cholesterol,17,18,89,100,"Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).",8480959_7,0,-1,0
11380,cholesterol,23,24,131,142,"Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).",8480959_7,0,-1,0
11381,Myopathy,0,1,0,8,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,1,1
11383,lovastatin,31,32,185,195,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,0,-1,0
11384,lovastatin,15,16,100,110,Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.,8480959_10,0,-1,0
11385,Lovastatin,2,3,12,22,CONCLUSION: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women.,8480959_11,0,-1,0
11387,Tetany,0,1,0,6,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1
11388,rhabdomyolysis,2,3,11,25,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1
11389,furosemide,6,7,47,57,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,0,-1,0
11390,magnesium,10,11,73,82,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,0,-1,0
11391,hypocalcemia,5,6,34,46,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,1,1
11393,tetany,16,17,111,117,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,1,1
11394,potassium,23,24,147,156,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,0,-1,0
11395,calcium,25,26,161,168,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,0,-1,0
11396,hypocalcemia,17,18,81,93,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,1,1
11397,magnesium,27,28,131,140,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,0,-1,0
11398,nephrotoxicity,1,2,22,36,Ciprofloxacin-induced nephrotoxicity in patients with cancer.,8494478_0,-1,1,1
11399,cancer,5,6,54,60,Ciprofloxacin-induced nephrotoxicity in patients with cancer.,8494478_0,-1,1,1
11400,Nephrotoxicity,0,1,0,14,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,-1,1,1
11401,ciprofloxacin,3,4,31,44,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,0,-1,0
11402,cancer,3,4,19,25,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,1,1
11404,ciprofloxacin,13,14,89,102,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,0,-1,0
11405,creatinine,5,6,30,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0,-1,0
11406,interstitial nephritis,1,3,9,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,1,1
11408,midazolam,3,4,24,33,Venous complications of midazolam versus diazepam.,8514073_0,0,-1,0
11409,diazepam,5,6,41,49,Venous complications of midazolam versus diazepam.,8514073_0,0,-1,0
11410,midazolam,11,12,84,93,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,0,-1,0
11411,diazepam,14,15,104,112,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,0,-1,0
11412,diazepam,12,13,96,104,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,0,-1,0
11413,midazolam,14,15,108,117,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,0,-1,0
11414,diazepam,8,9,54,62,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,0,-1,0
11415,midazolam,17,18,93,102,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,0,-1,0
11416,diazepam,18,19,72,80,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,0,-1,0
11417,midazolam,33,34,131,140,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,0,-1,0
11418,Pain,0,1,0,4,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,1,1
11419,diazepam,18,19,73,81,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,0,-1,0
11420,midazolam,32,33,131,140,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,0,-1,0
11421,Smoking,0,1,0,7,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,0,-1,0
11422,alcohol,17,18,103,110,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,0,-1,0
11423,pain,21,22,120,124,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,1,1
11424,visual hallucinations,1,3,26,47,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,-1,1,1
11425,chronic renal failure,7,10,66,87,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,-1,1,1
11426,Visual hallucinations,0,2,0,21,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1
11427,chronic renal failure,7,10,42,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1
11429,visual hallucinations,5,7,32,53,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,1,1
11431,chronic renal failure,12,15,71,92,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,1,1
11432,neurotoxic,33,34,212,222,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,1,1
11433,chronic renal failure,12,15,77,98,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,1,1
11435,tumors,7,8,56,62,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,1,1
11436,tumor,17,18,119,124,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,1,1
11437,vinorelbine,4,5,18,29,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,0,-1,0
11438,carcinoma,10,11,69,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,1,1
11439,Cancer,7,8,52,58,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1
11440,Cancer,10,11,82,88,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1
11441,vinorelbine,25,26,167,178,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0,-1,0
11443,carcinoma,39,40,255,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,1,1
11444,toxicity,14,15,115,123,Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for toxicity and response.,8558192_2,-1,1,1
11449,toxicity,12,13,72,80,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,1,1
11450,infection,5,6,15,24,"A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred.",8558192_11,-1,1,1
11451,deaths,16,17,67,73,"A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred.",8558192_11,-1,1,1
11452,neurotoxicity,8,9,45,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,1,1
11454,carcinoma,16,17,99,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,1,1
11455,toxicity,7,8,46,54,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,1,1
11457,hypertensive,12,13,111,123,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,1,1
11458,hypertensive,12,13,84,96,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,1,1
11459,hypertensive,26,27,171,183,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,1,1
11461,captopril,18,19,90,99,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,0,-1,0
11464,clonidine,19,20,95,104,"After 2 weeks, the rats were subjected to ganglionic blockade and 2 days later, an infusion of clonidine.",8586822_3,0,-1,0
11465,captopril,3,4,18,27,RESULTS: Lifetime captopril treatment significantly lowered mean arterial pressure in both groups.,8586822_4,0,-1,0
11466,hexamethonium,6,7,47,60,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,0,-1,0
11467,clonidine,9,10,74,83,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,0,-1,0
11473,Thiopentone,0,1,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0
11474,propofol,3,4,29,37,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0
11475,pain,5,6,48,52,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,-1,1,1
11476,propofol,3,4,24,32,This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.,8595686_1,0,-1,0
11477,pain,5,6,43,47,This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.,8595686_1,-1,1,1
11478,propofol,23,24,135,143,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,0,-1,0
11479,lidocaine,16,17,64,73,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0,-1,0
11480,thiopentone,29,30,103,114,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0,-1,0
11481,propofol,18,19,92,100,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0,-1,0
11482,pain,6,7,29,33,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,1,1
11483,propofol,9,10,57,65,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0,-1,0
11484,lidocaine,3,4,17,26,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0
11485,propofol,10,11,65,73,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0
11486,pain,12,13,84,88,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,-1,1,1
11487,thiopentone,17,18,120,131,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0
11488,Angioedema,0,1,0,10,Angioedema associated with droperidol administration.,8599504_0,-1,1,1
11489,Angioedema,0,1,0,10,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,1,1
11490,edema,6,7,40,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,1,1
11491,edema,17,18,100,105,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,1,1
11493,angioedema,17,18,96,106,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,1,1
11494,cardiotoxicity,1,2,5,19,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,1,1
11495,tumor,8,9,57,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,1,1
11496,tumors,10,11,71,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,1,1
11497,doxorubicin,25,26,151,162,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,0,-1,0
11498,doxorubicin,3,4,20,31,Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360).,8600333_3,0,-1,0
11499,cardiac toxicity,9,11,37,53,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1
11500,ventricular arrhythmias,27,29,142,165,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1
11501,doxorubicin,9,10,64,75,"No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status, except for heart rate variability.",8600333_7,0,-1,0
11502,cardiotoxicity,4,5,37,51,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,-1,1,1
11503,cardiotoxicity,18,19,110,124,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,-1,1,1
11504,caffeine,5,6,37,45,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,0,-1,0
11505,hypertension,11,12,78,90,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,-1,1,1
11506,caffeine,5,6,40,48,Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.,8607407_1,0,-1,0
11507,hypertensive,9,10,65,77,Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.,8607407_1,-1,1,1
11508,caffeine,2,3,6,14,"Thus, caffeine (3.3 mg/kg) versus placebo was tested in 48 healthy men (aged 20 to 35 years) selected after screening on 2 separate occasions.",8607407_2,0,-1,0
11509,hypertensive,1,2,11,23,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,1,1
11510,hypertension,12,13,59,71,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,1,1
11511,caffeine,11,12,75,83,Participants were then tested on 2 occasions after 12-hour abstinence from caffeine in each of 2 protocols; this required a total of 4 laboratory visits.,8607407_5,0,-1,0
11512,hypertensive,20,21,142,154,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,-1,1,1
11513,caffeine,24,25,171,179,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,0,-1,0
11514,hypertensive,4,5,20,32,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,1,1
11515,caffeine,10,11,63,71,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,0,-1,0
11516,caffeine,6,7,34,42,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,0,-1,0
11518,sertraline,4,5,21,31,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,0,-1,0
11520,haloperidol,12,13,89,100,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,0,-1,0
11521,haloperidol,11,12,81,92,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,0,-1,0
11522,haloperidol,14,15,103,114,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,0,-1,0
11523,sertraline,16,17,120,130,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,0,-1,0
11524,haloperidol,10,11,51,62,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,0,-1,0
11525,sertraline,12,13,61,71,"From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.",8617710_3,0,-1,0
11526,sertraline,25,26,116,126,"From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.",8617710_3,0,-1,0
11527,haloperidol,15,16,92,103,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,0,-1,0
11528,haloperidol,2,3,17,28,"When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.",8617710_6,0,-1,0
11529,sertraline,5,6,29,39,There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.,8617710_7,0,-1,0
11530,haloperidol,11,12,79,90,There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group.,8617710_7,0,-1,0
11531,sertraline,5,6,21,31,Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.,8617710_8,0,-1,0
11532,sertraline,5,6,28,38,The side effect profiles of sertraline and of placebo were similar.,8617710_10,0,-1,0
11533,Haloperidol,2,3,12,23,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,0,-1,0
11535,sertraline,16,17,110,120,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,0,-1,0
11536,paralysis,1,2,11,20,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,1,1
11537,corticosteroids,11,12,73,88,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,0,-1,0
11539,paralysis,3,4,22,31,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,1,1
11541,corticosteroids,27,28,191,206,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,0,-1,0
11542,paralysis,23,24,166,175,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,1,1
11543,corticosteroids,30,31,201,216,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,0,-1,0
11544,paralysis,6,7,39,48,We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.,8638206_4,-1,1,1
11545,corticosteroids,20,21,125,140,We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.,8638206_4,0,-1,0
11547,headache,6,7,51,59,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,1,1
11549,seizure,15,16,103,110,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,1,1
11550,progesterone,22,23,144,156,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,0,-1,0
11551,estradiol,24,25,161,170,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,0,-1,0
11554,hemorrhagic,4,5,29,40,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,1,1
11555,thrombosis,17,18,104,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,-1,1,1
11556,estradiol,11,12,52,61,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,0,-1,0
11557,progesterone,13,14,66,78,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,0,-1,0
11559,thrombosis,28,29,177,187,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,1,1
11560,cancer,7,8,56,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,1,1
11561,paclitaxel,9,10,68,78,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0,-1,0
11562,Paclitaxel,0,1,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0
11564,tumor,19,20,135,140,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1
11565,breast carcinoma,25,27,168,184,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1
11566,paclitaxel,6,7,31,41,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0,-1,0
11567,cancer,19,20,125,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,1,1
11569,Leukopenia,0,1,0,10,Leukopenia was dose limiting: as many as 62.5% of patients experienced grade 4 leukopenia.,8643966_3,-1,1,1
11570,leukopenia,15,16,79,89,Leukopenia was dose limiting: as many as 62.5% of patients experienced grade 4 leukopenia.,8643966_3,-1,1,1
11571,toxicity,5,6,33,41,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,1,1
11572,paclitaxel,9,10,54,64,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,0,-1,0
11575,Paclitaxel,0,1,0,10,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0,-1,0
11577,toxicities,1,2,12,22,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,1,1
11578,neutropenia,17,18,79,90,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,-1,1,1
11579,polyneuropathy,4,5,13,27,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1
11580,polyneuropathy,19,20,92,106,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1
11581,Nausea,0,1,0,6,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,1,1
11582,vomiting,2,3,11,19,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,1,1
11583,Paclitaxel,0,1,0,10,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0,-1,0
11584,toxicity,34,35,217,225,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,-1,1,1
11585,paclitaxel,5,6,30,40,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0
11587,paclitaxel,21,22,135,145,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0
11588,paclitaxel,5,6,22,32,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0
11589,cisplatin,7,8,38,47,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0
11590,cancers,15,16,88,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,1,1
11591,paclitaxel,11,12,83,93,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0,-1,0
11593,cancer,35,36,207,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,1,1
11594,ovarian cancer,53,55,342,356,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,1,1
11595,toxicity,11,12,62,70,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,1,1
11596,paclitaxel,14,15,85,95,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0
11597,cisplatin,19,20,127,136,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0
11598,carcinoma,35,36,257,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,1,1
11599,tumor,1,2,8,13,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,-1,1,1
11600,toxicity,5,6,29,37,"Of 20 patients evaluable for toxicity, four had stage III and 16 had stage IV disease.",8643971_6,-1,1,1
11601,paclitaxel,15,16,75,85,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0
11602,cisplatin,28,29,146,155,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0
11603,paclitaxel,5,6,39,49,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0,-1,0
11604,toxicity,19,20,129,137,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,-1,1,1
11605,paclitaxel,1,2,5,15,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0,-1,0
11607,myalgia,18,19,109,116,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,1,1
11608,toxicity,3,4,29,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,1,1
11609,cancer,12,13,98,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,1,1
11610,paclitaxel,8,9,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0,-1,0
11611,Paclitaxel,0,1,0,10,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0
11612,carboplatin,3,4,25,36,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0
11613,ovarian cancer,10,12,77,91,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,-1,1,1
11614,paclitaxel,12,13,62,72,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0
11616,carboplatin,32,33,173,184,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0
11617,ovarian cancer,41,43,235,249,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,1,1
11618,paclitaxel,44,45,251,261,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0
11619,carboplatin,4,5,18,29,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,0,-1,0
11620,carboplatin,6,7,22,33,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0
11621,paclitaxel,23,24,110,120,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0
11622,toxicity,2,3,18,26,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1
11623,myelosuppression,7,8,50,66,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1
11624,leukopenia,9,10,68,78,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1
11625,thrombocytopenia,14,15,102,118,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1
11626,Neurotoxicity,0,1,0,13,Neurotoxicity was largely moderate.,8643973_6,-1,1,1
11628,paclitaxel,6,7,36,46,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0
11629,carboplatin,21,22,136,147,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0
11630,paclitaxel,8,9,46,56,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0
11631,carboplatin,12,13,71,82,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0
11632,dyskinesia,3,4,32,42,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,1,1
11633,propranolol,5,6,46,57,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0,-1,0
11637,dyskinesia,13,14,79,89,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,1,1
11638,propranolol,16,17,108,119,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,0,-1,0
11639,dyskinesia,9,10,47,57,There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability.,8649546_2,-1,1,1
11641,dyskinesia,3,4,22,32,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,-1,1,1
11642,dystonia,9,10,68,76,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,-1,1,1
11643,dyskinesia,16,17,121,131,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,1,1
11645,steroid,3,4,17,24,Effects of acute steroid administration on ventilatory and peripheral muscles in rats.,8665051_0,0,-1,0
11646,myopathy,7,8,46,54,Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.,8665051_1,-1,1,1
11647,corticosteroids,17,18,107,122,Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.,8665051_1,0,-1,0
11648,myopathy,4,5,22,30,The mechanism of this myopathy is poorly understood.,8665051_2,-1,1,1
11649,methylprednisolone,18,19,89,107,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,0,-1,0
11651,steroid,10,11,77,84,Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment.,8665051_6,0,-1,0
11652,steroid,6,7,43,50,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,0,-1,0
11653,Steroid,0,1,0,7,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,0,-1,0
11654,atrophy,15,16,91,98,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1
11655,steroid,18,19,106,113,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,0,-1,0
11656,atrophy,25,26,153,160,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1
11657,necrosis,40,41,252,260,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1
11659,steroids,12,13,64,72,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0
11660,steroids,27,28,143,151,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0
11661,atrophy,32,33,183,190,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1
11662,steroid,48,49,279,286,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0,-1,0
11663,necrosis,51,52,301,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1
11664,atrophy,58,59,324,331,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,-1,1,1
11665,acetaminophen,3,4,16,29,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,0,-1,0
11666,chronic renal failure,9,12,51,72,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,-1,1,1
11667,phenacetin,16,17,92,102,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,0,-1,0
11668,phenacetin,14,15,88,98,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,0,-1,0
11669,chronic renal failure,21,24,137,158,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,1,1
11671,phenacetin,9,10,40,50,"As a result of these and other studies, phenacetin has now been withdrawn from the market in most countries.",8669433_2,0,-1,0
11672,acetaminophen,27,28,138,151,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,0,-1,0
11673,chronic renal failure,32,35,176,197,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,1,1
11675,phenacetin,5,6,32,42,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,0,-1,0
11676,acetaminophen,7,8,47,60,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,0,-1,0
11678,nephrotoxic,12,13,66,77,This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves.,8669433_5,-1,1,1
11679,acetaminophen,8,9,44,57,A lower relative risk would be expected for acetaminophen if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone.,8669433_6,0,-1,0
11680,acetaminophen,2,3,6,19,"Thus, acetaminophen has been used both as a single agent and in combination with other analgesics, whereas phenacetin was available only in combinations.",8669433_7,0,-1,0
11681,phenacetin,19,20,107,117,"Thus, acetaminophen has been used both as a single agent and in combination with other analgesics, whereas phenacetin was available only in combinations.",8669433_7,0,-1,0
11682,acetaminophen,6,7,37,50,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,0,-1,0
11684,mesna,4,5,42,47,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,0,-1,0
11687,toxicity,6,7,42,50,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,1,1
11688,ifosfamide,8,9,54,64,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0
11689,mesna,15,16,104,109,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0
11690,Mesna,0,1,0,5,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,0,-1,0
11691,mesna,5,6,46,51,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0,-1,0
11692,mesna,19,20,120,125,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0
11693,mesna,29,30,175,180,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0
11694,mesna,6,7,57,62,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0
11695,ifosfamide,24,25,162,172,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0
11696,hypotension,1,2,22,33,Acetaminophen-induced hypotension.,8682684_0,-1,1,1
11697,acetaminophen,7,8,36,49,"Through 30 years of widespread use, acetaminophen has been shown to be a remarkably safe medication in therapeutic dosages.",8682684_1,0,-1,0
11698,acetaminophen,3,4,18,31,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,0,-1,0
11699,toxicities,7,8,58,68,The potential for acetaminophen to produce cardiovascular toxicities is very low.,8682684_2,-1,1,1
11700,acetaminophen,2,3,9,22,"However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.",8682684_3,0,-1,0
11701,anaphylaxis,10,11,68,79,"However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.",8682684_3,-1,1,1
11702,hypotension,13,14,91,102,"However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.",8682684_3,-1,1,1
11703,hypotension,12,13,81,92,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,1,1
11704,acetaminophen,18,19,140,153,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,0,-1,0
11705,allergic reactions,3,5,18,36,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,-1,1,1
11706,hypotensive,1,2,4,15,The hypotensive episodes were severe enough to require vasopressor administration.,8682684_6,-1,1,1
11707,acetaminophen,9,10,59,72,The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.,8682684_7,0,-1,0
11708,hypotension,13,14,90,101,The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.,8682684_7,-1,1,1
11710,lignocaine,11,12,67,77,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0,-1,0
11711,lignocaine,12,13,54,64,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0,-1,0
11712,glucose,18,19,76,83,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0,-1,0
11713,pain,5,6,39,43,Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.,8686832_2,-1,1,1
11714,pain,28,29,134,138,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,1,1
11715,pain,10,11,35,39,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1
11716,pain,22,23,83,87,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,-1,1,1
11717,alcohol,27,28,107,114,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,0,-1,0
11719,lignocaine,14,15,77,87,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0,-1,0
11720,diabetic nephropathy,15,17,127,147,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,1,1
11721,diabetes,18,19,127,135,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,1,1
11722,streptozotocin,20,21,139,153,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0,-1,0
11723,diabetic,9,10,38,46,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,1,1
11724,diabetic,37,38,225,233,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,1,1
11725,Diabetic,0,1,0,8,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,1,1
11726,albuminuria,4,5,38,49,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,1,1
11731,dopamine,10,11,69,77,Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.,869641_0,0,-1,0
11733,norepinephrine,8,9,51,65,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,0,-1,0
11734,norepinephrine,29,30,202,216,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,0,-1,0
11735,hypotension,13,14,74,85,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,1,1
11736,bradycardia,15,16,87,98,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,1,1
11738,norepinephrine,20,21,131,145,Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine.,869641_5,0,-1,0
11739,bradycardia,5,6,29,40,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,-1,1,1
11740,norepinephrine,8,9,51,65,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,0,-1,0
11743,norepinephrine,19,20,101,115,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,0,-1,0
11745,dopamine,7,8,46,54,"Furthermore, the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors.",869641_9,0,-1,0
11746,norepinephrine,10,11,67,81,"Furthermore, the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors.",869641_9,0,-1,0
11747,hemolytic anemia,1,3,17,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,1,1
11749,tacrolimus,6,7,54,64,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0,-1,0
11750,hemolytic anemia,6,8,43,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,1,1
11753,tacrolimus,19,20,108,118,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0,-1,0
11755,corticosteroids,18,19,109,124,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0
11756,aspirin,20,21,126,133,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0
11757,dipyridamole,23,24,139,151,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0
11766,apnoea,5,6,52,58,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,-1,1,1
11767,succinylcholine,10,11,87,102,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,0,-1,0
11768,succinylcholine,16,17,106,121,It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine.,871943_5,0,-1,0
11771,cholestasis,11,12,104,115,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,1,1
11786,renal toxicity,9,11,61,75,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,-1,1,1
11787,nephrotoxic,1,2,4,15,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,1,1
11788,methotrexate,13,14,73,85,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0
11790,5-fluorouracil,18,19,93,107,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0
11792,cyclophosphamide,23,24,119,135,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0
11797,creatinine,4,5,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0
11798,creatinine,22,23,124,134,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0
11800,creatinine,14,15,75,85,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0
11801,creatinine,26,27,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0
11804,creatinine,15,16,92,102,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0
11805,creatinine,21,22,136,146,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0
11807,creatinine,18,19,105,115,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0
11808,creatinine,24,25,141,151,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0
11819,nephrotoxicity,4,5,26,40,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,1,1
11823,nicotine,4,5,38,46,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,0,-1,0
11825,nicotine,25,26,143,151,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,0,-1,0
11826,hyperactivity,46,47,224,237,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,1,1
11827,choline,8,9,62,69,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0,-1,0
11828,tyrosine,23,24,143,151,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0,-1,0
11829,depression,8,9,64,74,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,-1,1,1
11831,acetaminophen,29,30,176,189,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0,-1,0
11832,liver injury,36,38,239,251,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,1,1
11834,ethanol,35,36,197,204,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,0,-1,0
11836,ethanol,24,25,154,161,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,0,-1,0
11838,ethanol,25,26,148,155,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,0,-1,0
11839,liver damage,34,36,188,200,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,1,1
11840,ethanol,42,43,225,232,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,0,-1,0
11841,hepatitis,6,7,27,36,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,1,1
11842,hepatitis,7,8,50,59,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,1,1
11843,ethanol,12,13,84,91,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0,-1,0
11844,acetaminophen,16,17,98,111,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,0,-1,0
11845,hepatic damage,21,23,130,144,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,1,1
11847,Lithium,2,3,12,19,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,0,-1,0
11849,lithium,15,16,90,97,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,0,-1,0
11850,polyuria,19,20,107,115,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1
11851,tremor,21,22,120,126,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1
11852,lithium,25,26,140,147,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,0,-1,0
11853,cognitive deficits,30,32,169,187,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1
11854,bipolar,7,8,51,58,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,1,1
11855,lithium,10,11,73,80,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,0,-1,0
11857,lithium,9,10,53,60,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,0,-1,0
11859,lithium,34,35,210,217,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,0,-1,0
11860,bipolar,37,38,225,232,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,1,1
11862,lithium,14,15,88,95,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,0,-1,0
11863,bipolar,16,17,99,106,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,1,1
11864,hallucinations,2,3,15,29,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,1,1
11865,antidepressants,10,11,79,94,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,0,-1,0
11867,pain,23,24,148,152,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,1,1
11868,paroxetine,7,8,44,54,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0,-1,0
11870,hallucinations,10,11,71,85,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,1,1
11871,pain,9,10,47,51,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,-1,1,1
11872,pain,19,20,119,123,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,-1,1,1
11873,pain,23,24,139,143,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,-1,1,1
11876,Hypotension,2,3,12,23,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,1,1
11878,antidepressants,5,6,35,50,Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues.,8800187_2,0,-1,0
11879,calcium,7,8,59,66,Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues.,8800187_2,0,-1,0
11880,calcium,7,8,43,50,This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.,8800187_3,0,-1,0
11881,hypotension,13,14,104,115,This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.,8800187_3,-1,1,1
11882,overdose,19,20,127,135,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,-1,1,1
11885,hypotension,10,11,82,93,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,1,1
11886,bradycardia,16,17,117,128,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,1,1
11891,hypotension,9,10,41,52,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,1,1
11893,ventricular arrhythmias,3,5,17,40,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,1,1
11894,seizures,11,12,57,65,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,1,1
11897,hypotension,13,14,108,119,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,1,1
11899,toxicity,11,12,81,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,1,1
11900,calcium,8,9,41,48,These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.,8800187_14,0,-1,0
11901,hypotension,17,18,124,135,These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.,8800187_14,-1,1,1
11902,nifedipine,2,3,10,20,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0,-1,0
11903,tacrolimus,11,12,80,90,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0,-1,0
11904,nifedipine,3,4,14,24,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0,-1,0
11905,tacrolimus,14,15,93,103,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0,-1,0
11906,tacrolimus,5,6,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0
11907,hypertensive,18,19,104,116,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,-1,1,1
11908,nifedipine,23,24,145,155,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0
11909,nifedipine,33,34,221,231,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0
11910,Nifedipine,0,1,0,10,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0,-1,0
11911,creatinine,13,14,98,108,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0,-1,0
11912,nifedipine,5,6,32,42,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0,-1,0
11913,nephrotoxicity,9,10,59,73,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,-1,1,1
11914,tacrolimus,12,13,90,100,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0,-1,0
11915,hypertension,28,29,193,205,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,-1,1,1
11916,coma,3,4,15,19,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,-1,1,1
11917,hypoxia,10,11,67,74,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,-1,1,1
11919,alcohol,8,9,58,65,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,0,-1,0
11920,overdose,17,18,111,119,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,1,1
11921,overdose,4,5,28,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,1,1
11922,coma,19,20,124,128,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,1,1
11923,depression,10,11,79,89,The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed.,88336_6,-1,1,1
11924,coma,17,18,124,128,It is suggested that in both situations disturbed reticulo-thalamic interactions are important in the pathogenesis of alpha coma.,88336_7,-1,1,1
11928,hypertension,11,12,73,85,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,1,1
11929,edema,5,6,40,45,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,1,1
11930,hypertension,21,22,118,130,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,1,1
11933,epileptic,7,8,50,59,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,1,1
11934,phenytoin,10,11,75,84,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,0,-1,0
11935,phenytoin,11,12,63,72,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,0,-1,0
11936,atrophy,15,16,99,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,1,1
11937,seizure,10,11,68,75,"Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.",8864707_8,-1,1,1
11938,phenytoin,15,16,99,108,"Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.",8864707_8,0,-1,0
11939,phenytoin,11,12,63,72,"However, multiple regression for the daily dosage, duration of phenytoin treatment and cerebellar volume revealed a correlation of these parameters.",8864707_9,0,-1,0
11940,phenytoin,3,4,17,26,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,0,-1,0
11941,atrophy,11,12,80,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,1,1
11942,phenytoin,17,18,112,121,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,0,-1,0
11943,atrophy,25,26,166,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,1,1
11945,serotonin,3,4,25,34,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,0,-1,0
11946,serotonin,10,11,72,81,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,0,-1,0
11948,confusion,22,23,146,155,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,1,1
11949,agitation,24,25,157,166,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,1,1
11950,hyperthermia,26,27,171,183,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,1,1
11952,serotonin,21,22,117,126,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0,-1,0
11953,Venlafaxine,0,1,0,11,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0
11954,antidepressant,4,5,21,35,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0
11955,serotonin,11,12,72,81,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0
11956,norepinephrine,13,14,86,100,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0
11958,depression,20,21,135,145,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,1,1
11959,venlafaxine,15,16,75,86,He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.,8888541_5,0,-1,0
11961,tremors,13,14,73,80,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,1,1
11962,rigidity,15,16,85,93,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,1,1
11963,myoclonic jerks,19,21,101,116,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,1,1
11964,rigidity,22,23,118,126,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,1,1
11965,diazepam,26,27,130,138,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,0,-1,0
11968,thrombocytopenia,7,8,52,68,His subsequent course was remarkable for non-immune thrombocytopenia which resolved.,8888541_11,-1,1,1
11969,rhabdomyolysis,20,21,107,121,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,-1,1,1
11970,paralysis,12,13,88,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,-1,1,1
11971,hemolytic uremic syndrome,10,13,52,77,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,-1,1,1
11972,hemolytic uremic syndrome,6,9,26,51,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,1,1
11974,oral contraceptives,16,18,76,95,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0,-1,0
11975,heparin,4,5,21,28,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0
11976,dipyridamole,6,7,30,42,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0
11977,anuria,32,33,167,173,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,-1,1,1
11980,hypertension,25,26,152,164,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,1,1
11981,hemolytic anemia,28,30,186,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,1,1
11982,Cyclophosphamide,0,1,0,16,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,0,-1,0
11983,bladder cancer,2,4,28,42,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,-1,1,1
11984,cyclophosphamide,13,14,74,90,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,0,-1,0
11985,cancer,16,17,113,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,1,1
11986,cyclophosphamide,20,21,89,105,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,0,-1,0
11987,bladder cancer,22,24,117,131,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,-1,1,1
11988,tumors,3,4,13,19,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,1,1
11989,carcinoma,11,12,56,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,-1,1,1
11990,cancer,5,6,37,43,The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later.,8911359_6,-1,1,1
11991,Cyclophosphamide,2,3,13,29,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,0,-1,0
11992,tumor,5,6,49,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,1,1
11993,tumors,13,14,89,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,1,1
11994,encephalopathy,3,4,26,40,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,1,1
11998,necrosis,5,6,34,42,Lesions of the capillary included necrosis of endothelial cells.,8919272_5,-1,1,1
11999,necrotic,2,3,13,21,Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions.,8919272_9,-1,1,1
12000,hepatic damage,5,7,30,44,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1
12001,hyperammonemia,9,10,53,67,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1
12003,bleeding,2,3,19,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,1,1
12004,epinephrine,8,9,63,74,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,0,-1,0
12005,allergic reaction,17,19,95,112,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,1,1
12007,rash,7,8,42,46,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,1,1
12008,epinephrine,26,27,143,154,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,0,-1,0
12009,cardiac arrest,3,5,20,34,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,1,1
12011,Epinephrine,0,1,0,11,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,0,-1,0
12012,cardiac arrest,6,8,33,47,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1
12013,allergic reaction,21,23,123,140,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1
12014,hypertension,25,26,152,164,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1
12015,bradykinin,4,5,22,32,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,0,-1,0
12016,hypertension,15,16,100,112,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,-1,1,1
12017,hypertension,11,12,86,98,Cellular mechanisms which account for disruption the blood-brain barrier during acute hypertension are not clear.,8955532_1,-1,1,1
12018,bradykinin,13,14,73,83,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0,-1,0
12019,hypertension,26,27,163,175,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,-1,1,1
12020,dextran,11,12,92,99,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0,-1,0
12021,hypertension,17,18,146,158,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,1,1
12022,Phenylephrine,0,1,0,13,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0
12023,dextran,12,13,101,108,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0
12024,hypertension,11,12,79,91,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,-1,1,1
12025,bradykinin,19,20,135,145,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0,-1,0
12027,glycinamide ribonucleotide,6,8,43,69,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0,-1,0
12028,methotrexate,22,23,150,162,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,0,-1,0
12029,toxicities,16,17,121,131,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,1,1
12030,toxicity,6,7,49,57,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,1,1
12033,toxicity,20,21,132,140,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,1,1
12035,Thrombocytopenia,0,1,0,16,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1
12036,mucositis,2,3,21,30,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1
12037,toxicities,6,7,46,56,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1
12038,toxicity,7,8,49,57,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,1,1
12041,toxicity,21,22,172,180,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,1,1
12042,cancer,13,14,85,91,This information will facilitate the future evaluation of this class of compounds in cancer therapy.,8958188_10,-1,1,1
12043,delirium,2,3,14,22,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,1,1
12044,cocaine,4,5,33,40,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,0,-1,0
12046,deaths,5,6,27,33,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,1,1
12047,delirium,9,10,63,71,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,1,1
12048,deaths,6,7,39,45,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,1,1
12050,delirium,31,32,173,181,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,1,1
12051,death,29,30,155,160,"They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months.",8988571_4,-1,1,1
12052,hyperthermia,42,43,218,230,"They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months.",8988571_4,-1,1,1
12053,cocaine,4,5,27,34,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0,-1,0
12054,benzoylecgonine,6,7,39,54,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0,-1,0
12055,cocaine,11,12,80,87,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0,-1,0
12056,cocaine,22,23,153,160,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0,-1,0
12057,agitation,27,28,182,191,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1
12058,delirium,29,30,193,201,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1
12059,rhabdomyolysis,34,35,230,244,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1
12060,death,38,39,257,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1
12061,sensorineural hearing loss,3,6,16,42,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,1,1
12062,sensorineural hearing loss,28,31,145,171,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,1,1
12066,Ototoxicity,0,1,0,11,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,1,1
12068,aminoglycosides,17,18,121,136,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,0,-1,0
12069,furosemide,19,20,141,151,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,0,-1,0
12072,methylphenidate,14,15,102,117,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,0,-1,0
12076,benzodiazepines,10,11,85,100,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,0,-1,0
12078,overdose,13,14,103,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,1,1
12079,Seizure,0,1,0,7,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,1,1
12082,major depression,7,9,39,55,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,-1,1,1
12083,overdose,11,12,64,72,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,-1,1,1
12084,venlafaxine,13,14,76,87,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,0,-1,0
12085,venlafaxine,5,6,26,37,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,0,-1,0
12086,seizure,15,16,101,108,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,-1,1,1
12087,venlafaxine,10,11,53,64,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0,-1,0
12089,seizure,20,21,117,124,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,1,1
12090,venlafaxine,7,8,62,73,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0,-1,0
12092,seizure,15,16,97,104,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,1,1
12093,superoxide,1,2,11,21,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,0,-1,0
12095,acute liver failure,9,12,72,91,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,1,1
12096,superoxide,2,3,11,21,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,0,-1,0
12099,acute liver failure,20,23,136,155,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,1,1
12101,oxygen,5,6,22,28,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0,-1,0
12106,Superoxide,0,1,0,10,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0,-1,0
12110,Superoxide,0,1,0,10,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0,-1,0
12116,acetaminophen,10,11,79,92,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0,-1,0
12117,adriamycin,12,13,94,104,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0,-1,0
12119,hepatotoxic,29,30,166,177,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,1,1
12122,toxicity,49,50,319,327,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,1,1
12123,hepatotoxic,27,28,132,143,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,1,1
12124,acetaminophen,34,35,168,181,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0,-1,0
12125,cardiotoxic,44,45,239,250,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,1,1
12126,adriamycin,48,49,262,272,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0,-1,0
12128,death,20,21,117,122,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,1,1
12129,hepatotoxicity,31,32,199,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,1,1
12130,hypotension,6,7,55,66,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,1,1
12131,haemodilution,8,9,71,84,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,1,1
12133,hypotension,7,8,62,73,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,1,1
12134,haemodilution,9,10,78,91,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,1,1
12135,hypotension,24,25,116,127,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1
12136,haemodilution,37,38,164,177,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1
12137,hypotension,52,53,233,244,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1
12138,haemodilution,54,55,249,262,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1
12139,Haemodilution,0,1,0,13,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,1,1
12140,dextran,23,24,132,139,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0,-1,0
12141,hypotension,1,2,11,22,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,1,1
12143,hypotension,46,47,212,223,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,1,1
12144,bilirubin,68,69,307,316,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0,-1,0
12145,hypotension,14,15,86,97,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,1,1
12146,haemodilution,17,18,111,124,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,1,1
12147,hyperprolactinemia,9,10,46,64,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,1,1
12148,fluoxetine,12,13,76,86,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,0,-1,0
12149,serotonin,17,18,114,123,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,0,-1,0
12150,fluoxetine,11,12,60,70,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,0,-1,0
12151,hyperprolactinemia,19,20,119,137,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,1,1
12152,Fluoxetine,2,3,8,18,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,0,-1,0
12153,serotonin,5,6,22,31,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,0,-1,0
12154,hyperprolactinemia,20,21,107,125,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,1,1
12155,fluoxetine,12,13,80,90,RESULTS: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups.,9098464_7,0,-1,0
12156,fluoxetine,14,15,99,109,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,0,-1,0
12157,steroids,20,21,128,136,CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.,9098464_9,0,-1,0
12159,calcium,7,8,59,66,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,0,-1,0
12162,nifedipine,10,11,66,76,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0
12163,diltiazem,12,13,78,87,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0
12164,verapamil,15,16,93,102,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0,-1,0
12167,verapamil,27,28,180,189,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,0,-1,0
12168,nifedipine,29,30,194,204,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,0,-1,0
12169,verapamil,21,22,126,135,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,0,-1,0
12170,steroid,7,8,67,74,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,0,-1,0
12172,steroid,11,12,80,87,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,0,-1,0
12173,steroid,4,5,31,38,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,0,-1,0
12174,steroids,1,2,12,20,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0,-1,0
12175,seizures,9,10,81,89,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,1,1
12177,progesterone,5,6,44,56,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0,-1,0
12178,seizures,35,36,298,306,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,1,1
12179,Steroids,0,1,0,8,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,0,-1,0
12180,pilocarpine,21,22,145,156,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,0,-1,0
12181,seizures,29,30,196,204,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,1,1
12183,steroids,3,4,25,33,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0
12184,benzodiazepine,10,11,73,87,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0
12186,steroids,18,19,143,151,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0
12187,seizure,40,41,287,294,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,1,1
12188,steroids,50,51,357,365,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0,-1,0
12189,toxicity,55,56,390,398,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,1,1
12190,Steroids,0,1,0,8,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,0,-1,0
12191,seizures,20,21,128,136,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,1,1
12193,seizures,40,41,221,229,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,1,1
12194,steroid,8,9,35,42,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,0,-1,0
12195,seizures,25,26,143,151,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,1,1
12197,steroids,1,2,4,12,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,0,-1,0
12200,steroids,4,5,29,37,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0,-1,0
12201,seizures,15,16,118,126,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,1,1
12207,nephrotic,42,43,234,243,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,1,1
12213,risperidone,4,5,36,47,Neuroleptic malignant syndrome with risperidone.,9165568_0,0,-1,0
12215,dopamine,10,11,60,68,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,0,-1,0
12216,Risperidone,0,1,0,11,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0,-1,0
12217,serotonin,9,10,64,73,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0,-1,0
12218,extrapyramidal symptoms,11,13,58,81,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,-1,1,1
12219,risperidone,14,15,87,98,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,0,-1,0
12220,extrapyramidal symptoms,5,7,27,50,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,1,1
12223,risperidone,10,11,84,95,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,0,-1,0
12224,risperidone,5,6,42,53,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0
12225,bromocriptine,12,13,97,110,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0
12226,risperidone,11,12,78,89,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,0,-1,0
12228,sumatriptan,7,8,35,46,The site of common side effects of sumatriptan.,9195768_0,0,-1,0
12229,sumatriptan,7,8,54,65,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,0,-1,0
12230,toxicity,1,2,7,15,Macula toxicity after intravitreal amikacin.,9199746_0,-1,1,1
12231,amikacin,4,5,35,43,Macula toxicity after intravitreal amikacin.,9199746_0,0,-1,0
12232,aminoglycosides,4,5,34,49,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,0,-1,0
12234,amikacin,8,9,39,47,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0
12235,toxicity,10,11,56,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,1,1
12236,amikacin,14,15,90,98,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0
12237,vancomycin,16,17,103,113,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0
12238,fluorescein,1,2,7,18,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,0,-1,0
12239,toxicity,10,11,83,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,1,1
12240,toxicity,6,7,47,55,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,1,1
12241,catalepsy,13,14,106,115,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,1,1
12243,catalepsy,1,2,20,29,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,1,1
12245,catalepsy,26,27,211,220,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,1,1
12247,catalepsy,13,14,92,101,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,1,1
12248,propranolol,24,25,163,174,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0,-1,0
12249,propranolol,5,6,22,33,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0
12250,catalepsy,12,13,83,92,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,1,1
12251,propranolol,11,12,68,79,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0
12252,dopamine,5,6,37,45,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,0,-1,0
12253,haloperidol,8,9,55,66,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,0,-1,0
12254,catalepsy,8,9,75,84,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,1,1
12257,dopamine,34,35,281,289,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0,-1,0
12259,tamoxifen,9,10,61,70,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,0,-1,0
12260,tamoxifen,13,14,87,96,BACKGROUND: Increased attention has been focused recently on the estrogenic effects of tamoxifen.,9205462_1,0,-1,0
12261,tamoxifen,8,9,56,65,Review of the literature reveals an association between tamoxifen use and gynecologic tumors.,9205462_2,0,-1,0
12262,tumors,12,13,86,92,Review of the literature reveals an association between tamoxifen use and gynecologic tumors.,9205462_2,-1,1,1
12263,tamoxifen,9,10,58,67,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,0,-1,0
12264,estrogen,13,14,81,89,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,0,-1,0
12265,breast carcinoma,15,17,108,124,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,-1,1,1
12266,aspartate,1,2,4,13,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0,-1,0
12267,alanine,4,5,31,38,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0,-1,0
12268,tamoxifen,13,14,95,104,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0,-1,0
12272,tamoxifen,20,21,139,148,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,0,-1,0
12276,anemia,5,6,29,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,1,1
12280,phosphate,24,25,136,145,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,0,-1,0
12285,thrombocytopenia,9,10,51,67,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,1,1
12287,ketamine,16,17,89,97,Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine.,921394_0,0,-1,0
12288,ketamine,2,3,10,18,Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery.,921394_1,0,-1,0
12289,ketamine,2,3,14,22,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,0,-1,0
12290,depression,16,17,86,96,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,1,1
12291,depression,1,2,5,15,This depression was followed by the sudden appearance of a stimulatory phase.,921394_3,-1,1,1
12292,tachycardia,19,20,140,151,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,-1,1,1
12293,ketamine,23,24,145,153,This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery.,921394_5,0,-1,0
12294,tumors,17,18,128,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,1,1
12295,tumor,21,22,166,171,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,1,1
12296,cancers,13,14,77,84,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,1,1
12297,tumor,17,18,97,102,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,1,1
12298,tumor,4,5,27,32,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,1,1
12299,estrogen,9,10,64,72,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,0,-1,0
12300,estrogen,5,6,25,33,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0,-1,0
12301,tumor,10,11,55,60,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,1,1
12304,tumor,2,3,9,14,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,1,1
12308,estrogen,27,28,147,155,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,0,-1,0
12309,tumor,29,30,164,169,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,-1,1,1
12311,lithium,5,6,52,59,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,0,-1,0
12312,dehydration,11,12,68,79,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,1,1
12314,lithium,15,16,103,110,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,0,-1,0
12315,lithium,8,9,54,61,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,0,-1,0
12316,vasopressin,21,22,145,156,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,0,-1,0
12318,Lithium,0,1,0,7,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,0,-1,0
12320,polyuria,15,16,106,114,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,1,1
12321,lithium,24,25,161,168,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,0,-1,0
12323,amnesia,7,8,61,68,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,1,1
12324,amnesia,7,8,61,68,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,1,1
12325,amnesia,8,9,62,69,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,1,1
12327,amnesia,12,13,61,68,All compounds at 0.1-1 mg/kg p.o. significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.,9228650_6,-1,1,1
12328,scopolamine,15,16,80,91,All compounds at 0.1-1 mg/kg p.o. significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.,9228650_6,0,-1,0
12329,amnesia,19,20,98,105,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,1,1
12331,nicotine,3,4,12,20,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,0,-1,0
12333,Nicotine,0,1,0,8,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,0,-1,0
12335,nicotine,7,8,53,61,"Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.",9245658_2,0,-1,0
12336,atherosclerosis,14,15,96,111,"Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.",9245658_2,-1,1,1
12337,nicotine,3,4,18,26,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0,-1,0
12338,nicotine,22,23,154,162,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0,-1,0
12339,smoking,34,35,235,242,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0,-1,0
12341,Nicotine,0,1,0,8,Nicotine does not appear to enhance thrombosis among humans.,9245658_4,0,-1,0
12342,thrombosis,6,7,36,46,Nicotine does not appear to enhance thrombosis among humans.,9245658_4,-1,1,1
12343,nicotine,9,10,62,70,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,0,-1,0
12344,nicotine,17,18,111,119,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,0,-1,0
12345,nicotine,9,10,56,64,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,0,-1,0
12346,nicotine,18,19,104,112,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,0,-1,0
12347,tachycardia,5,6,62,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,1,1
12348,verapamil,7,8,80,89,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,0,-1,0
12349,dilated cardiomyopathy,19,21,176,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,1,1
12350,dilated cardiomyopathy,8,10,46,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,1,1
12351,tachycardia,14,15,109,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,1,1
12352,verapamil,10,11,67,76,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,0,-1,0
12353,dopamine,6,7,43,51,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0,-1,0
12354,parkinsonian,17,18,100,112,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,1,1
12355,dopamine,4,5,24,32,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,0,-1,0
12361,dyskinesias,18,19,183,194,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,1,1
12363,Levodopa,0,1,0,8,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0,-1,0
12365,parkinsonism,10,11,79,91,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,1,1
12366,levodopa,12,13,95,103,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0,-1,0
12367,dyskinesias,24,25,173,184,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,1,1
12368,levodopa,36,37,256,264,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0,-1,0
12370,levodopa,34,35,207,215,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,0,-1,0
12374,liver disease,2,4,12,25,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,1,1
12375,hepatotoxicity,6,7,46,60,Limited studies in animals indicate potential hepatotoxicity of some of these compounds.,9284778_2,-1,1,1
12376,liver disease,5,7,31,44,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,1,1
12377,"1,1-dichloro-2,2,2-trifluoroethane",21,22,129,163,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0
12378,"1-chloro-1,2,2,2-tetrafluoroethane",27,28,179,213,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0
12379,"1-bromo-1-chloro-2,2,2-trifluoroethane",9,10,50,88,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0
12380,halothane,11,12,90,99,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0
12381,hepatotoxicity,26,27,190,204,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,1,1
12382,halothane,28,29,208,217,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0
12383,liver disease,13,15,65,78,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,1,1
12384,necrosis,8,9,56,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,1,1
12385,necrosis,30,31,202,210,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,1,1
12387,liver injury,16,18,93,105,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,1,1
12388,hepatotoxicity,5,6,32,46,"Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.",9284778_13,-1,1,1
12389,danazol,10,11,75,82,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,0,-1,0
12390,danazol,18,19,95,102,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,0,-1,0
12391,pilocarpine,4,5,39,50,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,0,-1,0
12392,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1
12393,temporal lobe epilepsy,19,22,121,143,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,1,1
12395,pilocarpine,1,2,4,15,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,0,-1,0
12396,epilepsy,7,8,32,40,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,1,1
12398,seizures,21,22,133,141,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,1,1
12402,dyskinesias,69,70,376,387,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,1,1
12403,dyskinesias,90,91,488,499,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,1,1
12404,dyskinesias,3,4,20,31,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,1,1
12405,parkinsonism,10,11,68,80,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,1,1
12406,rigidity,16,17,114,122,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,1,1
12407,dyskinesias,4,5,31,42,"The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.",9321531_6,-1,1,1
12409,dyskinesias,12,13,99,110,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,1,1
12410,ventricular tachycardia,1,3,23,46,Clarithromycin-induced ventricular tachycardia.,9326871_0,-1,1,1
12411,Cardiotoxicity,0,1,0,14,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,1,1
12413,testosterone,8,9,42,54,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,0,-1,0
12415,Testosterone,4,5,23,35,MATERIALS AND METHODS: Testosterone and prolactin were determined by radioimmunoassay.,9334596_2,0,-1,0
12416,testosterone,5,6,31,43,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,0,-1,0
12417,low sexual desire,16,19,96,113,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,1,1
12418,testosterone,22,23,131,143,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,0,-1,0
12420,low sexual desire,10,13,81,98,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,1,1
12421,testosterone,4,5,31,43,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0
12423,bromocriptine,13,14,107,120,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0
12424,hyperprolactinemia,15,16,125,143,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,1,1
12425,Testosterone,2,3,9,21,RESULTS: Testosterone was less than 3 ng./ml.,9334596_8,0,-1,0
12426,testosterone,5,6,33,45,The prevalence of repeatedly low testosterone increased with age (4% before age 50 years and 9% 50 years or older).,9334596_10,0,-1,0
12427,tumors,2,3,14,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,1,1
12428,testosterone,6,7,43,55,Two pituitary tumors were discovered after testosterone determination.,9334596_11,0,-1,0
12429,testosterone,5,6,22,34,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,0,-1,0
12432,testosterone,1,2,12,24,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,0,-1,0
12433,low sexual desire,6,9,42,59,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,1,1
12434,testosterone,23,24,137,149,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,0,-1,0
12435,prolactinoma,2,3,7,19,Only 1 prolactinoma was discovered.,9334596_16,-1,1,1
12436,Bromocriptine,0,1,0,13,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,0,-1,0
12437,Testosterone,0,1,0,12,Testosterone was low in less than 50% of cases with prolactin greater than 35 ng./ml.,9334596_21,0,-1,0
12438,testosterone,8,9,48,60,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,0,-1,0
12440,tumors,22,23,140,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,1,1
12441,testosterone,8,9,41,53,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,0,-1,0
12442,low sexual desire,15,18,85,102,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,-1,1,1
12443,low sexual desire,8,11,48,65,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,1,1
12444,testosterone,14,15,87,99,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,0,-1,0
12445,risperidone,4,5,33,44,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0,-1,0
12446,haloperidol,6,7,49,60,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0,-1,0
12447,Risperidone,0,1,0,11,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0,-1,0
12448,dopamine,9,10,59,67,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0,-1,0
12449,serotonin,12,13,75,84,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0,-1,0
12450,risperidone,6,7,45,56,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,0,-1,0
12451,psychotic symptoms,16,18,124,142,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,1,1
12453,risperidone,4,5,24,35,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0
12454,risperidone,38,39,241,252,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0
12455,haloperidol,45,46,265,276,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0
12456,risperidone,1,2,5,16,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0,-1,0
12457,haloperidol,3,4,21,32,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0,-1,0
12458,haloperidol,10,11,75,86,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0,-1,0
12459,risperidone,12,13,90,101,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0,-1,0
12460,parkinsonism,1,2,13,25,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,-1,1,1
12461,risperidone,8,9,64,75,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,0,-1,0
12462,haloperidol,14,15,86,97,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,0,-1,0
12463,risperidone,13,14,79,90,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0,-1,0
12464,breast cancer,5,7,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1
12465,mitoxantrone,8,9,60,72,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0,-1,0
12467,toxicity,27,28,195,203,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1
12468,breast cancer,4,6,32,45,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,-1,1,1
12469,mitoxantrone,3,4,30,42,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0
12470,5-fluorouracil,6,7,54,68,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0
12472,breast cancer,15,17,107,120,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,1,1
12473,mitoxantrone,18,19,124,136,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0,-1,0
12476,anthracycline,6,7,37,50,Seven patients had been treated with anthracycline.,9390208_6,0,-1,0
12477,mitoxantrone,16,17,88,100,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0,-1,0
12478,toxicities,1,2,6,16,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1
12479,cardiotoxicity,3,4,22,36,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1
12480,leukopenia,5,6,41,51,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1
12481,toxicity,15,16,86,94,Eight patients were dead in the last follow-up; two of them died of treatment-related toxicity.,9390208_16,-1,1,1
12482,toxicity,10,11,70,78,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,1,1
12483,breast cancer,5,7,34,47,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,1,1
12484,aplastic anemia,1,3,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,-1,1,1
12485,aplastic anemia,9,11,63,78,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,-1,1,1
12486,ticlopidine,9,10,56,67,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,0,-1,0
12487,bone marrow suppression,17,20,95,118,There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression.,9401499_6,-1,1,1
12488,aplastic anemia,3,5,34,49,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,-1,1,1
12490,vasopressin,5,6,34,45,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,0,-1,0
12494,lithium,26,27,137,144,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0,-1,0
12495,polyuria,28,29,158,166,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,1,1
12497,polyuria,19,20,100,108,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,1,1
12498,sodium,1,2,7,13,Plasma sodium concentrations were found to be slightly increased in the Li-treated rats compared with those in controls.,9406968_4,0,-1,0
12504,spasm,9,10,55,60,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,1,1
12505,spasm,16,17,113,118,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,1,1
12506,dyskinesia,27,28,180,190,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,1,1
12507,spasm,5,6,26,31,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,1,1
12508,morphine,19,20,129,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,0,-1,0
12509,spasm,107,108,453,458,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,1,1
12510,spasm,20,21,139,144,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,1,1
12511,morphine,12,13,73,81,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,0,-1,0
12512,dyskinesia,26,27,146,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,1,1
12516,atropine,12,13,98,106,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12517,acetylcholine,22,23,173,186,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12518,naloxone,32,33,246,254,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12519,5-hydroxytryptamine4,52,53,419,439,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12520,5-hydroxytryptamine4,52,53,419,439,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12521,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12522,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12523,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12525,reserpine,69,70,667,676,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0
12526,amnesia,14,15,52,59,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,1,1
12527,scopolamine,17,18,71,82,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,0,-1,0
12528,acetylcholine,67,68,396,409,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0,-1,0
12529,rheumatoid arthritis,3,5,19,39,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1
12530,proteinuria,7,8,56,67,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1
12531,hyperactivity,22,23,151,164,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,-1,1,1
12532,glomerulonephritis,9,10,55,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,1,1
12533,pain,2,3,21,25,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,-1,1,1
12534,capsaicin,5,6,38,47,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,0,-1,0
12536,headache,28,29,159,167,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,1,1
12537,headache,35,36,190,198,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,1,1
12538,migraine,12,13,68,76,It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'.,9514561_2,-1,1,1
12539,migraine,21,22,121,129,It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'.,9514561_2,-1,1,1
12540,pain,8,9,53,57,"To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients.",9514561_3,-1,1,1
12541,migraine,26,27,149,157,"To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients.",9514561_3,-1,1,1
12542,capsaicin,4,5,18,27,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,0,-1,0
12543,migraine,11,12,67,75,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,1,1
12545,pain,27,28,157,161,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,1,1
12546,pain,26,27,158,162,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1
12547,headache,37,38,206,214,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,1,1
12551,sensorineural hearing loss,21,24,113,139,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,-1,1,1
12554,prilocaine,14,15,72,82,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0
12555,bupivacaine,24,25,115,126,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0
12556,prilocaine,2,3,15,25,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0
12558,bupivacaine,19,20,99,110,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0
12560,prilocaine,12,13,70,80,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0
12561,bupivacaine,17,18,97,108,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0
12563,bupivacaine,11,12,82,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0,-1,0
12564,bupivacaine,21,22,130,141,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,0,-1,0
12565,prilocaine,11,12,78,88,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0
12566,bupivacaine,13,14,93,104,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0
12567,lidocaine,16,17,115,124,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0
12569,lidocaine,14,15,97,106,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0
12570,bupivacaine,21,22,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0
12571,lidocaine,11,12,77,86,"However, identification of a short-acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal.",9523805_2,0,-1,0
12572,Prilocaine,0,1,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0
12573,lidocaine,15,16,85,94,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0
12574,prilocaine,9,10,66,76,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0
12575,lidocaine,11,12,82,91,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0
12576,bupivacaine,13,14,96,107,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0
12579,glucose,38,39,240,247,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0
12580,prilocaine,42,43,252,262,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0
12581,glucose,46,47,271,278,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0
12582,bupivacaine,51,52,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0
12583,glucose,55,56,308,315,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0
12585,lidocaine,7,8,39,48,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0
12587,prilocaine,16,17,94,104,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0
12588,bupivacaine,31,32,160,171,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0
12590,lidocaine,9,10,49,58,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0
12591,prilocaine,11,12,63,73,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0
12592,bupivacaine,28,29,146,157,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0
12593,Prilocaine,2,3,13,23,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0,-1,0
12594,lidocaine,7,8,45,54,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0,-1,0
12596,methylprednisolone,2,3,9,27,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0,-1,0
12599,methylprednisolone,21,22,128,146,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0,-1,0
12601,Cisapride,0,1,0,9,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0,-1,0
12604,cisapride,12,13,75,84,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0,-1,0
12606,diltiazem,18,19,126,135,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0,-1,0
12607,hypertension,30,31,188,200,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,1,1
12608,syncope,5,6,24,31,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,1,1
12609,cisapride,2,3,20,29,"After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.",9545159_5,0,-1,0
12610,cisapride,7,8,38,47,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0,-1,0
12611,diltiazem,18,19,109,118,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0,-1,0
12612,parkinsonian,4,5,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1
12613,dyskinesia,9,10,85,95,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1
12614,parkinsonian,33,34,195,207,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,1,1
12615,dyskinesia,45,46,276,286,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,1,1
12616,dyskinesia,57,58,334,344,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,1,1
12618,parkinsonian,2,3,15,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,1,1
12619,parkinsonian,21,22,151,163,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,1,1
12620,dyskinesia,18,19,131,141,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,1,1
12621,levofloxacin,3,4,25,37,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,0,-1,0
12622,levofloxacin,9,10,48,60,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,0,-1,0
12624,levofloxacin,7,8,43,55,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,0,-1,0
12625,diarrhea,7,8,49,57,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,1,1
12626,nausea,12,13,75,81,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,1,1
12627,levofloxacin,9,10,52,64,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0,-1,0
12628,carcinoma,4,5,32,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1
12629,breast cancer,8,10,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1
12630,Cancer,12,13,54,60,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1
12631,tamoxifen,14,15,76,85,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,0,-1,0
12632,breast cancer,19,21,104,117,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1
12633,breast cancer,30,32,172,185,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1
12634,endometrial cancer,6,8,45,63,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1
12635,tamoxifen,9,10,68,77,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,0,-1,0
12636,breast cancer,18,20,123,136,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1
12637,endometrial cancer,2,4,9,27,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1
12638,breast cancer,6,8,44,57,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1
12639,breast cancer,24,26,123,136,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1
12640,tamoxifen,4,5,23,32,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,0,-1,0
12641,endometrial cancer,11,13,72,90,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,1,1
12642,tamoxifen,24,25,132,141,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,0,-1,0
12643,tamoxifen,11,12,65,74,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,0,-1,0
12644,endometrial cancer,3,5,14,32,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1
12645,tamoxifen,8,9,50,59,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,0,-1,0
12646,endometrial cancer,19,21,123,141,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1
12647,tamoxifen,7,8,37,46,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,0,-1,0
12648,endometrial cancer,9,11,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1
12649,breast cancer,19,21,119,132,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1
12650,breast cancer,11,13,74,87,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,1,1
12651,cancers,1,2,12,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,-1,1,1
12652,tamoxifen,7,8,52,61,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,0,-1,0
12653,tamoxifen,3,4,18,27,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,0,-1,0
12654,breast cancer,5,7,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,1,1
12655,tamoxifen,8,9,52,61,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,0,-1,0
12656,breast cancer,14,16,92,105,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,-1,1,1
12657,cardiac arrest,1,3,22,36,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,1,1
12658,death,4,5,41,46,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,1,1
12659,cardiac arrest,7,9,39,53,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,1,1
12660,death,11,12,69,74,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,1,1
12661,suxamethonium,21,22,125,138,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,0,-1,0
12662,meningitis,9,10,45,55,"Five days after the onset of the symptoms of meningitis, the patient aspirated stomach contents and needed endotracheal intubation.",9587734_2,-1,1,1
12663,suxamethonium,5,6,33,46,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,0,-1,0
12664,bradycardia,7,8,48,59,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,-1,1,1
12665,cardiac arrest,9,11,64,78,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,-1,1,1
12666,potassium,4,5,19,28,The serum level of potassium was observed to be 8.4 mequiv L-1.,9587734_5,0,-1,0
12667,suxamethonium,35,36,213,226,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,0,-1,0
12668,death,5,6,26,31,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,-1,1,1
12669,hypersensitivity,9,10,46,62,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,-1,1,1
12670,suxamethonium,11,12,66,79,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0,-1,0
12671,hepatitis,1,2,6,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1
12672,autoimmune hemolytic anemia,3,6,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1
12673,ceftriaxone,11,12,84,95,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,0,-1,0
12674,hepatitis,5,6,33,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,1,1
12675,ceftriaxone,10,11,72,83,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,0,-1,0
12676,bilirubin,21,22,142,151,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,0,-1,0
12677,autoimmune hemolytic anemia,31,34,208,235,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,1,1
12678,steroids,4,5,28,36,These responded to systemic steroids and immunoglobulins.,9625142_3,0,-1,0
12679,glycine,3,4,20,27,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,0,-1,0
12681,glycine,13,14,67,74,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,0,-1,0
12684,haloperidol,5,6,31,42,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,0,-1,0
12685,"5,7-dichlorokynurenic acid",0,2,0,26,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0,-1,0
12687,glycine,8,9,51,58,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0,-1,0
12690,haloperidol,22,23,145,156,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,0,-1,0
12691,glycine,8,9,49,56,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,0,-1,0
12693,Carboplatin,0,1,0,11,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,0,-1,0
12694,carboplatin,6,7,33,44,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0
12695,cisplatin,13,14,71,80,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0
12696,neurotoxic,23,24,120,130,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,1,1
12697,neurotoxic,13,14,84,94,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,1,1
12698,Neurotoxicity,0,1,0,13,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,-1,1,1
12699,neurotoxicity,7,8,64,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,1,1
12700,Pain,0,1,0,4,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,-1,1,1
12701,neurotoxic,4,5,22,32,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,1,1
12702,neurotoxicity,31,32,167,180,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,1,1
12704,thyroxine,28,29,180,189,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,0,-1,0
12705,dopamine,3,4,30,38,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,0,-1,0
12707,antidepressant,9,10,43,57,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0,-1,0
12708,noradrenaline,24,25,141,154,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0,-1,0
12709,5-hydroxytryptamine,26,27,159,178,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0,-1,0
12710,antidepressant,4,5,21,35,The mechanism of its antidepressant activity is still unknown.,9660111_2,0,-1,0
12712,antidepressants,33,34,203,218,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,0,-1,0
12716,5-hydroxytryptophan,23,24,123,142,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,0,-1,0
12718,locomotor hyperactivity,7,9,43,66,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,1,1
12719,dopamine,17,18,146,154,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0,-1,0
12720,apomorphine,6,7,45,56,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,0,-1,0
12722,phenylephrine,7,8,49,62,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,0,-1,0
12723,aggressiveness,25,26,147,161,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,-1,1,1
12724,clonidine,28,29,172,181,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,0,-1,0
12725,antidepressants,9,10,47,62,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0,-1,0
12727,dopamine,21,22,142,150,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0,-1,0
12728,antidepressants,18,19,115,130,"A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants, suggested to be responsible for the antidepressant activity.",9660111_10,0,-1,0
12729,antidepressant,26,27,168,182,"A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants, suggested to be responsible for the antidepressant activity.",9660111_10,0,-1,0
12730,cisapride,2,3,11,20,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,0,-1,0
12734,cisapride,15,16,82,91,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,0,-1,0
12736,cisapride,32,33,188,197,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0,-1,0
12737,cisapride,14,15,124,133,RESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.,9669632_4,0,-1,0
12738,cisapride,23,24,135,144,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0
12739,cisapride,59,60,282,291,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0
12740,cisapride,95,96,436,445,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0
12741,constipation,7,8,43,55,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,1,1
12742,cisapride,29,30,164,173,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,-1,0
12743,pain,6,7,48,52,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,1,1
12744,cisapride,9,10,65,74,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0
12745,cisapride,25,26,122,131,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0
12746,Cisapride,2,3,12,21,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,0,-1,0
12747,breast cancer,2,4,14,27,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,-1,1,1
12748,tamoxifen,5,6,33,42,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,0,-1,0
12749,Tamoxifen,1,2,8,17,Italian Tamoxifen Prevention Study.,9672273_1,0,-1,0
12750,Tamoxifen,2,3,12,21,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,0,-1,0
12751,breast cancer,9,11,62,75,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1
12752,endometrial cancer,22,24,137,155,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1
12753,tamoxifen,9,10,53,62,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,0,-1,0
12754,tamoxifen,16,17,93,102,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,0,-1,0
12755,breast cancer,28,30,147,160,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,-1,1,1
12756,tamoxifen,5,6,33,42,"Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years.",9672273_5,0,-1,0
12757,deaths,8,9,48,54,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,1,1
12758,breast cancer,10,12,60,73,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,1,1
12759,breast cancer,3,5,12,25,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1
12760,deaths,13,14,62,68,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1
12761,breast cancer,15,17,74,87,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1
12762,tamoxifen,15,16,85,94,There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms.,9672273_13,0,-1,0
12763,breast cancer,7,9,50,63,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1
12764,tamoxifen,12,13,86,95,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,0,-1,0
12765,breast cancer,38,40,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1
12766,tamoxifen,49,50,304,313,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,0,-1,0
12768,tamoxifen,20,21,134,143,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,0,-1,0
12769,breast cancer,19,21,115,128,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,-1,1,1
12770,tamoxifen,27,28,167,176,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,0,-1,0
12771,tamoxifen,11,12,77,86,Women using hormone-replacement therapy appear to have benefited from use of tamoxifen.,9672273_17,0,-1,0
12772,deaths,3,4,14,20,There were no deaths from breast cancer recorded in women in the study.,9672273_18,-1,1,1
12773,breast cancer,5,7,26,39,There were no deaths from breast cancer recorded in women in the study.,9672273_18,-1,1,1
12774,tamoxifen,14,15,86,95,It is essential to continue follow-up to quantify the long-term risks and benefits of tamoxifen therapy.,9672273_19,0,-1,0
12775,seizure,1,2,21,28,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,1,1
12776,pethidine,7,8,63,72,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,0,-1,0
12777,pain,10,11,91,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,-1,1,1
12778,pethidine,9,10,67,76,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0,-1,0
12779,pain,22,23,155,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,1,1
12781,seizure,8,9,65,72,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,1,1
12782,pethidine,2,3,12,21,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0,-1,0
12783,toxicity,6,7,30,38,No other risk factors for CNS toxicity were identified.,9672936_4,-1,1,1
12784,pethidine,6,7,44,53,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0
12785,pethidine,15,16,104,113,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0
12786,pethidine,4,5,19,28,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,0,-1,0
12787,adrenaline,10,11,64,74,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,0,-1,0
12789,agitation,11,12,67,76,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,1,1
12791,adrenaline,47,48,297,307,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,0,-1,0
12792,labetalol,4,5,36,45,"After intravenous administration of labetalol, metoprolol and midazolam the patient's condition improved, and 15 min later he woke up.",9698967_2,0,-1,0
12793,metoprolol,6,7,47,57,"After intravenous administration of labetalol, metoprolol and midazolam the patient's condition improved, and 15 min later he woke up.",9698967_2,0,-1,0
12794,midazolam,8,9,62,71,"After intravenous administration of labetalol, metoprolol and midazolam the patient's condition improved, and 15 min later he woke up.",9698967_2,0,-1,0
12796,adrenaline,20,21,132,142,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,0,-1,0
12797,cholestasis,13,14,82,93,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,1,1
12798,hypersensitivity,7,8,70,86,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,1,1
12799,infection,18,19,136,145,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,1,1
12800,ibuprofen,28,29,194,203,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,0,-1,0
12802,prednisone,6,7,43,53,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0
12803,tacrolimus,10,11,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0
12804,cirrhosis,19,20,122,131,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,1,1
12805,primary pulmonary hypertension,3,6,18,48,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,-1,1,1
12806,appetite suppressants,8,10,65,86,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,0,-1,0
12807,Primary pulmonary hypertension,0,3,0,30,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,1,1
12808,appetite suppressants,20,22,127,148,The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants.,9727773_2,0,-1,0
12809,primary pulmonary hypertension,3,6,26,56,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,-1,1,1
12810,appetite suppressants,7,9,50,71,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,0,-1,0
12811,appetite suppressants,12,14,63,84,"Five patients died before the interview, all of them had taken appetite suppressants.",9727773_6,0,-1,0
12812,primary pulmonary hypertension,6,9,31,61,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,-1,1,1
12813,appetite suppressants,17,19,97,118,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,0,-1,0
12814,appetite suppressants,7,9,37,58,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,0,-1,0
12815,appetite suppressants,6,8,41,62,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,0,-1,0
12816,primary pulmonary hypertension,16,19,106,136,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,1,1
12817,appetite suppressants,2,4,10,31,Intake of appetite suppressants may accelerate the progression of the disease.,9727773_10,0,-1,0
12818,carbamazepine,3,4,21,34,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0
12819,vigabatrin,5,6,39,49,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0
12820,seizures,9,10,69,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,1,1
12821,Carbamazepine,0,1,0,13,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0,-1,0
12822,vigabatrin,2,3,18,28,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0,-1,0
12823,seizures,8,9,68,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,1,1
12824,carbamazepine,17,18,114,127,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,0,-1,0
12825,Vigabatrin,0,1,0,10,Vigabatrin was also used in the treatment of two children.,9746003_3,0,-1,0
12826,carbamazepine,9,10,62,75,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0
12827,myoclonic jerks,15,17,103,118,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,-1,1,1
12828,carbamazepine,23,24,152,165,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0
12829,vigabatrin,7,8,45,55,Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.,9746003_5,0,-1,0
12831,methadone,7,8,61,70,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,0,-1,0
12833,cocaine,12,13,103,110,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,0,-1,0
12834,methadone,22,23,152,161,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,0,-1,0
12835,cocaine,30,31,209,216,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,0,-1,0
12839,epileptic,25,26,173,182,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,1,1
12841,epileptic,4,5,15,24,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,1,1
12843,epileptic,1,2,4,13,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,1,1
12845,seizures,7,8,44,52,Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.,9758264_4,-1,1,1
12846,epileptic,2,3,17,26,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,1,1
12847,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0
12850,epileptic,3,4,17,26,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,1,1
12853,seizures,38,39,214,222,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,1,1
12855,epileptic,15,16,64,73,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,1,1
12862,extrapyramidal symptoms,12,14,91,114,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1
12865,orthostatic hypotension,37,39,232,255,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1
12866,sexual dysfunction,47,49,304,322,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1
12870,sexual dysfunction,29,31,167,185,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1
12871,seizure,36,37,212,219,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1
12872,clozapine,40,41,241,250,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,0,-1,0
12873,clozapine,46,47,274,283,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,0,-1,0
12874,Stroke,0,1,0,6,Stroke and cocaine or amphetamine use.,9799166_0,-1,1,1
12875,cocaine,2,3,11,18,Stroke and cocaine or amphetamine use.,9799166_0,0,-1,0
12876,amphetamine,4,5,22,33,Stroke and cocaine or amphetamine use.,9799166_0,0,-1,0
12877,cocaine,3,4,19,26,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,0,-1,0
12878,amphetamine,5,6,31,42,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,0,-1,0
12879,hemorrhagic,8,9,52,63,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,1,1
12880,ischemic stroke,10,12,68,83,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,1,1
12881,stroke,7,8,47,53,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,-1,1,1
12882,cocaine,11,12,65,72,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,0,-1,0
12883,amphetamine,13,14,80,91,The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.,9799166_2,0,-1,0
12884,strokes,6,7,38,45,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,1,1
12885,stroke,4,5,25,31,"There were 347 confirmed stroke cases and 1,021 controls.",9799166_7,-1,1,1
12886,stroke,6,7,38,44,The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).,9799166_8,-1,1,1
12887,cocaine,13,14,76,83,The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).,9799166_8,0,-1,0
12888,amphetamine,15,16,91,102,The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).,9799166_8,0,-1,0
12889,cocaine,15,16,95,102,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,0,-1,0
12890,amphetamine,17,18,110,121,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,0,-1,0
12891,cocaine,3,4,11,18,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,0,-1,0
12892,amphetamine,5,6,26,37,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,0,-1,0
12893,stroke,12,13,66,72,"The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.",9799166_10,-1,1,1
12894,haloperidol,7,8,58,69,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,0,-1,0
12897,haloperidol,19,20,95,106,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,0,-1,0
12900,haloperidol,16,17,89,100,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0,-1,0
12901,haloperidol,28,29,134,145,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0,-1,0
12903,haloperidol,17,18,104,115,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0,-1,0
12904,haloperidol,34,35,218,229,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0,-1,0
12905,haloperidol,12,13,66,77,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,0,-1,0
12906,haloperidol,20,21,124,135,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,0,-1,0
12907,Psychiatric,28,29,172,183,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,1,1
12910,haloperidol,1,2,9,20,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,0,-1,0
12911,haloperidol,10,11,71,82,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,0,-1,0
12912,haloperidol,6,7,44,55,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,0,-1,0
12919,acetylsalicylic acid,2,4,11,31,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0
12920,dipyridamole,5,6,33,45,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0
12921,hydrocortisone,8,9,51,65,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0
12922,myocardial injury,11,13,89,106,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,-1,1,1
12923,myocardial injury,6,8,43,60,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,-1,1,1
12924,epinephrine,9,10,62,73,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,0,-1,0
12925,acute myocardial infarction,30,33,199,226,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,-1,1,1
12926,epinephrine,2,3,13,24,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,0,-1,0
12927,calcium,3,4,29,36,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,0,-1,0
12930,calcium,8,9,56,63,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,0,-1,0
12931,calcium,5,6,29,36,per liter failed to increase calcium influx into the myocardial cell.,983936_5,0,-1,0
12932,acetylsalicylic acid,10,12,91,111,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0
12933,dipyridamole,13,14,115,127,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0
12934,hydrocortisone,16,17,136,150,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0
12935,epinephrine,21,22,168,179,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0
12936,calcium,1,2,11,18,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,0,-1,0
12938,Acetylsalicylic acid,0,2,0,20,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0
12939,dipyridamole,3,4,22,34,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0
12940,hydrocortisone,6,7,40,54,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0
12941,anthracycline,6,7,37,50,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,0,-1,0
12942,cardiomyopathy,16,17,112,126,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,1,1
12943,cardiotoxic,8,9,51,62,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,1,1
12944,cardiotoxicity,21,22,144,158,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,1,1
12945,doxorubicin,24,25,174,185,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,0,-1,0
12946,doxorubicin,23,24,122,133,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,0,-1,0
12947,doxorubicin,7,8,43,54,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,0,-1,0
12948,cardiomyopathy,23,24,165,179,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,1,1
12949,cardiotoxic,5,6,36,47,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,1,1
12950,cardiomyopathy,11,12,77,91,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,1,1
12951,doxorubicin,20,21,131,142,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,0,-1,0
12952,doxorubicin,12,13,71,82,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,0,-1,0
12953,cardiotoxic,2,3,14,25,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,-1,1,1
12954,doxorubicin,9,10,66,77,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,0,-1,0
12955,cardiomyopathy,13,14,69,83,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,1,1
12956,cardiotoxicity,11,12,62,76,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,1,1
12957,cardiotoxicity,17,18,125,139,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,1,1
12958,tacrolimus,9,10,74,84,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0,-1,0
12960,tacrolimus,17,18,119,129,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0,-1,0
12962,nephropathy,38,39,145,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,1,1
12968,fibrosis,40,41,248,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,1,1
12969,creatinine,2,3,10,20,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0,-1,0
12973,cholestasis,15,16,117,128,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,-1,1,1
12974,cholestasis,6,7,40,51,"Although hepatocyte TJs are impaired in cholestasis, attempts to localize the precise site of hepatocyte TJ damage by freeze-fracture electron microscopy have produced limited information.",9862868_2,-1,1,1
12975,cholestasis,6,7,35,46,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1
12978,cholestasis,16,17,100,111,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,1,1
12981,valvular heart disease,2,5,9,31,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,1,1
12982,mitral regurgitation,16,18,98,118,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,1,1
12983,mitral regurgitation,43,45,266,286,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,1,1
12984,valvular heart disease,22,25,98,120,"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.",9867728_8,-1,1,1
12986,valvular heart disease,10,13,54,76,CONCLUSION: Users of diet medications are at risk for valvular heart disease.,9867728_11,-1,1,1
12988,acetylcholine,12,13,87,100,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0,-1,0
12992,acetylcholine,24,25,184,197,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0,-1,0
12996,amnesia,26,27,122,129,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,1,1
12997,scopolamine,35,36,184,195,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,0,-1,0
12999,amnesia,24,25,121,128,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,1,1
13009,tobramycin,4,5,31,41,Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules.,9875685_0,0,-1,0
13010,toxicity,21,22,136,144,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,1,1
13011,tobramycin,10,11,63,73,MATERIALS AND METHODS: Patients undergoing treatment with i.v. tobramycin (4 mg/kg/day) were randomised to two groups.,9875685_2,0,-1,0
13012,tobramycin,12,13,48,58,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,0,-1,0
13013,Tobramycin,0,1,0,10,Tobramycin serum concentrations (peak and trough) were measured by enzyme multiplied immunoassay.,9875685_4,0,-1,0
13017,creatinine,2,3,16,26,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,0,-1,0
13018,nephrotoxicity,23,24,115,129,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,1,1
13019,tobramycin,12,13,74,84,CONCLUSION: This small study suggests that a once-daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice-daily regimen.,9875685_14,0,-1,0
13020,bradycardia,1,2,9,20,Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.,9915601_0,-1,1,1
13021,isoniazid,10,11,86,95,Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.,9915601_0,0,-1,0
13022,isoniazid,3,4,14,23,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,0,-1,0
13023,hypotension,5,6,33,44,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,1,1
13025,tachycardia,14,15,104,115,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,1,1
13026,bradycardia,16,17,119,130,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,1,1
13028,isoniazid,9,10,50,59,"In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.",9915601_2,0,-1,0
13029,bradycardia,11,12,63,74,"In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.",9915601_2,-1,1,1
13030,Isoniazid,0,1,0,9,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13031,bradycardia,3,4,34,45,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,1,1
13032,propranolol,5,6,52,63,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13033,labetalol,9,10,75,84,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13034,clonidine,17,18,116,125,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13035,hexamethonium,22,23,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13036,carbachol,24,25,158,167,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0
13037,isoniazid,7,8,50,59,These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone.,9915601_5,0,-1,0
13038,hypertension,4,5,29,41,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,1,1
13041,hypertension,10,11,61,73,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,1,1
13042,nephrotoxicity,12,13,78,92,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,1,1
13043,hypertension,7,8,44,56,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,1,1
13047,hypertension,18,19,106,118,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,1,1
13051,hypertension,5,6,30,42,d-1) prevented FK 506-induced hypertension in rats.,9931093_10,-1,1,1
13053,cardiomyopathy,8,9,75,89,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,1,1
13054,adriamycin,3,4,11,21,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0,-1,0
13056,cancer,8,9,31,37,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,1,1
13057,toxicity,18,19,105,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,1,1
13062,arrhythmias,13,14,79,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,1,1
13063,bradycardia,16,17,108,119,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,1,1
